NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF ETHYLBENZENE

(CAS NO. 100-41-4)

IN F344/N RATS AND B6C3F1 MICE

(INHALATION STUDIES)

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

January 1999

NTP TR 466

NIH Publication No. 99-3956

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

FOREWORD

The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation.

The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease.

The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The prechronic and chronic studies were conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice Regulations, and all aspects of the chronic studies were subjected to retrospective quality assurance audits before being presented for public review.

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. The interpretive conclusions presented in this Technical Report are based only on the results of these NTP studies. Extrapolation of these results to other species and quantitative risk analyses for humans require wider analyses beyond the purview of these studies. Selection *per se* is not an indicator of a chemical's carcinogenic potential.

Listings of all published NTP reports and ongoing studies are available from NTP Central Data Management, NIEHS, P.O. Box 12233, MD E1-02, Research Triangle Park, NC 27709 (919-541-3419). The Abstracts and other study information for 2-year studies are also available at the NTP's World Wide Web site: http://ntp-server.niehs.nih.gov.

NTP TECHNICAL REPORT

ON THE

TOXICOLOGY AND CARCINOGENESIS

STUDIES OF ETHYLBENZENE

(CAS NO. 100-41-4)

IN F344/N RATS AND B6C3F1 MICE

(INHALATION STUDIES)

NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

January 1999

NTP TR 466

NIH Publication No. 99-3956

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

These studies were supported in part by funds from the Comprehensive Environmental Response, Compensation, and Liability Act trust fund (Superfund) by an interagency agreement with the Agency for Toxic Substances and Disease Registry, U.S. Public Health Service.

CONTRIBUTORS

National Toxicology Program

Evaluated and interpreted results and reported findings

P.C. Chan, Ph.D., Study Scientist
D.A. Bridge, B.S.
J.R. Bucher, Ph.D.
R.E. Chapin, Ph.D.
J.R. Hailey, D.V.M.
J.K. Haseman, Ph.D.
J. Mahler, D.V.M.
R.R. Maronpot, D.V.M.
G.N. Rao, D.V.M., Ph.D.
J.H. Roycroft, Ph.D.
C.S. Smith, Ph.D.
G.S. Travlos, D.V.M.
D.B. Walters, Ph.D.
K.L. Witt, M.S., Oak Ridge Associated Universities

IIT Research Institute

Conducted 2-year studies, evaluated pathology findings

C. Aranyi, M.S., Principal Investigator D.T. Kirkpatrick, Ph.D. A. Snelson, Ph.D.

Experimental Pathology Laboratories, Inc.

Provided pathology quality assurance

J.F. Hardisty, D.V.M., Principal Investigator C.C. Shackelford, D.V.M., M.S., Ph.D.

Dynamac Corporation

Prepared quality assurance audits

S. Brecher, Ph.D., Principal Investigator

NTP Pathology Working Group

Evaluated slides, prepared pathology report on rats (13 July 1995)

J.C. Seely, D.V.M., Chairperson PATHCO, Inc. N. Barlow, Ph.D. North Carolina State University D. Dixon, D.V.M., Ph.D. National Toxicology Program J.R. Hailey, D.V.M. National Ťoxicology Program R.A. Herbert, D.V.M., Ph.D. National Toxicology Program A. Radovsky, D.V.M., Ph.D. National Toxicology Program C.C. Shackelford, D.V.M., M.S., Ph.D. Experimental Pathology Laboratories, Inc. M. Torii, D.V.M., Ph.D. National Toxicology Program D. Wolf, D.V.M., Ph.D. Chemical Industry Institute of Toxicology

Evaluated slides, prepared pathology report on mice (12 December 1995)

J.C. Seely, D.V.M., Chairperson PATHCO, Inc. S. Asanoi, Ph.D., Observer National Toxicology Program

- G.A. Boorman, D.V.M., Ph.D. National Toxicology Program
- R. Cattley, D.V.M., Ph.D. Chemical Industry Institute of Toxicology
- J. Hellman, D.V.M. National Toxicology Program
- R.A. Herbert, D.V.M., Ph.D. National Toxicology Program
- A. Radovsky, D.V.M., Ph.D. National Toxicology Program
- C.C. Shackelford, D.V.M., M.S., Ph.D. Experimental Pathology Laboratories, Inc.
- R.C. Sills, D.V.M., Ph.D. National Toxicology Program

Analytical Sciences, Inc. *Provided statistical analyses*

R.W. Morris, M.S., Principal Investigator S.R. Lloyd, M.S. N.G. Mintz, B.S.

Biotechnical Services, Inc.


Prepared Technical Report

S.R. Gunnels, M.A., Principal Investigator L.M. Harper, B.S. A.M. Macri-Hanson, M.A., M.F.A. E.S. Rathman, M.S.

CONTENTS

ABSTRACT		5
EXPLANATIO	ON OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY	10
TECHNICAL	REPORTS REVIEW SUBCOMMITTEE	11
SUMMARY O	OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS	12
INTRODUCT	ION	15
MATERIALS	AND METHODS	21
RESULTS		29
DISCUSSION	AND CONCLUSIONS	47
REFERENCE	s	51
Appendix A	Summary of Lesions in Male Rats in the 2-Year Inhalation Study of Ethylbenzene	57
Appendix B	Summary of Lesions in Female Rats in the 2-Year Inhalation Study of Ethylbenzene	99
Appendix C	Summary of Lesions in Male Mice in the 2-Year Inhalation Study of Ethylbenzene	131
Appendix D	Summary of Lesions in Female Mice in the 2-Year Inhalation Study of Ethylbenzene	167
Appendix E	Genetic Toxicology	201
Appendix F	Chemical Characterization and Generation of Chamber Concentrations	211
Appendix G	Ingredients, Nutrient Composition, and Contaminant Levels in NIH-07 Rat and Mouse Ration	221
Appendix H	Sentinel Animal Program	225

ABSTRACT



ETHYLBENZENE

CAS No. 100-41-4

Chemical Formula: C₈H₁₀

Molecular Weight: 106.16

Synonyms: EB; ethylbenzol; phenylethane

Ethylbenzene is mainly used in the manufacture of styrene. Ethylbenzene is also a major component of mixed xylenes used as solvents in agricultural and home insecticide sprays, rubber and chemical manufacturing, and household degreasers, paints, adhesives, and rust preventives. Ethylbenzene is also used as an antiknock agent in aviation and motor fuels. Ethylbenzene was nominated for study by the National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA) because of its potential for widespread human exposure and because of its structural similarity to benzene and toluene. Male and female F344/N rats and B6C3F1 mice were exposed to ethylbenzene (greater than 99% pure) by inhalation for 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium, mouse lymphoma cells, cultured Chinese hamster ovary cells, and mouse peripheral blood erythrocytes. In previously reported 13-week toxicity studies in which F344/N rats and B6C3F₁ mice were exposed to ethylbenzene by whole body inhalation exposure, no histopathologic changes were observed (NTP, 1992).

2-YEAR STUDY IN RATS

Groups of 50 male and 50 female F344/N rats were exposed to 0, 75, 250, or 750 ppm ethylbenzene by inhalation, 6 hours per day, 5 days per week, for 104 weeks.

Survival and Body Weights

Survival of male rats in the 750 ppm group was significantly less than that of the chamber controls. Mean body weights of 250 and 750 ppm males were generally less than those of the chamber controls beginning at week 20. Mean body weights of exposed groups of females were generally less than those of chamber controls during the second year of the study.

Pathology Findings

In male rats exposed to 750 ppm, the incidences of renal tubule adenoma and adenoma or carcinoma (combined) were significantly greater than the chamber control incidences. In addition, the incidence of renal tubule hyperplasia in 750 ppm males was significantly greater than that in the chamber controls. The findings from an extended evaluation (step section) of the kidneys showed a significant increase in the incidences of renal tubule adenoma and hyperplasia in 750 ppm males and females; the incidence of renal tubule adenoma or carcinoma (combined) was significantly increased in 750 ppm males. The severities of nephropathy in 750 ppm male and all exposed female rats were significantly increased relative to the chamber controls.

The incidence of interstitial cell adenoma in the testis of 750 ppm males was significantly greater than that in the chamber control group and slightly exceeded the historical control range for inhalation studies.

2-YEAR STUDY IN MICE

Groups of 50 male and 50 female $B6C3F_1$ mice were exposed to 0, 75, 250, or 750 ppm ethylbenzene by inhalation, 6 hours per day, 5 days per week, for 103 weeks.

Survival and Body Weights

Survival of exposed groups of male and female mice was similar to that of the chamber controls. Mean body weights of female mice exposed to 75 ppm were greater than those of the chamber controls from week 72 until the end of the study.

Pathology Findings

In 750 ppm males, the incidences of alveolar/ bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) were significantly greater than those in the chamber control group but were within the NTP historical control ranges. The incidence of alveolar epithelial metaplasia in 750 ppm males was significantly greater than that in the chamber controls.

In 750 ppm females, the incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) were significantly greater than those in the chamber control group but were within the historical control ranges. The incidence of eosinophilic foci in 750 ppm females was significantly increased compared to that in the chamber controls. There was a spectrum of nonneoplastic liver changes related to ethylbenzene exposure in male mice, including syncytial alteration of hepatocytes, hepatocellular hypertrophy, and hepatocyte necrosis.

The incidences of hyperplasia of the pituitary gland pars distalis in 250 and 750 ppm females and the incidences of thyroid gland follicular cell hyperplasia in 750 ppm males and females were significantly increased compared to those in the chamber control groups.

GENETIC TOXICOLOGY

Ethylbenzene gave little indication of mutagenicity, in vitro or in vivo. No induction of mutations was noted in Salmonella typhimurium strain TA97, TA98, TA100, or TA1535 with or without S9 metabolic activation, and no increases in sister chromatid exchanges or chromosomal aberrations were observed in cultured Chinese hamster ovary cells treated with ethylbenzene, with or without S9. In the mouse lymphoma assay, a significant mutagenic response was noted in the absence of S9, but only at the highest nonlethal dose tested and with accompanying cytotoxicity; the test was not performed with S9. No increases in the frequency of micronucleated erythrocytes were observed in vivo in peripheral blood samples from male and female mice exposed to ethylbenzene for 13 weeks.

CONCLUSIONS

Under the conditions of these 2-year inhalation studies, there was *clear evidence of carcinogenic activity*^{*} of ethylbenzene in male F344/N rats based on increased incidences of renal tubule neoplasms. The incidences of testicular adenoma were also increased. There was *some evidence of carcinogenic activity* of ethylbenzene in female F344/N rats based on increased incidences of renal tubule adenomas. There was *some evidence of carcinogenic activity* of ethylbenzene in male B6C3F₁ mice based on increased incidences of *carcinogenic activity* of ethylbenzene in female B6C3F₁ mice based on increased incidences of *carcinogenic activity* of ethylbenzene in female B6C3F₁ mice based on increased incidences of hepatocellular neoplasms.

Exposure of male and female rats to ethylbenzene resulted in increased incidences of renal tubule

hyperplasia and increased severities of nephropathy. Exposure of male mice to ethylbenzene resulted in increased incidences of alveolar epithelial metaplasia, syncytial alteration of hepatocytes, hepatocellular hypertrophy, hepatocyte necrosis, and thyroid gland follicular cell hyperplasia. In female mice, ethylbenzene exposure resulted in increased incidences of eosinophilic foci of the liver, pituitary gland pars distalis hyperplasia, and thyroid gland follicular cell hyperplasia.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 10. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 12.

	Male F344/N Rats	Female F344/N Rats	Male B6C3F ₁ Mice	Female B6C3F ₁ Mice
Concentrations in air	Chamber control, 75, 250, or 750 ppm	Chamber control, 75, 250, or 750 ppm	Chamber control, 75, 250, or 750 ppm	Chamber control, 75, 250, or 750 ppm
Body weights	250 and 750 ppm groups less than chamber controls	Exposed groups less than chamber controls	Exposed groups similar to chamber controls	75 ppm group greater than chamber controls
Survival rates	15/50, 14/50, 13/50, 2/50	31/50, 31/50, 34/50, 35/49	28/50, 36/50, 32/50, 30/50	35/50, 38/50, 40/50, 37/50
Nonneoplastic effects	<u>Kidney</u> : renal tubule hyperplasia (standard evaluation - 2/50, 2/50, 4/50, 12/50; standard and extended evaluations combined - 11/50, 9/50, 11/50, 23/50); severity of nephropathy (2.3, 2.4, 2.3, 3.5)	<u>Kidney</u> : renal tubule hyperplasia (standard evaluation - 0/50, 1/50, 3/50, 3/49; standard and extended evaluations combined - 1/50, 2/50, 4/50, 10/49); severity of nephropathy (1.3, 1.6, 1.7, 2.3)	Lung: alveolar epithelial metaplasia (0/50, 1/50, 2/50, 6/50) Liver: syncytial alteration (0/50, 5/50, 8/50, 23/50); hypertrophy (1/50, 0/50, 0/50, 17/50); necrosis (1/50, 1/50, 3/50, 10/50) Thyroid gland: follicular cell hyperplasia (21/50, 21/50, 29/50, 32/50)	Liver: eosinophilic focus (5/50, 7/50, 6/50, 22/50) Pituitary gland (pars distalis): hyperplasia (10/48, 12/49, 23/47, 22/49) Thyroid gland: follicular cell hyperplasia (18/50, 23/50, 25/50, 35/50)
Neoplastic effects	Kidney: renal tubule adenoma (standard evaluation - 0/50, 3/50, 2/50, 4/50; standard and extended evaluations combined - 3/50, 5/50, 7/50, 20/50); renal tubule adenoma or carcinoma (standard evaluation - 0/50, 3/50, 3/50, 7/50; standard and extended evaluations combined - 3/50, 5/50, 8/50, 21/50) <u>Testes</u> : adenoma (36/50, 33/50, 40/50, 44/50)	<u>Kidney</u> : renal tubule adenoma (standard evaluation - 0/50, 0/50, 0/50, 1/49; standard and extended evaluations combined - 0/50, 0/50, 1/50, 8/49)	Lung: alveolar/ bronchiolar adenoma (5/50, 9/50, 10/50, 16/50); alveolar/ bronchiolar adenoma or carcinoma (7/50, 10/50, 15/50, 19/50)	Liver: hepatocellular adenoma (6/50, 9/50, 12/50, 16/50); hepatocellular adenoma or carcinoma (13/50, 12/50, 15/50, 25/50)

Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Ethylbenzene

	Male F344/N Rats	Female F344/N Rats	Male B6C3F ₁ Mice	Female B6C3F ₁ Mice Some evidence	
Level of evidence of carcinogenic activity	Clear evidence	Some evidence	Some evidence		
Genetic toxicology Salmonella typhimu	rium gene mutations:	Negative	in strains TA97, TA98, TA10	0, and	
51	0		5 with and without S9		
Mouse lymphoma g		Positive	without S9		
Sister chromatid exe	0				
	ese hamster ovary cells in vitro:	Negative	with and without S9		
Chromosomal aberr		N T			
	ese hamster ovary cells in vitro:	Negative	with and without S9		
Micronucleated ervi	eral blood <i>in vivo</i> :	Negotine			
Mouse nerinhe	ral blood in vivo.	Negative			

Summary of the 2-Year Carcinogenesis and Genetic Toxicology Studies of Ethylbenzene (continued)

EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence, including animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results (**clear evidence** and **some evidence**); one category for uncertain findings (**equivocal evidence**); one category for no observable effects (**no evidence**); and one category for experiments that cannot be evaluated because of major flaws (**inadequate study**). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Report series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following five categories is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to potency or mechanism.

- Clear evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a dose-related
 (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- **Some evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- **Equivocal evidence** of carcinogenic activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemical related.
- No evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing no chemical-related increases in malignant or benign neoplasms.
- **Inadequate study** of carcinogenic activity is demonstrated by studies that, because of major qualitative or quantitative limitations, cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. Such consideration should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- adequacy of the experimental design and conduct;
- · occurrence of common versus uncommon neoplasia;
- · progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic to neoplastic lesions;
- some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to assume that benign neoplasms of those types have the potential to become malignant;
- combining benign and malignant tumor incidence known or thought to represent stages of progression in the same organ or tissue;
 latency in tumor induction;
- multiplicity in site-specific neoplasia;
- metastases:
- supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- presence or absence of dose relationships;
- statistical significance of the observed tumor increase;
- concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- · survival-adjusted analyses and false positive or false negative concerns;
- structure-activity correlations; and
- in some cases, genetic toxicology.

NATIONAL TOXICOLOGY PROGRAM BOARD OF SCIENTIFIC COUNSELORS TECHNICAL REPORTS REVIEW SUBCOMMITTEE

The members of the Technical Reports Review Subcommittee who evaluated the draft NTP Technical Report on ethylbenzene on 11 and 12 December 1996 are listed below. Subcommittee members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, subcommittee members have five major responsibilities in reviewing the NTP studies:

- · to ascertain that all relevant literature data have been adequately cited and interpreted,
- to determine if the design and conditions of the NTP studies were appropriate,
- to ensure that the Technical Report presents the experimental results and conclusions fully and clearly,
- to judge the significance of the experimental results by scientific criteria, and
- to assess the evaluation of the evidence of carcinogenic activity and other observed toxic responses.

Gary P. Carlson, Ph.D., Chairperson School of Health Sciences Purdue University West Lafayette, IN

Arnold L. Brown, M.D. University of Wisconsin Medical School Madison, WI

Thomas L. Goldsworthy, Ph.D., Principal Reviewer Department of Experimental Pathology and Toxicology Chemical Industry Institute of Toxicology Research Triangle Park, NC

Robert LeBoeuf, Ph.D. Corporate Professional and Regulatory Services Human Safety Department The Procter & Gamble Company Cincinnati, OH

Janardan K. Reddy, M.D., Principal Reviewer Department of Pathology Northwestern University Medical School Chicago, IL Irma Russo, M.D. Fox Chase Cancer Center Philadelphia, PA

- Louise Ryan, Ph.D., Principal Reviewer Division of Biostatistics Dana-Farber Cancer Institute Boston, MA
- Robert E. Taylor, M.D., Ph.D. Department of Pharmacology Howard University College of Medicine Washington, DC
- Frederick L. Tyson, Ph.D. St. Mary's Hospital and Medical Center Cancer Research Institute Grand Junction, CO
- Jerrold M. Ward, D.V.M., Ph.D.* National Cancer Institute Frederick, MD

* Did not attend on 12 December 1996

SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS

On 11 and 12 December 1996, the draft Technical Report on the toxicology and carcinogenesis studies of ethylbenzene received public review by the National Toxicology Program's Board of Scientific Counselors' Technical Reports Review Subcommittee. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, NC.

Dr. P.C. Chan, NIEHS, introduced the toxicology and carcinogenesis studies of ethylbenzene by discussing the uses of the chemical and the rationale for study, describing the experimental design, reporting on survival and body weight effects, and commenting on compound-related neoplastic and nonneoplastic lesions in rats and mice. The proposed conclusions were *clear evidence of carcinogenic activity* in male F344/N rats and *some evidence of carcinogenic activity* in female F344/N rats and male and female B6C3F₁ mice.

Dr. Reddy, a principal reviewer, agreed with the proposed conclusions. He said that for the purpose of contrasting findings with those of Maltoni *et al.* (1985), the Technical Report should cite information on types, sites, and incidences of neoplasms from that study. Dr. Chan said that in that study, the total number of neoplasms was provided but not differentiated by target organ. Dr. Reddy noted that the methods, such as immunochemistry, used to rule out $\alpha 2\mu$ -globulin nephropathy in male rats should be described in the Technical Report. Dr. J. Mahler, NIEHS, responded that the hematoxylin-eosin stain, a good screen for hyaline droplet accumulation, was used.

Dr. Goldsworthy, the second principal reviewer, agreed with the proposed conclusions for rats and female mice. He agreed that the inhalation route was appropriate, but he noted that ethylbenzene has been detected in surface and ground water. Dr. Goldsworthy thought that the additional information obtained from renal step sections was helpful but asked for justification of the decision to step section kidneys but not other organs, such as thyroid and pituitary glands. Dr. J.R. Hailey, NIEHS, said that the major reason to step section organs is to help interpret equivocal or uncertain effects, and that endocrine organs such as thyroid and pituitary glands are too small to step section. Dr. Goldsworthy suggested that *clear evidence of carcinogenic activity* may have been a better call in male mice, based on a positive exposure-response trend and the presence of metaplasia in the target tissue. Dr. Mahler said that metaplasia is an unusual lesion and is generally not recognized as a precursor to neoplasia.

Dr. Ryan, the third principal reviewer, agreed with the proposed conclusions for rats. She said that one of the reasons for studying the chemical was its structural similarity to benzene and toluene, and she questioned why the Technical Report did not include more discussion comparing the toxic effects of the three chemicals (see Table 12, page 49). She expressed concern that the 750 ppm exposure in female rats and in male and female mice may have been too low because there were no survival or body weight effects in these groups. Dr. J.R. Bucher, NIEHS, commented that prechronic studies were performed with ethylbenzene and that an NTP study report was published in 1992. Because there were essentially no histopathologic findings in the 13-week studies, the exposure selection for the 2-year study was based on a body weight deficit in male rats. Dr. Ryan said that it could be argued that there was clear evidence of carcinogenic activity in male mice based on an exposure-related increase in combined benign and malignant lung neoplasms and in female mice based on an exposure-related increase of combined benign and malignant hepatic neoplasms. Dr. J.K. Haseman. NIEHS. said that there were three reasons for the level of evidence chosen: first, the neoplasm rates fell within the historical control range; second, the neoplasms were primarily benign; and third, the lung neoplasms were seen only in males and the liver neoplasms only in females.

Dr. LeBoeuf commented that survival in 750 ppm male rats was only 4% but the level of evidence of carcinogenic activity in male rats was based on increased incidences of renal tubule neoplasms in the 750 ppm group. He said that he was uncomfortable

basing the level of evidence of carcinogenic activity on findings accompanied by such poor survival. Dr. Bucher responded that the fact that increased renal neoplasms were seen in both males and females and were accompanied by severe nephropathy, which is rarely if ever seen in females, suggests an intrinsic carcinogenic activity of ethylbenzene.


Dr. Ryan moved that the Technical Report on ethylbenzene be accepted with the revisions discussed and the conclusions as written for male rats, *clear evidence of carcinogenic activity*, and for female rats and male and female mice, *some evidence of carcinogenic activity*. Dr. Reddy seconded the motion, which was accepted unanimously with nine votes.

Later in the meeting, Dr. LeBoeuf made a motion to reopen the discussion on the neoplasm response in male rats. Dr. Taylor thought that the maker and seconder of the original motion should have to agree. Drs. Ryan and Reddy agreed to reopen the discussion. Dr. Goldsworthy seconded the motion to reopen the discussion, which was accepted by six yes votes to two no votes (Drs. Brown and Reddy). Dr. Ward was not present.

Dr. LeBoeuf stated that his primary concerns were the mortality in 750 ppm male rats and the interpretation of the data at that dose. He said that one of the original National Cancer Institute guidelines for the 2-year bioassays is that particular treatments should not affect survival, unless reduced survival is a result of neoplasia, and should not cause more than a 10% decrease in body weight gain. He said that in the ethylbenzene Technical Report, it was clear that the majority of the neoplasms in male rats were considered to be incidental to the cause of death. For this reason, he recommended changing the conclusion in male rats to some evidence of carcinogenic activity. Dr. Haseman pointed out that at week 84, the survival in 750 ppm male rats was still 70%. Dr. Goldsworthy stated that one issue to consider is when the first neoplasms arose. Dr. Bucher commented that nephropathy was likely the primary contributor to mortality. Dr. Haseman suggested that the conclusion for male rats, as with the report on oxazepam, could indicate that there was *clear evidence of carcinogenic* activity only at concentrations resulting in enhanced nephropathy. Dr. Bucher noted that in many past studies, the conclusions for carcinogenic activity were confirmed even when the maximum tolerated doses were exceeded. He noted that in most studies in which renal tubule neoplasms are associated with nephropathy in male rats, carcinomas are generally not seen; he further noted that in female rats, the incidences of nephropathy are generally less than in male rats and that 21 neoplasms is exceptionally high. Dr. Goldsworthy reminded the reviewers of the stipulation "Under the conditions of these studies..." Dr. Ryan pointed out that in the standard evaluation, the renal tubule neoplasm incidences in male rats exceeded the historical control range even in the 75 ppm group.

Dr. LeBoeuf moved that the conclusion for male rats be changed to *some evidence of carcinogenic activity*. Dr. Ryan seconded the motion, which was defeated by six no votes to two yes votes (Drs. LeBoeuf and Russo). Dr. Ward was not present.

INTRODUCTION



ETHYLBENZENE

CAS No. 100-41-4

Chemical Formula: C₈H₁₀

Molecular Weight: 106.16

Synonyms: EB; ethylbenzol; phenylethane

CHEMICAL AND PHYSICAL PROPERTIES

Ethylbenzene is a colorless, flammable, aromatic liquid with a melting point of -95.0° C, a boiling point of 136.2° C at 760 mm Hg, and a density of 0.866 at 25° C. Its vapor pressure is 10 mm Hg at 25.9° C, and its vapor density is 3.66. It is practically insoluble in water (0.014 g/100 mL) at 15° C but is soluble in most organic solvents (Verschueren, 1983; *Merck Index*, 1989). Ethylbenzene has a flash point of 15° C and an autoignition temperature of 432° C (Lewis, 1992).

PRODUCTION, USE, AND HUMAN EXPOSURE

Ethylbenzene is produced by two primary processes: heating of benzene and ethylene in the presence of aluminum chloride and by fractionation directly from the mixed xylene stream during petroleum refining *(Hawley's*, 1987). The United States production of ethylbenzene was 7.56 billion pounds in 1984 (USITC, 1985), 8.5 billion pounds in 1986 (Heylin, 1987), 11.11 billion pounds in 1992, and 11.76 billion pounds in 1993 (*Chem. Eng. News*, 1994). Ethylbenzene was the eighteenth highest in production volume for chemicals produced in the United States in 1985 (*Hawley's*, 1987). Ethylbenzene is mainly used in the manufacture of styrene (*Fed. Regist.*, 1987) and cellulose acetate (ILO, 1983). It has also been used as an intermediate in the production of diethylbenzene, acetophenone, and ethyl anthraquinone. Ethylbenzene is a major component (15% to 20%) of mixed xylenes (Toftgard and Nilsen, 1982), which are used as solvents in agricultural and household insecticide sprays, rubber and chemical manufacturing industries, and household degreasing cleaners, paint, adhesives, and rust preventives (Fishbein, 1985). The United States produced 6.49 billion pounds of mixed xylenes in 1984 (USITC, 1985). Ethylbenzene has also been used in motor and aviation fuels as an antiknock agent (NIOSH, 1979; ILO, 1983).

Ethylbenzene is widely distributed in the environment due to its use as a solvent and fuel additive; it is also naturally present in crude petroleum. It has been detected in ambient air, surface water and groundwater, and in human milk (National Research Council, 1981). Ethylbenzene concentrations of 10 to 26 mg/L have been detected in the Missouri River (STORET, 1986) and concentrations up to 7 mg/L have been found in samples of potable water in Canada (Otson *et al.*, 1982). Ethylbenzene has also been found in wastewater effluents from pulpwood mills (Nestmann *et al.*, 1980). Ethylbenzene was in a water sample from New Jersey, in eight air samples, and in 12 breath samples from workers exposed to ethylbenzene (Wallace *et al.*, 1984). Atmospheric air samples collected in the Los Angeles basin contained ethylbenzene, probably derived from vehicle exhaust (Lonneman *et al.*, 1968). No evidence of ethylbenzene bioaccumulation has been reported.

Based on irritant properties of ethylbenzene vapor, the American Conference of Governmental Industrial Hygienists (ACGIH, 1996) has set a threshold limit value of 100 ppm (435 mg/m³), with a short-term exposure limit of 125 ppm (545 mg/m³). The Occupational Safety and Health Administration (OSHA) set the permissible exposure limit at 100 ppm as an 8-hour time-weighted average and 125 ppm as a 15-minute short-term exposure limit (*Fed. Regist.*, 1989).

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Structurally, ethylbenzene is related to other aliphatic derivatives of aromatic compounds. Many of the biological activities of these chemicals are similar. For example, benzene, ethylbenzene, and toluene are well absorbed after inhalation exposure and are distributed to adipose tissue, liver, kidney, bone marrow, and nervous tissue. These chemicals are metabolized mainly by the hepatic cytochrome P_{450} systems and are central nervous system depressants (Tegeris and Balster, 1994). The toxic effect on the central nervous system, at least in part, is exerted by inhibiting the membrane-bound ATPase activities in astrocytes (Naskali *et al.*, 1994; Vaalavirta and Tähti, 1995), thereby disturbing the ATPase-dependent astrocytic regulatory functions.

Toluene is metabolized by the liver cytochrome P_{450} enzyme system to benzyl alcohol, benzaldehyde, and benzoic acid via methyl hydroxylation and is excreted in the urine as hippuric acid. A minor pathway of metabolism is via ring hydroxylation and excretion as cresol sulphates and glucuronides (Dean, 1978). In NTP (1990a) inhalation studies, toluene was neither genotoxic nor carcinogenic. Ono *et al.* (1995) did not find toluene to be teratogenic in inhalation studies.

Benzene is metabolized primarily by the hepatic cytochrome P₄₅₀ system to benzene oxide and then rearranged to form phenol, catechol, and benzoquinones (hydroquinones) and excreted in the urine or exhaled (NTP, 1986). Alternatively, oxidation and ring opening of catechol give rise to trans, transmuconaldehyde and muconic acid. Hydration of benzene oxide to dihydrodiol and ring oxidation to diolepoxide have also been postulated (Busby et al., 1990). Inhalation exposure to benzene in BDF₁ mice caused DNA damage in peripheral blood cells, bone marrow, and liver (Plappert et al., 1994). The hematotoxicity of benzene observed in rats and mice is mainly due to the metabolites hydroquinone and benzoquinone (Zhu et al., 1995). Xylene undergoes oxidation of the methyl group to give rise to methyl benzyl alcohols or aromatic hydroxylation to xylenols before excretion in the urine (Dean, 1978).

Percutaneous absorption rates of benzene, toluene, ethylbenzene, and aniline in male HRS/J hairless mice following an application of 5 mL of ¹⁴C-labeled test solution were 56, 49, 37, and 2.3 μ g/cm² per minute, respectively (Susten *et al.*, 1990). The excretion of benzene and aniline in expired air was greater during the first 15 minutes of exposure, whereas that of toluene and ethylbenzene was greatest during the second 15 minutes of exposure. These data suggested a two-compartment model might better describe the kinetics of the appearance of toluene and ethylbenzene in expired breath.

Differences in the metabolism of ethylbenzene in rats, rabbits, and humans are minor (Chin *et al.*, 1980; Climie *et al.*, 1983). Ethylbenzene metabolism appears to involve side-chain hydroxylation by liver microsomal enzymes (Pyykko *et al.*, 1987). Ring oxidation may also occur (Engström, 1984).

Experimental Animals

Ethylbenzene is readily absorbed from the atmosphere in Harlan-Wistar rats. In rats exposed to radiolabeled ethylbenzene for 6 hours by inhalation, radioactivity was found in the liver, gastrointestinal tract, and adipose tissue 42 hours after exposure (Chin *et al.*, 1980). One day following oral administration of radioactive ethylbenzene, radioactivity was found in the intestine, liver, kidney, and fat of rats (Climie *et al.*, 1983). Freundt *et al.* (1989) reported that the blood concentration of ethylbenzene was dose-dependent after a 2-hour inhalation of 120, 240, 350, or 650 ppm in rats.

In rats, ethylbenzene is metabolized to mandelic acid and phenylglyoxylic acid by side-chain oxidation and then excreted in the urine (Bardodej and Bardodejova, 1970; Engström, 1984; Gromiec and Piotrowski, 1984). Other minor metabolites found in urine included 1-phenylethanol, omega-hydroxyacetophenone, hippuric acid, benzoic acid, phenylacetic acid, and phenaceturic acid (Engström, 1984; Engström et al., 1985). Engström (1984) showed that in male Wistar rats exposed to ethylbenzene by inhalation for 6 hours per day, 5 days per week, for 3, 5, and 9 weeks at 50, 300, or 600 ppm, the total urinary elimination of ethylbenzene metabolites in 24 hours was dose dependent. Excretion of metabolites into urine increased in a dose-related manner but less than linearly. The total amount of metabolites excreted at each time point at each dose was constant. These data implied induction of a metabolic enzyme.

Humans

Human exposure to ethylbenzene is mainly via inhalation of vapor and/or mist. To a smaller extent, absorption also occurs through dermal contact or by ingestion (Dutkiewicz and Tyras, 1967). Ethylbenzene is readily absorbed from the atmosphere through the lungs in humans (Bardodej and Bardodejova, 1970; Gromiec and Piotrowski, 1984), and orally administered ethylbenzene is quickly and effectively absorbed as well (Climie et al., 1983). Absorption of liquid ethylbenzene through the skin is rapid when compared to similar hydrocarbon compounds such as benzene or styrene (Dutkiewicz and Tyras, 1967). Trace amounts of ethylbenzene were found in the subcutaneous fat (Wolf et al., 1977) and body fat (Engström and Bjurstrom, 1978) of humans exposed to the chemical either by the dermal or inhalation route.

In humans, as in rats, most of the absorbed ethylbenzene is metabolized by liver microsomal enzymes to mandelic acid and phenylglyoxylic acid by side-chain oxidation and then excreted in the urine (Bardodej and Bardodejova, 1970; Engström, 1984; Gromiec and Piotrowski, 1984). However, a small amount of phenolic derivatives (2- and 4-ethylphenol) is also found in the urine (Angerer and Lehnert, 1979; Engström, 1984), indicating the occurrence of ring oxidation. The presence of phenaceturic acid in urine implies oxidation of the ω -methyl group of the side chain (Figure 1; Engström, 1984).

TOXICITY Experimental Animals

The oral LD_{50} for ethylbenzene in male and female Wistar rats was estimated to be 3.5 g/kg (Wolf *et al.*, 1956), and the intraperitoneal LD_{50} for mice was 2.27 g/kg (DFG, 1985; Lewis, 1992). The 4-hour LC_{50} in female rats was 4,000 ppm, and the 1-hour LC_{50} was 8,000 ppm (Smyth *et al.*, 1962).

Ethylbenzene is a mucous membrane irritant; guinea pigs exposed for 1 minute to 0.2% ethylbenzene vapor experienced moderate eye and nasal irritation. Exposure to 0.1% ethylbenzene produced slight nasal irritation that ceased after 30 minutes. At 1%, ethylbenzene caused ataxia, loss of consciousness, tremor (Lewis, 1992), central nervous system depression, and death (ACGIH, 1986).

In Wistar rats, oral administration of ethylbenzene at 408 or 680 mg/kg per day or inhalation exposure at 1,250 or 2,200 ppm, 7 to 8 hours per day, 5 days per week for 6 months induced slight increases in kidney and liver weights and cloudy swelling of the tubular epithelium of the kidney and parenchymal cells of the liver (Wolf et al., 1956). Male Wistar rats exposed to ethylbenzene by inhalation at 300 or 600 ppm for 16 weeks exhibited increased activities of liver enzymes, including NADPH cytochrome c reductase, 7-ethoxycoumarin-O-deethylase, UDP-glucuronosyltransferase, and D-glucuronolactone dehydrogenase. Kidney 7-ethoxycoumarin-O-deethylase and UDPglucuronosyl-transferase activities were also increased (Elovaara et al., 1985). Electron microscopy showed that the cloudy swelling of the renal tubule epithelium was due to an increase in endoplasmic reticulum as a result of an adaptive response of increased microsomal enzyme activity (Elovaara et al., 1985). Rats exposed to ethylbenzene at 2,000 ppm for 3 days had increased hepatic cytochrome \dot{P}_{450} and NADPH cytochrome c reductase activities (Toftgard and Nilsen, 1982). F344/N rats and B6C3F₁ mice




FIGURE 1

Metabolism of ethylbenzene as reconstructed from urinary metabolites found in rat and human urine. The thickness of the arrows represents the extent of the respective route; the broken arrows indicate that only trace amounts were found. Unclear pathways are depicted by open arrows (Reproduced from Engström, 1984).

exposed to ethylbenzene by inhalation at 382 or 782 ppm 5 days per week for 4 weeks had significantly increased absolute and relative liver weights (Cragg *et al.*, 1989). The authors concluded that the no-observed-adverse-effect-level for rats and mice was 382 ppm.

In 13-week toxicity studies performed by the NTP (1992), F344/N rats and B6C3F₁ mice were exposed to ethylbenzene by inhalation at 0, 100, 250, 500, 750, or 1,000 ppm. Signs of toxicity included increased liver, lung, and kidney weights in exposed male and female rats and increased liver weights in exposed male and female mice. No evidence of histopathologic injury was noted in these studies. No animals died, and the mean body weight gains of the exposed rats and mice did not differ from those of the respective controls. Sperm or vaginal cytology evaluations of the exposed rats and mice revealed no changes from normal. Based on the changes in organ weights, the high dose selected for the 2-year studies was 750 ppm.

Humans

Ethylbenzene is a skin, eye, and respiratory irritant and a central nervous system depressant at an atmospheric concentration of 0.2%. Human volunteers breathing 0.1% ethylbenzene vapor reported initial eye irritation which gradually decreased, while exposure to a 0.2% atmospheric concentration was accompanied by extreme irritation of the eyes, nose, and throat (Yant et al., 1930) and central nervous system depression. Symptoms of central nervous system depression included headache; nausea; weakness; dizziness; sleepiness; loss of coordination, judgment, and consciousness; and coma or death (Lewis, 1992). Erythema and inflammation of the skin developed after dermal contact (Lewis, 1992). Prolonged exposure to ethylbenzene vapor may result in leukopenia and lymphocytosis, neurofunctional disorder, and hepatitis (ILO, 1983).

Reproductive AND DEVELOPMENTAL TOXICITY

Ethylbenzene is embryotoxic and teratogenic. The offspring of rats exposed to ethylbenzene at 1,000 ppm, 7 hours per day, 5 days per week for 3 weeks before mating, then exposed daily through day 19 of gestation had a higher incidence of super-

numerary ribs (Hardin *et al.*, 1981). In the offspring of CFY rats exposed to ethylbenzene at 552 ppm, 24 hours per day from days 7 to 15 of gestation, retardation of skeletal development, increased incidence of supernumerary ribs, and anomalies of the uropoietic apparatus were observed (Ungvary and Tatrai, 1985). An increased rate of malformation was also found in CFLP mice exposed to ethylbenzene. Maternal toxicity reported by these investigators included increased liver, kidney, and spleen weights.

Increased postimplantation loss of fetuses in dams was

CARCINOGENICITY

also observed.

Maltoni *et al.* (1985) reported a study in which Sprague-Dawley rats were administered 500 mg ethylbenzene/kg per day in olive oil by gavage, 4 or 5 days per week for 104 weeks. Incidences of malignant neoplasms were 35.0% (versus 26.7% in controls) in dosed males and 45.9% (versus 22.4% in controls) in dosed females. The results of this study were considered inconclusive. No other information on the carcinogenicity of ethylbenzene in experimental animals or humans was found in the literature. Benzene, a homologue of ethylbenzene, is carcinogenic in rats and mice (NTP, 1986; Farris *et al.*, 1993) and is a human carcinogen inducing acute myelogenous leukemia and aplastic anemia.

GENETIC TOXICITY

Ethylbenzene was not mutagenic in Salmonella typhimurium strain TA97, TA98, TA100, or TA1535 when tested up to toxic doses (1,000 μ g/plate) in the presence or absence of exogenous metabolic activation (S9) (Zeiger et al., 1992). It was also reported to be negative, with and without S9, in S. typhimurium strains TA1537 and TA1538 (Nestmann et al., 1980), in Escherichia coli WP2 and WP2uvrA, and in Saccharomyces cerevisiae JD1 (Dean et al., 1985). A weakly positive response was reported in a sister chromatid exchange test with human lymphocytes cultured in the presence of S9 (Norppa and Vainio, 1983), and an increase in mutant L5178Y mouse lymphoma cell colonies was observed at the highest nonlethal dose (80 µg/mL) of ethylbenzene tested in the absence of S9 (McGregor et al., 1988). Micronucleus assays in mouse peripheral blood were negative (NTP, 1992; Appendix E).

STUDY RATIONALE

Ethylbenzene was nominated for toxicity study by OSHA and NIOSH and was selected for study by the NTP because of its potential for widespread consumer exposure and its structural similarity to benzene and toluene. The present studies were undertaken following the designation of ethylbenzene as a priority chemical for toxicologic testing by the Interagency Agreement (Superfund) between the NTP and the United States Environmental Protection Agency (EPA). The studies were designed to determine the toxicologic and carcinogenic effects of ethylbenzene in F344/N rats and $B6C3F_1$ mice after a 2-year inhalation exposure. Data were needed for the EPA to make regulatory decisions mandated by the Clean Air Act (42 U.S.C. § 7412). The inhalation route of exposure was selected because human exposure to ethylbenzene is mainly by inhalation.

MATERIALS AND METHODS

PROCUREMENT AND CHARACTERIZATION OF ETHYLBENZENE

Ethylbenzene was obtained from ARCO Chemical Company (Newtown Square, PA) in two lots (A060989 and A051890). Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO). Reports on analyses performed in support of the ethylbenzene studies are on file at the National Institute of Environmental Health Sciences (NIEHS).

The chemical, a clear, colorless, pungent smelling, volatile liquid, was identified as ethylbenzene by infrared, ultraviolet/visible (lot A060989 only), and nuclear magnetic resonance spectroscopy. All spectra were consistent with the literature spectra of ethylbenzene. The boiling point and density of the chemical were also consistent with literature references.

The purity of lot A060989 was determined by elemental analyses, Karl Fischer water analysis, iodometric titration for peroxide determination, and gas chromatography. Elemental analyses for carbon and hydrogen were in agreement with the theoretical values for ethylbenzene. Karl Fischer water analysis indicated less than 0.05% water. Iodometric titration revealed no peroxide. Gas chromatography by two systems revealed a major peak and no impurities with areas greater than 0.1% relative to the major peak. Major peak comparisons of lot A060989 with a previously analyzed lot of ethylbenzene (lot K061786) not used in the current studies indicated a purity of $101.0\% \pm 0.5\%$ for lot A060989 relative to lot K061786. The overall purity of lot A060989 was determined to be greater than 99%.

Additional analyses of lot A060989 were performed with gas chromatography/mass spectrometry to identify and quantify cumene in the bulk ethylbenzene. In these analyses, 62 ± 3.1 ppm cumene was detected.

The purity of lot A051890 was determined by iodometric titration for peroxide and by gas chromatography. Less than 2 ppm peroxide was detected. Gas chromatography indicated one impurity with an area of 0.1% relative to the major peak. The overall purity of lot A051890 was determined to be greater than 99%.

Accelerated stability studies of the bulk chemical were performed by the analytical chemistry laboratory. These studies indicated that ethylbenzene is stable as a bulk chemical for at least 2 weeks when stored protected from light at temperatures up to 60° C. To ensure stability, the bulk chemical was stored at room temperature in the original steel containers until just prior to use, when it was transferred to amber glass bottles with Teflon[®]-lined caps and a nitrogen head-space. The rapid use and small shipment sizes of ethylbenzene made stability monitoring unnecessary during the studies; however, the peroxide content of the bulk chemical was tested monthly with iodometric titration. The concentration of peroxide ranged from 1.12 to 10.7 ppm.

VAPOR GENERATION AND EXPOSURE SYSTEM

Ethylbenzene vapor was produced by flash evaporator units. Nitrogen gas carried ethylbenzene vapor from the condensing column into heated stainless-steel transfer lines that led to exposure chambers. Each exposure chamber was supplied by a separate flash evaporator unit. Exposure concentrations for individual exposure chambers were created by varying the ethylbenzene flow rate to the individual flash evaporation units. At the chamber inlets, the ethylbenzene vapor was mixed with HEPA- and charcoal-filtered Stainless-steel chambers (Hazleton H-2000®) air. manufactured by Lab Products, Inc. (Maywood, NJ) were used throughout the studies. The 750 ppm chambers were sampled once during the first full week of exposure for the presence of aerosol by a Quartz Crystal Microbalance Cascade Impactor

(California Measurements, Sierra Madre, CA). Results indicated that aerosol formation due to test atmosphere generation was not significant.

VAPOR CONCENTRATION MONITORING

The chamber concentrations of ethylbenzene were monitored by an on-line gas chromatograph using a flame ionization detector. Samples were drawn from supply lines leading to exposure chambers and the control chamber at least once every hour. Summaries of chamber concentrations are presented in Table F1.

CHAMBER ATMOSPHERE

CHARACTERIZATION

The times for the exposure concentration to build up to 90% of the final exposure concentration (T_{90}) and to decay to 10% of the exposure concentration (T_{10}) were measured in the 750 ppm exposure chambers with animals present. At a chamber airflow rate of 15 air changes per hour, the theoretical value for both T_{90} and T_{10} is 10 minutes; analysis of chamber concentrations during the first 2 weeks of the studies indicated T_{90} and T_{10} values of 15 minutes; therefore, 15 minutes was used for the T_{90} throughout the studies.

Inhalation chambers were sampled to determine the uniformity of ethylbenzene concentrations; samples from 12 shelf positions within the exposure chambers were analyzed by gas chromatography. Chamber concentration uniformity was maintained throughout the studies.

The persistence of ethylbenzene following exposure was monitored by gas chromatography in the 750 ppm chambers with and without animals present. No ethylbenzene was detectable in the chambers 2 hours after exposure (detection limit 0.44 ppm).

The stability of ethylbenzene was monitored in the generator reservoirs of the 75 and 750 ppm chambers. No significant contaminants or degradation products were found in any of the generator reservoir samples.

Samples from occupied and unoccupied 75 and 750 ppm chambers were analyzed for degradation products before studies began, during the first week of the studies, and every 90 days thereafter. One small

impurity was detected in samples taken from the 750 ppm chambers.

2-YEAR STUDIES Study Design

Groups of 50 male and 50 female F344/N rats and B6C3F₁ mice were exposed by inhalation to 0, 75, 250, and 750 ppm ethylbenzene for 6 hours plus T_{90} (15 minutes) per day, 5 days per week, for 103 (mice) or 104 (rats) weeks. The high exposure concentration selected for these studies was 750 ppm ethylbenzene, roughly 19% of the 4-hour LC₅₀ for rats reported by Smyth *et al.* (1962). Following the last day of exposure, rats and mice were observed for 9 to 12 days prior to necropsy.

Source and Specification of Animals

Male and female F344/N rats and $B6C3F_1$ mice were obtained from Simonsen Laboratories, Inc. (Gilroy, CA) for use in the 2-year studies. Five male and five female rats and mice were randomly selected for parasite evaluation and gross observation of disease. Rats and mice were approximately 6 weeks old at the beginning of the studies. The health of the animals was monitored during the studies according to the protocols of the NTP Sentinel Animal Program (Appendix H).

Animal Maintenance

Rats and mice were housed individually. Feed and water were available *ad libitum*. Cages were rotated once weekly. Further details of animal maintenance are given in Table 1. Information on feed composition and contaminants is provided in Appendix G.

Clinical Examinations and Pathology

Animals were observed twice daily. Clinical findings were recorded approximately monthly. Body weights were recorded initially, weekly for the first 13 weeks, at week 16, monthly through the end of exposure, and prior to terminal necropsy. A complete necropsy and microscopic examination were performed on all rats and mice. At necropsy, all organs and tissues were examined for grossly visible lesions, and all major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6 μ m, and stained with hematoxylin and eosin for microscopic examination. For all paired organs (i.e., adrenal

gland, kidney, and ovary), samples from each organ were examined. Tissues examined microscopically are listed in Table 1.

Microscopic evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the Toxicology Data Management System. The slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assessment laboratory. The individual animal records and tables were compared for accuracy, the slide and tissue counts were verified, and the histotechnique was evaluated. A quality assessment pathologist evaluated slides from all tumors and all potential target organs. which included the kidney, liver, lung, and nose of male and female rats; bone marrow, parathyroid gland, prostate gland, and testis of male rats; pituitary gland of female rats; heart, kidney, liver, lung, nose, and thyroid gland of male and female mice; and pituitary gland of female mice.

The quality assessment report and the reviewed slides were submitted to the NTP Pathology Working Group (PWG) chairperson, who reviewed the selected tissues and addressed any inconsistencies in the diagnoses made by the laboratory and quality assessment pathologists. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnoses between the laboratory and quality assessment pathologists, or lesions of general interest were presented by the chairperson to the PWG for review. The PWG consisted of the quality assessment pathologist and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without any knowledge of dose groups or previously rendered diagnoses. When the PWG consensus differed from the opinion of the laboratory pathologist, the diagnosis was changed. Final diagnoses for reviewed lesions represent a consensus between the laboratory pathologist, reviewing pathologist(s), and the PWG. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). For subsequent analyses of the pathology data, the decision of whether to evaluate the diagnosed lesions for each tissue type separately or combined was generally based on the guidelines of McConnell et al. (1986).

STATISTICAL METHODS Survival Analyses

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals found dead of other than natural causes or missing were censored from the survival analyses; animals dying from natural causes were not censored. Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.

Calculation of Incidence

The incidences of neoplasms or nonneoplastic lesions are presented in Tables A1, A5, B1, B4, C1, C5, D1, and D5 as the numbers of animals bearing such lesions at a specific anatomic site and the numbers of animals with that site examined microscopically. For calculation of statistical significance, the incidences of most neoplasms (Tables A3, B3, C3, and D3) and all nonneoplastic lesions are given as the numbers of animals affected at each site examined microscopically. However, when macroscopic examination was required to detect neoplasms in certain tissues (e.g., harderian gland, intestine, mammary gland, and skin) before microscopic evaluation, or when neoplasms had multiple potential sites of occurrence (e.g., leukemia or lymphoma), the denominators consist of the number of animals on which a necropsy was performed. Tables A3, B3, C3, and D3 also give the survival-adjusted neoplasm rate for each group and each site-specific neoplasm, i.e., the Kaplan-Meier estimate of the neoplasm incidence that would have been observed at the end of the study in the absence of mortality from all other competing risks (Kaplan and Meier, 1958).

Analysis of Neoplasm Incidences

The majority of neoplasms in these studies were considered to be incidental to the cause of death or not rapidly lethal. Thus, the primary statistical method used was logistic regression analysis, which assumed that the diagnosed neoplasms were discovered as the result of death from an unrelated cause and thus did not affect the risk of death. In this approach, neoplasm prevalence was modeled as a logistic function of chemical exposure and time. Both linear and quadratic terms in time were incorporated initially, and the quadratic term was eliminated if the fit of the model was not significantly enhanced. The neoplasm incidences of exposed and control groups were compared on the basis of the likelihood score test for the regression coefficient of dose. This method of adjusting for intercurrent mortality is the prevalence analysis of Dinse and Lagakos (1983), further described and illustrated by Dinse and Haseman (1986). When neoplasms are incidental, this comparison of the time-specific neoplasm prevalences also provides a comparison of the time-specific neoplasm incidences (McKnight and Crowley, 1984).

In addition to logistic regression, other methods of statistical analysis were used, and the results of these tests are summarized in the appendixes. These methods include the life table test (Cox, 1972; Tarone, 1975), appropriate for rapidly lethal neoplasms, and the Fisher exact test and the Cochran-Armitage trend test (Armitage, 1971; Gart *et al.*, 1979), procedures based on the overall proportion of neoplasm-bearing animals.

Tests of significance included pairwise comparisons of each exposed group with controls and a test for an overall dose-related trend. Continuity-corrected tests were used in the analysis of neoplasm incidence, and reported P values are one sided. The procedures described in the preceding paragraphs were also used to evaluate selected nonneoplastic lesions. For further discussion of these statistical methods, refer to Haseman (1984).

Analysis of Nonneoplastic Lesion Incidences

Because all nonneoplastic lesions in this study were considered to be incidental to the cause of death or not rapidly lethal, the primary statistical analysis used was a logistic regression analysis in which nonneoplastic lesion prevalence was modeled as a logistic function of chemical exposure and time. For lesions detected at the interim evaluation, the Fisher exact test, a procedure based on the overall proportion of affected animals, was used.

Analysis of Continuous Variables

Average severity values were analyzed for significance with the Mann-Whitney U test (Hollander and Wolfe, 1973).

Historical Control Data

Although the concurrent control group is always the first and most appropriate control group used for evaluation, historical control data can be helpful in the overall assessment of neoplasm incidence in certain instances. Consequently, neoplasm incidences from the NTP historical control database, which is updated yearly, are included in the NTP reports for neoplasms appearing to show compound-related effects.

QUALITY ASSURANCE METHODS

The studies were conducted in compliance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). In addition, as records from the studies were submitted to the NTP Archives, these studies were audited retrospectively by an independent quality assurance contractor. Separate audits covered completeness and accuracy of the pathology data, pathology specimens, final pathology tables, and a draft of this NTP Technical Report. Audit procedures and findings are presented in the reports and are on file at NIEHS. The audit findings were reviewed and assessed by NTP staff, so all comments had been resolved or were otherwise addressed during the preparation of this Technical Report.

GENETIC TOXICOLOGY

The genetic toxicity of ethylbenzene was assessed by testing the ability of the chemical to induce mutations in various strains of *Salmonella typhimurium*, mutations in L5178Y mouse lymphoma cells, sister chromatid exchanges and chromosomal aberrations in cultured Chinese hamster ovary cells, and increases in the frequency of micronucleated erythrocytes in mouse peripheral blood. The protocols for these studies and the results are given in Appendix E.

The genetic toxicity studies of ethylbenzene are part of a larger effort by the NTP to develop a database that would permit the evaluation of carcinogenicity in experimental animals from the molecular structure and the effects of the chemical in short-term *in vitro* and *in vivo* genetic toxicity tests. These genetic toxicity tests were originally developed to study mechanisms of chemical-induced DNA damage and to predict carcinogenicity in animals, based on the electrophilicity theory of chemical mutagenesis and the somatic mutation theory of cancer (Miller and Miller, 1977; Straus, 1981; Crawford, 1985).

There is a strong correlation between a chemical's potential electrophilicity (structural alert to DNA reactivity), mutagenicity in *Salmonella*, and carcinogenicity in rodents. The combination of electrophilicity and *Salmonella* mutagenicity is highly correlated with the induction of carcinogenicity in rats and mice and/or at multiple tissue sites (Ashby and Tennant, 1991). Other *in vitro* genetic toxicity tests correlate less well with rodent carcinogenicity (Tennant *et al.*, 1987; Zeiger *et al.*, 1990), although these other tests can provide information on the types of DNA and chromosome effects that can be induced by the chemical being investigated. Data from NTP studies show that a positive response in *Salmonella* is

the most predictive *in vitro* test for rodent carcinogenicity (89% of the *Salmonella* mutagens are rodent carcinogens) and that there is no complementarity among the *in vitro* genetic toxicity tests. That is, no battery of tests that included the *Salmonella* test improved the predictivity of the *Salmonella* test alone.

The predictivity for carcinogenicity of a positive response in bone marrow chromosome aberration or micronucleus tests appears to be less than the *Salmonella* test (Shelby *et al.*, 1993; Shelby and Witt, 1995). Positive responses in long-term peripheral blood micronucleus tests have not been formally evaluated for their predictivity for rodent carcinogenicity. However, because of the theoretical and observed associations between induced genetic damage and adverse effects in somatic and germ cells, the determination of *in vivo* genetic effects is important to the overall understanding of the risks associated with exposure to a particular chemical.

TABLE 1

Experimental Design and Materials and Methods in the 2-Year Inhalation Studies of Ethylbenzene

Study Laboratory

IIT Research Institute (Chicago, IL)

Strain and Species

Rats: F344/N Mice: B6C3F₁

Animal Source Simonsen Laboratories, Inc. (Gilroy, CA)

Time Held Before Studies Rats: 13 days Mice: 11 days

Average Age When Studies Began Rats: 6 weeks Mice: 6 weeks

Date of First Exposure

Rats: 7 March 1990 Mice: 5 March 1990

Duration of Exposure

Rats: 5 days per week for 104 weeks Mice: 5 days per week for 103 weeks

Date of Last Exposure

Rats: 28 February 1992 Mice: 21 February 1992

Necropsy Dates

Rats: 9-11 March 1992 Mice: 2-5 March 1992

Average Age at Necropsy

Rats: 111 weeks Mice: 110 weeks

Size of Study Groups

50 males and 50 females

Method of Distribution

Animals were distributed randomly into groups of approximately equal initial mean body weights.

Animals per Cage

1

Method of Animal Identification

Tail tattoo

Diet

NIH-07 open formula pelleted diet (Zeigler Brothers Inc., Gardners, PA), available ad libitum

Water Distribution

Untreated coarse-filtered City of Chicago drinking water provided via automatic watering system (Edstrom Industries, Waterford, WI), available ad libitum

TABLE 1

Experimental Design and Materials and Methods in the 2-Year Inhalation Studies of Ethylbenzene (continued)

Cages

Rats: Models R-16 and R-20 (males) and models R-20 and R-24 (females) stainless steel inhalation cages (Lab Products Inc., Maywood, NJ), rotated weekly

Mice: Model M-40 stainless steel inhalation cages (Lab Products Inc., Maywood, NJ), rotated weekly

Cage Board

Techsorb® (Shepherd Specialty Papers Inc., Kalamazoo, MI)

Chamber Air Supply Filters

Coarse prefilter, activated carbon absorber, and HEPA filter (R & R Equipment Sales, Rosemont, IL)

Inhalation Chambers

Model H-2000[®] 2 m³ stainless steel (Lab Products Inc., Maywood, NJ)

Racks

Stainless steel (Lab Products Inc., Maywood, NJ)

Chamber Environment

Temperature: 21° to 28° C (rats) 21° to 27° C (mice) Relative humidity: 37% to 76% (rats) 32% to 72% (mice) Fluorescent light: 12 hours/day Chamber air flow: 500 ± 66 L/minute

Exposure Concentrations

0, 75, 250, or 750 ppm

Type and Frequency of Observation

Observed twice daily; clinical findings recorded approximately monthly; body weights recorded initially, weekly for the first 13 weeks, at week 16, monthly through the end of exposure, and at study termination.

Method of Sacrifice

CO₂ asphyxiation

Necropsy

Necropsy performed on all animals.

Histopathology

Complete histopathologic examinations were performed on all chamber control and exposed rats and mice surviving to the end of the study as well as on animals that died early. In addition to gross lesions and tissue masses, the tissues examined included: adrenal gland, blood vessel (aorta), bone and marrow, brain, clitoral gland, esophagus, gallbladder (mice), heart, large intestine (cecum, colon, and rectum), small intestine (duodenum, jejunum, and ileum), kidney, larynx, liver, lung, lymph nodes (bronchial, mandibular, mesenteric, and mediastinal), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus.

RESULTS

RATS

Survival

Estimates of 2-year survival probabilities for male and female rats are shown in Table 2 and in the Kaplan-Meier survival curves (Figure 2). Survival of male rats in the 750 ppm group was significantly less than that of the chamber controls. The survival of male rats followed a negative trend, decreasing with increasing dose.

Body Weights and Clinical Findings

Mean body weights of 250 and 750 ppm males were generally less than those of the chamber controls from week 20 until the end of the study (Figure 3; Tables 3 and 4). The mean body weights of exposed groups of females were generally less than those of the chamber controls during the second year of the study. No clinical findings were attributed to ethylbenzene exposure.

TABLE 2 Survival of Rats in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ppm	750 ppm
Male				
Animals initially in study	50	50	50	50
Moribund	28	20	26	26
Natural deaths	7	16	11	22
Animals surviving to study termination	15	14	13	2
Percent probability of survival at the end of the study		28	26	4
Mean survival (days) ^b	651	639	651	604
Survival analysis ^c	P< 0.001	P=0.888	P= 0.953	P< 0.001
Female				
Animals initially in study	50	50	50	50
Missing ^d	0	0	0	1
Moribund	7	14	8	6
Natural deaths	12	5	8	8
Animals surviving to study termination	31 ^e	31	34	35
Percent probability of survival at the end of the study	62	62	68	72
Mean survival (days)	661	690	696	706
Survival analysis	P=0.248N	P=1.000N	P=0.620N	P=0.326N

^a Kaplan-Meier determinations

^b Mean of all deaths (uncensored, censored, and terminal sacrifice)

^c The result of the life table trend test (Tarone, 1975) is in the chamber control column, and the results of the life table pairwise comparisons (Cox, 1972) with the chamber controls are in the exposed group columns. A negative trend or lower mortality in an exposure group is indicated by **N**.

^d Censored from survival analyses

^e Includes one animal that died during the last week of the study




FIGURE 2 Kaplan-Meier Survival Curves for Male and Female Rats Exposed to Ethylbenzene by Inhalation for 2 Years




FIGURE 3 Growth Curves for Male and Female Rats Exposed to Ethylbenzene by Inhalation for 2 Years

 TABLE 3

 Mean Body Weights and Survival of Male Rats in the 2-Year Inhalation Study of Ethylbenzene

Weeks	Chambe	r Control	75 ppm				250 ppm			750 ppm	
on	Av. Wt.	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	124	50	124	100	50	122	98	50	121	98	50
2	161	50	158	99	50	154	96	50	151	94	50
3	193	50	192	99	50	186	96	50	180	93	50
4	223	50	218	98	50	214	96	50	209	94	50
5	247	50	242	98	50	238	96	50	233	95	50
6	267	50	263	98	50	257	96	50	256	96	50
7	282	50	276	98	50	274	97	50	270	96	50
8	300	50	295	99	50	290	97	50	286	96	50
9	315	50	309	98	50	303	96	50	299	95	50
10	328	50	322	98	50	315	96	50	313	95	50
11	339	50	333	98	50	328	97	50	326	96	50
12	351	50	344	98	50	338	97	50	336	96	50
13	361	50	354	98	50	344	95	50	345	96	50
16	384	50	376	98	50	369	96	50	368	96	50
20	414	50	400	97	50	392	95	50	391	94	50
24	431	50	415	96	50	404	94	50	407	95	50
28	444	50	430	97	50	415	94	50	421	95	50
32	460	50	444	97	50	430	94	50	433	94	50
36	470	50	456	97	49	441	94	50	443	94	50
40	478	50	465	97	49	450	94	49	450	94	50
44	483	50	469	97	49	455	94	49	462	96	50
48	400	50	403	97	48	461	94 94	49	464	95	50
52	493	49	484	98	47	467	95	49	465	94	50
56	495	49	488	99	47	407	95	49	469	95	48
60	506	48	400	98	47	479	95	49	403	94	40
64	507	48	495	98	46	480	95	48	476	94	47
68	506	48	496	98	46	482	95	40	475	94 94	47
72	503	46	496	99	40	482	97	46	475	94 94	46
76	503 501	40	493	98	40	405	96	40	460	92	40
80	500	40	493	99	43	473	95	44	400	91	39
84	493	43	432	97	43	466	95 95	43	434	87	35
88	490	36	400	98	35	400	97	36	423	90	23
92	490	33	478	101	33 27	474	97	33	442	88	20
92 96	475	26	460	98	25	409	99 92	33 30	418	85	20 12
90 100	467	20	407	98 97	20	443	92 90	30 24	380	8J 81	7
100	457	15	432	97	20 14	420	94	14	417	91	2
104	457	15	445	57	14	431	54	14	417	51	2
Mean for	weeks										
1-13	269		264	98		259	96		256	95	
14-52	455		441	97		428	94		430	95	
53-104	491		481	98		466	95		444	90	

 TABLE 4

 Mean Body Weights and Survival of Female Rats in the 2-Year Inhalation Study of Ethylbenzene

Weeks	Chambe	Chamber Control 75 ppm		250 ppm			750 ppm				
on	Av. Wt.	No. of	Av. Wt	. Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)		Survivors
1	104	50	100	97	50	104	100	50	102	98	50
2	122	50	119	98	50	119	98	50	116	96	50
3	135	50	134	99	50	133	99	50	131	97	50
4	149	49	146	98	50	145	97	50	144	96	50
5	158	49	157	99	50	156	99	50	154	98	50
6	168	49	166	98	50	164	97	50	161	96	50
7	173	49	172	99	50	169	98	50	170	98	50
8	179	49	176	98	50	173	97	50	174	98	50
9	185	49	180	98	50	179	97	50	180	98	50
10	190	49	185	98	50	184	97	50	185	98	50
11	194	49	190	98	50	188	97	50	188	97	50
12	198	49	193	98	50	189	96	50	192	97	50
13	201	49	196	98	50	194	97	50	192	97	50
16	210	49	206	98	50	204	97	50	206	98	50
20	220	48	213	97	50	210	96	50	215	98	50
24	225	48	219	97	50 50	210	97	50 50	222	99	50 50
24	223	48	215	98	50 50	226	98	50 50	229	99	50 50
32	247	40	237	96	50 50	234	95	50 50	237	96	50 50
36	257	47	245	95	50 50	243	94	50 50	237	96	50 50
30 40	266	47	245	95 96	50 50	243	94 95	50 50	240	90 95	50 50
40	200	47	255	90 94	50 50	262	95 95	50 50	252	93 92	50 50
44	270	47	200	94 94	50 50	262	93 94	50 50	269	92 94	50 50
40 52	287	40	270	94 95	50 50	282	94 95	50 50	209	94 95	50 50
52 56	306	40	201	95 95	50 50	282	93 93	50 50	283	95 94	50 50
50 60	312	40	290	95 94	50 49	285	93 94	30 49	200	94 95	50 50
	312					294 301			296		50 50
64		46	300 302	94 93	49	301	94	49		95	
68 79	324	46			48		94	48	311	96	48
72	328	44	305	93	47	308	94	47	314	96	48
76	336	43	309	92	46	314	94	46	317	94	47
80	340	43	317	93	45	318	94	46	320	94	47
84	340	43	319	94	45	323	95	46	322	95	47
88	347	43	329	95	41	330	95	45	332	96	46
92	343	42	326	95	40	333	97	44	328	96	45
96	347	37	327	94	37	329	95	40	329	95	42
100	347	34	327	94	36	325	94	36	326	94	41
104	334	32	320	96	34	324	97	34	325	97	35
Mean for	weeks										
1-13	166		162	98		161	97		161	97	
14-52	252		241	96		240	95		241	96	
53-104	333		313	94		315	95		316	95	
101	000		010			010	55		010	55	

Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of mononuclear cell leukemia as well as neoplasms and/or nonneoplastic lesions of the kidney, testis, and other organs. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analysis of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendix A for male rats and Appendix B for female rats.

Kidney: In male rats exposed to 750 ppm, the incidences of renal tubule proliferative lesions were significantly increased relative to those in the chamber control group (Tables 5 and A3). The incidences of renal tubule adenoma and adenoma or carcinoma (combined) in this group were significantly greater than the chamber control group incidences. Renal tubule carcinomas were found in four exposed male rats, one in the 250 ppm group and three in the 750 ppm group. The incidences of renal tubule adenoma in 75 and 750 ppm males, renal tubule carcinoma in 250 and 750 ppm males, and renal tubule adenoma or carcinoma (combined) in all exposed groups of males exceeded the historical control ranges (Tables 5 and A4a). In addition, the incidence of renal tubule hyperplasia in 750 ppm males was significantly greater than that in the chamber control group (Tables 5 and A5).

Renal tubule hyperplasia, adenoma, and carcinoma constitute a morphologic and biologic continuum. Hyperplasia was a focal lesion consisting of tubules which were enlarged up to two to three times the diameter of a normal tubule and which were lined by increased numbers of epithelial cells that partially or totally filled the tubule lumen (Plate 1). Hyperplasia was considered a preneoplastic lesion and was distinguished from regenerative epithelial changes commonly seen as a component of chronic nephropathy. Renal tubule adenomas were discrete proliferative lesions, which were larger than focal hyperplasia and which tended to form more complex, usually multilobulated structures (Plate 2). Most adenomas ranged in size from 0.4 to 1 mm in size. Carcinomas were macroscopic tumors, 0.5 to 1.5 cm in size, which projected beyond the capsular surface (Plate 3). Microscopically, carcinomas were characterized by more pleomorphic cells, more prominent vascular supply, and large central areas of necrosis (Plate 4).

Initially, a single section of each kidney was examined microscopically. Because of the increased incidences of proliferative lesions in exposed males and a suggestion of a similar effect in females, additional step sections of kidney were prepared from remaining formalin-fixed tissues. Four additional sections per kidney from each male and female rat were prepared and examined. Numerous additional incidences of focal hyperplasia and adenoma were identified in the kidneys of both males and females. The incidences of these proliferative lesions observed in the extended evaluation and the combined incidences of standard and step sections are presented in Table 5. In males, there were significant increases in the incidences of renal tubule adenoma and hyperplasia in the step sections of the 750 ppm group compared to those of the chamber controls. Incidences of multiple adenomas were found in both 250 and 750 ppm males. No additional renal tubule carcinomas were identified. In the extended evaluation of females, additional incidences of renal tubule adenoma were found only in the 250 and 750 ppm groups, and the adenoma incidence in the 750 ppm group was significantly increased over chamber controls in which no adenomas were identified in either the standard or step sections. The incidence of renal tubule hyperplasia in the extended evaluation was also significantly increased in 750 ppm females.

The severities of nephropathy in 750 ppm male and all exposed female rats were significantly increased relative to chamber controls (Table 5). Nephropathy was characterized by a spectrum of changes, including dilation of renal tubules with hyaline or cellular casts, interstitial fibrosis and mononuclear inflammatory cell infiltration, foci of tubular regeneration, and transitional epithelial hyperplasia of the renal papilla. The enhanced nephropathy was more severe in males than in females, generally moderate to marked in severity, and involved most of the renal parenchyma. Several nonrenal changes which were considered secondary to the exacerbated nephropathy in 750 ppm males were significantly increased in severity relative to controls, including parathyroid gland hyperplasia, mineralization of blood vessel walls and the stomach, and fibrous osteodystrophy of bone.

	Chambo	er Control	ן 75	ppm	250) ppm	750	ррт
Male								
Number Examined Microscopically	50		50		50		50	
Single Sections (Standard Evaluation)		() h		(- .)		<i>(</i>)		<i>(</i>)
Nephropathy ^a	47	$(2.3)^{b}$	43	(2.4)	47	(2.3)	48	(3.5)**
Renal Tubule Hyperplasia	2	(3.0)	2	(2.0)	4	(1.3)	12**	(1.8)
Renal Tubule Adenoma ^c	0		3		2		4*	
Renal Tubule Adenoma ^c Renal Tubule Carcinoma ^d	0		Õ		ĩ		3	
Renal Tubule Adenoma or Carcinoma ^c	0		3		3		7**	
Step Sections (Extended Evaluation)								
Renal Tubule Hyperplasia	10		7		9		17*	
Renal Tubule Adenoma, Multiple	0		0		2		4	
Renal Tubule Adenoma (includes multiple)	3		2		7		17**	
Renal Tubule Carcinoma	0		õ		1		3	
Renal Tubule Adenoma or Carcinoma	3		2		8		18**	
Single Sections and Step Sections (Combined)	11	(2,0)	0	(9.9)	11	(9.1)	00**	(9.5)
Renal Tubule Hyperplasia	11	(2.0)	9	(2.3)	11	(2.1)	23**	(2.5)
Renal Tubule Hyperplasia, Oncocytic	2	(3.0)	3	(2.3)	0		1	(2.0)
Renal Tubule Adenoma, Multiple	0		0		2		4	
Renal Tubule Adenoma (includes multiple)	3		5		7		20**	
Renal Tubule Carcinoma	0		0		1		3	
Renal Tubule Adenoma or Carcinoma	3		5		8		21**	
Oncocytoma	0		1		1		2	
Female								
Number Examined Microscopically	50		50		50		49	
Single Sections (Standard Evaluation)								
Nephropathy	38	(1.3)	42	(1.6)*	43	(1.7)**	46	(2.3)**
Renal Tubule Hyperplasia	0	()	12	(1.0)	3	(2.3)	3	(1.3)
Renal Tubule Adenoma	0		0	. ,	0		1	. ,
Step Sections (Extended Evaluation) Renal Tubule Hyperplasia	1		1		1		8*	
ivenar i ubute riyperpiasia	1		1		1		0	
Renal Tubule Adenoma	0		0		1		7*	
ingle Sections and Step Sections (Combined)								
Renal Tubule Hyperplasia	1	(1.0)	2	(1.0)	4	(2.2)	10**	(1.8)
	_					, ,		
Renal Tubule Adenoma	0		0		1		8**	

TABLE 5 Incidences of Neoplasms and Nonneoplastic Lesions of the Kidney in Rats in the 2-Year Inhalation Study of Ethylbenzene

Significantly different (P≤0.05) from the chamber control group by the logistic regression test (incidence) or by the Mann-Whitney U test (severity) ** P≤0.01

а Number of animals with lesion

b Average severity grade of lesions in affected animals: 1= minimal; 2= mild; 3= moderate; 4= marked

с Historical incidence for 2-year inhalation studies with chamber control groups (mean \pm standard deviation): 6/652 (0.9% \pm 1.3%); range, 0%-4%

d Historical incidence: 0/652 *Testis*: The incidence of interstitial cell adenoma in 750 ppm males was significantly greater than that in the chamber control group and slightly exceeded the historical control range; the incidence of bilateral testicular adenoma was also significantly increased in 750 ppm males (Tables 6, A3, and A4b). This common neoplasm in male F344/N rats is composed of nodular aggregates of large polyhedral cells with

foamy or eosinophilic cytoplasm that extend between and cause compression of the surrounding seminiferous tubules. This neoplasm will develop in nearly all male rats if they are allowed to complete their natural life span; ethylbenzene appeared to enhance its development. The incidence of interstitial cell hyperplasia in 750 ppm males was significantly decreased.

TABLE 6

Incidences of Neoplasms and Nonneoplastic Lesions of the Testis in Male Rats in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ррт	750 ppm
Number Examined Microscopically	50 b	50	50	50
Interstitial Cell Hyperplasia ^a	14 (1.5) ^b	19 (1.2)	12 (1.3)	8* (1.1)
Bilateral Adenoma				
Overall rate ^c	27/50 (54%)	23/50 (46%)	32/50 (64%)	40/50 (80%)
Adjusted rate ^d	96.0%	91.0%	96.5%	100.0%
Terminal rate ^e	14/15 (93%)	12/14 (86%)	12/13 (92%)	2/2 (100%)
First incidence (days)	608	538	590	500
Logistic regression test ^f	P< 0.001	P=0.313N	P = 0.177	P< 0.001
Adenoma ^g				
Overall rate	36/50 (72%)	33/50 (66%)	40/50 (80%)	44/50 (88%)
Adjusted rate	100.0%	100.0%	100.0%	100.0%
Terminal rate	15/15 (100%)	14/14 (100%)	13/13 (100%)	2/2 (100%)
First incidence (days)	497	538	420	483
Logistic regression test	P< 0.001	P = 0.404N	P = 0.194	P = 0.001

* Significantly different (P<0.05) from the chamber control group by the logistic regression test

^a Number of animals with lesion

^b Average severity grade of lesions in affected animals: 1= minimal; 2= mild; 3= moderate; 4= marked

^c Number of animals with neoplasm per number of animals with testis examined microscopically

^d Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

^e Observed incidence in animals surviving until the end of the study

^f In the chamber control column are the P values associated with the trend test. In the exposed group columns are the P values corresponding to the pairwise comparisons between the chamber controls and that exposed group. The logistic regression test regards neoplasms in animals dying prior to terminal kill as nonfatal. A lower incidence in an exposure group is indicated by N.

^g Historical incidence for 2-year inhalation studies with chamber control groups (mean ± standard deviation): 450/655 (68.7% ± 8.7%); range, 54%-83%

Other organs: The incidences of several nonneoplastic lesions were significantly greater in the 750 ppm males than in chamber controls (Table A5). Incidences of edema (chamber control, 1/50; 75 ppm, 0/50; 250 ppm, 0/50; 750 ppm, 6/50), congestion (1/50, 2/50, 0/50, 6/50), and hemorrhage (0/50, 2/50, 1/50, 8/50) in the lungs as well as hemorrhage in mesenteric (3/49, 5/50, 4/50, 8/50) and renal (0/9, 0/8, 1/9, 8/14) lymph nodes were slightly increased. These circulatory lesions were considered to be agonal changes in moribund animals and not directly related to chemical toxicity. The incidence of cystic degeneration of the liver was also increased in 750 ppm males (15/50, 12/50, 19/50, 30/49); the biologic significance of this increase in the absence of other hepatotoxic changes is unclear.

Compared to the chamber control group, the incidences of prostate gland inflammation in all exposed groups of males were significantly increased (11/50, 29/50, 22/50, 25/50; Table A5). This inflammatory change consisted of infiltration by predominantly mononuclear inflammatory cells into glandular acini

and interstitium, increased interstitial fibrosis, and loss of secretory material in affected areas. Relative to chamber controls, males exposed to 75 or 750 ppm exhibited increased incidences of hyperplasia of the bone marrow characterized by hypercellularity due to increased numbers of erythroid and myeloid precursor cells (7/49, 16/49, 9/50, 19/50). The relationship of these changes to ethylbenzene exposure is uncertain due to the lack of clear concentration-dependent responses.

Mononuclear cell leukemia: The incidence of mononuclear cell leukemia was decreased in 750 ppm males (27/50, 26/50, 32/50, 9/50; Table A3). While this decrease was statistically significant by logistic regression, it was not significant by life table analysis, the more appropriate test for this generally fatal neoplasm. This decrease was due in large part to the reduced survival in the 750 ppm group as a result of nephropathy and, therefore, was not considered to be related to ethylbenzene exposure.

MICE

Survival

Estimates of 2-year survival probabilities for male and female mice are shown in Table 7 and in the Kaplan-Meier survival curves (Figure 4). Survival of exposed groups of male and female mice was similar to that of the chamber controls.

Body Weights and Clinical Findings

Mean body weights of female mice exposed to 75 ppm were greater than those of the chamber controls from week 72 until the end of the study; mean body weights of 750 ppm females were generally less than those of the chamber controls from week 24 through week 68 but were similar to those of the chamber controls from week 72 until the end of the study (Tables 8 and 9; Figure 5). No clinical findings were attributed to ethylbenzene exposure.

 TABLE 7

 Survival of Mice in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ppm	750 ppm
Male				
Animals initially in study	50	50	50	50
Accidental deaths ^a	1	0	0	1
Aoribund	6	2	5	6
Vatural deaths	15	12	13	13
Animals surviving to study termination	28	36	32 ^d	30
Percent probability of survival at the end of the study ^D	57	72	64	61
Mean survival (days) ^c	636	684	692	665
Survival analysis ^e	P=0.975	P=0.177N	P=0.459N	P=0.673N
Female				
Animals initially in study	50	50	50	50
Accidental deaths ^a	1	0	1	0
Aoribund	5	6	1	4
Vatural deaths	9	6	8	9
Terminal sacrifice	35 ^d	38	40	37
Percent probability of survival at the end of the study	71	76	82	74
Mean survival (days)	689	700	701	692
urvival analysis	P = 0.995N	P = 0.762N	P=0.304N	P=0.886N

^a Censored from survival analyses

^b Kaplan-Meier determinations

^c Mean of all deaths (uncensored, censored, and terminal sacrifice)

^d Includes one animal that died during the last week of the study

^e The result of the life table trend test (Tarone, 1975) is in the chamber control column, and the results of the life table pairwise comparisons (Cox, 1972) with the chamber controls are in the exposed group columns. A negative trend or lower mortality in an exposure group is indicated by N.




FIGURE 4 Kaplan-Meier survival Curves for Male and Female Mice Exposed to Ethylbenzene by Inhalation for 2 Years

 TABLE 8

 Mean Body Weights and Survival of Male Mice in the 2-Year Inhalation Study of Ethylbenzene

Weeks	Chambe	er Control		75 ppm			250 ppm			750 ppm	
on	Av. Wt.	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	23.0	50	22.3	97	50	22.9	100	50	22.4	97	50
2	24.9	50	24.2	97	50	25.0	100	50	25.0	100	50
3	26.6	50	26.2	99	50	26.9	101	50	27.3	103	50
4	27.8	50	27.6	99	50	28.1	101	50	28.2	101	50
5	29.0	48	28.8	99	50	29.4	101	50	29.3	101	50
6	30.2	48	30.4	101	50	30.2	100	50	30.1	100	50
7	30.9	48	30.3	98	50	30.7	99	50	31.5	102	50
8	31.6	48	31.5	100	50	31.8	101	50	31.7	100	50
9	32.0	48	32.2	100	50	32.2	101	50	32.3	100	50
10	32.3	48	32.2	100	50	32.4	100	50	33.5	101	50
10	32.8	48	33.5	100	50	33.4	100	50	33.4	104	50
12	33.6	48	33.8	102	50 50	34.0	102	50	34.1	102	50 50
12	34.1	48	34.9	101	50 50	34.8	101	50 50	34.6	102	50 50
16	35.7	48	34.5	102	50 50	36.9	102	50 50	36.6	102	50 50
20	33.7	48	30.4	102	50 50	30.9	103	50 50	30.0 39.0	103	50 50
20 24	38.0 38.7	48	30.4 40.1	101	50 50	39.3 40.2	103	50 50	39.0 39.7	103	50 50
28	40.4	48	41.4	103	50	41.6	103	50	40.2	100	49
32	41.6	47	44.0	106	50	43.5	105	50	42.5	102	49
36	42.8	47	44.5	104	50	45.0	105	50	44.2	103	49
40	43.9	47	45.3	103	50	45.2	103	50	45.1	103	48
44	45.9	46	46.4	101	50	46.1	100	50	45.6	99	48
48	45.6	46	47.4	104	50	46.9	103	50	47.0	103	48
52	46.7	46	48.5	104	50	47.6	102	50	47.2	101	48
56	47.1	46	47.8	102	48	47.4	101	50	46.7	99	48
60	47.2	46	47.8	101	48	48.6	103	50	46.8	99	48
64	48.1	46	48.6	101	48	48.5	101	50	47.5	99	46
68	47.7	45	48.5	102	48	48.4	102	50	47.9	100	46
72	47.2	45	48.1	102	47	48.5	103	49	48.2	102	45
76	47.0	43	47.7	102	46	48.1	102	48	47.4	101	44
80	46.2	41	48.3	105	44	48.3	105	48	47.2	102	44
84	45.7	40	48.3	106	42	48.6	106	43	48.0	105	42
88	47.9	35	47.9	100	41	48.7	102	41	47.6	99	41
92	47.1	33	46.9	100	41	47.5	101	41	47.7	101	39
96	46.8	31	47.2	101	39	46.8	100	40	46.6	100	35
100	46.7	31	46.6	100	38	45.7	98	36	46.0	99	32
104	45.0	29	44.8	100	37	45.4	101	33	44.0	98	31
Mean for	wooks										
Mean for 1-13	weeкs 29.9		29.8	100		30.1	101		30.3	101	
14-52	41.9		43.2	103		43.2	103		42.7	102	
53-104	46.9		47.6	101		47.7	102		47.0	100	

 TABLE 9

 Mean Body Weights and Survival of Female Mice in the 2-Year Inhalation Study of Ethylbenzene

Weeks	Chambe	er Control		75 ppm			250 ppr	n		750 ppm	
on	Av. Wt.	No. of	Av. Wt.	Wt. (% o	f No. of	Av. Wt.	Wt. (% o	f No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	18.5	50	18.6	101	50	18.6	101	50	18.0	97	50
2	20.1	50	19.9	99	50	20.0	100	50	19.5	97	49
3	21.4	50	20.7	97	50	21.1	99	50	21.4	100	49
4	22.4	50	21.6	96	50	22.3	100	50	22.5	100	49
5	23.3	50	22.8	98	50	23.2	100	50	23.5	101	49
6	24.3	50	23.4	96	50	24.2	100	50	23.8	98	49
7	24.4	50	24.0	98	50	24.4	100	50	24.5	100	49
8	25.1	50	24.6	98	50	24.9	99	50	25.1	100	49
9	26.0	50	25.7	99	50	25.6	99	50	26.1	100	49
10	26.0	50	25.4	98	50	25.9	100	50	26.1	100	49
11	26.7	50	26.2	98	50	26.0	97	50	27.0	101	49
12	26.6	50	26.5	100	50	26.7	100	50	26.6	100	49
13	27.3	50	27.2	100	50	26.7	98	49	27.0	99	49
16	28.4	50	28.0	99	50	27.3	96	49	28.8	101	49
20	31.0	50	29.9	97	50	28.8	93	49	30.5	98	49
24	32.0	50	31.2	98	50	29.9	93	49	29.8	93	49
28	33.1	50	32.9	99	50	30.9	93	49	30.5	92	48
32	34.1	49	33.8	99	50	32.5	95	49	31.7	93	48
36	35.7	49	35.5	99	50	35.3	99	49	33.1	93	48
40	36.3	49	36.7	101	50	35.8	99	49	33.4	92	48
44	39.1	49	38.4	98	49	36.8	94	49	35.2	90	48
48	39.8	49	40.0	101	49	40.0	101	49	37.2	94	48
52	40.9	49	41.8	102	49	41.2	101	49	39.4	96	48
56	42.6	49	43.6	102	49	43.0	101	49	39.4	93	48
60	43.1	49	44.4	103	49	43.7	101	49	40.7	94	48
64	44.6	48	45.2	101	49	44.6	100	48	40.5	91	48
68	46.3	48	47.3	102	49	46.5	100	47	43.2	93	48
72	45.6	48	48.6	107	48	47.3	104	47	44.3	97	48
76	46.0	47	48.1	105	48	47.8	104	47	44.4	97	48
80	46.0	47	49.0	107	48	49.5	108	47	44.9	98	48
84	45.8	45	49.8	109	46	49.5	108	47	45.0	98	47
88	45.8	43	50.8	111	44	49.0	107	47	45.2	99	46
92	47.0	40	51.8	110	43	49.9	106	47	45.6	97	45
96	47.0	40	50.3	107	42	49.0	104	46	45.7	97	44
100	47.0	38	49.9	106	42	47.6	101	44	46.4	99	43
104	45.9	36	49.9	109	38	45.2	99	40	45.5	99	37
Maan f	waaka										
Mean for			00.0	00		00.0	00		00.0	100	
1-13	24.0		23.6	98		23.8	99 07		23.9	100	
14-52	35.0		34.8	99 100		33.9	97 102		33.0	94	
53-104	45.6		48.4	106		47.1	103		43.9	96	




FIGURE 5 Growth Curves for Male and Female Mice Exposed to Ethylbenzene by Inhalation for 2 Years

Pathology and Statistical Analysis

This section describes the statistically significant or biologically noteworthy changes in the incidences of neoplasms and/or nonneoplastic lesions of the lung, liver, and other organs. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analysis of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendix C for male mice and Appendix D for female mice.

Lung: Incidences of alveolar/bronchiolar adenoma and alveolar/ bronchiolar adenoma or carcinoma (combined) in males increased with a positive trend (Tables 10 and C3). In 750 ppm males, the incidences of alveolar/bronchiolar adenoma and

alveolar/bronchiolar adenoma or carcinoma (combined) were significantly greater than those in the chamber control group but were within the historical control ranges (Tables 10, C3, and C4). In 750 ppm females, the incidence of alveolar/ bronchiolar adenoma was greater than that in the chamber control group. This difference was not significant, but the incidence exceeded the historical control range (Tables 10, D3, and D4a). Alveolar/bronchiolar neoplasms were nodular proliferations within the lung parenchyma which caused variable compression depending on size (Plate 5). Adenomas were typically well circumscribed nodules composed of monomorphic cuboidal cells arranged in solid or papillary patterns. In carcinomas, the borders were less distinct and the neoplastic cells were cuboidal to columnar in shape and exhibited greater cytologic atypia.

 TABLE 10

 Incidences of Neoplasms and Nonneoplastic Lesions of the Lung in Mice in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Contro	l 75 ppm	250 ppm	750 ppm
Male				
Number Examined Microscopically	50	50	50	50
Alveolar Epithelium, Hyperplasia ^a	1 (1.0) ^b	5 (2.6)	2 (1.5)	4 (2.0)
Alveolar Epithelium, Metaplasia	0	1 (1.0)	2 (1.0)	6* (1.2)
Alveolar/bronchiolar Adenoma ^c	5	9	10	16**
Alveolar/bronchiolar Carcinoma	2	1	5	3
Alveolar/bronchiolar Adenoma or Carcinoma ^d	7	10	15	19**
Female				
Number Examined Microscopically	50	50	49	50
Alveolar Epithelium, Hyperplasia	0	1 (2.0)	3 (2.0)	1 (3.0)
Alveolar Epithelium, Metaplasia	0	0	0	1 (2.0)
Alveolar/bronchiolar Adenoma ^e	4	4	5	8
Alveolar/bronchiolar Adenoma or Carcinoma ^f	4	6	5	8

* Significantly different ($P \le 0.05$) from the chamber control group by the logistic regression test

** (P < 0.01)

^a Number of animals with lesion

^b Average severity grade of lesions in affected animals: 1= minimal; 2= mild; 3= moderate; 4= marked

^c Historical incidence for 2-year inhalation studies with chamber control groups (mean ± standard deviation): 141/947 (14.9% ± 7.0%); range, 6%-36%
 ^d Userial incidence 105 (047 (01 70) = 0.00) mean = 100 (400)

^d Historical incidence: 205/947 (21.7% ± 8.0%); range, 10%-42%

^e Historical incidence: 61/939 ($6.5\% \pm 3.2\%$); range, 0%-14%

^f Historical incidence: 97/939 (10.3% ± 3.7%); range, 0%-16%

Another proliferative change in the lung was observed only in exposed mice and was diagnosed as alveolar epithelial metaplasia. In males, the incidence of this lesion increased with increasing exposure concentration and was significantly increased in the 750 ppm group (Tables 10 and C5). Alveolar epithelial metaplasia was also observed in one 750 ppm female. Metaplasia was characterized by the presence of cells morphologically similar to bronchiolar epithelial cells lining the alveolar spaces adjacent to terminal bronchioles (Plate 6).

The incidences of hepatocellular adenoma Liver: and adenoma or carcinoma (combined) in females occurred with a positive trend (Table D3). These incidences in 750 ppm females were significantly greater than those in the chamber controls but did not exceed the historical control ranges (Tables 11, D3, and D4b). Although hepatocellular carcinomas also occurred with a positive trend, incidences in exposed groups were not significantly greater than in chamber controls and did not exceed historical control ranges. Multiple adenomas were found in all exposed groups of females, and multiple carcinomas were found in two 750 ppm females, but multiple liver neoplasms were not found in chamber control females. Hepatocellular adenomas consisted of nodules of hepatocytes which compressed adjacent liver parenchyma and lacked the normal lobular and sinusoidal pattern. Hepatocellular carcinomas were large masses composed of anaplastic hepatocytes forming solid sheets or trabecular patterns.

In addition to liver neoplasms, the incidence of eosinophilic foci in the liver was significantly greater in 750 ppm females than in chamber controls (Tables 11 and D5). This lesion, composed of focal collections of cells, which have altered staining characteristics and which blend into surrounding hepatic cords with little or no compression, is considered to be a precursor to hepatocellular neoplasia.

A spectrum of nonneoplastic liver changes related to ethylbenzene exposure in male mice included syncytial alteration of hepatocytes, hepatocellular hypertrophy, and hepatocyte necrosis (Tables 11 and C5). These changes were minimal to mild in severity. Syncytial alteration was seen in all groups of exposed males, with concentration-dependent increases in incidence. This change consisted of the presence of greatly enlarged hepatocytes containing multiple nuclei, generally five or more, either randomly scattered throughout the liver lobule or with a tendency to cluster in centrilobular areas (Plate 7). Hypertrophy of hepatocytes occurred in the centrilobular zones of 750 ppm males and was characterized by cells with increased amounts of cytoplasm and enlarged nuclei. Syncytial alteration and hypertrophy frequently occurred in the same animal. Hepatocellular necrosis was evident as random single cell necrosis, generally of hypertrophied cells.

Other organs: Significantly increased incidences of hyperplasia of the pituitary gland pars distalis were limited to 250 and 750 ppm females (chamber control, 10/48; 75 ppm, 12/49; 250 ppm, 23/47; 750 ppm, 22/49; Table D5). This hyperplasia was seen as focal, poorly delineated, monomorphic increases of cells which had no compressive features or altered arrangement. Positive trends in the incidences of thyroid follicular cell hyperplasia occurred in both males (21/50, 21/50, 29/50, 32/50; Table C5) and females (18/50, 23/50, 25/50, 35/50; Table D5), with significant increases in incidences relative to chamber controls in 750 ppm males and females. Thyroid hyperplasia was typically a focal noncompressive proliferation with simple papillary infoldings of follicular epithelial cells. There were no corresponding increases in the incidences of adenomas of either the pituitary gland or thyroid gland (Tables C1 and D1).

	Chambe	er Control	75 j	ppm	250) ppm	750 ppm
Male							
Number Examined Microscopically	50		50		50		50
Hepatocyte, Hypertrophy ^a	1	$(1.0)^{b}$	0		0		17** (1.1)
Hepatocyte, Necrosis	1	(1.0)	1	(2.0)	3	(1.3)	10** (1.8)
Hepatocyte, Syncytial Alteration	0		5	(1.0)	8*	* (1.4)	23** (1.1)
Female							
Number Examined Microscopically	50		50		50		50
Eosinophilic Focus	5	(1.8)	7	(1.4)	6	(1.5)	22** (2.0)
Hepatocellular Adenoma, Multiple	0		1		3		4
Hepatocellular Adenoma (includes multiple) ^c	6		9		12		16*
Hepatocellular Carcinoma, Multiple	0		0		0		2
Hepatocellular Carcinoma (includes multiple)	7		4		3		12
Hepatocellular Adenoma or Carcinoma ^d	13		12		15		25*

TABLE 11 Incidences of Neoplasms and Nonneoplastic Lesions of the Liver in Mice in the 2-Year Inhalation Study of Ethylbenzene

* Significantly different (P \le 0.05) from the chamber control group by the logistic regression test

** ($P \le 0.01$)

^a Number of animals with lesion

^b Average severity grade of lesions in affected animals: 1= minimal; 2= mild; 3= moderate; 4= marked

^c Historical incidence for 2-year inhalation studies with chamber control groups (mean \pm standard deviation): 114/937 (12.2% \pm 9.7%);

range, 0%-40%

^d Historical incidence: 200/937 (21.3% ± 11.9%); range, 3%-54%

GENETIC TOXICOLOGY

Ethylbenzene was not mutagenic in *Salmonella typhimurium* strain TA97, TA98, TA100, or TA1535 with or without Aroclor-induced rat or hamster liver S9 (Table E1; Zeiger *et al.*, 1988). A positive response was observed with ethylbenzene in the L5178Y mouse lymphoma cell assay in the absence of S9 at the highest nonlethal dose tested (80 μ g/mL); the assay was not performed with S9 (Table E2; McGregor *et al.*, 1988). A significant amount of

cytotoxicity was noted at this dose level (relative total growth was reduced to 34% and 13% of the control level in each of two trials). No increases in sister chromatid exchanges (Table E3) or chromosomal aberrations (Table E4) were induced by ethylbenzene in cultured Chinese hamster ovary cells, with or without S9. *In vivo*, no increases in micronucleated erythrocytes were observed in peripheral blood samples from male and female mice exposed to ethylbenzene for 13 weeks by inhalation (Table E5).




Plate 1

Renal tubule hyperplasia in the kidney of a male F344/N rat exposed to 750 ppm ethylbenzene by inhalation for 2 years. The hyperplastic tubule (between arrows) consists of epithelial cells which fill the lumen. Note the changes of chronic nephropathy in the surrounding parenchyma including dilated tubules and thickened interstitium. H&E; $100\times$




Plate 2

Renal tubule adenoma in the kidney of a male F344/N rat exposed to 750 ppm ethylbenzene by inhalation for 2 years. The adenoma is just under the capsular surface and is well circumscribed and multilobulated. Note the changes of chronic nephropathy in the surrounding parenchyma including dilated tubules filled with protein casts, thickened interstitium, and focal mineralization. H&E; $35\times$




Plate 3

Renal tubule carcinoma in the kidney of a male F344/N rat exposed to 750 ppm ethylbenzene by inhalation for 2 years. The 1 cm diameter mass protrudes coutside the capsular surface and extends deep into the parenchyma near the papilla (P). Note the cystic necrosis of the center. H&E; $6\times$




Plate 4

Higher magnification of Plate 3. Irregular lobules of pleomorphic tumor cells are separated by fine septae and compress the surrounding parenchyma (arrow). Note the central necrosis of one lobule (*). H&E; $100\times$




Plate 5

Alveolar/bronchiolar adenoma in the lung of a male B6C3F₁ mouse exposed to 750 ppm ethylbenzene by inhalation for 2 years. The adenoma is well demarcated from the adjacent compressed lung parenchyma, and there is bulging of the pleural surface. H&E; $20\times$




Plate 6

Alveolar epithelial metaplasia in the lung of a male $B6C3F_1$ mouse exposed to 750 ppm ethylbenzene by inhalation for 2 years. Multiple foci of dark-staining epithelial cells (arrows) are in the alveolar spaces adjacent to one branch of a terminal bronchiole bifurcation. H&E; $85\times$




Plate 7

Syncytial alteration of hepatocytes in the liver of a male $B6C3F_1$ mouse exposed to 750 ppm ethylbenzene by inhalation for 2 years. Two large syncytial cells (arrows), each containing approximately 10 nuclei, are adjacent to a central vein. H&E; $140\times$

DISCUSSION AND CONCLUSIONS

Ethylbenzene is mainly used in the manufacture of styrene. Ethylbenzene is also a major component of mixed xylenes used as solvents in agricultural and home insecticide sprays, rubber and chemical manufacturing, and household degreasers, paints, adhesives, and rust preventives (Fishbein, 1985). Ethylbenzene has been used as an antiknock agent in aviation and motor fuels (NIOSH, 1979).

The National Institute for Occupational Safety and Health and the Occupational Safety and Health Administration nominated ethylbenzene for study because of its widespread human exposure and because of its structural similarity to benzene and toluene.

In previous studies, male and female F344/N rats and B6C3F₁ mice were exposed to ethylbenzene by inhalation for 13 weeks at concentrations of 0, 100, 250, 500, 750, or 1,000 ppm (NTP, 1992). In the current studies, male and female F344/N rats and B6C3F₁ mice were exposed to ethylbenzene by inhalation for 2 years at concentrations of 0, 75, 250, or 750 ppm.

In the 2-year study, the survival rate and the mean body weights of the 750 ppm male rats were less than those of the chamber control group after week 75 of the study. Female rats generally had higher survival rates than males, and this was probably related to the typical occurrence of nephropathy in male F344/N rats, which was enhanced by ethylbenzene exposure. The mean body weights of exposed groups of female rats were less than those of the chamber controls during the second year of the study. Survival rates of exposed male and female mice were similar to those of the respective chamber controls. Female mice exposed to 75 ppm had greater mean body weights than those of the chamber controls.

In the 13-week studies, increased absolute and relative kidney weights were observed in male rats exposed to 750 or 1,000 ppm ethylbenzene, although no accompanying histopathologic changes were seen (NTP, 1992). In the standard histopathologic evaluation of the kidney in the 2-year study, the incidence of renal tubule adenoma in the 750 ppm male rats was signifi-

cantly greater than that in the chamber control group. The incidence in 750 ppm males exceeded the NTP historical control range. An extended evaluation of the kidneys in the 2-year study identified many more adenomas. In addition, multiple renal tubule adenomas were found in the 250 and 750 ppm males. The standard evaluation and extended evaluation (combined) showed significantly increased incidences of renal tubule adenoma, renal tubule adenoma or carcinoma (combined), and renal tubule hyperplasia in 750 ppm male rats, as well as positive trends across exposure groups. No renal lesions were observed in females in the NTP 13-week study. In the standard evaluation in the 2-year study, no significant increases in incidences of renal lesions were observed in female rats. In the extended evaluation of the kidneys, the incidences of renal tubule hyperplasia and renal tubule adenoma were significantly increased in the 750 ppm female rats compared to those in the chamber controls.

Kurokawa et al. (1983) first reported that a greater incidence of rat kidney lesions was found when multiple kidney sections were examined compared with single sections. This was expected, considering the very small size of many of the tubule cell adenomas typically seen in the kidney. The NTP has compared lesions from single and multiple kidney sections and found increased incidences of renal tubule hyperplasia and renal tubule adenoma in multiple sections from male rats (Eustis et al., 1994), agreeing with the findings of Kurokawa et al. (1983). However, few additional neoplasms were identified in female rats or in male or female mice (Eustis et al., 1994). In the present studies, additional incidences of renal tubule hyperplasia and renal tubule adenoma were found in step sections from male and female rats.

Nephropathy is commonly found in aging male and, to a lesser degree, female rats; in the current study, the severities of nephropathy were increased in 750 ppm male rats and in all exposed female rat groups. In the extended evaluation of the kidneys in the 2-year study of ethylbenzene, the incidences of renal tubule hyperplasia in 750 ppm males and females were increased. Ethylbenzene may have exacerbated the age-related nephropathy development in rats or exerted toxic injury to the renal cells and induced compensatory cell replication of the renal tubule epithelium. Whether they were a direct effect of ethylbenzene or an indirect result of ethylbenzeneinduced cytotoxicity, the renal tubule lesions in male and female rats were considered exposure related. Males appeared to be more sensitive to the renal toxic effect of ethylbenzene than females, and that may

Following exposure to certain hydrocarbons, male rats develop renal tubule hyaline droplets, attributed to accumulation of $\alpha 2\mu$ -globulin in the kidney. The accumulation of $\alpha 2\mu$ -globulin is known to lead to nephropathy and renal tubule neoplasm development in male rats. This spectrum of nonneoplastic changes differs from the chronic progressive nephropathy commonly found in aging male rats (USEPA, 1991). No clear evidence of hyaline droplets was seen in the kidneys of male F344/N rats exposed to ethylbenzene for 13-weeks (NTP, 1992) or 2 years, and, thus, this proposed mechanism did not appear to contribute to the proliferative renal tubule lesions in male or female F344/N rats in the studies reported here.

account for the early deaths in 750 ppm males.

After a 6-hour inhalation exposure to ethylbenzene in male Wistar rats, the major metabolites identified in the urine were 1-phenylethanol (α-methylbenzyl alcohol), mandelic acid, phenylglyoxylic acid, phenylacetic acid, and benzoic acid. Minor metabolites included omega-hydroxyacetophenone, 1-phenyl-1,2ethanediol, acetophenone, p-hydroxyacetophenone, and phenylglyoxal. Blood metabolites were difficult to identify and measure (Engström, 1984). None of the urinary metabolites, except 1-phenylethanol, are considered ultimate carcinogens likely reactive with cellular macromolecules. Ethylbenzene is neither mutagenic nor clastogenic. Both 1- and 2-phenylethanol were negative for mutagenicity and did not induce sister chromatid exchanges in cultured human lymphocytes (NTP, 1990b; Norppa and Vainio, 1983). It is possible that in the process of metabolizing ethylbenzene to 1- and 2-phenylethanol, an epoxide intermediate is formed. A gender difference in epoxide formation may account for the differential sensitivity for neoplasia between the male and female mouse lungs.

α-Methylbenzyl alcohol (1-phenylethanol), a metabolite of ethylbenzene (Engström, 1984), has been shown to enhance nephropathy and induce renal tubule adenoma or adenocarcinoma in male F344/N rats (NTP, 1990b) but had no effect on nephropathy or renal tubule lesions in female F344/N rats. Since kidney toxicity and carcinogenicity were observed in both male and female rats in the present studies, the data suggested that the renal effect of ethylbenzene is more potent than that of α -methylbenzyl alcohol. Other metabolites, such as an epoxide or diolepoxide after ring oxidation (Engström, 1984), phenylglyoxal bearing a reactive aldehyde group, or those metabolites postulated in benzene metabolism, such as hydroquinone, benzoquinone, or benzene diolepoxide (NTP, 1986; Busby et al., 1990), may contribute to the renal toxicity and carcinogenicity of ethylbenzene. However, no reactive metabolite has been identified. Further studies to identify the active species are needed. It should be noted that neither ethylbenzene nor α-methylbenzyl alcohol is mutagenic or clastogenic.

Structurally, ethylbenzene is related to benzene and toluene (Table 12). Toluene is negative for carcinogenic activity (NTP, 1990a). Benzene is a multipotential carcinogen suppressing bone marrow cellularity and inducing leukopenia and leukemia and neoplasms in the Zymbal's gland, oral cavity, and skin in rats and Zymbal's gland, lymph gland, lung, harderian gland, preputial gland, mammary gland, ovary, forestomach, and liver in mice after gavage dosing (NTP, 1986). Benzene is metabolized to benzene oxide, benzene oxepin, benzene dihydrodiol, phenol, hydroquinone, trihydroxybenzene, catechol, benzoquinone, and trans, trans-muconaldehyde (Snyder and Hedli, 1996; Sabourin et al., 1989, 1992). The metabolites proposed for the hematotoxicity in rats are hydroquinone, benzoquinone, and trans, trans-muconaldehyde (Zhu et al., 1995), and for lung tumors in mice, the metabolite is benzene diolepoxide-2 (Busby et al., 1990). Although benzene and ethylbenzene are structurally related, the metabolites, target organs, and mechanism of action of benzene appear quite different from those of ethylbenzene.

TABLE 12

Results of Carcinogenicity and Mutagenicity Tests of Benzene, Toluene, and Ethylbenzene in Male and Female F344/N Rats and Male and Female B6C3F Mice in 2-Year Studies 1 ^a

		Carcino	genicity		Salmonella
Chemical and Route Benzene (gavage) (NTP, 1986)	Male Rat + Zymbal's gland, oral cavity, skin	Female Rat + Zymbal's gland, oral cavity	Male Mouse + Zymbal's gland, lymph gland, lung, harderian gland, preputial gland, forestomach	Female Mouse + Zymbal's gland, lymph gland, lung, harderian gland, mammary gland, ovary, forestomach,	Test Result —
Toluene (inhalation) (NTP, 1990a)	_			liver —	
Ethylbenzene (inhalation)	+ kidney, testis	+ kidney	+ lung	+ liver	

^aCarcinogenic response: + = some or clear evidence of carcinogenic activity; - = no evidence of carcinogenic activity

The increased incidence of testicular adenoma observed in male rats in the 750 ppm group was considered related to ethylbenzene exposure. This is evidenced by the finding that 92% (22/24) of the 750 ppm male rats that died between days 400 and 600 had testicular adenoma, whereas only 33% (3/9) of the chamber controls that died early had testicular adenoma. The incidence of bilateral adenoma was also increased in 750 ppm males. Testicular adenoma develops in nearly all rats in the latter part of their lives, but in inhalation studies, the incidence is low compared with those in feed and gavage studies (Haseman et al., 1997); ethylbenzene appeared to

hasten the development of testicular adenoma. How ethylbenzene accomplishes this effect is not clear. There were no testicular effects detected in the 13-week studies (NTP, 1992). α -Methylbenzyl alcohol, a metabolite of ethylbenzene, may not be involved because it inhibits testicular adenoma (NTP, 1990b).

In addition to inducing renal tubule neoplasms in rats, ethylbenzene exposure may have induced bone marrow hyperplasia characterized by hypercellularity of erythroid and myeloid precursor cells. Cragg et al. (1989) also reported that Fischer 344/N rats exposed to ethylbenzene at 782 ppm for 4 weeks had a small increase in leukocyte counts. On the other hand, ethylbenzene depressed mononuclear cell leukemia in 750 ppm males, but this was considered to be due largely to reduced survival in this group.

In the 2-year mouse studies, the incidences of alveolar epithelial metaplasia and alveolar/bronchiolar adenoma or carcinoma (combined) were significantly increased in 750 ppm male mice but not in 750 ppm female mice. Estimated differences in inhaled air volume alone (male mice have a greater ventilation volume per body weight than do female mice) could not explain the difference between males and females in their responses to ethylbenzene inhalation.

The incidence of hepatocellular adenoma or carcinoma (combined) was significantly greater in the 750 ppm group of female mice compared to that in the chamber controls. The incidence of liver eosinophilic foci was also significantly greater in the 750 ppm group of female mice. A significant increase in absolute liver weight was observed in male and female mice exposed to ethylbenzene at 750 ppm and higher in the 13-week studies (NTP, 1992). Increased absolute and relative liver weights were also reported in female B6C3F₁ mice exposed to ethylbenzene by inhalation (Cragg *et al.*, 1989). The female mouse liver appears to be more sensitive to the effects of ethylbenzene.

It is also not clear why male and female $B6C3F_1$ mice had different neoplasm responses to ethylbenzene exposure. There are little data available on which to judge why ethylbenzene affected the male and female endocrine systems differently, although an exposurerelated increase in the incidence of pituitary gland (pars distalis) hyperplasia was seen in female mice. Ethylbenzene induced an exposure-related increase in the incidences of hyperplasia in the thyroid gland of male and female mice, but there was no difference between males and females in incidence observed.

Phenylglyoxylic and mandelic acids were effective in causing brain dopamine depletion *in vitro* (Mutti and Franchini, 1987) and *in vivo* (Mutti *et al.*, 1988). On the other hand, Andersson *et al.* (1981) reported that

neurotoxic effects would disturb brain function and cause neurobehavioral and neuroendocrine changes and may be related to the gender difference in response to ethylbenzene exposure.

The gender and species differences and organ specificity in the carcinogenic effects of ethylbenzene are unexpected findings. The mechanisms of action of ethylbenzene carcinogenesis in rats and mice remain to be defined.

CONCLUSIONS

Under the conditions of these 2-year inhalation studies, there was *clear evidence of carcinogenic activity*^{*} of ethylbenzene in male F344/N rats based on increased incidences of renal tubule neoplasms. The incidences of testicular adenoma were also increased. There was *some evidence of carcinogenic activity* of ethylbenzene in female F344/N rats based on increased incidences of renal tubule adenomas. There was *some evidence of carcinogenic activity* of ethylbenzene in male B6C3F₁ mice based on increased incidences of *carcinogenic activity* of ethylbenzene in male B6C3F₁ mice based on increased incidences of *carcinogenic activity* of ethylbenzene in female B6C3F₁ mice based on increased incidences of *carcinogenic activity* of ethylbenzene in female B6C3F₁ mice based on increased incidences of hepatocellular neoplasms.

Exposure of male and female rats to ethylbenzene resulted in increased incidences of renal tubule hyperplasia and increased severities of nephropathy. Exposure of male mice to ethylbenzene resulted in increased incidences of alveolar epithelial metaplasia, syncytial alteration of hepatocytes, hepatocellular hypertrophy, hepatocyte necrosis, and thyroid gland follicular cell hyperplasia. In female mice, ethylbenzene exposure resulted in increased incidences of eosinophilic foci of the liver, pituitary gland pars distalis hyperplasia, and thyroid gland follicular cell hyperplasia.

^{*} Explanation of Levels of Evidence of Carcinogenic Activity is on page 10. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 12.

REFERENCES

American Conference of Governmental Industrial Hygienists (ACGIH) (1986). *Documentation of the Threshold Limit Values and Biological Exposure Indices*, 5th ed. Cincinnati, OH.

American Conference of Governmental Industrial Hygienists (ACGIH) (1996). 1996 Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH.

Andersson, K., Fuxe, K., Nilsen, O.G., Toftgård, R., Eneroth, P., and Gustafsson, J.-Å. (1981). Production of discrete changes in dopamine and noradrenaline levels and turnover in various parts of the rat brain following exposure to xylene, *ortho-*, *meta-*, and *para-*xylene, and ethylbenzene. *Toxicol. Appl. Pharmacol.* **60**, 535-548.

Angerer, J., and Lehnert, T. (1979). Occupational chronic exposure to organic solvents. VIII. Phenolic compounds -- metabolites of alkylbenzenes in man. Simultaneous exposure to ethylbenzene and xylenes. *Int. Arch. Occup. Environ. Health* **43**, 145-150.

Armitage, P. (1971). *Statistical Methods in Medical Research*, pp. 362-365. John Wiley and Sons, Inc., New York.

Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. *Mutat. Res.* **257**, 229-306.

Bardodej, Z., and Bardodejova, E. (1970). Biotransformation of ethylbenzene, styrene, and alphamethylstyrene in man. *Am. Ind. Hyg. Assoc. J.* **31**, 206-209.

Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ. Busby, W.F., Jr., Wang, J.-S., Stevens, E.K., Padykula, R.E., Aleksejczyk, R.A., and Berchtold, G.A. (1990). Lung tumorigenicity of benzene oxide, benzene dihydrodiols and benzene diolepoxides in the BLU:Ha newborn mouse assay. *Carcinogenesis* **11**, 1473-1478.

Caspary, W.J., Lee, Y.J., Poulton, S., Myhr, B.C., Mitchell, A.D., and Rudd, C.J. (1988). Evaluation of the L5178Y mouse lymphoma cell mutagenesis assay: Quality-control guidelines and response categories. *Environ. Mol. Mutagen.* **12** (Suppl. 13), 19-36.

Chemical Engineering News. 11 April 1994; 72, 13.

Chin, B.H., McKelvey, J.A., Tyler, T.R., Calisti, L.R., Kozbelt, S.J., and Sullivan, L.J. (1980). Absorption, distribution, and excretion of ethylbenzene, ethylcyclohexane, and methylethylbenzene isomers in rats. *Bull. Environ. Contam. Toxicol.* **24**, 477-483.

Climie, I.J.G., Hutson, D.H., and Stoydin, G. (1983). The metabolism of ethylbenzene hydroperoxide in the rat. *Xenobiotica* **13**, 611-618.

Code of Federal Regulations (CFR) 21, Part 58.

Cox, D.R. (1972). Regression models and life-tables. *J. R. Stat. Soc.* **B34**, 187-220.

Cragg, S.T., Clarke, E.A., Daly, I.W., Miller, R.R., Terrill, J.B., and Quellette, R.E. (1989). Subchronic inhalation toxicity of ethylbenzene in mice, rats, and rabbits. *Fundam. Appl. Toxicol.* **13**, 399-408.

Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In Advances in Modern Environmental Toxicology. Mechanisms and Toxicity of Chemical Carcinogens and Mutagens (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co., Inc., Princeton, NJ. Dean, B.J. (1978). Genetic toxicology of benzene, toluene, xylenes and phenols. *Mutat. Res.* **47**, 75-97.

Dean, B.J., Brooks, T.M., Walker, G.H., and Hutson, D.H. (1985). Genetic toxicity testing of 41 industrial chemicals. *Mutat. Res.* **153**, 57-77.

Deutsche Forschungsgemeinschaft (DFG) (1985). Gesundheitsschadliche Arbeitsstoffe. Toxikologisch Arbeitsmedizinische Begrundung von MAK-Werten. 11th ed. VCH Verlagsgesellschaft, Weinheim.

Dinse, G.E., and Haseman, J.K. (1986). Logistic regression analysis of incidental-tumor data from animal carcinogenicity experiments. *Fundam. Appl. Toxicol.* **6**, 44-52.

Dinse, G.E., and Lagakos, S.W. (1983). Regression analysis of tumour prevalence data. *Appl. Statist.* **32**, 236-248.

Dutkiewicz, T., and Tyras, H. (1967). A study of the skin absorption of ethylbenzene in man. *Br. J. Ind. Med.* **24**, 330-332.

Elovaara, E., Engström, K., Nickels, J., Aitio, A., and Vainio, H. (1985). Biochemical and morphological effects of long term inhalation exposure of rats to ethylbenzene. *Xenobiotica* **15**, 299-308.

Engström, J., and Bjurstrom, R. (1978). Exposure to xylene and ethylbenzene. II. Concentration in subcutaneous adipose tissue. *Scand. J. Work Environ. Health* **4**, 195-203.

Engström, K., Elovaara, E., and Aitio, A. (1985). Metabolism of ethylbenzene in the rat during longterm intermittent inhalation exposure. *Xenobiotica* **15**, 281-286.

Engström, K.M. (1984). Metabolism of inhaled ethylbenzene in rats. *Scand. J. Work Environ. Health* **10**, 83-87.

Eustis, S.L., Hailey, J.R., Boorman, G.A., and Haseman, J.K. (1994). The utility of multiple-section sampling in the histopathological evaluation of the kidney for carcinogenicity studies. *Toxicol. Pathol.* **22**, 457-472.

Farris, G.M., Everitt, J.I., Irons, R.D., and Popp, J.A. (1993). Carcinogenicity of inhaled benzene in CBA mice. *Fundam. Appl. Toxicol.* **20**, 503-507.

Federal Register (1987). Twentieth Report of the Interagency Testing Committee to the Administrator; Receipt of Report and Request for Comments Regarding Priority List of Chemicals. Vol. 52, pp. 19,020-19,026.

Federal Register (1989). Ethyl Benzene. Vol. 54, pp. 2460-2461.

Fishbein, L. (1985). An overview of environmental and toxicological aspects of aromatic hydrocarbons. IV. Ethylbenzene. *Sci. Total Environ.* **44**, 269-287.

Freundt, K.J., Römer, K.G., and Federsel, R.J. (1989). Decrease of inhaled toluene, ethyl benzene, m-xylene, or mesitylene in rat blood after combined exposure to ethyl acetate. *Bull. Environ. Contam. Toxicol.* **42**, 495-498.

Galloway, S.M., Armstrong, M.J., Reuben, C., Colman, S., Brown, B., Cannon, C., Bloom, A.D., Nakamura, F., Ahmed, M., Duk, S., Rimpo, J., Margolin, B.H., Resnick, M.A., Anderson, B., and Zeiger, E. (1987). Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: Evaluations of 108 chemicals. *Environ. Mol. Mutagen.* **10** (Suppl. 10), 1-175.

Gart, J.J., Chu, K.C., and Tarone, R.E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. *JNCI* **62**, 957-974.

Gromiec, J.P., and Piotrowski, J.K. (1984). Urinary mandelic acid as an exposure test for ethylbenzene. *Int. Arch. Occup. Environ. Health* **55**, 61-72.

Hardin, B.D., Bond, G.P., Sikov, M.R., Andrew, F.D., Beliles, R.P., and Niemeier, R.W. (1981). Testing of selected workplace chemicals for teratogenic potential. *Scand. J. Work Environ. Health* **7**, 66-75. Haseman, J.K. (1984). Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies. *Environ. Health Perspect.* **58**, 385-392.

Haseman, J.K., Young, E., Eustis, S.L., and Hailey, J.R. (1997). Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. *Toxicol. Pathol.* **25**, 256-263.

Hawley's Condensed Chemical Dictionary (1987). 11th ed. (N.I. Sax and R.J. Lewis, Sr., Eds.), p. 479. Van Nostrand Reinhold, New York.

Heylin, M. (1987). Facts & figures for the chemical industry. *Chem. Eng. News* **65**, 23-76.

Hollander, M., and Wolfe, D.A. (1973). *Nonparametric Statistical Methods*, pp. 120-123. John Wiley and Sons, New York.

International Labor Office (ILO) (1983). *Encyclopedia of Occupational Health and Safety*. Vol. I and II, p. 214. ILO, Geneva, Switzerland.

Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* **53**, 457-481.

Kurokawa, Y., Hayashi, Y., Maekawa, A., Takahashi, M., Kokubo, T., and Odashima, S. (1983). Carcinogenicity of potassium bromate administered orally to F344 rats. *JNCI* **71**, 965-972.

Lewis, R.J., Sr., Ed. (1992). Sax's Dangerous Properties of Industrial Materials. 8th ed., p. 1579. Van Nostrand Reinhold, New York.

Lonneman, W.A., Bellar, T.A., and Altshuller, A.P. (1968). Aromatic hydrocarbons in the atmosphere of the Los Angeles basin. *Environ. Sci. Tech.* **2**, 1017-1020.

McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *JNCI* **76**, 283-289.

McGregor, D.B., Brown, A., Cattanach, P., Edwards, I., McBride, D., Riach, C., and Caspary, W.J. (1988). Responses of the L5178Y tk⁺/tk⁻ mouse lymphoma cell forward mutation assay: III. 72 coded chemicals. *Environ. Mol. Mutagen.* **12**, 85-154.

MacGregor, J.T., Wehr, C.M., and Langlois, R.G. (1983). A simple fluorescent staining procedure for micronuclei and RNA in erythrocytes using Hoescht 33258 and pyronin Y. *Mutat. Res.* **120**, 269-275.

MacGregor, J.T., Wehr, C.M., Henika, P.R., and Shelby, M.D. (1990). The *in vivo* erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. *Fundam. Appl. Toxicol.* **14**, 513-522.

McKnight, B., and Crowley, J. (1984). Tests for differences in tumor incidence based on animal carcinogenesis experiments. *J. Am. Stat. Assoc.* **79**, 639-648.

Maltoni, C., Conti, B., Cotti, G., and Belpoggi, F. (1985). Experimental studies on benzene carcinogenicity at the Bologna Institute of Oncology: Current results and ongoing research. *Am. J. Ind. Med.* **7**, 415-446.

Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.

The Merck Index (1983). 10th ed. (M. Windholz, Ed.), p. 546. Merck and Company, Rahway, NJ.

The Merck Index (1989). 11th ed. (S. Budavari, Ed.), p. 595. Merck and Company, Rahway, NJ.

Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In *Origins of Human Cancer* (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Mutti, A., and Franchini, I. (1987). Toxicity of metabolites to dopaminergic systems and the behavioural effects of organic solvents. *Br. J. Ind. Med.* **44**, 721-723.

Mutti, A., Falzoi, M., Romanelli, A., Bocchi, M.C., Ferroni, C., and Franchini, I. (1988). Brain dopamine as a target for solvent toxicity: Effects of some monocyclic aromatic hydrocarbons. *Toxicology* **49**, 77-82.

Naskali, L., Oksanen, H., and Tähti, H. (1994). Astrocytes as targets for CNS effects of organic solvents *in vitro*. *Neurotoxicology* **15**, 609-612.

National Cancer Institute (NCI) (1976). Guidelines for Carcinogen Bioassay in Small Rodents. Technical Report Series No. 1. NIH Publication No. 76-801. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

National Institute of Occupational Safety and Health (NIOSH) (1979). Ethylbenzene Data Sheet for Prioritized NIOSH/OSHA Substances for the National Toxicology Program. NIOSH, Rockville, MD.

National Institutes of Health (NIH) (1978). Open Formula Mouse and Rat Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, NIH, Bethesda, MD.

National Research Council (1981). *The Alkyl Benzenes*. National Academy Press, Washington, DC.

National Toxicology Program (NTP) (1986). Toxicology and Carcinogenesis Studies of Benzene (CAS No. 71-43-2) in F344/N Rats and B6C3F₁ Mice (Gavage Studies). Technical Report Series No. 289. NIH Publication No. 86-2545. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC. National Toxicology Program (NTP) (1990a). Toxicology and Carcinogenesis Studies of Toluene (CAS No. 108-88-3) in F344/N Rats and B6C3F₁ Mice (Inhalation Studies). Technical Report Series No. 371. NIH Publication No. 90-2826. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

National Toxicology Program (NTP) (1990b). Toxicology and Carcinogenesis Studies of α -Methylbenzyl Alcohol (CAS No. 98-85-1) in F344/N Rats and B6C3F₁ Mice (Gavage Studies). Technical Report Series No. 369. NIH Publication No. 89-2824. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

National Toxicology Program (NTP) (1992). Toxicity Studies of Ethylbenzene in F344/N Rats and B6C3F₁ Mice (Inhalation Studies). Toxicity Study Report Series No. 10. NIH Publication No. 92-3129. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

Nestmann, E.R., Lee, E.G.-H., Matula, T.I., Douglas, G.R., and Mueller, J.C. (1980). Mutagenicity of constituents identified in pulp and paper mill effluents using the *Salmonella*/mammalianmicrosome assay. *Mutat. Res.* **79**, 203-212.

Norppa, H., and Vainio, H. (1983). Induction of sister-chromatid exchanges by styrene analogues in cultured human lymphocytes. *Mutat. Res.* **116**, 379-387.

Ono, A., Sekita, K., Ohno, K., Hirose, A., Ogawa, Y., Saito, M., Naito, K., Kaneko, T., Furuya, T., and Matsumoto, K. (1995). Reproductive and developmental toxicity studies of toluene. I. Teratogenicity study of inhalation exposure in pregnant rats. *J. Toxicol. Sci.* **20**, 109-134. Otson, R., Williams, D.T., and Bothwell, P.D. (1982). Volatile organic compounds in water at thirty Canadian potable water treatment facilities. *J. Assoc. Off. Anal. Chem.* **65**, 1370-1374.

Plappert, U., Barthel, E., and Seidel, H.J. (1994). Reduction of benzene toxicity by toluene. *Environ. Mol. Mutagen.* **24**, 283-292.

Pyykko, K., Paavilainen, S., Metsa-Ketela, T., and Laustiola, K. (1987). The increasing and decreasing effects of aromatic hydrocarbon solvents on pulmonary and hepatic cytochrome P-450 in the rat. *Pharmacol. Toxicol.* **60**, 288-293.

Sabourin, P.J., Bechtold, W.E., Griffith, W.C., Birnbaum, L.S., Lucier, G., and Henderson, R.F. (1989). Effect of exposure concentration, exposure rate, and route of administration on metabolism of benzene by F344 rats and $B6C3F_1$ mice. *Toxicol. Appl. Pharmacol.* **99**, 421-444.

Sabourin, P.J., Muggenburg, B.A., Couch, R.C., Lefler, D., Lucier, G., Birnbaum, L.S., and Henderson, R.F. (1992). Metabolism of [¹⁴C]benzene by cynomolgus monkeys and chimpanzees. *Toxicol. Appl. Pharmacol.* **114**, 277-284.

Sadtler Standard Spectra. IR No. 246; UV No. 97; NMR No. 10210M. Sadtler Research Laboratories, Philadelphia.

Schmid, W. (1976). The micronucleus test for cytogenetic analysis. In *Chemical Mutagens. Principles and Methods for their Detection* (A. Hollaender, Ed.), Vol. 4, pp. 31-53. Plenum Press, New York.

Shelby, M.D., and Witt, K.L. (1995). Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. *Environ. Mol. Mutagen.* **25**, 302-313.

Shelby, M.D., Erexson, G.L., Hook, G.J., and Tice, R.R. (1993). Evaluation of a three-exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals. *Environ. Mol. Mutagen.* **21**, 160-179.

Smyth, H.F., Jr., Carpenter, C.P., Weil, C.S., Pozzani, U.C., and Striegel, J.A. (1962). Range-finding toxicity data: List VI. *Am. Ind. Hyg. Assoc. J.* **23**, 95-107.

Snyder, R., and Hedli, C.C. (1996). An overview of benzene metabolism. *Environ. Health Perspect.* **104** (Suppl. 6), 1165-1171.

Storage and Retrieval of Water Quality Information (STORET) (1986). Water Quality Control Information System [database]. U.S. Environmental Protection Agency, Washington, DC.

Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. *JNCI* **67**, 233-241.

Susten, A.S., Niemeier, R.W., and Simon, S.D. (1990). In vivo percutaneous absorption studies of volatile organic solvents in hairless mice. II. Toluene, ethylbenzene and aniline. *J. Appl. Toxicol.* **10**, 217-225.

Tarone, R.E. (1975). Tests for trend in life table analysis. *Biometrika* **62**, 679-682.

Tegeris, J.S., and Balster, R.L. (1994). A comparison of the acute behavioral effects of alkylbenzenes using a functional observational battery in mice. *Fundam. Appl. Toxicol.* **22**, 240-250.

Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from *in vitro* genetic toxicity assays. *Science* **236**, 933-941.

Toftgard, R., and Nilsen, O.G. (1982). Effects of xylene and xylene isomers on cytochrome P-450 and *in vitro* enzymatic activities in rat liver, kidney, and lung. *Toxicology* **23**, 197-212.

Ungvary, G., and Tatrai, E. (1985). On the embryotoxic effects of benzene and its alkyl derivatives in mice, rats, and rabbits. *Arch. Toxicol.* **8** (Suppl.), 425-430.

United States Code (U.S.C.) 42 § 7412.

U.S. Environmental Protection Agency (USEPA) (1991). Alpha_{2u}-globulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the Male Rat. EPA/625/3-91/019F. Risk Assessment Forum, USEPA, Washington, DC.

U.S. International Trade Commission (USITC) (1985). Synthetic Organic Chemicals. United States Production and Sales, 1984. USITC Publication No. 1745. USITC, Washington, DC.

Vaalavirta, L., and Tähti, H. (1995). Effects of selected organic solvents on the astrocyte membrane ATPase in vitro. *Clin. Exp. Pharmacol. Physiol.* **22**, 293-294.

Verschueren, K. (1983). *Handbook of Environmental Data on Organic Chemicals*, 2nd ed., p. 628. Van Nostrand and Reinhold Company, New York, NY.

Wallace, L., Pellizzari, E., Hartwell, T., Rosenzweig, M., Erickson, M., Sparacino, C., and Zelon, H. (1984). Personal exposure to volatile organic compounds. I. Direct measurements in breathing-zone air, drinking water, food and exhaled breath. *Environ. Res.* **35**, 293-319.

Wolf, M.A., Rowe, V.K., McCollister, R.L., and Oyen, F. (1956). Toxicological studies of certain alkylated benzenes and benzene. *A.M.A. Arch. Ind. Health* **14**, 387-398.

Wolf, M.S., Daum, S.M., Lorimer, W.V., Selikoff, I.J., and Aubrey, B.B. (1977). Styrene and related hydrocarbons in subcutaneous fat from polymerization workers. *J. Toxicol. Environ. Health* **2**, 997-1005.

Yant, W.P., Schrenk, H.H., Waite, C.P., and Patty, F.A. (1930). Acute response of guinea pigs to vapors of some new commercial organic compounds. II. Ethylbenzene. *Public Health Rep.* **45**, 1241-1250.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1988). *Salmonella* mutagenicity tests: IV. Results from the testing of 300 chemicals. *Environ. Mol. Mutagen.* **11** (Suppl. 12), 1-158.

Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. *Environ. Mol. Mutagen.* **16** (Suppl. 18), 1-14.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. *Environ. Mol. Mutagen.* **19** (Suppl. 21), 2-141.

Zhu, H., Li, Y., and Trush, M.A. (1995). Differences in xenobiotic detoxifying activities between bone marrow stromal cells from mice and rats: Implications for benzene-induced hematotoxicity. *J. Toxicol. Environ. Health* **46**, 183-201.

APPENDIX A SUMMARY OF LESIONS IN MALE RATS IN THE 2-YEAR INHALATION STUDY OF ETHYLBENZENE

TABLE A1	Summary of the Incidence of Neoplasms in Male Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	57
TABLE A2	Individual Animal Tumor Pathology of Male Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	62
TABLE A3	Statistical Analysis of Primary Neoplasms in Male Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	84
TABLE A4a	Historical Incidence of Renal Tubule Neoplasms	
	in Chamber Control Male F344/N Rats	91
TABLE A4b	Historical Incidence of Testicular Adenoma	
	in Chamber Control Male F344/N Rats	91
TABLE A5	Summary of the Incidence of Nonneoplastic Lesions in Male Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	92

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene^a

	Chamber Control	75 ppm	250 ppm	750 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths	00	00	00	00
Moribund	28	20	26	26
Natural deaths	7	16	11	22
Survivors				
Terminal sacrifice	15	14	13	2
Animals examined microscopically	50	50	50	50
Alimentary System				
Esophagus	(50)	(50)	(50)	(50)
Intestine large, colon	(50)	(48)	(48)	(48)
Sarcoma	1 (2%)		x -7	× -7
Intestine large, rectum	(48)	(49)	(48)	(48)
Intestine large, cecum	(46)	(44)	(46)	(39)
Intestine small, duodenum	(48)	(48)	(50)	(50)
Intestine small, jejunum	(42)	(39)	(44)	(34)
Intestine small, ileum	(45)	(44)	(45)	(37)
Liver	(50)	(50)	(50)	(49)
Hepatocellular adenoma		3 (6%)		
Histiocytic sarcoma		1 (2%)		
Osteosarcoma, metastatic, spleen	1 (2%)	. ,		
Mesentery	(4)	(5)	(3)	(3)
Lipoma			1 (33%)	
Sarcoma	1 (25%)		· · ·	
Oral mucosa	(2)		(1)	(1)
Pharyngeal, squamous cell papilloma	2 (100%)		1 (100%)	1 (100%)
Pancreas	(50)	(49)	(50)	(50)
Duct, carcinoma		1 (2%)	, <i>,</i>	, ,
Salivary glands	(50)	(49)	(50)	(50)
Stomach, forestomach	(50)	(50)	(50)	(50)
Stomach, glandular	(50)	(49)	(50)	(50)
Tongue	(1)			
Squamous cell papilloma	1 (100%)			
Cardiovascular System				
Heart	(50)	(50)	(50)	(50)
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(50)
Osteosarcoma, metastatic, spleen	1 (2%)			
Adrenal medulla	(50)	(50)	(49)	(48)
Osteosarcoma, metastatic, spleen	1 (2%)			
Pheochromocytoma malignant		1 (2%)		2 (4%)
Pheochromocytoma benign	6 (12%)	10 (20%)	6 (12%)	9 (19%)
Bilateral, pheochromocytoma benign	7 (14%)	3 (6%)	3 (6%)	3 (6%)
Islets, pancreatic	(50)	(50)	(50)	(50)
Adenoma	3 (6%)	4 (8%)	4 (8%)	4 (8%)
Carcinoma	2 (4%)	1 (2%)		
Parathyroid gland	(45)	(46)	(46)	(46)
Adenoma		1 (2%)		

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Endocrine System (continued)				
Pituitary gland	(49)	(50)	(50)	(45)
Pars distalis, adenoma	23 (47%)	18 (36%)	18 (36%)	18 (40%)
Pars distalis, adenoma, multiple	2 (4%)	1 (2%)	1 (2%)	
Thyroid gland	(50)	(49)	(50)	(50)
Bilateral, C-cell, adenoma	2 (4%)			
C-cell, adenoma	1 (2%)	6 (12%)	3 (6%)	2 (4%)
C-cell, carcinoma	2 (4%)	4 (22.1)		4 (22.1)
Follicular cell, carcinoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
General Body System				
Peritoneum		(1)		
Genital System				
Epididymis	(50)	(50)	(50)	(50)
Preputial gland	(49)	(50)	(49)	(50)
Adenoma	3 (6%)	1 (2%)	1 (2%)	2 (4%)
Bilateral, adenoma				2 (4%)
rostate	(50)	(50)	(50)	(50)
eminal vesicle	(49)	(49)	(50)	(50)
lestes	(50)	(50)	(50)	(50)
Bilateral, interstitial cell, adenoma	27 (54%)	23 (46%)	32 (64%)	40 (80%)
Interstitial cell, adenoma	9 (18%)	10 (20%)	8 (16%)	4 (8%)
Iematopoietic System				
Bone marrow	(49)	(49)	(50)	(50)
Histiocytic sarcoma		1 (2%)		
Lymph node	(9)	(8)	(9)	(14)
.ymph node, bronchial	(44)	(34)	(39)	(28)
Histiocytic sarcoma		1 (3%)	(10)	(7.0)
ymph node, mandibular	(47)	(48)	(49)	(50)
Lymph node, mesenteric	(49)	(50)	(50)	(50)
Histiocytic sarcoma	(49)	1 (2%)	(50)	(17)
Lymph node, mediastinal	(48)	(48) 1 (2%)	(50)	(47)
Histiocytic sarcoma	(50)	1 (2%)	(50)	(50)
pleen Histiocytic sarcoma	(50)	(49) 1 (2%)	(50)	(50)
Osteosarcoma	1 (2%)	1 (2/0)		
Thymus	(46)	(44)	(46)	(44)
Histiocytic sarcoma	(10)	1 (2%)	(10)	(**)
Thymoma benign			1 (2%)	
ntegumentary System				
Mammary gland	(46)	(47)	(46)	(49)
Adenoma	(01)	(17)	1 (2%)	(01)
Fibroadenoma	2 (4%)	2 (4%)	2 (4%)	
Fibroadenoma, multiple	~ (170)	1 (2%)	~ (1/0)	
Fibroma		2 (4%)		

TABLE A1 Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

C	Chamber Control	75 ppm	250 ppm	750 ppm
Integumentary System (continued)				
Skin	(50)	(50)	(50)	(50)
Basal cell adenoma			1 (2%)	
Basal cell carcinoma				1 (2%)
Keratoacanthoma	3 (6%)	2 (4%)	2 (4%)	2 (4%)
Squamous cell papilloma	2 (4%)	1 (2%)	1 (2%)	
Pinna, schwannoma benign Pinna, schwannoma malignant		1 (2%)	1 (2%)	
Sebaceous gland, adenoma			1 (2%) 1 (2%)	
Subcutaneous tissue, fibroma	1 (2%)	1 (2%)	3 (6%)	
Subcutaneous tissue, fibrosarcoma	1 (270)	1 (2%)	0 (0/0)	
Subcutaneous tissue, lipoma		- ()		1 (2%)
Subcutaneous tissue, myxoma			1 (2%)	
Subcutaneous tissue, sarcoma		2 (4%)		
Musculoskeletal System				
Bone	(49)	(50)	(50)	(50)
Histiocytic sarcoma		1 (2%)		
Turbinate, chondroma			1 (2%)	
Skeletal muscle	(1)	(1)		(1)
Histiocytic sarcoma		1 (100%)		
Osteosarcoma, metastatic, spleen	1 (100%)			4 (4000())
Sarcoma				1 (100%)
Nervous System				
Brain	(50)	(50)	(50)	(50)
Glioma malignant			1 (2%)	1 (2%)
Respiratory System				
Larynx	(40)	(44)	(41)	(35)
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	2 (4%)	1 (2%)		1 (2%)
Alveolar/bronchiolar carcinoma	1 (2%)			
Carcinoma, metastatic, thyroid gland Histiocytic sarcoma	2 (4%)	1 (90/)		
Osteosarcoma, metastatic, spleen	1 (2%)	1 (2%)		
Mediastinum, osteosarcoma, metastatic, splee				
Nose	(49)	(49)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)
Leiomyosarcoma			1 (2%)	
Special Senses System				
Harderian gland			(1)	
Carcinoma			1 (100%)	
Zymbal's gland	(1)		(1)	(1)
Carcinoma	1 (100%)		1 (100%)	

Summary of the Incidence of Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Histiocytic sarcoma		1 (2%)		
Lipoma	1 (2%)			
Renal tubule, adenoma		3 (6%)	2 (4%)	4 (8%)
Renal tubule, carcinoma			1 (2%)	3 (6%)
Urinary bladder	(49)	(49)	(50)	(49)
Transitional epithelium, papilloma		1 (2%)		
Systemic Lesions Multiple organs ^b Histiocytic sarcoma Leukemia mononuclear Mesothelioma malignant	(50) 27 (54%)	(50) 1 (2%) 26 (52%) 2 (4%)	(50) 32 (64%) 1 (2%)	(50) 9 (18%)
Neoplasm Summary				
Total animals with primary neoplasms ^c	49	45	50	50
Total primary neoplasms	134	131	134	111
Total animals with benign neoplasms	48	44	48	48
Total benign neoplasms	97	95	94	93
Total animals with malignant neoplasms	33	32	37	17
Total malignant neoplasms	37	36	40	18
Total animals with metastatic neoplasms	3			
Total metastatic neoplasms	8			

а Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms

b

с

Number of Days on Study	3 5 4	9	4 7 9	4 9 7	2	5 4 7	5	7	5 7 4	8	5 9 0	6 0 2	6 0 8	6 0 9	6 1 8	6 2 3	6 3 0	6 3 9	6 4 0	6 4 0	6 4 4	6 5 2	6 5 3	6 6 1	6 6 8	
Carcass ID Number	0 4 8	0 3 8	0 0 9	0 3 9	0 2 5	0 0 8	0 2 4	0 4 5	0 3 6	0 5 0	0 1 9	0 0 3	0 2 3	0	0 2 9	0 3 2	0 2 7	0 4 1	0 0 4		0 1 1	0 1 2	0 4 4	0 1 4	2	
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon Sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	А	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	+	+	+	+	+	+	А	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	+	А	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	А	A	+	А	+	+	+	А	+	+	Α	+	+	+	+	+	+	+	+	+	А	+	+	+	+	
Intestine small, ileum	А	. +	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	А	+	+	+	+	
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Osteosarcoma, metastatic, spleen											Х															
Mesentery				+																						
Sarcoma				Х																						
Oral mucosa																										
Pharyngeal, squamous cell papilloma																										
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Tongue								+																		
Squamous cell papilloma								Х																		
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
	'		'		1			'	'	'	'	'	1			'	1	'	'	'	'	'	'	1		
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Osteosarcoma, metastatic, spleen											Х															
Adrenal medulla	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Osteosarcoma, metastatic, spleen											Х															
Pheochromocytoma benign										Х			v			Х								Х		
Bilateral, pheochromocytoma benign													Х												Х	
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma											37															
Carcinoma Dentilemental alema											Х															
Parathyroid gland	+	+	+	+	+	+			+																Μ	
Pituitary gland	+		+		+	+	+	+	+	+	+				+		+	+	+	+	+				+	
Pars distalis, adenoma		X	Х		Х	Х	Х					Х		Х	Х	X						Х	Х			
Pars distalis, adenoma, multiple																										
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Bilateral, C-cell, adenoma																										
C-cell, adenoma																								v		
C-cell, carcinoma																								Х		
Follicular cell, carcinoma																										

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: Chamber Control

+: Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

Number of Days on Study	6 8				6 8	6 9	7 1	7 1	7 1	7 1	7 1	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	7 3	
	5	ą)	9	9	2	0	0	3	4	5	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	
	0	()	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Total
Carcass ID Number	4				3 3	1 3	0 2	3 4	0 6	4 6	4 7		1 0	1 5	1 6	1 8	2 0	2 1	2 6	3 0	3 1	3 5	3 7		4	4 9	Tissues/ Tumors
A line and anne Stratan					0	Ū	~	1	U	U			U	Ū	U	U	U	-	U	U		Ū		0	~	U	Tumors
Alimentary System Esophagus		. 1	M	-	т	-	-	-	+	-	-	-	т.	-	_	-	-	-	-	т.	-		-	_			49
Intestine large, colon	-		v1 ⊢	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	50
Sarcoma										'							'					x					1
Intestine large, rectum	+		F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, cecum	+		4	+	+	+	+	Å	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	46
Intestine small, duodenum	_		L .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	48
Intestine small, jejunum	_		Δ.	+	+	+	+	Å	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	42
Intestine small, ileum	+	. /	ì	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	45
Liver	-		⊾ ⊢	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	50
Osteosarcoma, metastatic, spleen																						'					1
Mesentery				+																+						+	4
Sarcoma																											1
Oral mucosa				+																						+	2
Pharyngeal, squamous cell papilloma				x																						x	2
Pancreas	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
Salivary glands	-		-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	50
Stomach, forestomach	-		-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	50
Stomach, glandular	-		-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. <u>+</u>	50
Tongue				'			'				'			'				'				'				'	1
Squamous cell papilloma																											1
Cardiovascular System																											
Blood vessel	+		F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System Adrenal cortex	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Osteosarcoma, metastatic, spleen																											1
Adrenal medulla	+		F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Aurenai meuuna																											1
											Х									х	Х						6
Osteosarcoma, metastatic, spleen											Λ																7
Osteosarcoma, metastatic, spleen Pheochromocytoma benign		2	K I	х			х				л	Х					Х										
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign	+	2	X : ⊢		+	+	X +	+	+	+	л +	X +	+	+	+	+	X +	+	+	+	+	+	+	+	+	+	50
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic	+	2			+		X +	+	+ X	+			+	+	+	+	X +	+	+	+	+	+	+	+	+ X		
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma	+	2			+	+ X		+		+	+		+	+	+	+	X +	+	+	+	+	+	+	+			3
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma	+	2			+			+	Х		+ X		+	+	+	+	X + +	+	+	+	+	+	+	+			3 2
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland	+	2	+	+	+	X +	++	+	X +	+	+ X M	+++		+++++		+++++	++		+ + M	+++++	+++++	+++++	+++++	+ + +	X +	+	3 2 45
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland	+ + +	2	+	+	+ + +	X +		+ +	X + +	++	+ X M +	+ + +	+	+		+ + + X	++	+	+ + M	+ + +				+ + +	X + +	+++++++++++++++++++++++++++++++++++++++	3 2 45 49
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma	+ + +		+	+	+	X +	++	+ +	X + +	++	+ X M +	+++	+	+	+	+ + X	++		+ + M	+ + +		+ + X		+ + +	X +	+++++++++++++++++++++++++++++++++++++++	3 2 45 49 23
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Pars distalis, adenoma, multiple	+ +		+	+	+	X +	++	+ +	X + +	++	+ X M +	+ + +	+	+			++	+	+ + M +		Х			++++++	X + +	++	3 2 45 49 23 2
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Pars distalis, adenoma, multiple Thyroid gland	+ + +		+	+	+	X +	++	+ +	X + +	++	+ X M +	+ + +	+	+	+		++	+	+ + M +	+	X +	X +		+++++++++++++++++++++++++++++++++++++++	X + + X	++	3 2 45 49 23 2 50
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Pars distalis, adenoma, multiple Thyroid gland Bilateral, C-cell, adenoma	+ + +		+	+	+	X +	++	+ +	X + +	++	+ X M +	+ + +	+	+ X +	+		++	+	+ + M +	+	Х	X +		+++++++	X + + X	++	3 2 45 49 23 2 50 2
Osteosarcoma, metastatic, spleen Pheochromocytoma benign Bilateral, pheochromocytoma benign Islets, pancreatic Adenoma Carcinoma Parathyroid gland Pituitary gland Pars distalis, adenoma Pars distalis, adenoma, multiple Thyroid gland	+ + +		+	+	+	X +	++	+ +	X + +	++	+ X M +	+ + +	+	+	+		++	+	+ + M +	+	X +	X +		+++++++	X + + X	++	3 2 45 49 23 2 50

(continued)	
Number of Days on Study	3 3 4 4 5 5 5 5 5 5 6
Carcass ID Number	0 0
General Body System Tissue NOS	+
Genital System Epididymis Preputial gland Adenoma Prostate Seminal vesicle Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ + + + + + + + + + + + + + + + + + +
Hematopoietic System Bone marrow Lymph node Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Osteosarcoma Thymus	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Integumentary System Mammary gland Fibroadenoma Skin Keratoacanthoma Squamous cell papilloma Subcutaneous tissue, fibroma	+ + + + + + + + + + + + + + + + + + +
Musculoskeletal System Bone Skeletal muscle Osteosarcoma, metastatic, spleen	+ + + + M + + + + + + + + + + + + + + +
Nervous System Brain	+ + + + + + + + + + + + + + + + + + + +
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	M M M M M + + + M M + + M M + + + M +
Carcinoma, metastatic, thyroid gland Osteosarcoma, metastatic, spleen Mediastinum, osteosarcoma, metastatic, spleen Nose Trachea	X X + + + + M + + + + + + + + + + + + + + +

(continued)																										
Number of Days on Study	6 8 5	6 8 9	6 8 9	6 8 9	6 9 2	7 1 0	1	7 1 3	÷.	7 1 5	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	
Carcass ID Number	0 4 3	0 0 1	0 1 7	0 3 3	0 1 3	0 0 2	3	0	4	0 4 7	0 0 7	0 1 0	0 1 5	1	1	0 2 0	0 2 1	2	0 3 0	0 3 1	0 3 5	0 3 7	0 4 0	0 4 2	0 4 9	Total Tissues/ Tumors
General Body System Tissue NOS																										1
Genital System Epididymis Preputial gland Adenoma Prostate Seminal vesicle Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ + + + X	+ + + + +	+ + + + +	+ + + + X	+ + + + X	+ + + + X	+ + A + X		+ + + + X	+ + + + +	+ + + + X	+ + + + X	+ + + + + + X	+ + + + X	+ + + + X		+ + + + X	+ + + X	+ + + X	+ + + + X	+ M + + X	+ + + X	+ + + X	+ + + + X	+ + + + X	50 49 3 50 49 50 27 9
Hematopoietic System Bone marrow Lymph node Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Osteosarcoma Thymus	+ + + + + +	+ M + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + + + +	+ M + + +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + +	+ + + + + + + +	+ M + + + + +	+ + + + + + +	+ + + + + + +	+ + + + + +	+ + + + +	49 9 44 47 49 48 50 1 46
Integumentary System Mammary gland Fibroadenoma Skin Keratoacanthoma Squamous cell papilloma Subcutaneous tissue, fibroma	+	+ +	++	+ +	+ +	+ +	+	+	+	M +	+	+ +	+ + X	+	+ +	+	+ X +	+ + X	+	+ +	+ + X	++	M +	+ +	+ X +	46 2 50 3 2 1
Musculoskeletal System Bone Skeletal muscle Osteosarcoma, metastatic, spleen	+	+	÷	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	49 1 1
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Carcinoma, metastatic, thyroid gland Osteosarcoma, metastatic, spleen Mediastinum, osteosarcoma,	++	+ +	++	++	+ +	+ +	+ +	+ +	+ + X X	++	+++	+ + X	+++	+++	+ +	+ +	++	+ +	++	+++	+ + X	++	+++	++	+ +	40 50 2 1 2 1
metastatic, spleen Nose Trachea	+ +	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	1 49 50

(continued)	
Number of Days on Study	3 3 4 4 5 5 5 5 5 6
Carcass ID Number	0 0
Special Senses System Eye Zymbal's gland Carcinoma	+ * X
Urinary System Kidney Lipoma Urinary bladder	+ + + + + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +

Number of Days on Study	6 6 6 6 7	
Carcass ID Number	0 0	Total Tissues/ Tumors
Special Senses System Eye Zymbal's gland Carcinoma		1 1 1
Urinary System Kidney Lipoma Urinary bladder	+ + + + + + + + + + + + + + + + + + +	50 1 49
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +	50 27

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm 2 3 3 4 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 Number of Days on Study 4 0 5 1 1 3 4 6 8 8 8 9 0 0 0 1 1 1 2 3 3 3 3 4 5 4 8 2 6 8 8 9 0 2 4 4 6 0 1 7 5 7 9 6 1 4 7 9 0 4 **Carcass ID Number** 2 0 5 0 2 2 4 1 4 0 2 0 3 0 3 4 4 0 3 1 1 1 4 3 0 2 3 0 8 9 4 9 7 2 4 1 7 2 1 8 4 65 3 5 1 9 0 7 9 **Alimentary System** Esophagus Intestine large, colon + Α Α + Intestine large, rectum Α + + + + + + ++ + Intestine large, cecum А А + А + + А Α + + + ++ + + Intestine small, duodenum + A + + + + + + + + + + + Intestine small, jejunum A A A + + А Α А А А + + + + + + + + Intestine small, ileum A A Α + + + А + + + + + + Α + + + + + + + Liver + + + Hepatocellular adenoma Х Х Histiocytic sarcoma Х Mesentery Pancreas Duct, carcinoma Salivary glands Μ Stomach, forestomach Stomach, glandular А + **Cardiovascular System** Blood vessel + + + + + + + + + + + Heart + + $^{+}$ + $^{+}$ ++ + + + + ++++ ++++ $^{+}$ ++ ++**Endocrine System** Adrenal cortex + + Adrenal medulla Pheochromocytoma malignant Pheochromocytoma benign Х Х Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + X + + + + + ++ $^{+}$ + + Adenoma Carcinoma Parathyroid gland + M + + + M + + Adenoma Х Pituitary gland + $\begin{array}{c} + & + \\ X & X \end{array}$ Pars distalis, adenoma Х Х ХХ Х Х X Pars distalis, adenoma, multiple Thyroid gland + A + + + + + + + + + + + + + $^{+}$ C-cell, adenoma Follicular cell, carcinoma **General Body System** Peritoneum **Genital System** Epididymis Preputial gland Adenoma Х Prostate + + Seminal vesicle А + + + + + ++ + +++ ++ + + + + + ++ + + Testes + Bilateral, interstitial cell, adenoma Х Х Х х Х Х Interstitial cell, adenoma Х Х ХХ

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm (continued) 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 77 7 7 7 7 7 7 7 7 7 Number of Days on Study 6 7 9 9 9 0 1 1 1 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 2 3 5 7 3 4 8 0 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 8 Total 1 **Carcass ID Number** 3 4 2 2 3 4 3 2 1 4 0 0 1 1 1 1 1 2 2 3 3 3 4 2 4 Tissues/ 3 5 1 5 7 0 3 9 8 6 5 2 6 0 2 3 4 8 0 6 1 4 6 7 8 Tumors **Alimentary System** Esophagus 50 Intestine large, colon 48 Intestine large, rectum 49 + 44 Intestine large, cecum A Intestine small, duodenum A 48 + + Intestine small, jejunum А А А 39 + Intestine small, ileum 44 + + А + ++ + + + + + X Liver 50 Hepatocellular adenoma 3 Histiocytic sarcoma 1 Mesentery 5 Pancreas 49 Duct, carcinoma Х 1 49 Salivary glands Stomach, forestomach 50 Stomach, glandular 49 + + + + + ++ + + +**Cardiovascular System** Blood vessel + 50 + Heart 50 + + ++ + + + ++ ++ + ++ ++++ ++++ $^{+}$ +**Endocrine System** 50 Adrenal cortex Adrenal medulla 50 Pheochromocytoma malignant Х 1 Х Pheochromocytoma benign Х ХХ Х Х Х Х 10 X + + + + Х Bilateral, pheochromocytoma benign Х 3 Islets, pancreatic + 50 + + + + + + + + + Adenoma 4 Carcinoma 1 Parathyroid gland + M + + + Μ + + + 46 Adenoma 1 Pituitary gland + + 50 Pars distalis, adenoma ХХ ХХ 18 Х Х X Х Pars distalis, adenoma, multiple 1 49 Thyroid gland + + + + + + + + + + X ХХ Х C-cell, adenoma 6 Follicular cell, carcinoma Х 1 **General Body System** 1 Peritoneum + **Genital System** Epididymis 50 Preputial gland 50 Adenoma 1 Prostate 50 Seminal vesicle 49 + ++ +++ + +++ + + + +++++ + 50 Testes ++ + + Bilateral, interstitial cell, adenoma Х Х X X хххх Х ХХ Х Х Х ХХХ Х 23 Interstitial cell. adenoma Х Х Х Х Х 10

	y of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm (continued)
Number of Days on Study	2 3 3 4 5 5 5 5 5 5 6
Carcass ID Number	1 1
Hematopoietic System Bone marrow Histiocytic sarcoma	+ A + + + + + + + + + + + + + + + + + +
Lymph node Lymph node, bronchial Histiocytic sarcoma	+ M + + + M + + + + + M + + + + M + + + + M
Lymph node, mandibular Lymph node, mesenteric Histiocytic sarcoma	+ A + + + + + + + + + + + + + + M + + + +
Lymph node, mediastinal Histiocytic sarcoma Spleen	+ + + + M + + + + M + + + + + + + + + +
Histiocytic sarcoma Thymus Histiocytic sarcoma	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Integumentary System Mammary gland Fibroadenoma Fibroadenoma, multiple	+ M + + + + + + + + + + + + + + + + + +
Fibroma Skin Keratoacanthoma	X + + + + + + + + + + + + + + + + + + +
Squamous cell papilloma Pinna, schwannoma benign Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, sarcoma	Х
Musculoskeletal System Bone Histiocytic sarcoma Skeletal muscle Histiocytic sarcoma	+ + + + + + + + + + + + + + + + + + +
Nervous System Brain	+ + + + + + + + + + + + + + + + + + + +
Respiratory System Larynx Lung	+ A M + + + M + M M + + M + + + + + + +
Alveolar/bronchiolar adenoma Histiocytic sarcoma	Х

 TABLE A2

 Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm (continued)

			<u>.</u>	•	<u> </u>		~	~	~	~	~	~	~	~	~	~	1	1	~	~	~	~	~	~	~	~	
Number of Days on Study		56 37			66 99) N	/	1	1	1	7 2	1	/ 2	7 3	1	7 3	7 3		7 3								
Number of Days on Study	6				9 8 3 5		7	3	4	8	2 0	23	3 4		3 4	3 4	3 4	3 4		3 4							
	1	1	1	1	1 1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number	4									2	1	4	0		1	1	1		1	2	2	3	3	3		4	Tissues/
					5 7											2											Tumors
Hematopoietic System																											
Bone marrow	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Histiocytic sarcoma																											1
Lymph node					+				+							+						+		+			8
Lymph node, bronchial	-	+ -	+ I	M	+ -	+	M	М	+	Μ	Μ	+	+	Μ	+	Μ	+	+	Μ	Μ	+	+	+	Μ	+	+	34
Histiocytic sarcoma																											1
Lymph node, mandibular	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Lymph node, mesenteric	-	+ -	+ -	+	+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma Lymph node, mediastinal																											1 48
Histiocytic sarcoma	-	r	T	٣	- F -	17	- F	т	т	Ŧ	Ŧ	+	+	+	+	+	+	+	+	т	т	+	+	+	+	т	40
Spleen	-	+ -	+ -	+	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Histiocytic sarcoma						•						1		'	'	'	'		1			'		'		'	1
Thymus	-	+ -	+ -	+	+ -	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Histiocytic sarcoma																											1
Integumentary System																											
Mammary gland	-	+ -	+ -	+	+ -	+	+ 1	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Fibroadenoma																				Х					Х		2
Fibroadenoma, multiple															Х												1
Fibroma							Х																				2
Skin	-	+ -	+ -	+	+ -	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Keratoacanthoma										Х																	2
Squamous cell papilloma															Х												1
Pinna, schwannoma benign								• •															Х				1
Subcutaneous tissue, fibroma								Х																			1
Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, sarcoma		x					Х																				1 2
	1	7					Л																_	_	_	—	2
Musculoskeletal System																											50
Bone Histiocytic sarcoma	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Skeletal muscle																											1
Histiocytic sarcoma																											1
Nervous System																											
Brain	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																											
Larynx	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Lung	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma								Х																			1
Histiocytic sarcoma																											1
Nega	-	+ -	+ -	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 50
Nose Trachea																											

72

TABLE A2

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm (continued) 2 3 3 4 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 Number of Days on Study $4 \quad 0 \quad 5 \quad 1 \quad 1 \quad 3 \quad 4 \quad 6 \quad 8 \quad 8 \quad 8 \quad 9 \quad 0 \quad 0 \quad 0 \quad 1 \quad 1 \quad 1 \quad 2 \quad 3 \quad 3 \quad 3 \quad 3 \quad 4 \quad 5$ **Carcass ID Number Urinary System** Kidney Histiocytic sarcoma Renal tubule, adenoma X X + + + + + + + + + + + A + + + + + + + + + + + + + + + Urinary bladder Transitional epithelium, papilloma Systemic Lesions + + + X Multiple organs + + + + + + + + + + + + + + ++ +Histiocytic sarcoma Leukemia mononuclear Х ХХ ХХХ Х ХХХ Х Mesothelioma malignant

 TABLE A2

 Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene:
 75 ppm (continued)

Number of Days on Study	6 6 8	6 7 1	6 9 2	6 9 3	6 9 5	7 0 7	7 1 3	7 1 4	7 1 8	7 2 0	7 2 3	7 3 4														
Carcass ID Number	1 2 3	1 3 5	1 4 1	1 2 5	1 2 7	1 3 0	1 4 3	1 3 9	1 2 8	1 1 6	1 4 5	1 0 2	1 0 6	1 1 0	1 1 2	1 1 3	1 1 4	1 1 8	1 2 0	1 2 6	1 3 1	1 3 4	1 3 6	1 4 7	1 4 8	Total Tissues/ Tumors
Urinary System Kidney Histiocytic sarcoma	+	+	4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Renal tubule, adenoma Urinary bladder Transitional epithelium, papilloma	+	+	4	- +	+	+	+	X +	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	3 49 1
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear Mesothelioma malignant	+	+ X	-+ 		+ X X	+	+	+ X	+ X	+ X	+ X X	+ X	+ X	+	+	+ X	+	+ X	+	+	+ X	+	+ X	+ X	+ X	50 1 26 2

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm 2 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 Number of Days on Study 6 2 6 9 0 2 2 5 8 9 9 9 9 9 1 2 2 4 4 6 6 6 7 7 8 6 0 7 6 9 7 8 6 9 0 0 1 1 6 9 4 9 3 4 5 8 9 1 1 6 **Carcass ID Number** 3 3 1 0 0 4 4 0 3 2 2 2 4 2 3 3 1 4 2 1 2 2 0 3 5 8 7 9 4 9323 3 2 3 8 9 5 2 0 7 5 6 6 9 4 1 5 0 **Alimentary System** Esophagus Intestine large, colon Α Α + + Intestine large, rectum + + + А + + + + + А + + ++ + + ++ Intestine large, cecum Α + А + Α Α + + + + + + + + + + + + + Intestine small, duodenum + + + + + + + + + + + + + Intestine small, jejunum А А Α А + + + + + + + + + + + + + + Intestine small, ileum Α + А + А А + + + + + + + + + + +++ + + ++ + + Liver + + + Mesentery + Х Lipoma Oral mucosa Pharyngeal, squamous cell papilloma Pancreas Salivary glands + + + + Stomach, forestomach Stomach, glandular + + + + ++ ++ + + + + +++ +++ +**Cardiovascular System** Blood vessel + Heart + ++ + + + ++ + + + + + + + + + + +++++++**Endocrine System** Adrenal cortex + Adrenal medulla + M + + + + Pheochromocytoma benign Х Х Bilateral, pheochromocytoma benign Islets, pancreatic + + + + + + + + + Adenoma Parathyroid gland + + + M+ + + + + + + + + + + Pituitary gland $^+_{\rm X}$ + + X + X x ХХ x х Х Pars distalis, adenoma Х Pars distalis, adenoma, multiple Thyroid gland + + + + + + + + + + + + + + + + + X + C-cell, adenoma Follicular cell, carcinoma **General Body System** None **Genital System** Epididymis Preputial gland Adenoma Prostate + + + + + ++ + + ++ + Seminal vesicle + + + + + + + + + + + + + + + + + + ++ $^{+}$ ++ Testes + Bilateral, interstitial cell, adenoma Х $X \ X \ X \ X$ Х XXXXXX Interstitial cell, adenoma Х ХХ Х Х

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

6	6	3	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
8	ę) (0	0	0	0	0	0	1	1	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	
8	6	3 3	3	3	3	4	7	8	2	3	0	3	4	4	4	4	4	4	4	4	4	4	4	4	4	
2	2	2 :	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	Total
~ 1							2															2				Tissues/
8				-	-		õ										-		3							Tumors
			-	-	-	-		_	-	-	_	-		÷	-	-	_	-	-	-	_	-		_		
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+		+ 1	A	+	+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
+		+ •	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
									+																	3
																										1
																										1
																	X									1
+		⊦ ·	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+		+ .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
																										50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	50
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+				49
	,														Х								Х	Х	Х	6
X																										3
+		+ •	+	+	+		+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	50
																										4
+		+ •	+	+		+	+														+	+	+	+	+	46
+		+ •			+	+	+	+	+					+		+	+	+	+		+				+	50
				х						Х		Х	Х		Х				37	Х		Х	Х			18
																										1
+		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	50
															v					Å						3 1
															Λ									_		
-		÷ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
т 1		 + .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- -	+	۔ ب	50 49
+	-		r	т.	77	-			7	7	т.	7-	7	7*	-		7	-17	-17	x	-	Ŧ	-	-		49
	_	F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		-	т.	<u>т</u>	50
+		, ⊢	г +		 	 	 	 	+	+	+ +	+	 +		-r +	+		-r +	-r +		 	- -	- -	-T 	 	50 50
		1° '	E	т.	-1-	-r	-1-	-T-	-T*	-T*	т.	-T-	7	Ч.	-17	Τ.	-1-	77	77	- T	-17	т.	-T	- T	-17	
+		F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		1	_ل_	+	50
+ \ \		+ ·	+ X	+	\mathbf{x}^+	+ X	\mathbf{x}^+	+	+ X	+	+ X	+	\mathbf{x}^+	\mathbf{x}^+	X^+	\mathbf{x}^+	+ X	\mathbf{x}^+	$^+_{\rm X}$	\mathbf{x}^+	+	\mathbf{x}^+	\mathbf{x}^+	+ X	+ X	50 32
	88 2 1 8 + + + + + + + + + + + + + + + + + +	8 9 8 6 2 2 1 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	8 9 0 0 0 0 1 1 1 2 2 3 3 4 7 8 2 3 0 3 4 2	8 9 0 0 0 0 1 1 1 2 2 3 3 3 4 7 8 2 3 0 3 4 4 2	8 9 0 0 0 0 1 1 2 2 3 3 3 2 3 3 3 0 0 0 3 4 4 4 4 2	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	8 9 0 0 0 1 1 2 2 3	8 9 0 0 0 1 1 2 2 3	8 9 0 0 0 1 1 2 2 3	8 9 0 0 0 1 1 2 2 3	8 9 0 0 0 1 1 2 2 3	8 9 0 0 0 1 1 2 2 3

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued) 2 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 Number of Days on Study 6 2 6 9 0 2 2 5 8 9 9 9 9 9 1 2 $2 \ 4 \ 4$ 6 6 6 7 7 8 6 0 7 6 9 7 8 6 9 0 0 1 1 6 9 4 9 3 4 5 8 9 1 1 6 2 **Carcass ID Number** 3 1 0 0 4 4 0 3 2 2 2 4 2 3 3 1 4 2 1 2 2 0 3 5 3 8 7 9 4 9 3 2 3 3 2 3 8 9 5 2 0 7 5 6 6 9 4 1 5 0 **Hematopoietic System** Bone marrow Lymph node Lymph node, bronchial Μ Μ Μ + + Μ + Μ + + Μ + + + Μ ++ + ++ ++ + Lymph node, mandibular + + + + + + + + + + + + + + Lymph node, mesenteric + + + + + + + + + + + + Lymph node, mediastinal + + + + + + + Spleen + + +++ + ++ ++ ++ + + + + + + + + Thymus Μ М Μ + + + + + + + + Μ + Thymoma benign **Integumentary System** + + M + + + M + + XMammary gland M + + + + Adenoma Fibroadenoma Skin Basal cell adenoma Keratoacanthoma Squamous cell papilloma Pinna, schwannoma malignant Х Х Sebaceous gland, adenoma Subcutaneous tissue, fibroma Х Subcutaneous tissue, myxoma **Musculoskeletal System** Bone Turbinate, chondroma **Nervous System** Brain Glioma malignant Peripheral nerve + Spinal cord + **Respiratory System** Larynx ММ ΜМ Μ + Μ M + + + +++ М + + Lung + + + + + + + + + + + + + + + + + + + Nose + + + + + + + + + + + + + + Trachea + Leiomyosarcoma **Special Senses System** Harderian gland + Х Carcinoma Zymbal's gland Carcinoma **Urinary System** Kidney + + + + + X + + Renal tubule, adenoma Renal tubule, carcinoma Urinary bladder + + + + + + + + + + +++ +++ + ++ + + +

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued) 6 6 7 7 7 7 7 7 7 7 7 777 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 8 9 0 0 0 0 0 0 1 1 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 8 6 3 3 3 4 7 8 $2 \ 3 \ 0 \ 3 \ 4 \ 4$ 4 4 4 4 4 4 4 4 4 4 4 2 Total **Carcass ID Number** 0 3 4 4 0 2 4 3 1 3 3 0 0 0 1 1 1 1 1 2 2 4 4 1 4 Tissues/ 8 6 4 6 8 7 0 4 9 5 1 6 2 5 8 0 1 2 3 4 1 7 0 1 7 Tumors **Hematopoietic System** Bone marrow 50 Lymph node 9 Lymph node, bronchial 39 Μ Μ Μ М + ++ + Lymph node, mandibular 49 Μ Lymph node, mesenteric 50 + Lymph node, mediastinal 50 Spleen 50 + Thymus 46 Thymoma benign X 1 **Integumentary System** Mammary gland 46 Μ Adenoma 1 Fibroadenoma 2 Х Skin 50 Basal cell adenoma Х 1 Х Х Keratoacanthoma 2 Х Squamous cell papilloma 1 Pinna, schwannoma malignant 1 Sebaceous gland, adenoma 1 Subcutaneous tissue, fibroma Х Х Х 3 Subcutaneous tissue, myxoma 1 **Musculoskeletal System** 50 Bone + Turbinate, chondroma Х 1 **Nervous System** Brain 50 Glioma malignant 1 Peripheral nerve 2 + Spinal cord 3 + **Respiratory System** Larynx 41 50 Lung + + + Nose + 50 + + + + ++ + 50 Trachea + + + Leiomyosarcoma Х 1 **Special Senses System** Harderian gland 1 Carcinoma 1 Zymbal's gland 1 X Carcinoma 1 **Urinary System** Kidney 50 $^+_{\rm X}$ + 2 Renal tubule, adenoma Renal tubule, carcinoma Х 1 Urinary bladder 50 + +

TABLE A2

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

Number of Days on Study	6	4 2 0	4 6 7	9	0		2	5	8	9	9	9	9	9	6 1 9	2	2	4	4	6	6	6	7	6 7 1	8
Carcass ID Number	3	2 3 7	1	0	0	4	4	0	3	2	2	2	4	2	3	3	1	4	2	1	2	2	0	2 3 5	5
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+	÷	+	+ X	+ X	+ X	+	+ X			+ X		+ X			+	+		+ X			+	+	+	+

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

Number of Days on Study	8		0	0	0	7 0 4	0	0	1	1	2	2	3	3	3	3	3	3	3	3	3	3			3	
Carcass ID Number	1	0		4	4	2 0 7	2	4	3	1	3	3	0	0	0	1	2 1 1	1	1	1	2	2	2 4 0	2 4 1		Total Tissues/ Tumors
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+ X	+	+	+ X	+ X	+	+ X	+ X	+	+	+ X	+ X		+	50 32 1

	3	-	3	4	5	5	5					55		5	5	5		5	5	5	5		5	
Number of Days on Study	7 7	8 3	9 3	8 3	0 0	0 7	3 8	3 9				6 37		7 2	8 4	8 6	8 7	8 7	8 7	8 8	9 0	9 0	9 1	9 4
	3	3	3	3	3	3	3	3	3	3	3	33	3	3	3	3	3	3	3	3	3	3	3	3
Carcass ID Number	4 4	4 7	2 9	2 7	4 3	3 6	1 5			0 9		20 14		1 7	2 4	1 3	1 1	1 9	2 5		1 4	3 7		4 9
Alimentary System																								
Esophagus	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	+	А	+	+	+	+	+	+	+	+ ·	+ +	A	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	Α	+	+	+	+	+	+	+	+	+
Intestine large, cecum	+	+	А	А	+	А	+	+	+	А	A	+ +	A	Α	Α	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	+	+	+	+	+	+						+		+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	+	A			A							+ +				+	+	+	+	+	+	+	+	+
Intestine small, ileum	+	А	А		А			+				+ +				+	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+
Mesentery												+					+					+		
Oral mucosa																								
Pharyngeal, squamous cell papilloma																								
Pancreas	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	+
Cardiovascular System																								
Blood vessel	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Heart	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																								
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+ •	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+ •	+ +	+	Μ	+	+	+	+	+	+	+	Μ	+	+
Pheochromocytoma malignant						Х											Х							
Pheochromocytoma benign										Х								Х		Х				
Bilateral, pheochromocytoma benign									Х															
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma																								
Parathyroid gland	+	+	+	+	М	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+
Pituitary gland	+	+	+	Μ	М	+	+	+	+	+	+	+ +	M	[+	М	+	+	+	+	М	+	+	+	+
Pars distalis, adenoma	Х						Х					ХХ					Х				Х	Х	Х	
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+
C-cell, adenoma																								
Follicular cell, carcinoma																								
General Body System																								
None																								
Genital System																								
					,															,	,			
Epididymis Preputial gland	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	+
Adenoma	+	+	+	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+
					v				v															
Bilateral, adenoma					X				X											,				
Prostate Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	• +	+	+	+	+	+	+	+	+	+	+	+
Festes Bilateral, interstitial cell, adenoma	+	+	+	+	\mathbf{v}^+	+ X	+	\mathbf{v}^+	$^+$ v	+ V	+ · v ·	+ + X X		+	+	$^+$ v	+	$^+$ v	\mathbf{v}^+	+ X	\mathbf{v}^+	$^+$ v	\mathbf{v}^+	\mathbf{v}^+
Dilateral, interstitual Cell, adenomia					Λ	Λ		Λ	Λ	Λ	Λ.	ΛĂ	Λ	А		Х		Λ	л	~	~	~	Λ	Δ

5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 Number of Days on Study 9 9 1 2 2 4 4 4 5 5 6 6 6 6 7 7 8 8 9 9 0 0 1 3 3 6 7 6 6 7 1 3 5 1 2 1 3 5 8 2 9 0 1 6 6 2 9 9 4 4 3 Total **Carcass ID Number** 4 1 3 3 4 0 4 2 2 2 3 3 0 3 3 2 1 4 4 0 3 0 0 1 3 Tissues/ 3 8 4 9 0 5 2 0 2 8 2 5 2 1 0 3 2 6 8 1 8 7 3 0 Tumors 1 **Alimentary System** Esophagus 50 Intestine large, colon 48 Intestine large, rectum 48 Α + + + + Intestine large, cecum 39 Α A Α + + + + + + + + + + + + + Intestine small, duodenum 50 + + + + + + + + + + + Intestine small, jejunum Α A А А А А Α 34 + + + + + + + + + + + + Intestine small, ileum 37 A А Α А + + + + + + + + + + + + + + +++ ++ + Liver 49 Mesentery 3 Oral mucosa 1 Pharyngeal, squamous cell papilloma Х 1 Pancreas + 50 + +50 Salivary glands + ++ + + + + Stomach, forestomach 50 + + +++ + + Stomach, glandular 50 + + + **Cardiovascular System** Blood vessel 50 + + +++ + + ++ + ++ ++ + + ++ + ++ Heart + 50 + + + + **Endocrine System** Adrenal cortex 50 Adrenal medulla 48 + + + + + + + + + Pheochromocytoma malignant 2 Pheochromocytoma benign Х Х хх ХХ 9 Bilateral, pheochromocytoma benign Х 3 50 Islets, pancreatic + + + + + + Adenoma Х Х Х 4 Parathyroid gland M + Μ + Μ 46 Pituitary gland 45 + + + + + + + Х Х Х 18 Pars distalis, adenoma Х Х Х Х Х Х Х Thyroid gland 50 + + + Х C-cell, adenoma Х 2 Follicular cell, carcinoma 1 Х **General Body System** None **Genital System** Epididymis 50 50 2 Preputial gland + X + + Х Adenoma 2 Bilateral, adenoma Prostate 50 + + 50 Seminal vesicle + + + + + + + + + + + ++ + + + + ++ + Testes + + + + + + + + 50 + + + + + + + + + + + + + + Bilateral, interstitial cell, adenoma x x x x x x x x x ХХ X X X X X X X X X X X X X 40 Interstitial cell, adenoma ХХ 4

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued)

TABLE A2

	-						-	-	-	-	~	-	~	~	~	~	~	~	~	~	~	~	~	-	~
Number of Dave on Study	3		33 39		45 80	5 0		5 3	5	5 4	5 5	5 6	5 6	5 6	5 7	5 0	5 0	5 8	5 8	5 8	5 8	5 9	5 9	5 9	5 9
Number of Days on Study	7 7		5 8 3 3		3 0			3 9	4 6	4 7	5 5	6 3	6 7	6 9	7 2	8 4	8 6	o 7		о 7	о 8	9 0	9 0	9 1	
	3		3 3		33	3	3	3	3	3			3		3		3		3		3	3	3	3	3
Carcass ID Number	4 4		42 79		24 73				1 6		0 8		0 4		1 7		1 3					1 4	3 7	4 5	
Hematopoietic System																									
Bone marrow	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node				_	_		+		+			+		+				+		+					+
Lymph node, bronchial	+		+ +	- 1	M +	• +	+	+		+			+							+	+	+	Μ	Μ	+
Lymph node, mandibular	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node, mesenteric	+		+ +		+ +	· +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node, mediastinal	+		+ +		+ +	·N	1 +						M +		+		+ +	++	+	++	+	+	+	+	+
Spleen Thymus	+		+ +		+ + + +	· +	· +	+ M	++				++								+ M	+	+	+	+ +
Integumentary System																									
Mammary gland	+		+ +		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Skin	- +		 + .		 + .+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	, +	+	+	, +	+	+
Basal cell carcinoma	Т				. т		1.	1.	'		'	'	'		1		'		'	'	'	'	'	'	
Keratoacanthoma																									
Subcutaneous tissue, lipoma																									
Musculoskeletal System																									
Bone	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Skeletal muscle																									
Sarcoma																									
Nervous System																									
Brain	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Glioma malignant					Х	C .																			
Respiratory System																									
Larynx	Ν	1	+ +		+ N	1 +	M	[+	+	+	+	Μ	М	Μ	+	+	М	+	+	М	М	+	М	М	М
Lung	+		+ +		+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma																									
Nose	+		+ +		+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Frachea	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Special Senses System																									
Zymbal's gland																									
Urinary System																									
Kidney	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Renal tubule, adenoma																			Х						
Renal tubule, carcinoma																		Х							
Urinary bladder	+		+ +	- 1	A +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Systemic Lesions																									
Multiple organs	+		+ +		+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Leukemia mononuclear		-	XX	ί.			Х		Х			Х								Х					Х

5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 Number of Days on Study 9 9 1 2 2 4 4 4 5 5 6 6 6 6 7 7 8 8 9 9 0 0 1 3 3 6 7 6 6 7 1 3 5 1 2 1 3 5 8 2 9 0 1 6 6 2 9 9 4 4 3 Total **Carcass ID Number** $0 \ \ 4 \ \ 2 \ \ 2 \ \ 2 \ \ 3 \ \ 3 \ \ 0 \ \ 3 \ \ 3 \ \ 2 \ \ 1 \ \ 4 \ \ 4 \ \ 0 \ \ 3 \ \ 0 \ \ 0 \ \ 1$ 3 4 1 3 3 4 Tissues/ 3 8 4 9 0 5 2 0 2 8 2 5 2 1 0 3 2 6 8 1 8 7 3 0 Tumors 1 **Hematopoietic System** Bone marrow 50 Lymph node 14 + + Lymph node, bronchial 28 Μ M М ММММ Μ M Μ + + + ++ + +Μ + Lymph node, mandibular 50 + + Lymph node, mesenteric 50 Lymph node, mediastinal 47 Spleen 50 + + + + + + + + + + + + + Thymus 44 Μ Μ **Integumentary System** Mammary gland 49 Μ + + + Skin 50 + + + + + + + x Basal cell carcinoma 1 Keratoacanthoma Х Х 2 Х Subcutaneous tissue, lipoma 1 **Musculoskeletal System** 50 Bone + + Skeletal muscle + 1 Х Sarcoma 1 **Nervous System** Brain 50 + Glioma malignant 1 **Respiratory System** 35 Larynx M Μ 50 Lung + + Alveolar/bronchiolar adenoma 1 X Nose 50 + + + Trachea 50 ++ +**Special Senses System** Zymbal's gland 1 + **Urinary System** Kidney 50 + + Х Renal tubule, adenoma Х 4 Renal tubule, carcinoma Х 3 Х Urinary bladder 49 + + + + + + + ++ Systemic Lesions 50 Multiple organs + 9 Leukemia mononuclear Х Х

Individual Animal Tumor Pathology of Male Rats in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued)

TABLE A3 Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ppm	750 ppm
Adrenal Medulla: Benign Pheochromocytoma				
Overall rate ^a	13/50 (26%)	13/50 (26%)	9/49 (18%)	12/48 (25%)
Adjusted rate ^b	48.8%	62.0%	42.6%	100.0%
Ferminal rate ^C	4/15 (27%)	7/14 (50%)	4/13 (31%)	2/2 (100%)
First incidence (days)	584	584	590	546
Life table test ^d	P = 0.003	P = 0.545	P = 0.279N	P = 0.014
Logistic regression test	P = 0.211	P = 0.552	P = 0.233N	P = 0.307
Cochran-Armitage test ^d	P = 0.516N			
Fisher exact test ^d		P=0.590N	P=0.251N	P=0.547N
Adrenal Medulla: Benign or Malignant Pheochro	mocytoma			
Overall rate	13/50 (26%)	13/50 (26%)	9/49 (18%)	14/48 (29%)
Adjusted rate	48.8%	62.0%	42.6%	100.0%
Terminal rate	4/15 (27%)	7/14 (50%)	4/13 (31%)	2/2 (100%)
First incidence (days)	584	584	590	507
Life table test	P< 0.001	P = 0.545	P=0.279N	P=0.005
Logistic regression test	P=0.106	P = 0.552	P=0.233N	P = 0.214
Cochran-Armitage test	P = 0.379			
Fisher exact test		P = 0.590N	P = 0.251 N	P=0.450
Kidney (Renal Tubule): Adenoma (Single Sections				
Overall rate	0/50 (0%)	3/50 (6%)	2/50 (4%)	4/50 (8%)
Adjusted rate	0.0%	11.2%	11.0%	56.9%
Ferminal rate	0/15 (0%)	0/14 (0%)	1/13 (8%)	1/2 (50%)
First incidence (days)	e	617	671	587
Life table test	P = 0.006	P = 0.120	P = 0.236	P = 0.008
ogistic regression test	P = 0.064	P = 0.119	P = 0.240	P = 0.037
Cochran-Armitage test	P = 0.109			
ïsher exact test		P=0.121	P = 0.247	P = 0.059
Kidney (Renal Tubule): Adenoma (Step Sections)				
Overall rate	3/50 (6%)	2/50 (4%)	7/50 (14%)	17/50 (34%)
Adjusted rate	13.4%	14.3%	39.7%	88.8%
Cerminal rate	0/15 (0%)	2/14 (14%)	4/13 (31%)	1/2 (50%)
First incidence (days)	685 D 0 001	734 (T)	671 D 0 144	572 D 0 001
ife table test	P< 0.001	P = 0.519N	P = 0.144	P< 0.001
Logistic regression test	P< 0.001	P = 0.516N	P = 0.159	P< 0.001
Cochran-Armitage test Fisher exact test	P< 0.001	P=0.500N	P=0.159	P< 0.001
(idnov (Donal Tubulo). Adonoma (Single and Sta	n Sactions)			
Kidney (Renal Tubule): Adenoma (Single and Ste Dverall rate	3/50 (6%)	5/50 (10%)	7/50 (14%)	20/50 (40%)
Adjusted rate	13.4%	23.9%	39.7%	100.0%
erminal rate	0/15 (0%)	2/14 (14%)	4/13 (31%)	2/2 (100%)
First incidence (days)	685	617	671	572
Life table test	P< 0.001	P = 0.343	P = 0.144	P< 0.001
ogistic regression test	P< 0.001	P=0.337	P = 0.159	P< 0.001
Cochran-Armitage test	P< 0.001			
Fisher exact test		P = 0.357	P = 0.159	P< 0.001

TABLE A	A 3
---------	------------

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ррт	250 ppm	750 ppm
Kidney (Renal Tubule): Carcinoma (Single Sect	ions)			
Overall rate	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Adjusted rate	0.0%	0.0%	7.7%	12.5%
Ferminal rate	0/15 (0%)	0/14 (0%)	1/13 (8%)	0/2 (0%)
First incidence (days)	_	_	734 (T)	587
Life table test	P = 0.002	f	P = 0.471	P = 0.063
logistic regression test	P = 0.018	_	P = 0.471	P = 0.129
Cochran-Armitage test	P = 0.021			
Fisher exact test		_	P = 0.500	P=0.121
Kidney (Renal Tubule): Carcinoma (Step Sectio	ns)			
Overall rate	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Adjusted rate	0.0%	0.0%	7.7%	12.5%
'erminal rate	0/15 (0%)	0/14 (0%)	1/13 (8%)	0/2 (0%)
'irst incidence (days)	_	_	734 (T)	587
Life table test	P = 0.002	_	P = 0.471	P = 0.063
ogistic regression test	P = 0.018	_	P = 0.471	P = 0.129
Cochran-Armitage test	P = 0.021			- 01180
isher exact test		_	P = 0.500	P=0.121
Kidney (Renal Tubule): Carcinoma (Single and	Sten Sections)			
Overall rate	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Adjusted rate	0.0%	0.0%	7.7%	12.5%
'erminal rate	0/15 (0%)	0/14 (0%)	1/13 (8%)	0/2 (0%)
irst incidence (days)	_	_	734 (T)	587
ife table test	P = 0.002	_	P = 0.471	P = 0.063
ogistic regression test	P = 0.002 P = 0.018	_	P = 0.471	P = 0.129
Cochran-Armitage test	P = 0.021		1 - 0.171	1 - 0.120
isher exact test	1 0.001	_	P= 0.500	P=0.121
Kidney (Renal Tubule): Adenoma or Carcinoma	a (Single Sections)			
Overall rate	0/50 (0%)	3/50 (6%)	3/50 (6%)	7/50 (14%)
Adjusted rate	0.0%	11.2%	18.4%	62.4%
'erminal rate	0/15 (0%)	0/14 (0%)	2/13 (15%)	1/2 (50%)
irst incidence (days)	_	617	671	587
life table test	P< 0.001	P = 0.120	P = 0.111	P< 0.001
ogistic regression test	P = 0.003	P = 0.119	P = 0.121	P = 0.006
Cochran-Armitage test	P = 0.007			
isher exact test		P=0.121	P=0.121	P=0.006
Kidney (Renal Tubule): Adenoma or Carcinoma	a (Step Sections)			
Overall rate	3/50 (6%)	2/50 (4%)	8/50 (16%)	18/50 (36%)
Adjusted rate	13.4%	14.3%	46.4%	89.1%
'erminal rate	0/15 (0%)	2/14 (14%)	5/13 (38%)	1/2 (50%)
irst incidence (days)	685	734 (T)	671	572
ife table test	P< 0.001	P = 0.519N	P = 0.087	P< 0.001
ogistic regression test	P< 0.001	P = 0.516N	P = 0.008	P< 0.001
Cochran-Armitage test	P< 0.001	1 0.01010	1 0.000	1 . 0.001
	1 . 5.001			P< 0.001

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ррт
Kidney (Renal Tubule): Adenoma or Caro	cinoma (Single and Step Section	s)		
Overall rate	3/50 (6%)	5/50 (10%)	8/50 (16%)	21/50 (42%)
Adjusted rate	13.4%	23.9%	46.4%	100.0%
Terminal rate	0/15 (0%)	2/14 (14%)	5/13 (38%)	2/2 (100%)
First incidence (days)	685	617	671	572
Life table test	P< 0.001	P = 0.343	P = 0.087	P< 0.001
Logistic regression test	P< 0.001	P = 0.337	P = 0.098	P< 0.001
Cochran-Armitage test	P< 0.001			
Fisher exact test		P=0.357	P = 0.100	P< 0.001
Liver: Hepatocellular Adenoma				
Overall rate	0/50 (0%)	3/50 (6%)	0/50 (0%)	0/49 (0%)
Adjusted rate	0.0%	9.7%	0.0%	0.0%
Terminal rate	0/15 (0%)	0/14 (0%)	0/13 (0%)	0/2 (0%)
First incidence (days)	_	560	_	_
Life table test	P = 0.326N	P = 0.112	_	_
Logistic regression test	P = 0.246N	P = 0.125	_	_
Cochran-Armitage test	P=0.259N			
Fisher exact test		P=0.121	—	—
Lung: Alveolar/bronchiolar Adenoma or (Carcinoma			
Overall rate	3/50 (6%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
Adjusted rate	18.4%	5.3%	0.0%	10.0%
Terminal rate	2/15 (13%)	0/14 (0%)	0/13 (0%)	0/2 (0%)
First incidence (days)	714	713	_	679
Life table test	P = 0.643	P = 0.309N	P = 0.146N	P = 0.593
Logistic regression test	P = 0.635N	P=0.310N	P=0.119N	P = 0.740N
Cochran-Armitage test	P = 0.339N			
Fisher exact test		P = 0.309N	P=0.121N	P=0.309N
Mammary Gland: Fibroadenoma				
Overall rate	2/50 (4%)	3/50 (6%)	2/50 (4%)	0/50 (0%)
Adjusted rate	13.3%	21.4%	13.8%	0.0%
Terminal rate	2/15 (13%)	3/14 (21%)	1/13 (8%)	0/2 (0%)
First incidence (days)	734 (T)	734 (T)	720	— D. 0.700N
Life table test	P = 0.547N	P = 0.467	P = 0.657	P = 0.726N
Logistic regression test	P = 0.503N	P = 0.467	P = 0.681	P = 0.726N
Cochran-Armitage test	P = 0.116N	D 0 700	D 0 001N	D 0.047N
Fisher exact test		P = 0.500	P = 0.691N	P=0.247N
Mammary Gland: Fibroma, Fibroadenon		F/F0 (100/)	0/50 (00/)	0/50 (00/)
Overall rate	2/50 (4%)	5/50 (10%)	3/50 (6%)	0/50 (0%)
Adjusted rate	13.3%	27.1%	16.5%	0.0%
Terminal rate	2/15 (13%) 724 (T)	3/14 (21%)	1/13 (8%)	0/2 (0%)
First incidence (days) Life table test	734 (T) P- 0 282N	549 P-0 102	643 P- 0 470	— P_ 0 726N
Life table test Logistic regression test	P = 0.382N $P = 0.180N$	P = 0.193 P = 0.199	P = 0.470 P = 0.507	P = 0.726N P = 0.726N
	P = 0.180 N P = 0.073 N	r = 0.199	r = 0.307	r = 0.7201N
Cochran-Armitage test Fisher exact test	P = 0.073 N	P=0.218	P = 0.500	P=0.247N
risher exact test		$r = 0.21\delta$	r = 0.300	r = 0.2471N

TABLE A3 Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Oral Cavity (Oral Mucosa and Tongue): S	guamous Call Panilloma			
Oral Cavity (Oral Mucosa and Tongue). S	3/50 (6%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
Adjusted rate	12.6%	0.0%	7.7%	4.0%
Ferminal rate	1/15 (7%)	0/14 (0%)	1/13 (8%)	0/2 (0%)
First incidence (days)	570	0/14 (0/0) —	734 (T)	596
Life table test	P = 0.618	P = 0.132N	P = 0.335N	P = 0.639N
Logistic regression test	P = 0.505N	P = 0.124N	P = 0.303N	P = 0.348N
Cochran-Armitage test	P = 0.442N	1 - 0.12414	1 - 0.00010	1 - 0.0401
Fisher exact test	1 - 0.1161	P=0.121N	P = 0.309N	P=0.309N
ancreatic Islets: Adenoma				
Overall rate	3/50 (6%)	4/50 (8%)	4/50 (8%)	4/50 (8%)
Adjusted rate	16.0%	17.5%	22.5%	60.5%
Ferminal rate	1/15 (7%)	1/14 (7%)	2/13 (15%)	1/2 (50%)
First incidence (days)	692	560	671	645
Life table test	P = 0.033	P = 0.492	P = 0.477	P = 0.043
Logistic regression test	P = 0.220	P = 0.483	P = 0.509	P = 0.163
Cochran-Armitage test	P = 0.493			
Fisher exact test		P = 0.500	P = 0.500	P = 0.500
Pancreatic Islets: Adenoma or Carcinoma				
Overall rate	5/50 (10%)	5/50 (10%)	4/50 (8%)	4/50 (8%)
Adjusted rate	23.3%	23.9%	22.5%	60.5%
Cerminal rate	1/15 (7%)	2/14 (14%)	2/13 (15%)	1/2 (50%)
First incidence (days)	590	560	671	645
Life table test	P = 0.116	P = 0.617	P = 0.523N	P = 0.152
ogistic regression test	P = 0.464	P = 0.612	P = 0.492N	P = 0.462
Cochran-Armitage test	P = 0.429N			
isher exact test		P = 0.630N	P = 0.500 N	P=0.500N
Pituitary Gland (Pars Distalis): Adenoma				
Overall rate	25/49 (51%)	19/50 (38%)	19/50 (38%)	18/45 (40%)
Adjusted rate	79.7%	66.7%	65.8%	82.7%
Cerminal rate	9/14 (64%)	7/14 (50%)	6/13 (46%)	1/2 (50%)
First incidence (days)	391	518	420	377
ife table test	P = 0.034	P = 0.222N	P=0.237N	P = 0.068
ogistic regression test	P = 0.355N	P=0.147N	P = 0.135N	P = 0.234N
Cochran-Armitage test	P = 0.314N			
isher exact test		P=0.135N	P=0.135N	P=0.194N
reputial Gland: Adenoma				
Overall rate	3/49 (6%)	1/50 (2%)	1/49 (2%)	4/50 (8%)
Adjusted rate	12.5%	2.3%	7.7%	42.7%
erminal rate	1/14 (7%)	0/14 (0%)	1/13 (8%)	0/2 (0%)
irst incidence (days)	574	560	734 (T)	500
ife table test	P = 0.048	P=0.318N	P = 0.314N	P=0.172
ogistic regression test	P = 0.228	P = 0.291N	P = 0.302N	P = 0.502
Cochran-Armitage test	P = 0.227			
Fisher exact test		P = 0.301N	P=0.309N	P = 0.511

TABLE A3 Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Skin: Keratoacanthoma				
Overall rate	3/50 (6%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
Adjusted rate	11.2%	9.1%	15.4%	54.5%
Terminal rate	1/15 (7%)	0/14 (0%)	2/13 (15%)	1/2 (50%)
First incidence (days)	528	637	734 (T)	672
Life table test	P = 0.306	P = 0.516N	P = 0.543N	P = 0.462
Logistic regression test	P = 0.608	P = 0.501N	P = 0.500N	P = 0.606N
Cochran-Armitage test	P = 0.491N	1 0100111	1 0100011	
Fisher exact test	1 0110111	P=0.500N	P = 0.500 N	P = 0.500N
skin: Squamous Cell Papilloma or Kerat	oacanthoma			
Overall rate	5/50 (10%)	3/50 (6%)	3/50 (6%)	2/50 (4%)
Adjusted rate	20.1%	15.6%	23.1%	54.5%
Ferminal rate	2/15 (13%)	1/14 (7%)	3/13 (23%)	1/2 (50%)
First incidence (days)	528	637	734 (T)	672
Life table test	P = 0.483	P = 0.393N	P = 0.407N	P = 0.646
Logistic regression test	P = 0.422N	P = 0.368N	P = 0.353N	P = 0.342N
Cochran-Armitage test	P = 0.225N			
isher exact test		P=0.357N	P = 0.357N	P=0.218N
Skin: Squamous Cell Papilloma, Keratoa	icanthoma, Basal Cell Adenoma,	, or Basal Cell Ca	arcinoma	
Overall rate	5/50 (10%)	3/50 (6%)	4/50 (8%)	3/50 (6%)
Adjusted	20.1%	15.6%	26.2%	69.7%
Terminal	2/15 (13%)	1/14 (7%)	3/13 (23%)	1/2 (50%)
First incidence (days)	528	637	688	672
Life table	P = 0.183	P = 0.393N	P = 0.548N	P = 0.358
ogistic regression	P = 0.535	P = 0.368N	P = 0.497N	P = 0.575N
Cochran-Armitage	P = 0.389N			
isher exact		P=0.357N	P = 0.500N	P=0.357N
Skin (Subcutaneous Tissue): Fibroma				
Overall rate	1/50 (2%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
Adjusted rate	6.7%	5.3%	18.8%	0.0%
Ferminal rate	1/15 (7%)	0/14 (0%)	2/13 (15%)	0/2 (0%)
First incidence (days)	734 (T)	713	688	_
Life table test	P = 0.624	P=0.759	P = 0.269	P=0.882N
ogistic regression test	P = 0.690 N	P=0.759	P = 0.302	P=0.882N
Cochran-Armitage test	P = 0.339N			
risher exact test		P=0.753N	P=0.309	P=0.500N
Skin (Subcutaneous Tissue): Fibrosarcon	1a or Sarcoma			
(0/50 (0%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
	0.004	10.9%	0.0%	0.0%
Overall rate	0.0%		0/13 (0%)	0/2 (0%)
Overall rate Adjusted rate	0.0% 0/15 (0%)	0/14 (0%)	0/13 (0%)	0/2 (0/0)
Overall rate Adjusted rate Ferminal rate		0/14 (0%) 560	0/13 (0%) —	
Overall rate Adjusted rate Ferminal rate First incidence (days)		· · ·	0/13 (0%) 	
Overall rate Adjusted rate Ferminal rate First incidence (days) Life table test	0/15 (0%)	560	0/13 (0%) 	
Overall rate Adjusted rate Ferminal rate First incidence (days) Life table test Logistic regression test Cochran-Armitage test	0/15 (0%) — P=0.380N	560 P= 0.122		

TABLE A	43
---------	----

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Skin (Subcutaneous Tissue): Fibroma, Myxoma,	Fibrosarcoma or Sarco	ma		
Overall rate	1/50 (2%)	4/50 (8%)	4/50 (8%)	0/50 (0%)
Adjusted rate	6.7%	15.6%	20.4%	0.0%
Ferminal rate	1/15 (7%)	0/14 (0%)	2/13 (15%)	0/2 (0%)
First incidence (days)	734 (T)	560	266	
Life table test	P = 0.487N	P = 0.182	P = 0.157	P=0.882N
ogistic regression test	P = 0.323N	P = 0.171	P = 0.181	P = 0.882N
Cochran-Armitage test	P = 0.155N	1 0.171	1 0.101	1 0.00011
Fisher exact test	1 - 0.10010	P=0.181	P=0.181	P=0.500N
estes: Bilateral Adenoma				
Overall rate	27/50 (54%)	23/50 (46%)	32/50 (64%)	40/50 (80%)
Adjusted rate	96.0%	91.0%	96.5%	100.0%
'erminal rate	14/15 (93%)	12/14 (86%)	12/13 (92%)	2/2 (100%)
First incidence (days)	608	538	590	500
Life table test	P< 0.001	P = 0.364N	P = 0.185	P< 0.001
Logistic regression test	P< 0.001	P = 0.313N	P = 0.103 P = 0.177	P< 0.001
Cochran-Armitage test	P< 0.001	1 - 0.01010	1 = 0.177	1 < 0.001
isher exact test	1 < 0.001	P = 0.274N	P=0.208	P=0.005
Cestes: Adenoma				
Overall rate	36/50 (72%)	33/50 (66%)	40/50 (80%)	44/50 (88%)
Adjusted rate	100.0%	100.0%	100.0%	100.0%
'erminal rate	15/15 (100%)	14/14 (100%)	13/13 (100%)	2/2 (100%)
irst incidence (days)	497	538	420	483
life table test	P< 0.001	P = 0.480N	P = 0.259	P< 0.001
ogistic regression test	P< 0.001	P = 0.404N	P = 0.194	P = 0.001
Cochran-Armitage test	P = 0.010	1 0.10111	1 0.101	1 0.001
isher exact test	1 0.010	P=0.333N	P = 0.241	P=0.039
Thyroid Gland (C-cell): Adenoma	0/50 (00/)	0/40 (100/)	0/50 (00/)	0/50 (40()
Overall rate	3/50 (6%)	6/49 (12%)	3/50 (6%)	2/50 (4%)
adjusted rate	20.0%	32.7%	13.0%	30.8%
Cerminal rate	3/15 (20%)	3/14 (21%)	1/13 (8%)	0/2 (0%)
irst incidence (days)	734 (T)	617	591	665 D
ife table test	P = 0.366	P = 0.223	P = 0.633	P = 0.208
ogistic regression test	P = 0.539N	P = 0.217	P = 0.659N	P = 0.390
Cochran-Armitage test Fisher exact test	P=0.217N	P=0.233	P = 0.661N	P=0.500N
Fhyroid Gland (C-cell): Adenoma or Carcinoma Dverall rate	5/50 (10%)	6/49 (12%)	3/50 (6%)	2/50 (4%)
	5/50 (10%) 27.5%	6/49 (12%) 32.7%	3/50 (6%) 13.0%	2/50 (4%) 30.8%
Adjusted rate	27.5% 3/15 (20%)			
Ferminal rate		3/14 (21%)	1/13 (8%)	0/2 (0%)
'irst incidence (days)	661 D 0 552	617 D 0 481	591 D 0 284N	665 D 0 444
ife table test	P = 0.553	P = 0.481	P = 0.384N	P = 0.444
ogistic regression test	P = 0.342N	P = 0.474	P = 0.349N	P = 0.676N
Cochran-Armitage test	P = 0.112N	D 0 490	D 0.957N	D 0.910M
isher exact test		P = 0.486	P = 0.357N	P = 0.218N

TABLE	A3
-------	----

Statistical Analysis of Primary Neoplasms in Male Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
All Organs: Mononuclear Cell Leukemia				
Overall rate	27/50 (54%)	26/50 (52%)	32/50 (64%)	9/50 (18%)
Adjusted rate	74.7%	79.3%	83.1%	62.2%
Terminal rate	7/15 (47%)	8/14 (57%)	7/13 (54%)	1/2 (50%)
First incidence (days)	570	582	496	383
Life table test	P = 0.412N	P = 0.543	P = 0.264	P = 0.287N
Logistic regression test	P< 0.001N	P = 0.555N	P = 0.166	P< 0.001N
Cochran-Armitage test	P< 0.001N			
Fisher exact test	1 . 0.00111	P = 0.500N	P=0.208	P< 0.001N
All Organs: Benign Neoplasms				
Overall rate	48/50 (96%)	44/50 (88%)	48/50 (96%)	48/50 (96%)
Adjusted rate	100.0%	100.0%	100.0%	100.0%
Terminal rate	15/15 (100%)	14/14 (100%)	13/13 (100%)	2/2 (100%)
First incidence (days)	391	518	266	377
Life table test	P< 0.001	P = 0.452N	P = 0.475	P< 0.001
Logistic regression test	P = 0.184	P = 0.205N	P = 0.667	P = 0.586
Cochran-Armitage test	P = 0.296		1 01001	1 01000
Fisher exact test		P = 0.134N	P=0.691N	P=0.691N
All Organs: Malignant Neoplasms				
Overall rate	33/50 (66%)	32/50 (64%)	37/50 (74%)	17/50 (34%)
Adjusted rate	83.6%	85.7%	89.6%	85.3%
Terminal rate	9/15 (60%)	9/14 (64%)	9/13 (69%)	1/2 (50%)
First incidence (days)	497	560	420	383
Life table test	P = 0.225	P = 0.532	P = 0.310	P = 0.368
Logistic regression test	P = 0.001N	P = 0.551N	P = 0.247	P = 0.003N
Cochran-Armitage test	P< 0.001N			
Fisher exact test		P = 0.500N	P=0.257	P=0.001N
All Organs: Benign or Malignant Neoplasms				
Overall rate	49/50 (98%)	45/50 (90%)	50/50 (100%)	50/50 (100%)
Adjusted rate	100.0%	100.0%	100.0%	100.0%
Terminal rate	15/15 (100%)	14/14 (100%)	13/13 (100%)	2/2 (100%)
First incidence (days)	391	518	266	377
Life table test	P< 0.001	P = 0.454N	P = 0.430	P< 0.001
Logistic regression test	P = 0.059	P = 0.151N	P = 0.349	_
Cochran-Armitage test	P = 0.081		- 0.010	
Fisher exact test	1 - 0.001	P = 0.102N	P = 0.500	P = 0.500

(T)Terminal sacrifice

^a Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, kidney, liver, lung, pancreatic islets, pituitary gland, preputial gland, testes, and thyroid gland; for other tissues, denominator is number of animals necropsied.

^b Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by **N**.

^e Not applicable; no neoplasms in animal group

f Value of statistic cannot be computed.

TABLE A4a

Historical Incidence of Renal Tubule Neoplasms in Chamber Control Male F344/N Rats^a

		Incidence in Controls		
Study	Adenoma	Carcinoma	Adenoma or Carcinoma	
Historical Incidence at IIT Researc	ch Institute			
Isobutyl Nitrite	0/45	0/45	0/45	
Overall Historical Incidence				
Total Standard deviation Range	6/652 (0.9%) 1.3% 0%-4%	0/652 (0%)	6/652 (0.9%) 1.3% 0%-4%	

^a Data as of 12 May 1995

TABLE A4b Historical Incidence of Testicular Adenoma in Chamber Control Male F344/N Rats^a

Study	Incidence in Controls
Historical Incidence at IIT Research Institute	
Isobutyl Nitrite	31/46
Overall Historical Incidence	
Total Standard deviation Range	450/655 (68.7%) 8.7% 54%-83%

^a Data as of 12 May 1995

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 2-Year Inhalation Study of Ethylbenzene^a

	Chamber Control	75 ppm	250 ppm	750 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths		00	00	
Moribund	28	20	26	26
Natural deaths	7	16	11	22
Survivors				
Terminal sacrifice	15	14	13	2
Animals examined microscopically	50	50	50	50
A limontary System				
Alimentary System Intestine large, colon	(50)	(48)	(48)	(48)
Hemorrhage	(30)	(46)	(40)	(40)
Inflammation		1 (2%)		
Mineralization	1 (2%)	1 (2%)		1 (2%)
Intestine large, rectum	(48)	(49)	(48)	(48)
Thrombosis	(10)	(10)	1 (2%)	(10)
Intestine large, cecum	(46)	(44)	(46)	(39)
Inflammation	1 (2%)	2 (5%)	(10)	1 (3%)
Mineralization	- (270)	~ (3/0)		1 (3%)
Necrosis		1 (2%)		1 (0/0)
Ulcer	1 (2%)	_ (= + + +)		
Intestine small, duodenum	(48)	(48)	(50)	(50)
Mineralization	1 (2%)	()	()	(00)
Necrosis			1 (2%)	
ntestine small, jejunum	(42)	(39)	(44)	(34)
Inflammation				1 (3%)
Intestine small, ileum	(45)	(44)	(45)	(37)
Inflammation				1 (3%)
Liver	(50)	(50)	(50)	(49)
Angiectasis			2 (4%)	1 (2%)
Basophilic focus	6 (12%)	5 (10%)	2 (4%)	4 (8%)
Clear cell focus	2 (4%)	3 (6%)	3 (6%)	
Cyst		1 (2%)		
Degeneration	1 (2%)			
Degeneration, cystic	15 (30%)	12 (24%)	19 (38%)	30 (61%)
Eosinophilic focus	5 (10%)	11 (22%)	4 (8%)	9 (18%)
Fibrosis		3 (6%)		
Hemorrhage		2 (4%)		
Hepatodiaphragmatic nodule		1 (2%)		1 (2%)
Inflammation, chronic	1 (2%)	1 (2%)	1 (2%)	
Inflammation, chronic active		1 (2%)		
Mineralization				1 (2%)
Mixed cell focus	1 (2%)	2 (4%)		0 (1001)
Necrosis	2 (4%)	4 (8%)		8 (16%)
Pigmentation	1 (2%)		1 (004)	
Thrombosis	0 (100()	10 (0001)	1 (2%)	
Vacuolization cytoplasmic	8 (16%)	10 (20%)	7 (14%)	4 (8%)
Bile duct, hyperplasia		1 (00/)		1 (2%)
Bile duct, inflammation, suppurative		1 (2%)	1 (00/)	
Kupffer cell, hyperplasia			1 (2%)	

^a Number of animals examined microscopically at the site and the number of animals with lesion

	Chamber Control	75 ppm	250 ppm	750 ppm
Alimentary System (continued)				
Mesentery	(4)	(5)	(3)	(3)
Inflammation	× /	1 (20%)		
Fat, necrosis	3 (75%)	4 (80%)	2 (67%)	3 (100%)
Pancreas	(50)	(49)	(50)	(50)
Inflammation		2 (4%)	1 (2%)	1 (2%)
Acinus, atrophy	24 (48%)	21 (43%)	20 (40%)	18 (36%)
Acinus, hyperplasia	4 (8%)		1 (2%)	
Artery, degeneration		1 (2%)	1 (2%)	
Artery, inflammation		1 (2%)		
Artery, mineralization		1 (2%)		
Stomach, forestomach	(50)	(50)	(50)	(50)
Hyperkeratosis	1 (2%)		1 (2%)	
Hyperplasia	8 (16%)	5 (10%)	8 (16%)	8 (16%)
Inflammation	1 (2%)	1 (2%)	3 (6%)	3 (6%)
Mineralization	2 (4%)	1 (2%)	1 (2%)	5 (10%)
Ulcer	9 (18%)	9 (18%)	9 (18%)	10 (20%)
Stomach, glandular	(50)	(49)	(50)	(50)
Degeneration			1 (2%)	, ,
Degeneration, cystic				1 (2%)
Inflammation	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Mineralization	4 (8%)	4 (8%)	3 (6%)	18 (36%)
Necrosis	5 (10%)	2 (4%)	2 (4%)	· · /
Ulcer		2 (4%)		2 (4%)
Blood vessel Mineralization Aorta, inflammation Aorta, mineralization Heart Cardiomyopathy Inflammation Mineralization Atrium, thrombosis Valve, fibrosis	(50) $\begin{array}{c} 2 & (4\%) \\ (50) \\ 26 & (52\%) \\ 2 & (4\%) \\ 5 & (10\%) \\ 1 & (2\%) \end{array}$	 (50) 2 (4%) (50) 21 (42%) 1 (2%) 7 (14%) 	(50) 1 (2%) 4 (8%) (50) 15 (30%) 1 (2%) 7 (14%)	(50) 1 (2%) 1 (2%) 14 (28%) (50) 30 (60%) 7 (14%)
Endocrine System Adrenal cortex	(50)	(50)	(50)	(50)
Cytoplasmic alteration	(/	1 (2%)	(/	(/
Degeneration			1 (2%)	
Degeneration, cystic	1 (2%)	2 (4%)	1 (2%)	3 (6%)
Hyperplasia	1 (2%)	. /	1 (2%)	2 (4%)
Hypertrophy				1 (2%)
Necrosis			1 (2%)	2 (4%)
Pigmentation	1 (2%)		, ,	, /
Vacuolization cytoplasmic	13 (26%)	18 (36%)	16 (32%)	11 (22%)
Bilateral, atrophy	1 (2%)	· ·		
Capsule, inflammation				1 (2%)
Adrenal medulla	(50)	(50)	(49)	(48)
Hyperplasia	10 (20%)	7 (14%)	13 (27%)	8 (17%)
	, ,			1 (2%)
Necrosis				1 (2/0)

	Chamber Control	75 ppm	250 ppm	750 ppm
Endocrine System (continued)				
slets, pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	2 (4%)	5 (10%)	4 (8%)	
Parathyroid gland	(45)	(46)	(46)	(46)
Fibrosis			1 (2%)	
Hyperplasia	12 (27%)	6 (13%)	16 (35%)	35 (76%)
Pituitary gland	(49)	(50)	(50)	(45)
Pars distalis, angiectasis	5 (10%)	11 (22%)	5 (10%)	4 (9%)
Pars distalis, cyst	1 (2%)	6 (12%)	5 (10%)	4 (9%)
Pars distalis, degeneration			1 (2%)	
Pars distalis, hemorrhage		1 (2%)	1 (2%)	
Pars distalis, hyperplasia	12 (24%)	11 (22%)	12 (24%)	12 (27%)
Pars distalis, necrosis			1 (2%)	
Pars distalis, pigmentation	1 (2%)		2 (4%)	
Pars intermedia, angiectasis	1 (2%)			
Thyroid gland	(50)	(49)	(50)	(50)
Cyst		1 (2%)		
C-cell, hyperplasia	6 (12%)	5 (10%)	5 (10%)	
Follicle, cyst	1 (2%)	1 (2%)		2 (4%)
General Body System None				
Jone				
None G enital System Epididymis	(50)	(50)	(50)	(50)
None G enital System Epididymis Granuloma sperm	(50)	1 (2%)	1 (2%)	
None G enital System Epididymis Granuloma sperm Inflammation	(50)			1 (2%)
None Genital System Epididymis Granuloma sperm Inflammation Mineralization		1 (2%) 1 (2%)	1 (2%) 1 (2%)	1 (2%) 1 (2%)
Tone Genital System Epididymis Granuloma sperm Inflammation Mineralization reputial gland	(50) (49)	1 (2%)	1 (2%) 1 (2%) (49)	1 (2%)
Jone Genital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy	(49)	1 (2%) 1 (2%) (50)	1 (2%) 1 (2%)	1 (2%) 1 (2%) (50)
None Genital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia	(49) 2 (4%)	1 (2%) 1 (2%) (50) 2 (4%)	1 (2%) 1 (2%) (49) 1 (2%)	1 (2%) 1 (2%) (50) 1 (2%)
None Genital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation	(49) 2 (4%) 19 (39%)	1 (2%) 1 (2%) (50) 2 (4%) 7 (14%)	1 (2%) 1 (2%) (49) 1 (2%) 8 (16%)	1 (2%) 1 (2%) (50) 1 (2%) 10 (20%)
None Genital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate	(49) 2 (4%) 19 (39%) (50)	1 (2%) 1 (2%) (50) 2 (4%) 7 (14%) (50)	1 (2%) 1 (2%) (49) 1 (2%) 8 (16%) (50)	1 (2%) 1 (2%) (50) 1 (2%)
Jone Genital System Epididymis Granuloma sperm Inflammation Mineralization Vreputial gland Atrophy Hyperplasia Inflammation rostate Hyperplasia	(49) 2 (4%) 19 (39%)	1 (2%) 1 (2%) (50) 2 (4%) 7 (14%) (50) 1 (2%)	1 (2%) 1 (2%) (49) 1 (2%) 8 (16%)	1 (2%) 1 (2%) (50) 1 (2%) 10 (20%)
Sone Genital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte	(49) 2 (4%) 19 (39%) (50) 1 (2%)	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ \end{array} $	1 (2%) 1 (2%) (49) 1 (2%) 8 (16%) (50) 1 (2%)	1 (2%) 1 (2%) (50) 1 (2%) 10 (20%) (50)
Sone Senital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte Inflammation	(49) 2 (4%) 19 (39%) (50) 1 (2%) 11 (22%)	$\begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \end{array}$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \end{array} $	1 (2%) 1 (2%) (50) 1 (2%) 10 (20%) (50) 25 (50%)
Sone Senital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Seminal vesicle	(49) 2 (4%) 19 (39%) (50) 1 (2%)	$\begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ \hline (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \\ (49) \end{array}$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ \end{array} $	1 (2%) 1 (2%) (50) 1 (2%) 10 (20%) (50)
Sone Senital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Seminal vesicle Inflammation	(49) 2 (4%) 19 (39%) (50) 1 (2%) 11 (22%) (49)	$\begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \end{array}$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \end{array} $	1 (2%) 1 (2%) (50) 1 (2%) 10 (20%) (50) 25 (50%)
Jone Genital System Epididymis Granuloma sperm Inflammation Mineralization reputial gland Atrophy Hyperplasia Inflammation rostate Hyperplasia Inflitration cellular, lymphocyte Inflammation eminal vesicle Inflammation Mineralization	 (49) 2 (4%) 19 (39%) (50) 1 (2%) 11 (22%) (49) 1 (2%) 	$\begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ \hline (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \\ (49) \\ 1 & (2\%) \\ \end{array}$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \end{array} $ $ \begin{array}{c} 25 & (50\%) \\ (50) \end{array} $
Tone Cenital System Epididymis Granuloma sperm Inflammation Mineralization reputial gland Atrophy Hyperplasia Inflammation rostate Hyperplasia Infiltration cellular, lymphocyte Inflammation eminal vesicle Inflammation Mineralization Sestes	(49) $(2 (4%))$ $19 (39%)$ (50) $1 (2%)$ $(11 (22%)$ (49) $1 (2%)$ (50)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ (50) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \end{array} $ $ \begin{array}{c} 25 & (50\%) \\ (50) \\ \end{array} $
Jone Senital System Epididymis Granuloma sperm Inflammation Mineralization reputial gland Atrophy Hyperplasia Inflammation rostate Hyperplasia Infiltration cellular, lymphocyte Inflammation eminal vesicle Inflammation Mineralization čestes Atrophy	 (49) 2 (4%) 19 (39%) (50) 1 (2%) 11 (22%) (49) 1 (2%) 	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ 25 & (50\%) \\ (50) \\ (50) \\ 6 & (12\%) \end{array} $
Jone Genital System Epididymis Granuloma sperm Inflammation Mineralization Vreputial gland Atrophy Hyperplasia Inflammation Vrostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Vermal vesicle Inflammation Mineralization Vestes Atrophy Degeneration	 (49) 2 (4%) 19 (39%) (50) 1 (2%) (11 (22%) (49) 1 (2%) (50) 10 (20%) 	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ (50) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \end{array} $ $ \begin{array}{c} 25 & (50\%) \\ (50) \\ \end{array} $
Genital System Epididymis Granuloma sperm Inflammation Mineralization Vreputial gland Atrophy Hyperplasia Inflammation Vrostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Veminal vesicle Inflammation Mineralization Vestes Atrophy Degeneration Hemorrhage	(49) $(2 (4%))$ $19 (39%)$ (50) $1 (2%)$ $(11 (22%)$ (49) $1 (2%)$ (50)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ (50) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \hline 25 & (50\%) \\ (50) \\ \hline (50) \\ 6 & (12\%) \\ 1 & (2\%) \end{array} $
Senital System Epididymis Granuloma sperm Inflammation Mineralization Vreputial gland Atrophy Hyperplasia Inflammation rostate Hyperplasia Infiltration cellular, lymphocyte Inflammation eminal vesicle Inflammation Mineralization Sestes Atrophy Degeneration Hemorrhage Mineralization	 (49) 2 (4%) 19 (39%) (50) 1 (2%) (11 (22%) (49) 1 (2%) (50) 10 (20%) 	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \\ (49) \\ 1 & (2\%) \\ (50) \\ 7 & (14\%) \\ 1 & (2\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 10 & (20\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ 25 & (50\%) \\ (50) \\ (50) \\ 6 & (12\%) \end{array} $
Sone Senital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Seminal vesicle Inflammation Mineralization Sestes Atrophy Degeneration Hemorrhage Mineralization Arteriole, inflammation	(49) $(2 (4%))$ $19 (39%)$ (50) $1 (2%)$ $11 (22%)$ (49) $1 (2%)$ (50) $1 (2%)$ $1 (2%)$ $1 (2%)$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \\ (49) \\ 1 & (2\%) \\ (50) \\ 7 & (14\%) \\ 1 & (2\%) \\ 1 & (2\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 10 & (20\%) \\ 1 & (2\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \hline 25 & (50\%) \\ (50) \\ \hline (50) \\ 6 & (12\%) \\ 1 & (2\%) \\ 2 & (4\%) \end{array} $
Sone Senital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Seminal vesicle Inflammation Mineralization Cestes Atrophy Degeneration Hemorrhage Mineralization Arteriole, inflammation Bilateral, atrophy	 (49) 2 (4%) 19 (39%) (50) 1 (2%) (11 (22%) (49) 1 (2%) (50) 10 (20%) 	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \\ (49) \\ 1 & (2\%) \\ (50) \\ 7 & (14\%) \\ 1 & (2\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 10 & (20\%) \\ \end{array} $ $ \begin{array}{c} 1 & (2\%) \\ 5 & (10\%) \\ \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \hline 25 & (50\%) \\ (50) \\ \hline (50) \\ 6 & (12\%) \\ 1 & (2\%) \end{array} $
Sone Cenital System Epididymis Granuloma sperm Inflammation Mineralization Preputial gland Atrophy Hyperplasia Inflammation Prostate Hyperplasia Infiltration cellular, lymphocyte Inflammation Seminal vesicle Inflammation Seminal vesicle Inflammation Mineralization Festes Atrophy Degeneration Hemorrhage Mineralization Arteriole, inflammation	(49) $(2 (4%))$ $19 (39%)$ (50) $1 (2%)$ $11 (22%)$ (49) $1 (2%)$ (50) $1 (2%)$ $1 (2%)$ $1 (2%)$	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 2 & (4\%) \\ 7 & (14\%) \\ (50) \\ 1 & (2\%) \\ 1 & (2\%) \\ 29 & (58\%) \\ (49) \\ 1 & (2\%) \\ (50) \\ 7 & (14\%) \\ 1 & (2\%) \\ 1 & (2\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (49) \\ 1 & (2\%) \\ 8 & (16\%) \\ (50) \\ 1 & (2\%) \\ 22 & (44\%) \\ (50) \\ 1 & (2\%) \\ (50) \\ 10 & (20\%) \\ 1 & (2\%) \end{array} $	$ \begin{array}{c} 1 & (2\%) \\ 1 & (2\%) \\ (50) \\ 1 & (2\%) \\ 10 & (20\%) \\ (50) \\ \hline 25 & (50\%) \\ (50) \\ \hline (50) \\ 6 & (12\%) \\ 1 & (2\%) \\ 2 & (4\%) \end{array} $

	Chambe	r Control	75	5 ppm	250	ppm	75) ppm
Hematopoietic System								
Bone marrow	(49)		(49)		(50)		(50)	
Atrophy					1	(2%)	1	(2%)
Hemorrhage		(2%)				(4%)		(8%)
Hyperplasia	7	(14%)		(33%)	9	(18%)	19	(38%)
Inflammation		()	1	(2%)			_	
Myelofibrosis		(6%)					5	(10%)
Myeloid cell, atrophy		(2%)	(0)		(0)		(1.1)	
ymph node	(9)		(8)		(9)	(110/)	(14)	
Hemorrhage			1	(190/)	1	(11%)		
Lumbar, hemorrhage				(13%)				
Lumbar, hyperplasia, plasma cell Pancreatic, fibrosis			1	(13%)	1	(110/)		
Pancreatic, fibrosis Pancreatic, pigmentation						(11%) (11%)		
Renal, ectasia						(11%) (22%)	1	(7%)
Renal, hemorrhage						(11%)		(7%)
Renal, hyperplasia, lymphoid					1	(11/0)		(7%)
Renal, hyperplasia, plasma cell					1	(11%)		(7%)
Renal, infiltration cellular, histiocyte			1	(13%)	1	(11/0)	1	(. /0)
Renal, pigmentation			1	(-0,0)	1	(11%)	2	(14%)
ymph node, bronchial	(44)		(34)		(39)	(11/0)	(28)	(11/0)
Ectasia	()		(0-)			(3%)	()	
Hemorrhage	7	(16%)	4	(12%)		(10%)	7	(25%)
Infiltration cellular, histiocyte						(5%)		. ,
Pigmentation	3	(7%)	3	(9%)		. ,	5	(18%)
ymph node, mandibular	(47)		(48)		(49)		(50)	
Atrophy			1	(2%)				
Hemorrhage	1	(2%)					1	(2%)
Hyperplasia, plasma cell	4	(9%)	1	(2%)	1	(2%)	4	(8%)
Inflammation					1	(2%)		
Pigmentation		(2%)						
.ymph node, mesenteric	(49)		(50)		(50)		(50)	
Atrophy			1	(2%)				
Ectasia						(2%)		
Hemorrhage	3	(6%)	5	(10%)		(8%)		(16%)
Inflammation			1.00			(2%)		(2%)
.ymph node, mediastinal	(48)	(00/)	(48)	(00/)	(50)		(47)	(00/)
Edema		(2%)		(2%)	10	(900/)		(6%)
Hemorrhage		(25%)		(21%)	10	(20%)	17	(36%)
Hyperplasia, plasma cell Infiltration cellular, histiocyte		(2%)		(2%)			1	(90/)
Inflitration cellular, histocyte	Z	(4%)	1	(2%)	1	(90/)	1	(2%)
Pigmentation	0	(10%)	o	(17%)		(2%) (14%)	7	(15%)
pleen	(50)	(19%)	o (49)	(17%)	(50)	(14%)	(50)	(15%)
Atrophy	(50)		(49)		(50)			(4%)
Congestion	1	(2%)	1	(2%)			2	(470)
Depletion cellular	1	(~ / U)		(4%)	ર	(6%)	4	(8%)
Fibrosis	3	(6%)		(2%)		(8%)		(2%)
Hematopoietic cell proliferation		(6%)		(8%)		(2%)		(4%)
Inflammation, chronic	0	(-, 0)	1	((2%)	2	(1/0)
Necrosis	2	(4%)			1	(, 0)	2	(4%)
Pigmentation	2	· · · ·	1	(2%)			2	()
Red pulp, depletion cellular			1	(·····	1	(2%)		

	Chamber Control	75 ppm	250 ppm	750 ppm
Hematopoietic System (continued)				
Thymus	(46)	(44)	(46)	(44)
Čyst Hemorrhage		1 (2%)		1 (2%) 1 (2%)
Integumentary System				
Mammary gland	(46)	(47)	(46)	(49)
Fibrosis			1 (2%)	
Galactocele	11 (24%)	11 (23%)	11 (24%)	9 (18%)
Hyperplasia	3 (7%)	3 (6%)	4 (9%)	3 (6%)
Inflammation	1 (2%)	2 (4%)	1 (2%)	
Mineralization				1 (2%)
Pigmentation	1 (2%)	4 (9%)	2 (4%)	6 (12%)
Skin	(50)	(50)	(50)	(50)
Cyst epithelial inclusion	1 (2%)	4 (8%)	2 (4%)	
Hyperkeratosis	1 (2%)			1 (2%)
Inflammation				1 (2%)
Inflammation, granulomatous		1 (2%)		
Epidermis, hyperplasia		- ()	1 (2%)	
Subcutaneous tissue, inflammation		2 (4%)		
Musculoskeletal System	(10)	(50)	(50)	(50)
Bone Etheres extendent and	(49)	(50)	(50)	(50)
Fibrous osteodystrophy	1 (2%)	1 (2%)	5 (10%) 9 (40()	9 (18%)
Hyperostosis Turbinata humanatasia	1 (90/)	1 (90/)	2 (4%)	1 (90/)
Turbinate, hyperostosis	1 (2%)	1 (2%)		1 (2%)
Nervous System				
Brain	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Hydrocephalus	1 (2%)	2 (4%)	1 (2%)	
Mineralization			1 (2%)	
Necrosis	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Respiratory System				
Larynx	(40)	(44)	(41)	(35)
Foreign body	(10)	(11)	1 (2%)	(00)
Infiltration cellular, lymphocyte	1 (3%)	1 (2%)	1 (2%)	1 (3%)
Inflammation	1 (3%)	3 (7%)	3 (7%)	1 (3%)
Necrosis	1 (070)	1 (2%)	0 (170)	1 (070)
Respiratory epithelium, hyperplasia	1 (3%)	4 (9%)	1 (2%)	1 (3%)
Respiratory epithelium, metaplasia, squamo		1 (2%)	1 (2%)	2 (6%)
incorporatory optimicitum, inclupitusia, squamo	1 (0/0)	1 (270)	1 (270)	~ (070)

	Chamber Control	75 ppm	250 ppm	750 ppm
Respiratory System (continued)				
Lung	(50)	(50)	(50)	(50)
Congestion	1 (2%)	2 (4%)		6 (12%)
Edema	1 (2%)			6 (12%)
Fibrosis			1 (2%)	1 (2%)
Foreign body			1 (2%)	
Hemorrhage		2 (4%)	1 (2%)	8 (16%)
Infiltration cellular, histiocyte	2 (4%)	1 (2%)		
Inflammation, acute		1 (2%)	1 (2%)	1 (2%)
Inflammation, chronic	1 (2%)	- /	1 (2%)	2 (4%)
Inflammation, chronic active	2 (4%)	3 (6%)	2 (4%)	7 (14%)
Inflammation, granulomatous	1 (2%)	1 (2%)		0 (00()
Mineralization	1 (2%)	1 (2%)	1 (00()	3 (6%)
Alveolar epithelium, hyperplasia	2 (4%)	2 (4%)	1 (2%)	2 (4%)
Artery, mineralization			1 (00/)	1 (2%)
Goblet cell, hyperplasia		1 (00/)	1 (2%)	
Interstitium, fibrosis		1 (2%)		1 (00/)
Interstitium, inflammation	(40)	(40)	(50)	1 (2%)
Nose	(49)	(49)	(50)	(50)
Angiectasis			1 (2%)	1 (90/)
Congestion	9 (40/)	9 (40/)	9 (40/)	1 (2%)
Foreign body	2 (4%)	2 (4%) 1 (2%)	2 (4%)	1 (2%)
Infiltration cellular, lymphocyte Inflammation	9 (160/)	8 (16%)	9 (18%)	9 (18%)
Necrosis	8 (16%)	8 (10%)	9 (18%)	9 (18%) 1 (2%)
Glands, cyst		1 (2%)		1 (270)
Goblet cell, hyperplasia	2 (4%)	1 (2/0)	1 (2%)	
Nasolacrimal duct, inflammation	1 (2%)	1 (2%)	1 (2%)	
Olfactory epithelium, inflammation	1 (2/0)	1 (2/0)	1 (278)	1 (2%)
Olfactory epithelium, metaplasia				1 (2%)
Respiratory epithelium, hyperplasia	9 (18%)	7 (14%)	9 (18%)	6 (12%)
Respiratory epithelium, inflammation	1 (2%)	(11/0)	0 (1070)	3 (6%)
Respiratory epithelium, metaplasia, squamou				1 (2%)
Respiratory epithelium, ulcer	1 (2%)		1 (2%)	1 (270)
Trachea	(50)	(50)	(50)	(50)
Mineralization	(00)	(00)	(00)	1 (2%)
				1 (w/0)
Special Senses System				
Eye	(1)	(1)		
Lens, cataract	1 (100%)			
Retina, degeneration	1 (100%)			
Zymbal's gland	(1)		(1)	(1)
Cyst				1 (100%)
Hyperplasia				1 (100%)

	Chambe	r Control	75	ó ppm	250	ppm	750) ppm
Urinary System								
Kidney	(50)		(50)		(50)		(50)	
Cyst			4	(8%)	1	(2%)	10	(20%)
Hemorrhage			1	(2%)				
Infarct	2	(4%)					1	(2%)
Inflammation			1	(2%)				
Mineralization	1	(2%)	1	(2%)	1	(2%)	9	(18%)
Necrosis	1	(2%)					1	(2%)
Nephropathy	47	(94%)	43	(86%)	47	(94%)	48	(96%)
Pigmentation		(18%)		(12%)	9	(18%)		(4%)
Renal tubule, hyperplasia	2	(4%)	2	(4%)	4	(8%)		(24%)
Transitional epithelium, hyperplasia	12	(24%)		(28%)		(30%)		(68%)
Urinary bladder	(49)	. ,	(49)		(50)	. ,	(49)	. ,
Hemorrhage	. ,	(2%)		(4%)			. ,	(2%)
Inflammation		(2%)		(6%)	1	(2%)		
Necrosis				(2%)				
Transitional epithelium, hyperplasia				(4%)	1	(2%)		

APPENDIX B SUMMARY OF LESIONS IN FEMALE RATS IN THE 2-YEAR INHALATION STUDY OF ETHYLBENZENE

TABLE B1	Summary of the Incidence of Neoplasms in Female Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	100
TABLE B2	Individual Animal Tumor Pathology of Female Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	104
TABLE B3	Statistical Analysis of Primary Neoplasms in Female Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	120
TABLE B4	Summary of the Incidence of Nonneoplastic Lesions in Female Rats	
	in the 2-Year Inhalation Study of Ethylbenzene	125

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene^a

	Chamber Control	75 ppm	250 ppm	750 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Moribund	7	14	8	6
Natural deaths	12	5	8	8
Survivors	1			
Died last week of study Terminal sacrifice	1 30	31	34	35
Missing	50	51	54	1
wiissing				1
Animals examined microscopically	50	50	50	49
Alimentary System				
Intestine large, colon	(47)	(49)	(48)	(49)
Intestine large, rectum	(49)	(50)	(47)	(49)
Polyp adenomatous			1 (2%)	
Intestine large, cecum	(44)	(50)	(47)	(49)
Intestine small, duodenum	(47)	(48)	(47)	(48)
Intestine small, jejunum	(41)	(49)	(47)	(45)
Intestine small, ileum Liver	(41) (50)	(48)	(47)	(46) (49)
Histiocytic sarcoma	(50)	(50)	(50)	(49)
Mesentery	(7)	(4)	(6)	(7)
Oral mucosa		(1)	(0)	(1)
Pharyngeal, squamous cell papilloma				1 (100%)
Pancreas	(49)	(50)	(50)	(49)
Histiocytic sarcoma	1 (2%)			. ,
Salivary glands	(50)	(50)	(50)	(49)
Stomach, forestomach	(49)	(50)	(50)	(49)
Stomach, glandular	(49)	(49)	(49)	(49)
Fongue			(1)	(1)
Schwannoma malignant				1 (100%)
Squamous cell papilloma			1 (100%)	
Cardiovascular System				
Heart	(50)	(50)	(50)	(49)
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(49)
Adenoma		1 (2%)	1 (2%)	
Carcinoma	(50)	(50)	1 (2%)	
Adrenal medulla	(50)	(50)	(50)	(49)
Pheochromocytoma malignant	9 (40/)	1 (2%)	2 (4%)	
Pheochromocytoma benign	2 (4%)	9 (40/)		
Bilateral, pheochromocytoma benign	(50)	2 (4%) (50)	(50)	(49)
íslets, pancreatic Adenoma	(50) 1 (2%)	(30)	(50)	(49)
AULIUIIIa	1 (2/0)		1 (2/0)	1 (2/0)

	Chamber Control	75 ppm	250 ppm	750 ppm
Endocrine System (continued)				
Pituitary gland	(49)	(49)	(50)	(49)
Pars distalis, adenoma	27 (55%)	17 (35%)	24 (48%)	24 (49%)
Pars distalis, adenoma, multiple	3 (6%)	6 (12%)	1 (2%)	3 (6%)
Pars distalis, carcinoma		1 (2%)	1 (2%)	
Гhyroid gland	(48)	(50)	(50)	(49)
Bilateral, C-cell, adenoma		1 (2%)		
C-cell, adenoma	2 (4%)	3 (6%)	2 (4%)	3 (6%)
C-cell, carcinoma				1 (2%)
General Body System None				
Genital System Clitoral gland	(47)	(49)	(48)	(47)
Adenoma	2 (4%)	()	(10)	()
Carcinoma	1 (2%)		1 (2%)	
Dvary	(50)	(50)	(50)	(49)
Histiocytic sarcoma				1 (2%)
Jterus	(50)	(50)	(50)	(49)
Polyp stromal	2 (4%)	3 (6%)	4 (8%)	3 (6%)
Bilateral, polyp stromal		4 (00.1)	1 (2%)	
Endometrium, sarcoma stromal		1 (2%)		
Hematopoietic System				
Bone marrow	(49)	(50)	(50)	(49)
Lymph node	(3)	(3)	(4)	(4)
Lumbar, histiocytic sarcoma	1 (33%)			
Lymph node, bronchial	(37)	(34)	(41)	(38)
_ymph node, mandibular	(49)	(50)	(50)	(49)
_ymph node, mesenteric	(49)	(50)	(50)	(49)
Lymph node, mediastinal	(49)	(49)	(50)	(49)
Rhabdomyosarcoma, metastatic,			1 (2%)	
uncertain primary site Spleen	(49)	(50)	1 (2%) (49)	(49)
Fhymus	(49)	(47)	(49)	(49)
Rhabdomyosarcoma, metastatic,	(10)	(17)	(11)	(11)
uncertain primary site			1 (2%)	
p			- (2.0)	
Integumentary System	(10)		(10)	(10)
Mammary gland	(48)	(50)	(49)	(49)
Adenoma	1 (2%)	2 (4%)	0 (10))	1 (2%)
Carcinoma	2 (4%)	1 (2%)	2 (4%)	1 (00/)
Carcinoma, multiple	1 (2%)	10 (000/)	10 (070/)	1 (2%)
Fibroadenoma Fibroadenoma multinla	13 (27%)	18 (36%)	18 (37%)	15 (31%)
Fibroadenoma, multiple	6 (13%)	1 (2%)	3 (6%)	6 (12%)

	Chamber Control	75 ppm	250 ppm	750 ppm
Integumentary System (continued)				
Skin	(50)	(50)	(50) 1 (2%)	(49)
Squamous cell carcinoma Squamous cell papilloma			2 (4%)	
Sebaceous gland, carcinoma				1 (2%)
Subcutaneous tissue, fibroma	1 (2%)	1 (00/)		
Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, lipoma		1 (2%) 1 (2%)		
Subcutaneous tissue, sarcoma		1 (2%)		
Musculoskeletal System				
Skeletal muscle		(1)		
Nervous System				
Brain	(50)	(50)	(50)	(49)
Astrocytoma malignant Carcinoma, metastatic, pituitary gland	1 (2%)	1 (2%)	1 (2%)	
Caremonia, measure, pranary gama		1 (270)	1 (270)	
Respiratory System		(10)		(47)
Larynx Lung	(45) (50)	(43) (50)	(44)	(45) (49)
Alveolar/bronchiolar adenoma	(30)	(30)	(50) 1 (2%)	(49)
Alveolar/bronchiolar adenoma, multiple	1 (4/0)	1 (2%)		
Carcinoma, metastatic, mammary gland			1 (2%)	
Histiocytic sarcoma	1 (2%)	1 (90/)		
Sarcoma, metastatic, uncertain primary site Mediastinum, sarcoma, metastatic,		1 (2%)		
uncertain primary site		1 (2%)		
Nose	(50)	(50)	(50)	(49)
Glands, adenoma	(50)	1 (2%)	(50)	(40)
Trachea	(50)	(50)	(50)	(49)
Special Senses System				
Ear	(3)			
External ear, sarcoma Zymbal's gland	1 (33%) (1)	(1)		
Adenoma	1 (100%)	(1)		
Carcinoma	- (,	1 (100%)		
Urinary System				
Kidney	(50)	(50)	(50)	(49)
Renal tubule, adenoma	(10)	(10)	(10)	1 (2%)
Urinary bladder	(48)	(49)	(49)	(48)

Summary of the Incidence of Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(49)
Histiocytic sarcoma	2 (4%)			1 (2%)
Leukemia granulocytic		1 (2%)		
Leukemia mononuclear	13 (26%)	18 (36%)	16 (32%)	11 (22%)
Lymphoma malignant	1 (2%)	1 (2%)		
Neoplasm Summary Total animals with primary neoplasms ^C Total primary neoplasms Total animals with benign neoplasms Total benign neoplasms Total animals with malignant neoplasms Total analignant neoplasms Total animals with metastatic neoplasms	42 84 37 62 20 22	45 84 39 57 24 27 2	43 84 37 60 21 24 3	46 74 39 58 14 16
Total metastatic neoplasms		3	4	
Total animals with malignant neoplasms				

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а

b

с

Number of Days on Study	0	1	9		8	9	0	3	5	5	5	6	6 6	8	8	6 8	0	7 2	7 2	7	3	3	3	3	7 3
	8	1	4	-	6	6	7	8		4	9							1		4	4	4	4	4	
Carcass ID Number	0 9 1	0 6 2	0 6 9	0	9	0 6 5	0 5 6	0 5 3	5	0 8 6	0 7 6	9	0 8 1	9	8	0 7 1	0 8 9	0 7 0	0 8 7	0 5 7	0 6 0	0 6 7	0 8 3	0 9 6	5
Alimentary System																									
Esophagus	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon	А	A	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	+	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	А	A	A	. +	+	+	+	+	+	+	+	А	А	+	А	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	А	A	A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	А	A	A	A	A	+	+	+	+	+	+	А	+	+	А	+	+	А	+	+	+	+	+	+	+
Intestine small, ileum	А	A	A	A	. +	+	+	+	+	+	А	А	А	+	А	+	А	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma														Х											
Mesentery										+	+								+			+	+	+	
Pancreas	+	А	. +	• +	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+
Histiocytic sarcoma														Х											
Salivary glands	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	А	. +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	А	. +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Tooth															+										
Cardiovascular System						_	_																		
Blood vessel	+	+	+	• +	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Heart	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma benign																						Х			
Islets, pancreatic	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+
Adenoma																				Х					
Parathyroid gland	+	+	Ν	1 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+
Pars distalis, adenoma						Х		Х		Х			Х					Х			Х		Х		Х
Pars distalis, adenoma, multiple																				Х				Х	
Thyroid gland	+	А	N	1 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
C-cell, adenoma																		Х		Х					
General Body System None																									
Constal Sustan																									
Genital System																									
Clitoral gland	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	M	+	+	+	+
Adenoma																									
Carcinoma																									
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Uterus	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Polyp stromal																		Х							

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: Chamber Control

+: Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: Chamber Control (continued)

Number of Days on Study	7 3 5	3	7 3 5	7 3 5	7 3 5	7 3 5	3	7 3 5	3	3	3	77 33 55	3	7 3 6											
Carcass ID Number	0 5 4	5	0 5 9	0 6 1	0 6 3	0 6 4	7	7	7	7	8) () 9 () 2 () 2 ()	5	0 6 6	0 6 8	0 7 2	0 7 5	0 7 8	0 8 0	0 8 2	0 8 8	0 9 4	0 9 8	9	Total Tissues/ Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	44
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small, jejunum	+	+	+	+	+	Μ	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	41
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	41
Liver	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																									1 7
Mesentery Pancreas																						+	++	+	7 49
Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+ ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	49
Salivary glands																									50
Stomach, forestomach	+		+ +	+ +	+ +	+ +	- -	- -	- -	- -	т -	т т ц	 	+ +	+ +	- -	+ +	+ +	- -	- -	+ +	- -	+	+ +	50 49
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+ .	· ·	· +	+	+	+	+	+	+	+	+	+	+	+	49
Footh						'																			10
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	49
Heart	+	+	+	+	+	+	+	+	+	+	+ •	+ +	· +	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	± .	+ +		+	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+ .	· ·	· +	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma benign								x	'																2
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma																									1
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	48
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma		Х	Х	Х			Х			Х		Х	Χ		Х		Х	Х	Х	Х	Х	Х	Х	Х	27
Pars distalis, adenoma, multiple											Х														3
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	48
C-cell, adenoma																									2
G eneral Body System None		_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	
Genital System																									
Clitoral gland	+	+	+	+	+	+	+	+	+	+	M ·	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	47
Adenoma	т	X			'		X			•		. 1			'		'		'			'		1	2
Carcinoma		<u>,</u> ,			Х		••																		1
Ovary	+	+	+	+	+	+	+	+	+	+	+ •	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Uterus	+	+	+	+	+	+	+	+	+	+	+ .	· ·	- +	+	+	+	+	+	+	+	+	+	+	+	50 50
Polyp stromal	X																				-			-	2

(continucu)		
Number of Days on Study	0 1 1 3 4 4 5 6 6 6 6 6 6 7 3 3 3	
Carcass ID Number	0 0 1 0	
Hematopoietic System Bone marrow Lymph node	+ + A + + + + + + + + + + + + + + + + +	
Lumbar, histiocytic sarcoma Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Thymus	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
Integumentary System Mammary gland Adenoma Carcinoma	+ + M + + + + + + + + + + + + + + + + +	
Carcinoma, multiple Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibroma	X X X X X X + + + + + + + + + + + + + +	
Musculoskeletal System Bone	+ + + + + + + + + + + + + + + + + + + +	
Nervous System Brain Astrocytoma malignant	+ + + + + + + + + + + + + + + + + + +	
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Histiocytic sarcoma	+ + + M + + M + + + + + + + M + + + + +	
Nose Trachea	A + + + + + + + + + + + + + + + + + + +	
Special Senses System Ear External ear, sarcoma	+ X	
Eye Zymbal's gland Adenoma	+ X	
Urinary System Kidney Urinary bladder	+ + + + + + + + + + + + + + + + + + +	
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear Lymphoma malignant	+ + + + + + + + + + + + + + + + + + +	

(continueu)																											
Number of Days on Study	7 3 5	3	3	7 3 5	7 3 5	7 3 5	7 3 5	3	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	
Carcass ID Number	0 5 4	5	5	5	6	0 6 3	0 6 4	7	7	7	0 7 9	0 8 5	9	0 9 5	0 5 1	6	0 6 8	0 7 2	0 7 5	0 7 8	0 8 0	0 8 2	0 8 8	0 9 4	9		Total Tissues/ Tumors
Hematopoietic System Bone marrow Lymph node Lumbar, histiocytic sarcoma Lymph node, bronchial Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Thymus	+ + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ M + + + +	+ M + + + + +	+ M + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ M + + + + +	+ M + + + +	+ + + + + + +	+ + + + + + + + +	+ M + + + + + +	+ + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + + +	+ M + + + +	+ + + + + + + + +	+ M + + + + +	+ + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	49 3 1 37 49 49 49 49 49 48
Integumentary System Mammary gland Adenoma Carcinoma Carcinoma, multiple Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibroma	+	+	+	+ X	+ X +	+	+ X +		+	+ X +	+	+ X +	+	+	+	+	+ X +	+	+ + X	+ X +	+ X +	+ X +	+ X +	+ X +	+ X +	+	48 1 2 1 13 6 50 1
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System Brain Astrocytoma malignant	H	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Histiocytic sarcoma Nose Trachea	+ + - -	+ +	+ + +	+++++	+ + + +	+ + + + +	+ + X + +	+ + + +	+++++++	+++++++	+ + + +	++++++	++++++	++++++	+ + + + +	+ + + + +	++++++	+ + + +	++++++	++++++	M + +	++++++	+ + + + +	+ + + + +	+ + + +	+++++++++++++++++++++++++++++++++++++++	45 50 1 1 50 50
Special Senses System Ear External ear, sarcoma Eye Zymbal's gland Adenoma																	+	+	+								3 1 1 1 1
Urinary System Kidney Urinary bladder	- -	+ -	+ +	+ +	+ +	+ +	+++	+++	+ +	+ +	+ +	++++	++	++	++	+ +	+++	+ +	++++	+++	+++	++	+++	+++	+++	++	50 48
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear Lymphoma malignant	+	+	+ X	+	+ X	+	+ X	+	+ X	+	+	+	+	+	+	+	+ X	+	+	+ X	+	+ X	+	+	+	+	50 2 13 1

Individual Animal Tumor Pathology	of Fema	ale	Ra	ITS 1	in t	the	Z -)	Yea	ar .	In	hal	ati	on	5 11	iay	(0)	IE	uų	yID	en	zen	e.	/J	P P	pm
	4	4	4	5	5	6	6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	1	6	7	0	3	0	0	0	1	3	4	4		8	1	2	2	3	3	3	3	3	3	3	3
	2	2	5	6	1	1	9	9	0	6	6	7	8	6	9	4	4	1	1	4	4	4	4	5	5
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Carcass ID Number	7	5	5	7	8	6	8	9	7	8	5	8	7	6	7	9	9	5	9	6	6	8	9	5	6
	4	2	9	5	6	8	8	9	3	5	8	2	7	6	9	2	5	5	1	3	4	3	8	6	2
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ntestine large, colon	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ntestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ntestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ntestine small, duodenum	+	Α	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ntestine small, jejunum	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ntestine small, ileum	+	+	+	А	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Mesentery	+																								
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, glandular	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Ieart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma		·	Ċ	Ċ	·		·		x	·	·	Ċ	·	·		·	·		Ċ		Ċ		Ċ	·	
Adrenal medulla	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma malignant					'	'							'				'							'	i.
Bilateral, pheochromocytoma benign															х		Х								
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Parathyroid gland	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+
Pituitary gland	+	+	+	Í	+			+	+	+	+	+	+	+		+	+	+	+	+	+		+		
Pars distalis, adenoma	1		x		x	'		x					x			x	'			x			x		I
Pars distalis, adenoma, multiple			Λ		Λ			Λ					Λ			Λ			Х	Λ			Λ	Λ	
Pars distalis, carcinoma															Х				1						
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+
Bilateral, C-cell, adenoma	Ŧ	г	т	г	r.	1-	1.	1.	1.	ſ	ſ	C.	r.		1.	r.	Г	г	F	Т	Г	г	F	Г	
C-cell, adenoma																			х						
G eneral Body System None																									
Genital System																									
Clitoral gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Dvary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Jterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Polyp stromal			•			x				÷		x					x		•	•	•		•		
Endometrium, sarcoma stromal		Х				••						••					••								
/agina					+	+											+								
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node												+		+				+							
_ymph node, bronchial	+	+	+	Μ	Μ	+	М	+	+	+	+	+	+	+	+	+	Μ	+	Μ	+	+	+	Μ	Μ	М
_ymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Jymph node, manufbular																									

 TABLE B2

 Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm

Individual Animal Tumor Pathology	or rem		IVO	115	un (ne	L - ب		u 1	<u> </u>	uai	1011	5	սսյ	y U.		<u> </u>			2011	с.		ויי	h	(continueu)
Number of Days on Study	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	3	3	7 7 3 3 5 5	3 3	3	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	3	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	
Carcass ID Number	1 6 9	1 7 0	1 7 1	1 7 8	8	8		9	1 1 9 9 6 7) 5		1 5 4	1 5 7	6	1 6 1	1 6 5	1 6 7	7	1 7 6	1 8 1	1 8 9	1 9 0	1 9 4	0	Total Tissues/ Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, cecum	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, ileum	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Liver	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Mesentery																			+		+			+	4
Pancreas	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, glandular	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adenoma			·		·	·						·			·	·	·		·						1
Adrenal medulla	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma malignant			·		·	·				ĸ					·	·	·		·	Ċ	·		Ċ	•	1
Bilateral, pheochromocytoma benign																									2
slets, pancreatic	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Parathyroid gland	+	+	М	+	+	+	+	+	+ -	+ N	Λ +	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Pituitary gland	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma	Х							Х			Х		Х	Х			Х	Х		Х		Х			17
Pars distalis, adenoma, multiple				Х			Х		Х										Х		Х				6
Pars distalis, carcinoma																									1
Гhyroid gland	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Bilateral, C-cell, adenoma																			Х						1
C-cell, adenoma									2	X													Х		3
G eneral Body System None																									
Genital System																									
Clitoral gland	+	+	+	+	+	+	+	+	+ -	+ -		+	+	+	+	+	+	+	+	+	м	+	+	+	49
Dvary	+	+	+	+	+	+	+	+ .	+ -	 +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Jterus	+	+	+	+	+	+	+	+	· + -	, + +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Polyp stromal																									3
Endometrium, sarcoma stromal																									1
/agina																									3
Iematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+ -	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node	1				·	•	•		•		'				·	·	•	•	•	·				•	3
Lymph node, bronchial	N/	ΙM	[+	+	М	М	M	+	+ -	+ -	- N	1+	М	+	+	+	+	+	+	+	+	м	+	+	34
Lymph node, mandibular	1V. +	+	+	+	+	+	+	+	+ -	 +		- +	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node, mesenteric	- -	+	+	+	+	+	+	+	+ -	 +		+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
-JF 10000, 110000110110	т	1.				•	•		•	. 1		. I.													00

Individual Animal Tumor Patholog	
	4 4 4 5 5 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7
Number of Days on Study	1 6 7 0 3 0 0 0 1 3 4 4 6 8 1 2 2 3 3 3 3 3 3 3 3
	2 2 5 6 1 1 9 9 0 6 6 7 8 6 9 4 4 1 1 4 4 4 4 5 5
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Carcass ID Number	7 5 5 7 8 6 8 9 7 8 5 8 7 6 7 9 9 5 9 6 6 8 9 5 6
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Hematopoietic System (continued)	
Lymph node, mediastinal	+ + + M + + + + + + + + + + + + + + + +
Spleen	+ + + + + + + + + + + + + + + + + + + +
Гĥуmus	+ + + M + + + + + + + + + + + + + M +
Integumentary System	
Mammary gland	+ + + + + + + + + + + + + + + + + + + +
Adenoma	
Carcinoma Fibroadenoma	X X X X X X X X X X
Fibroadenoma, multiple	X
Skin	л + + + + + + + + + + + + + + + + + + +
Subcutaneous tissue, fibrosarcoma	· · · · · · · · · · · · · · · · · · ·
Subcutaneous tissue, lipoma	
Subcutaneous tissue, sarcoma	
Musculoskeletal System	
Bone	+ + + + + + + + + + + + + + + + + + + +
Skeletal muscle	+
Nervous System	
Brain	+ + + + + + + + + + + + + + + + + + + +
Carcinoma, metastatic,	
pituitary gland	Х
Respiratory System	
Larynx	+ + + + + + + M + + + + + + + + M +
Lung	+ + + + + + + + + + + + + + + + + + + +
Alveolar/bronchiolar adenoma,	
multiple	
Sarcoma, metastatic,	
uncertain primary site	Х
Mediastinum, sarcoma, metastatic,	
uncertain primary site	Х
Nose Clanda, adaptaria	+ + + + + + + + + + + + + + + + + + +
Glands, adenoma Trachea	X + + + + + + + + + + + + + + + + + + +
Second Longon Sector	
Special Senses System	
Zymbal's gland Carcinoma	+ X
	Δ
Urinary System	
Kidney Urinary bladder	+ + + + + + + + + + + + + + + + + + +
•	
Systemic Lesions Multiple organs	+ + + + + + + + + + + + + + + + + + + +
Leukemia granulocytic	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Leukemia mononuclear	X XXXXX X XX
Lymphoma malignant	X
-Jbuonia man2nam	4 ×

Number of Days on Study	7 3 5		3	7 7 3 3 5 5			7 3 5	7 3 5	7 3 5	3	3	7 3 6	3	3	-	3		3	3	7 3 6		7 3 6	7 3 6	7 3 6	3	
Carcass ID Number	1 6 9		7	1 1 7 7 1 8	8	8	1 8 7	9	9	9	5	5	1 5 4	5	6	6	1 6 5	6		7		8	1 9 0		0	Total Tissues/ Tumors
Hematopoietic System (continued) Lymph node, mediastinal Spleen Thymus	+ + +		+ + + +	+ - + -	⊢ + ⊢ +	- + - + - +	+ + +	++++	+ + +	+ + +	+ + +	+ + M	+ + +	+ + +	+ + + + + + + + + + + + + + + + + + + +	+ + +	+ + + +	+ + +	+ + +	+ + +	+++++	+++++	+ + +	++++++	+ + +	49 50 47
Integumentary System Mammary gland Adenoma Carcinoma Fibroadenoma Fibroadenoma, multiple Skin Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, lipoma Subcutaneous tissue, sarcoma	+ X X +	ζ	+ -	+ -	+ +	- +	+ X + X	+	+ X +	+	+	+	+ X +	+	+	+ X +		+ X X +	+	+ + X	+	+ X +	+ X +		+ X +	50 2 1 18 1 50 1 1 1
Musculoskeletal System Bone Skeletal muscle	+		+ ·	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Nervous System Brain Carcinoma, metastatic, pituitary gland	+		+ ·	+ -	⊦ +	- +	+	+	+	+	+	+	+	+	+	÷	+	÷	+	÷	+	+	+	+	+	50 1
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma, multiple Sarcoma, metastatic, uncertain primary site Mediastinum, sarcoma, metastatic, uncertain primary site Nose Glands, adenoma Trachea	+ +		+ ·	+ - + -	⊢ N ⊢ + X	- +	+ + + +	++++++	++++++	M + + +	+ + +	+ + +	+	+	+		+	+		+	+ + +	+	M + + +	+++++	+	43 50 1 1 1 50 1 50
Special Senses System Zymbal's gland Carcinoma																										1 1
Urinary System Kidney Urinary bladder	+ +		+ -	+ -	+ +	- +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	++++	+ +	++++	+++	+ +	50 49
Systemic Lesions Multiple organs Leukemia granulocytic Leukemia mononuclear Lymphoma malignant	+		+ •	+ -	+ + X	- + (+ X	+	+ X	+	+	+ X	+ X	+	+	+	+	+ X	+ X	+	+	+	+	+ X	+ X	50 1 18 1

Individual Animal Tumor Patholo	of remaie rais in	ii uie 2- i ear	innalation Study	of Eurymenzene.	200 ppm
	3 4 4 5	6 6 6 6 6	6 6 6 6 6 6	777777	777
Sumber of Days on Study	9 4 8 0	0 2 5 5 5	6788990) 3 3 3 3 3 3	3 3 3
i i	3 9 6 2 2	2 4 1 8 9	2 4 5 9 4 9 9	9 4 4 5 5 5 5	5 5 5
	2 2 3 2	2 2 2 2 2	2 2 2 2 2 2 2 2	2 2 2 2 2 2 2 2	2 2 2
Carcass ID Number	5706	8 9 6 9 5	7 8 8 5 6 7 8	8 6 7 5 5 5 6	6 6 6
	6 2 0 5	6 7 9 5 8		3 2 1 1 4 5 1	3 4 7
Alimentary System					
Esophagus	+ + + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
ntestine large, colon	+ + + + + .	A + + + A	+ + + + + + +	+ + + + + + +	+ + +
Intestine large, rectum	+ A + + .	A + + + A	+ + + + + + +	+ + + + + + +	+ + +
Polyp adenomatous					Х
Intestine large, cecum	+ + + + + + + + + + + + + + + + + + +	A + + + A	+ + + A + + +	+ + + + + + +	+ + +
Intestine small, duodenum	+ + A + .	A + + + A	+ + + + + + +	+ + + + + + +	+ + +
ntestine small, jejunum	+ A + + +	A + + + A	+ + + + + + +	+ + + + + + +	+ + +
ntestine small, ileum	+ A + + +	A + + + A	+ + + + + + +	+ + + + + + +	+ + +
Liver	+ + + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Mesentery	+		+ +		
Pancreas	+ + + + +	+ + + + +	+ + + + + + + +	+ + + + + + +	+ + +
Salivary glands	+ + + + +	+ + + + +	+ + + + + + + +		+ + +
Stomach, forestomach	+ + + + +	+ + + + + +	+ + + + + + + +		+ + +
Stomach, glandular	+ + + + +	+ + + + + A	+ + + + + + + +		+ + +
Fongue	· T T T			. .	
Squamous cell papilloma					
C					
C ardiovascular System Blood vessel					
	+ + + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Heart	+ + + + •	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Endocrine System					
Adrenal cortex	+ + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Adenoma					
Carcinoma					
Adrenal medulla	+ + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Pheochromocytoma malignant		Х			
Islets, pancreatic	+ + + +	+ + + + +		+ + + + + + +	+ + +
Adenoma			Х		
Parathyroid gland	+ + + +]	M + + M +	+ + M + + + 1	M + M + + + +	+ + +
Pituitary gland	+ + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Pars distalis, adenoma	X	Х	X X Z		ХХХ
Pars distalis, adenoma, multiple				Х	
Pars distalis, carcinoma					
Thyroid gland	+ + + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
C-cell, adenoma				X	
General Body System					
None					
Genital System					
Clitoral gland	+ + + + +	+ + + + +	+ + + + + + +	+ + + + + + +	+ + +
Carcinoma	· T T T	. .		X	
Ovary	± · · ·			<u>ה</u> יייע ביבי	
Uterus		+ + + + + +	· · · · · · ·	+ + + + 	+ + +
	+ + + + •	- + + + +	- + + + + + ·	- + + + + + +	τ † †
Polyp stromal Bilateral, polyp stromal				Х	

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm

77 7 7 7 7 7 7 7 7 7 7 7 7 7 77 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 5 6 6 6 6 6 Total **Carcass ID Number** 7 7 7 8 8 8 9 9 9 5 5 5 6 6 7 7 8 8 8 9 9 9 9 9 7 Tissues/ 3 6 7 9 1 2 9 0 2 3 4 2 3 9 0 8 0 5 0 5 8 1 6 8 9 Tumors **Alimentary System** Esophagus 50 Intestine large, colon 48 + + Intestine large, rectum 47 Polyp adenomatous 1 Intestine large, cecum 47 Intestine small, duodenum 47 Intestine small, jejunum 47 + + + Intestine small, ileum 47 50 Liver Mesentery 6 50 Pancreas + + + + + + + Salivary glands 50 + + + + + + + + + + + + + Stomach, forestomach + + + 50 + + + + + + + + Stomach, glandular 49 + + + Tongue 1 Squamous cell papilloma Х 1 **Cardiovascular System** Blood vessel + + + + + + 50 + + + Heart 50 $^{+}$ $^{+}$ + + ++ ++ ++ + + +++ + +++ +++ + **Endocrine System** 50 Adrenal cortex $_{\rm X}^+$ + Adenoma 1 Carcinoma Х 1 Adrenal medulla + 50 Pheochromocytoma malignant 2 Islets, pancreatic 50 Adenoma 1 Parathyroid gland 42 M + + M M + + + + + + + + ++ ++ + $^{+}$ + ++++ +Pituitary gland + + + $\begin{array}{ccccc} + & + & + & + \\ X & X & X & X \end{array}$ + 50 + + + + ++ + + Pars distalis, adenoma Х Х Х ХХ Х хххх 24 Pars distalis, adenoma, multiple 1 Pars distalis, carcinoma Х 1 Thyroid gland + + + + + + 50 C-cell, adenoma х 2 **General Body System** None **Genital System** Clitoral gland 48 Μ Carcinoma 1 Ovary 50 + Uterus 50 + + + + + + + + + + + + + +Polyp stromal Х Х Х Х 4 Bilateral, polyp stromal 1

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued) 3 4 4 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 9 4 8 0 0 2 5 5 5 6 7 8 8 9 9 0 3 3 3 3 3 3 3 3 3 3 9 6 2 2 4 1 8 9 2 4 5 9 4 9 9 4 4 5 5 5 5 5 5 5 5 2 **Carcass ID Number** 7 0 6 8 9 6 9 5 7 8 8 5 6 7 8 6 7 5 5 5 6 6 6 6 5 6 2 0 5 6 7 9 5 8 4 4 7 7 6 8 3 2 1 1 5 1 3 4 7 4 **Hematopoietic System** Bone marrow Lymph node Lymph node, bronchial M +M + + Μ + + M M M + ++ ++ ++ + ++Lymph node, mandibular + Lymph node, mesenteric + + + + + + + + + + + + Lymph node, mediastinal Rhabdomyosarcoma, metastatic, uncertain primary site Х Spleen + + + + + + + + Α + + + ++ + ++ Thymus + + + + M + Μ Rhabdomyosarcoma, metastatic, uncertain primary site Х **Integumentary System** Mammary gland M + Carcinoma Х Fibroadenoma Х Х ХХ ХХ Х Fibroadenoma, multiple + X Skin + + + + + ++ +Squamous cell carcinoma Squamous cell papilloma **Musculoskeletal System** Bone **Nervous System** Brain Carcinoma, metastatic, pituitary gland **Respiratory System** Larynx M M M + M ++ + + M Lung Alveolar/bronchiolar adenoma Carcinoma, metastatic, mammary gland Х Nose + Trachea +**Special Senses System** Eye + + **Urinary System** Kidney Urinary bladder + + + Α + + + + + + + + + + + Systemic Lesions Multiple organs + + + + + + + + + + + + + + + + + ++ ++++ + Leukemia mononuclear Х ХХ ХХХ Х Х Х

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

			~ -		-			~ -						~	<i>j</i>			J							rr-	(0011111100
Number of Days on Study	7 3 5	; ;	3	3				77 33 55	3	3	7 3 5	7 3 6														
Carcass ID Number	2 7 3		7	7	7	8		22 89 90	9	9	2 9 4	2 5 2	2 5 3	2 5 9		2 6 8	2 7 0	2 7 5	2 8 0	2 8 5	2 8 8	2 9 1	2 9 6	2 9 8		Total Tissues/ Tumors
Hematopoietic System																										
Bone marrow	+	+ -	+	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node																										4
Lymph node, bronchial	+	+ -	+	+	+	+	+ ·	+ 1	Л+	- +	+	Μ	+	+	+	+	+	+	+	+	+	+	N	[+	+	41
Lymph node, mandibular	+	+ -	+ •	+	+	+	+ •	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node, mesenteric	+		+ •	+ •	+	+	+ •	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
Lymph node, mediastinal Rhabdomyosarcoma, metastatic, uncertain primary site	+		+	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1
Spleen	+	+ -	+	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Thymus	+	+ -	+ 1	Μ	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Rhabdomyosarcoma, metastatic, uncertain primary site																										1
Integumentary System Mammary gland	4	+ -	+	+	+	+	+ •	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Carcinoma													·											-		2
Fibroadenoma		2	X	Х		Х	X	ху	Χ	K						Х						Х	Х		Х	18
Fibroadenoma, multiple	Х	ζ													Х			Х								3
Skin	+	+ -	+	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell carcinoma Squamous cell papilloma														х							х					1 2
Squamous ten papinoma														Л							Л					2
Musculoskeletal System Bone	4	+ -	+	+	+	+	+ -	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System																										
Brain	+	+ -	+	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Carcinoma, metastatic,																										
pituitary gland																		Х								1
Respiratory System																										
Larynx	+	⊦ l	M	+	+	+	+ ·	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Lung	+	+ -	+	+	+	+	+ ·	+ -	- +	- +	+	+	+		+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma														Х												1
Carcinoma, metastatic, mammary gland Nose										,										,						1 50
Trachea	+	 	+	+ +	+ +	+	+ •	+ -++ -	- + - +	· +	++	++	++	++	++	++	++	++	++	++	++	++	++	+	++	50 50
																										0
Special Senses System																				+						3
Eye Urinary System																										
Eye Urinary System Kidney		+ -	+ -	+	+	+	+ -	+ -	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Eye	+	+ -	+ •	+ +	+	++	+ -	+ -	- +	- +	+++	++	++	++++	+ +	+ +	+ +	+ +	+ +	+ +	++	+++	++	+ +	+ +	50 49
Eye Urinary System Kidney Urinary bladder	+	+ -	+ •	+++	+	+ +	+ •	+ -	- +	- +	++	+++	+ +													
Eye Urinary System Kidney	+		+ + + + + + X		+++++++++++++++++++++++++++++++++++++++	+ +	+ ·	+ - + - + - X	- + - +	- +	+ + + X	++++	++++++	++++++	+++++++	++++	+ + X	+++++	++++	++++	++++	++++	+ + X		+ + X	

Individual Animal Tumor Pathology	gy of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm
	4 4 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7
Number of Days on Study	4 6 0 2 4 5 6 9 9 0 0 1 2 2 3 3 3 3 3 3 3 3 3 3 3
	8 2 4 9 6 5 7 0 9 3 9 1 2 3 4 4 4 4 4 5 5 5 5 5
	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Carcass ID Number	5 5 5 5 7 9 7 7 8 9 6 6 7 5 6 6 8 8 9 5 6 6 7 7
	3 6 8 1 7 6 3 8 8 5 7 3 5 2 8 9 2 7 2 7 1 5 4 6
Alimentary System	
Esophagus	+ + + + + + + + + + + + + + + + + + + +
Intestine large, colon	+ + + + + + + + + + + + + + + + + + + +
Intestine large, rectum	
Intestine large, cecum	
Intestine small, duodenum	A + + + + + + + + + + + + + + + + + + +
Intestine small, jejunum	A + + + + + + + + + + + + + + + + + + +
Intestine small, jejunum	A A + + A + + + + + + + + + + + + + + +
Liver	
	+ + + + + + + + + + + + + + + + + + + +
Mesentery	+ + +
Oral mucosa	
Pharyngeal, squamous cell papilloma	
Pancreas	+ + + + + + + + + + + + + + + + + + + +
Salivary glands	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Stomach, forestomach	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Stomach, glandular	+ + + + + + + + + + + + + + + + + + +
Tongue	+
Schwannoma malignant	Х
Cardiovascular System	
Blood vessel	
Heart	+ + + + + + + + + + + + + + + + + + + +
Endocrine System	
Adrenal cortex	+ + + + + + + + + + + + + + + + + + +
Adrenal medulla	+ + + + + + + + + + + + + + + + + + + +
Islets, pancreatic	+ + + + + + + + + + + + + + + + + + +
Adenoma	Х
Parathyroid gland	+ + + + + + + + + + M + + + + + + + + +
Pituitary gland	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Pars distalis, adenoma	X X X X X X X X X X X X X
Pars distalis, adenoma, multiple	Х
Thyroid gland	+ + + + + + + + + + + + + + + + + + + +
C-cell, adenoma	X
C-cell, carcinoma	
General Body System	
None	
Genital System	
	+ + + + + + + + + + M + + + + + + + + +
Clitoral gland	
	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$
Ovary	+ + + + + + + + + + + + + + + + + + + +
	+ + + + + + + + + + + + + + + + + + + +

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm

	sy of rema		Iva		n u		~ 1	L CU			una		- ~ .		, .			,				•••	- 1	pp-	(continueu)
Number of Days on Study	7 3 5	7 3 5	3	3	3		3	3		3 3	77 33 66	3	3	7 3 6	3										
Carcass ID Number	3 7 9	8	8	8	8	9	9	9	9	9 5	3 3 5 5 4 5	5	6	3 6 2	3 6 4	3 6 6	3 7 0	3 7 2	3 8 0	3 8 3	3 8 9	3 9 1	3 9 8	0	Total Tissues/ Tumors
Alimentary System																									
Esophagus	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, colon	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	· +	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	45
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	46
Liver	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
Mesentery													+			+		+						+	7
Oral mucosa														+											1
Pharyngeal, squamous cell papilloma														Х											1
Pancreas	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Salivary glands	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, glandular	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
Tongue																									1
Schwannoma malignant																									1
Cardiovascular System																									
Blood vessel	+	+	+	+	+	+	+	+ -	+	+ -	+ +	- +	. +	+	+	+	+	+	+	+	+	+	+	+	49
Heart	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	· +	+	+	+	+	+	+	+	+	+	+	+	49
Endocrine System																									10
Adrenal cortex	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
Adrenal medulla	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
Adenoma																									1
Parathyroid gland	+	+	+	+	+	+	+	+	+ ·	+ -	+ +	- +	• +	+	+	+	+	+	+	+	M	+	+	+	47
Pituitary gland	+	+	+			+	+	+	+		+ +				+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma		Х	v		Х					2	ХУ	(X		Х	Х	Х		Х	Х		Х		37	Х	24
Pars distalis, adenoma, multiple			Х																				Х		3
Thyroid gland	+		+	+	+	+	+		+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	49
C-cell, adenoma		Х							Х												• •				3
C-cell, carcinoma																					Х				1
General Body System None																									
Genital System																									
Clitoral gland	.1	+	+	+	+	+	+	+	+	+	+	- N	/ ∟	+		<u>ــ</u>	<u>ــ</u>	_	÷	-		_	<u>ـــ</u>	+	47
Ovary	+	+	+	+	+	+	+	т	+ ·	т - ,		- 1V	1 + ,	+	+	+	+	+	+	+	+	+	+	+	47 49
Histiocytic sarcoma	+ X	+	+	+	+	+	+	+	+	τ ·		- +	• +	+	+	+	+	+	+	+	+	+	+	+	49 1
Uterus																									49
Polyp stromal	+	+	+	+ X	+	+	+	+	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	
															Х			Х							3

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued) 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 4 4 7 7 7 7 7 7 7 Number of Days on Study 0 1 2 2 3 3 3 3 3 4 6 0 2 4 5 6 9 9 0 3 3 3 3 3 8 2 4 9 6 5 7 0 9 3 9 1 2 3 4 4 4 4 4 5 5 5 5 5 **Carcass ID Number** 5 5 5 7 9 7 7 8 9 6 6 7 5 6 6 8 8 9 5 6 6 7 7 5 3 6 8 1 7 6 3 8 8 5 7 3 5 2 8 9 2 7 2 7 1 5 4 6 **Hematopoietic System** Bone marrow + + + + + Lymph node + Lymph node, bronchial + Μ + Μ M M M M ++ + ++ + + Μ + +++ +Lymph node, mandibular + + + + + + + + + + + Lymph node, mesenteric + + + + + + + + Lymph node, mediastinal + + + + + + + + + + Spleen + + + + + + + ++ + +++ + + + + + + ++ + Thymus + + + **Integumentary System** Mammary gland + + + Adenoma Carcinoma, multiple Х Х Fibroadenoma Х ХХХ х Х Fibroadenoma, multiple Х Skin + + + + + + + + + + + + + + + + Sebaceous gland, carcinoma Musculoskeletal System Bone **Nervous System** Brain + + ++ + + + + + + + + + + + + + + + + + + ++ **Respiratory System** Larynx Μ Μ Μ + + + + + + + + + + + + + + ++++ + Lung + $^{+}$ + + + + + + + + + ++ + + ++++ ++ + ++ Nose + + + + + + ++ + + + + + + + + + + + + + + + + Trachea + + + + + + + + + + + + + + + + + + ++ + + + + **Special Senses System** Eye Harderian gland + **Urinary System** Kidney + + + + + + + Renal tubule, adenoma Urinary bladder + + + A + + $^{+}$ + + + + + + + + + + + + + + + +Systemic Lesions Multiple organs + + + + ++++ + ++ + + Histiocytic sarcoma Leukemia mononuclear ХХХ ХХ Х

Individual Animal Tumor Pathology of Female Rats in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued) 77 7 7 7 7 7 7 77 7 7 77 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 3 Total **Carcass ID Number** 8 8 8 8 9 9 9 9 9 5 5 5 6 6 6 6 7 7 8 8 8 7 9 9 0 Tissues/ 9 1 4 5 6 0 3 4 7 9 4 5 9 0 2 4 6 0 2 0 3 9 1 8 0 Tumors **Hematopoietic System** Bone marrow 49 Lymph node 4 Lymph node, bronchial 38 Μ Μ М + Μ +Lymph node, mandibular 49 + + + + Lymph node, mesenteric 49 + + + + Lymph node, mediastinal 49 + + Spleen 49 + + + ++ + + + + + + + + + + + + + + + Thymus М 47 Μ + + **Integumentary System** 49 Mammary gland + + + + Adenoma 1 Carcinoma, multiple Х 1 ХХ Fibroadenoma ХХ Х ХХ Х 15 Х Fibroadenoma, multiple ххх 6 49 Skin + + + + + + ++ + + + + Sebaceous gland, carcinoma Х 1 Musculoskeletal System 49 Bone + + ++++ ++++ +++ ++++ ++ ++++ + **Nervous System** Brain 49 + + + + + + + + + + + ++ + + + + + + + +**Respiratory System** Larynx 45 Μ + + ++ Lung 49 + + + + + + + + + + + + ++ + + + 49 Nose ++ Trachea + + + + + + + + + + + + + + 49 + + + + + + + + + + + **Special Senses System** 1 Eye + Harderian gland 1 **Urinary System** 49 Kidney + Renal tubule, adenoma Х 1 Urinary bladder 48 + + + + + + Systemic Lesions 49 Multiple organs ^+_X + + + +Histiocytic sarcoma 1 Leukemia mononuclear 11 ХХ Х ХХ

TABLE	R 3
IADLL	DO

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ppm	750 ppm
Adrenal Medulla: Benign or Malignant	Pheochromocytoma			
Overall rate ^a	2/50 (4%)	3/50 (6%)	2/50 (4%)	0/49 (0%)
Adjusted rate ^b	6.5%	8.6%	5.0%	0.0%
Ferminal rate ^C	2/31 (6%)	1/31 (3%)	0/34 (0%)	0/35 (0%)
First incidence (days)	734 (T)	719	659	e
Life table test ^d	P = 0.101N	P = 0.516	P = 0.664N	P = 0.212N
ogistic regression test	P = 0.105N	P = 0.514	P = 0.678N	P = 0.212N
Cochran-Armitage test ^d	P = 0.120N			
isher exact test ^d		P = 0.500	P = 0.691N	P = 0.253N
Clitoral Gland: Adenoma or Carcinom	a			
Overall rate	3/47 (6%)	0/49 (0%)	1/48 (2%)	0/47 (0%)
Adjusted rate	10.3%	0.0%	3.1%	0.0%
Cerminal rate	3/29 (10%)	0/30 (0%)	1/32 (3%)	0/34 (0%)
First incidence (days)	734 (T)		734 (T)	
Life table test	P = 0.137N	P = 0.114N	P = 0.269N	P = 0.094N
Logistic regression test	P = 0.137N	P = 0.114N	P = 0.268N	P = 0.094N
Cochran-Armitage test	P = 0.162N	1 011111	1 0120011	1 0100111
Fisher exact test	1 0.10811	P=0.113N	P = 0.301 N	P=0.121N
Kidney (Renal Tubule): Adenoma (Step	Sections)			
Overall rate	0/50 (0%)	0/50 (0%)	1/50 (2%)	7/49 (14%)
Adjusted rate	0.0%	0.0%	2.9%	19.4%
Cerminal rate	0/31 (0%)	0/31 (0%)	1/34 (3%)	6/35 (17%)
First incidence (days)	_		734 (T)	722
ife table test	P< 0.001	f	P = 0.518	P = 0.015
ogistic regression test	P< 0.001	_	P = 0.518	P = 0.014
Cochran-Armitage test	P< 0.001			
isher exact test		_	P = 0.500	P=0.006
Kidney (Renal Tubule): Adenoma (Sing	de and Step Sections)			
Overall rate	0/50 (0%)	0/50 (0%)	1/50 (2%)	8/49 (16%)
Adjusted rate	0.0%	0.0%	2.9%	22.2%
Ferminal rate	0/31 (0%)	0/31 (0%)	1/34 (3%)	7/35 (20%)
irst incidence (days)	_ ```	_ ` ´	734 (T)	722
ife table test	P< 0.001	_	P = 0.518	P = 0.008
ogistic regression test	P< 0.001	_	P = 0.518	P = 0.007
Cochran-Armitage test	P< 0.001			
isher exact test		_	P = 0.500	P=0.003
Aammary Gland: Fibroadenoma				
Overall rate	19/50 (38%)	19/50 (38%)	21/50 (42%)	21/49 (43%)
Adjusted rate	55.8%	49.7%	55.0%	53.8%
erminal rate	16/31 (52%)	12/31 (39%)	17/34 (50%)	17/35 (49%)
First incidence (days)	687	609	651	699
ife table test	P = 0.512N	P = 0.564N	P = 0.561	P = 0.541N
ogistic regression test	P = 0.549N	P = 0.554N	P = 0.509	P = 0.543N
Cochran-Armitage test	P=0.333			
Fisher exact test		P = 0.582N	P = 0.419	P=0.387

TABLE B3 Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ррт	750 ppm
Mammary Gland: Fibroadenoma or Adenoma				
Overall rate	20/50 (40%)	20/50 (40%)	21/50 (42%)	21/49 (43%)
Adjusted rate	56.9%	52.3%	55.0%	53.8%
Ferminal rate	16/31 (52%)	13/31 (42%)	17/34 (50%)	17/35 (49%)
First incidence (days)	651	609	651	699
Life table test	P = 0.421N	P = 0.567N	P=0.519N	P = 0.458N
ogistic regression test	P = 0.454N	P = 0.550N	P = 0.575N	P = 0.466N
Cochran-Armitage test	P = 0.419			
Fisher exact test		P=0.581N	P = 0.500	P=0.466
Aammary Gland: Carcinoma				
Overall rate	3/50 (6%)	1/50 (2%)	2/50 (4%)	1/49 (2%)
Adjusted rate	9.2%	3.2%	4.5%	2.9%
Cerminal rate	2/31 (6%)	1/31 (3%)	0/34 (0%)	1/35 (3%)
irst incidence (days)	704	734 (T)	502	734 (T)
Life table test	P = 0.306N	P = 0.301N	P = 0.471N	P = 0.263N
Logistic regression test	P = 0.353N	P = 0.295N	P = 0.511N	P = 0.266N
Cochran-Armitage test	P = 0.351N	1 0.20010		
Fisher exact test	1 3.00111	P=0.309N	P=0.500N	P=0.316N
Mammary Gland: Adenoma or Carcinoma				
Overall rate	4/50 (8%)	2/50 (4%)	2/50 (4%)	2/49 (4%)
Adjusted rate	11.4%	6.5%	4.5%	5.7%
Terminal rate	2/31 (6%)	2/31 (6%)	0/34 (0%)	2/35 (6%)
First incidence (days)	651	734 (T)	502	734 (T)
.ife table test	P = 0.327N	P = 0.342N	P = 0.313N	P = 0.290N
Logistic regression test	P = 0.327 N P = 0.378 N	P = 0.342N P = 0.322N	P = 0.313N P = 0.349N	P = 0.200 N P = 0.303 N
		r = 0.3221N	P = 0.349 N	P = 0.305 N
Cochran-Armitage test Fisher exact test	P=0.385N	P=0.339N	P=0.339N	P=0.349N
	a .			
Mammary Gland: Fibroadenoma, Adenoma, or		00/50 (100/)	00/50 (100/)	00/10 (150/)
Overall rate	22/50 (44%)	20/50 (40%)	23/50 (46%)	22/49 (45%)
Adjusted rate	61.0%	52.3%	57.0%	56.3%
Cerminal rate	17/31 (55%)	13/31 (42%)	17/34 (50%)	18/35 (51%)
First incidence (days)	651 D. 0.000N	609 D 0 410N	502 D. 0 500N	699 D. 0.007N
ife table test	P = 0.396N	P = 0.412N	P = 0.509N	P = 0.367N
ogistic regression test	P = 0.449N	P = 0.377N	P = 0.561N	P = 0.368N
Cochran-Armitage test	P = 0.436	D 0 (000)	D 0 700	
ïsher exact test		P = 0.420N	P = 0.500	P = 0.545
Pituitary Gland (Pars Distalis): Adenoma				
Overall rate	30/49 (61%)	23/49 (47%)	25/50 (50%)	27/49 (55%)
Adjusted rate	78.5%	61.2%	63.6%	65.4%
erminal rate	23/31 (74%)	17/31 (55%)	20/34 (59%)	21/35 (60%)
'irst incidence (days)	496	475	449	629
ife table test	P = 0.298N	P = 0.122N	P = 0.112N	P = 0.155N
ogistic regression test	P = 0.377N	P = 0.061N	P = 0.096N	P = 0.151N
Cochran-Armitage test	P = 0.546			
Fisher exact test		P = 0.112N	P = 0.178N	P = 0.341N

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ррт	750 ppm
Pituitary Gland (Pars Distalis): Adenoma	or Carcinoma			
Overall rate	30/49 (61%)	24/49 (49%)	26/50 (52%)	27/49 (55%)
Adjusted rate	78.5%	62.3%	66.2%	65.4%
Ferminal rate	23/31 (74%)	17/31 (55%)	21/34 (62%)	21/35 (60%)
First incidence (days)	496	475	449	629
ife table test	P = 0.264N	P = 0.167N	P = 0.149N	P = 0.155N
Logistic regression test	P = 0.332N	P = 0.089N	P = 0.134N	P = 0.151N
Cochran-Armitage test	P = 0.511N			
isher exact test		P = 0.155N	P=0.235N	P=0.341N
Skin: Squamous Cell Papilloma or Squan	nous Cell Carcinoma			
Overall rate	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/49 (0%)
Adjusted rate	0.0%	0.0%	8.8%	0.0%
Ferminal rate	0/31 (0%)	0/31 (0%)	3/34 (9%)	0/35 (0%)
First incidence (days)		_	734 (T)	_
Life table test	P = 0.617N	_	P = 0.137	_
Logistic regression test	P = 0.617N	_	P = 0.137 P = 0.137	_
Cochran-Armitage test	P = 0.656N		1 0.107	
Fisher exact test	1 - 0.0001	_	P=0.121	_
Гhyroid Gland (C-cell): Adenoma				
Overall rate	2/48 (4%)	4/50 (8%)	2/50 (4%)	3/49 (6%)
Adjusted rate	6.2%	12.4%	5.9%	8.6%
erminal rate	1/31 (3%)	3/31 (10%)	2/34 (6%)	3/35 (9%)
First incidence (days)	721	731	734 (T)	734 (T)
Life table test	P = 0.580N	P = 0.348	P = 0.666N	P = 0.554
ogistic regression test	P = 0.585N	P = 0.354	P = 0.675N	P = 0.558
Cochran-Armitage test	P = 0.567	1 01001		1 01000
isher exact test	1 0000	P=0.359	P=0.676N	P=0.510
Thyroid Gland (C-cell): Adenoma or Car	cinoma			
Dverall rate	2/48 (4%)	4/50 (8%)	2/50 (4%)	4/49 (8%)
Adjusted rate	6.2%	12.4%	5.9%	11.4%
Ferminal rate	1/31 (3%)	3/31 (10%)	2/34 (6%)	4/35 (11%)
First incidence (days)	721	731	734 (T)	734 (T)
Life table test	P = 0.436	P = 0.348	P = 0.666N	P = 0.394
Logistic regression test	P = 0.431	P = 0.354	P = 0.675N	P = 0.396
Cochran-Armitage test	P = 0.371	1 0.001	2 0.07011	1 0.000
Fisher exact test	1 01011	P= 0.359	P=0.676N	P=0.349
Uterus: Stromal Polyp				
Overall rate	2/50 (4%)	3/50 (6%)	5/50 (10%)	3/49 (6%)
Adjusted rate	6.2%	7.5%	14.7%	8.6%
Cerminal rate	1/31 (3%)	0/31 (0%)	5/34 (15%)	3/35 (9%)
First incidence (days)	721	601	734 (T)	734 (T)
Life table test	P = 0.569	P = 0.511	P = 0.252	P = 0.554
Logistic regression test	P = 0.546	P = 0.508	P = 0.238	P = 0.558
Cochran-Armitage test	P = 0.495			
Sisher exact test	_ 0.100	P = 0.500	P=0.218	P = 0.490

TABLE B3 Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ррт
Uterus: Stromal Polyp or Stromal Sarcoma				
Overall rate	2/50 (4%)	4/50 (8%)	5/50 (10%)	3/49 (6%)
Adjusted rate	6.2%	9.3%	14.7%	8.6%
Terminal rate	1/31 (3%)	0/31 (0%)	5/34 (15%)	3/35 (9%)
First incidence (days)	721	462	734 (T)	734 (T)
Life table test	P = 0.545N	P = 0.355	P = 0.252	P = 0.554
Logistic regression test	P = 0.585	P = 0.309	P = 0.238	P = 0.558
Cochran-Armitage test	P = 0.568	1 01000	1 01200	1 01000
Fisher exact test	1 01000	P=0.339	P=0.218	P=0.490
All Organs: Mononuclear Cell Leukemia				
Overall rate	13/50 (26%)	18/50 (36%)	16/50 (32%)	11/49 (22%)
Adjusted rate	34.0%	46.2%	38.3%	25.0%
Terminal rate	7/31 (23%)	11/31 (35%)	9/34 (26%)	5/35 (14%)
First incidence (days)	507	412	486	448
Life table test	P = 0.118N	P = 0.217	P = 0.429	P = 0.315N
Logistic regression test	P = 0.195N	P = 0.222	P = 0.370	P = 0.458N
Cochran-Armitage test	P = 0.196N			
Fisher exact test		P=0.194	P=0.330	P=0.430N
All Organs: Benign Neoplasms				
Overall rate	37/50 (74%)	39/50 (78%)	37/50 (74%)	39/49 (80%)
Adjusted rate	90.1%	88.5%	88.0%	86.7%
Terminal rate	27/31 (87%)	26/31 (84%)	29/34 (85%)	29/35 (83%)
First incidence (days)	496	475	449	629
Life table test	P = 0.293N	P = 0.441	P = 0.341N	P = 0.386N
Logistic regression test	P = 0.444N	P = 0.565	P = 0.381N	P = 0.500N
Cochran-Armitage test	P = 0.346			
Fisher exact test		P=0.408	P=0.590N	P=0.337
All Organs: Malignant Neoplasms				
Overall rate	20/50 (40%)	25/50 (50%)	22/50 (44%)	14/49 (29%)
Adjusted rate	47.8%	56.7%	49.2%	31.9%
Terminal rate	10/31 (32%)	13/31 (42%)	12/34 (35%)	7/35 (20%)
First incidence (days)	318	412	393	448
Life table test	P = 0.029N	P = 0.264	P = 0.538	P = 0.107N
Logistic regression test	P = 0.055N	P = 0.335	P = 0.527	P = 0.165N
Cochran-Armitage test	P = 0.044N			
Fisher exact test		P = 0.211	P = 0.420	P = 0.162N

Statistical Analysis of Primary Neoplasms in Female Rats in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
All Organs: Benign or Malignant Neoplasms				
Overall rate	42/50 (84%)	45/50 (90%)	44/50 (88%)	46/49 (94%)
Adjusted rate	93.3%	90.0%	89.8%	93.9%
Terminal rate	28/31 (90%)	26/31 (84%)	29/34 (85%)	32/35 (91%)
First incidence (days)	318	412	393	448
Life table test	P = 0.389N	P = 0.395	P=0.470N	P = 0.494N
Logistic regression test	P = 0.236	P = 0.442	P = 0.595	P=0.318
Cochran-Armitage test	P = 0.124			
Fisher exact test		P = 0.277	P = 0.387	P=0.106

(T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, clitoral gland, kidney, pituitary gland, thyroid gland, and uterus; for other tissues, denominator is number of animals necropsied.

^b Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by **N**.

^e Not applicable; no neoplasms in animal group

^f Value of statistic cannot be computed.

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 2-Year Inhalation Study of Ethylbenzene^a

	Chamber Control	75 ppm	250 ppm	750 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths	~		0	0
Moribund Natural deaths	7 12	14	8	6
Natural deaths Survivors	12	5	8	8
Died last week of study	1			
Terminal sacrifice	30	31	34	35
Missing				1
Animals examined microscopically	50	50	50	49
Alimentary System				
Intestine large, colon	(47)	(49)	(48)	(49)
Inflammation	1 (2%)			
Intestine large, rectum	(49)	(50)	(47)	(49)
Arteriole, inflammation	1 (2%)	(50)	(17)	(40)
Intestine large, cecum Inflammation	(44)	(50)	(47)	(49)
Inflammation Intestine small, ileum	1 (2%)	(40)	(17)	(40)
	(41)	(48)	(47) 1 (2%)	(46)
Hyperplasia Inflammation			1 (2%) 1 (2%)	
Liver	(50)	(50)	(50)	(49)
Angiectasis	3 (6%)	(30)	(50)	6 (12%)
Basophilic focus	23 (46%)	29 (58%)	33 (66%)	29 (59%)
Clear cell focus	3 (6%)	3 (6%)	1 (2%)	4 (8%)
Congestion	1 (2%)		1 (2%)	1 (2%)
Degeneration		1 (2%)	2 (4%)	
Eosinophilic focus	2 (4%)	3 (6%)	8 (16%)	5 (10%)
Fibrosis		1 (2%)		
Hematopoietic cell proliferation	1 (2%)			
Hemorrhage	1 (2%)			
Hepatodiaphragmatic nodule	4 (8%)	4 (8%)	4 (8%)	5 (10%)
Infiltration cellular, lymphocyte			1 (2%)	1 (00/)
Inflammation, acute	9 (00/)	9 (10/)	9 (00/)	1 (2%)
Inflammation, chronic Mixed cell focus	3 (6%) 5 (10%)	2 (4%)	3 (6%) 1 (2%)	2 (4%)
Nixed cell locus Necrosis	5 (10%) 1 (2%)	1 (2%)	1 (2%) 2 (4%)	2 (4%)
Vacuolization cytoplasmic	11 (22%)	12(24%)	14 (28%)	14 (29%)
Centrilobular, degeneration	11 (22.76) 1 (2%)	16 (61/0)	11 (20/0)	11 (2070)
Portal vein, thrombosis	- (870)	1 (2%)		
Mesentery	(7)	(4)	(6)	(7)
Artery, degeneration			1 (17%)	
Artery, inflammation	1 (14%)		1 (17%)	
Fat, necrosis	6 (86%)	4 (100%)	5 (83%)	7 (100%)
Pancreas	(49)	(50)	(50)	(49)
Cyst			1 (2%)	
Inflammation	2 (4%)	40 (0001)	10 (2221)	10 (2221)
Acinus, atrophy	18 (37%)	18 (36%)	18 (36%)	19 (39%)
Arteriole, inflammation	1 (90/)		1 (2%)	1 (2%)
Artery, inflammation	1 (2%)		1 (2%)	

 a Number of animals examined microscopically at the site and the number of animals with lesion

	Chamber Control	75 ppm	250 ppm	750 ppm
Alimentary System (continued)				
Stomach, forestomach	(49)	(50)	(50)	(49)
Hemorrhage				1 (2%)
Hyperkeratosis	2 (4%)		1 (2%)	- ()
Hyperplasia	3 (6%)	1 (2%)	3 (6%)	8 (16%)
Inflammation	1 (2%)	1 (2%)	1 (00/)	6 (12%)
Ulcer	3 (6%)	4 (8%)	1 (2%)	(10)
Stomach, glandular	(49)	(49)	(49)	(49)
Cyst	1 (90/)			1 (2%)
Hyperplasia	1 (2%)			9 (49/)
Inflammation	5 (100/)		1 (90/)	2 (4%)
Necrosis	5 (10%) 1 (20%)		1 (2%)	1 (2%)
Pigmentation	1 (2%)	4 (80/)		1 (90/)
Ulcer Clands, syst		4 (8%)		1 (2%)
Glands, cyst				1 (2%)
Cardiovascular System				
Blood vessel	(49)	(50)	(50)	(49)
Degeneration			1 (2%)	
Inflammation			1 (2%)	
Aorta, inflammation	1 (2%)			
Heart	(50)	(50)	(50)	(49)
Cardiomyopathy	6 (12%)	1 (2%)		6 (12%)
Fibrosis				1 (2%)
Inflammation			1 (2%)	
Atrium, inflammation			1 (2%)	
Atrium, thrombosis				1 (2%)
Endocardium, hyperplasia		1 (2%)	1 (2%)	
Myocardium, hypertrophy		1 (2%)		
Valve, degeneration	1 (2%)			
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(49)
Angiectasis	3 (6%)	3 (6%)	4 (8%)	3 (6%)
Cytoplasmic alteration	1 (2%)	3 (6%)	1 (2%)	. ,
Degeneration		· /	· /	1 (2%)
Degeneration, cystic	5 (10%)	3 (6%)	2 (4%)	4 (8%)
Hemorrhage	4 (8%)	5 (10%)	2 (4%)	1 (2%)
Hyperplasia	3 (6%)	4 (8%)	2 (4%)	3 (6%)
Hypertrophy		· /	3 (6%)	
Necrosis	1 (2%)		1 (2%)	1 (2%)
Pigmentation	· · ·		1 (2%)	1 (2%)
Vacuolization cytoplasmic	12 (24%)	5 (10%)	12 (24%)	6 (12%)
Adrenal medulla	(50)	(50)	(50)	(49)
Hemorrhage	. ,	1 (2%)		· ·
Hyperplasia	4 (8%)	· /	2 (4%)	2 (4%)
Infiltration cellular, lymphocyte			1 (2%)	
Necrosis		1 (2%)	· /	
Parathyroid gland	(48)	(46)	(42)	(47)
Atrophy	1 (2%)	, .		· ·
Hyperplasia	5 (10%)	2 (4%)	4 (10%)	5 (11%)

	Chamber Control	75 ppm	250 ppm	750 ppm
Endocrine System (continued)				
Pituitary gland	(49)	(49)	(50)	(49)
Cyst	1 (2%)			
Infiltration cellular, mixed cell	1 (2%)			
Necrosis	1 (2%)			
Pars distalis, angiectasis	2 (4%)	16 (33%)	6 (12%)	2 (4%)
Pars distalis, cyst	5 (10%)	1 (2%)	3 (6%)	3 (6%)
Pars distalis, degeneration Pars distalis, hemorrhage		$ \begin{array}{cccc} 1 & (2\%) \\ 2 & (4\%) \end{array} $		
Pars distalis, hyperplasia	11 (22%)	2 (478) 9 (18%)	14 (28%)	17 (35%)
Pars distalis, pigmentation	11 (2270)	2 (4%)	14 (2070)	17 (5570)
Pars intermedia, angiectasis		2 (4%)		
Thyroid gland	(48)	(50)	(50)	(49)
Hyperplasia			1 (2%)	
Inflammation	1 (2%)			
Bilateral, C-cell, hyperplasia				1 (2%)
C-cell, hyperplasia	5 (10%)	5 (10%)	5 (10%)	5 (10%)
C-cell, inflammation	1 (2%)		1 (00/)	
Follicle, cyst			1 (2%)	
Genital System Clitoral gland Cyst Hyperplasia	(47) 4 (9%)	(49) 3 (6%)	(48) 1 (2%)	(47) 1 (2%) 3 (6%)
Inflammation	6 (13%)	5 (10%)	4 (8%)	4 (9%)
Bilateral, hyperplasia				1 (2%)
Ovary	(50)	(50)	(50)	(49)
Cyst	5 (10%)	6 (12%)	5 (10%)	5 (10%)
Corpus luteum, hyperplasia	1 (2%)	(7.0)		
Uterus				(40)
	(50) (2%)	(50)	(50)	(49)
Angiectasis	1 (2%)			
Angiectasis Hydrometra		(50) 3 (6%)	1 (2%)	4 (8%)
Angiectasis Hydrometra Inflammation	1 (2%)			4 (8%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst	1 (2%)		1 (2%)	4 (8%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis	1 (2%)	3 (6%) (3) 1 (33%)	1 (2%)	4 (8%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina	1 (2%)	3 (6%) (3)	1 (2%)	4 (8%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration	1 (2%)	3 (6%) (3) 1 (33%)	1 (2%)	4 (8%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System	1 (2%) 1 (2%)	3 (6%) (3) 1 (33%) 1 (33%)	1 (2%) 1 (2%)	4 (8%) 1 (2%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow	1 (2%) 1 (2%) (49)	3 (6%) (3) 1 (33%)	1 (2%)	4 (8%) 1 (2%) 1 (2%) (49)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow Atrophy	(49) 1 (2%)	3 (6%) (3) 1 (33%) 1 (33%) (50)	1 (2%) 1 (2%)	4 (8%) 1 (2%) 1 (2%) (49) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow Atrophy Hemorrhage	(49) 1 (2%) 1 (2%) 3 (6%)	3 (6%) (3) 1 (33%) 1 (33%) (50) 2 (4%)	1 (2%) 1 (2%) (50)	4 (8%) 1 (2%) 1 (2%) (49) 1 (2%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow Atrophy Hemorrhage Hyperplasia	(49) 1 (2%)	3 (6%) (3) 1 (33%) 1 (33%) (50) 2 (4%) 8 (16%)	1 (2%) 1 (2%)	4 (8%) 1 (2%) 1 (2%) (49) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow Atrophy Hemorrhage Hyperplasia Hyperplasia, mast cell	(49) 1 (2%) 1 (2%) 3 (6%) 7 (14%)	3 (6%) (3) 1 (33%) 1 (33%) (50) 2 (4%)	1 (2%) 1 (2%) (50)	4 (8%) 1 (2%) 1 (2%) (49) 1 (2%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow Atrophy Hemorrhage Hyperplasia Hyperplasia, mast cell Myelofibrosis	(49) 1 (2%) 1 (2%) 3 (6%)	3 (6%) (3) 1 (33%) 1 (33%) (50) 2 (4%) 8 (16%) 1 (2%)	1 (2%) 1 (2%) (50) 7 (14%)	4 (8%) 1 (2%) 1 (2%) (49) 1 (2%) 1 (2%)
Angiectasis Hydrometra Inflammation Endometrium, cyst Vagina Fibrosis Arteriole, degeneration Hematopoietic System Bone marrow Atrophy Hemorrhage Hyperplasia, mast cell	(49) 1 (2%) 1 (2%) 3 (6%) 7 (14%)	3 (6%) (3) 1 (33%) 1 (33%) (50) 2 (4%) 8 (16%)	1 (2%) 1 (2%) (50)	4 (8%) 1 (2%) 1 (2%) (49) 1 (2%) 1 (2%)

	Chambe	r Control	75	б ррт	250	ppm	75) ppm
Hematopoietic System (continued)								
Lymph node	(3)		(3)		(4)		(4)	
Pancreatic, hemorrhage					1	(25%)	1	(25%)
Pancreatic, infiltration cellular, histiocyte							1	(25%)
Renal, hemorrhage							2	(50%)
Renal, pigmentation							1	(25%)
Lymph node, bronchial	(37)		(34)		(41)		(38)	
Atrophy		(3%)	. ,					
Ectasia					1	(2%)		
Hemorrhage	4	(11%)	6	(18%)		(12%)	3	(8%)
Hyperplasia, lymphoid	-	(11/0)		(3%)	Ŭ	(12/0)	0	(070)
Infiltration cellular, histiocyte				(0/0)	1	(2%)		
Necrosis						(2%)		
Pigmentation	ß	(16%)	7	(21%)		(17%)	F	(13%)
		(10/0)		(~1/0)		(17/0)		(13/0)
Lymph node, mandibular	(49)		(50)	(90/)	(50)	(90/)	(49)	
Ectasia	0	(00/)		(2%)	1	(2%)	0	(00/)
Hemorrhage		(6%)		(4%)		(2%)		(6%)
Hyperplasia, plasma cell		(4%)	9	(18%)	4	(8%)	3	(6%)
Infiltration cellular, histiocyte	1	(2%)						
Pigmentation								(2%)
Lymph node, mesenteric	(49)		(50)		(50)		(49)	
Amyloid deposition		(2%)						
Atrophy	1	(2%)						
Ectasia					3	(6%)		
Hemorrhage	8	(16%)	6	(12%)	8	(16%)	7	(14%)
Hyperplasia								(2%)
Hyperplasia, plasma cell					1	(2%)		
Infiltration cellular, histiocyte	1	(2%)			_	/		
Inflammation		(2%)			1	(2%)		
Lymph node, mediastinal	(49)	(/ 0)	(49)		(50)	((49)	
Edema	(40)			(2%)	(00)		(40)	
Hemorrhage	91	(43%)		(31%)	19	(26%)	91	(43%)
		(43%)	10	(01/0)	15	(20/0)	21	(10/0)
Hyperplasia, plasma cell								
Infiltration cellular, histiocyte		(2%)						
Necrosis		(2%)	0.0	(450/)	~~	(500())	~-	(550())
Pigmentation		(45%)		(45%)		(50%)		(55%)
Spleen	(49)	(100)	(50)	(00)	(49)	(00)	(49)	(22.1)
Hematopoietic cell proliferation	6	(12%)		(6%)	3	(6%)	3	(6%)
Hemorrhage				(4%)				
Hyperplasia, lymphoid			1	(2%)				
Necrosis							1	(2%)
Pigmentation	1	(2%)	1	(2%)				
Red pulp, atrophy		(2%)						
Fhymus	(48)		(47)		(47)		(47)	
Atrophy		(2%)	()		()		()	
Cyst	1	(2	(4%)
ojst.							~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	(1/0)
Integumentary System								
Mammary gland	(48)		(50)		(49)		(49)	
Galactocele	10	(21%)		(20%)		(20%)	11	(22%)
Hyperplasia		(27%)		(38%)		(43%)		(37%)
J 1				(2%)				. ,

	Chamber Control	75 ppm	250 ppm	750 ppm
Integumentary System (continued)				
Skin	(50)	(50)	(50)	(49)
Cyst epithelial inclusion		4 (00()	1 (2%)	
Infiltration cellular, lymphocyte Inflammation, chronic	1 (2%)	1 (2%)		
Ulcer	1 (2%)		1 (2%)	2 (4%)
Epidermis, hyperplasia	1 (270)		2 (4%)	1 (2%)
Subcutaneous tissue, fibrosis		1 (2%)	a (1/0)	1 (17,0)
Subcutaneous tissue, inflammation			1 (2%)	
Ausculoskeletal System				
Bone	(50)	(50)	(50)	(49)
Fibrous osteodystrophy	<u> </u>	1 (2%)	x/	·/
Hyperostosis	2 (4%)	5 (10%)	5 (10%)	1 (2%)
Turbinate, hyperostosis		2 (4%)	2 (4%)	1 (2%)
Nervous System				
Brain	(50)	(50)	(50)	(49)
Hemorrhage	1 (2%)			1 (2%)
Hydrocephalus		1 (2%)		1 (2%)
Necrosis	1 (2%)			
Respiratory System				
Larynx	(45)	(43)	(44)	(45)
Infiltration cellular, lymphocyte		3 (7%)	1 (2%)	0 (40/)
Inflammation Motaplasia squamous	1 (90/)	2 (5%)	1 (2%)	2 (4%)
Metaplasia, squamous Respiratory epithelium, hyperplasia	1 (2%)		1 (2%)	2 (4%)
Respiratory epithelium, metaplasia, squamou	ıs 1 (2%)	1 (2%)	1 (2/0)	2 (4%) 2 (4%)
ung	(50)	(50)	(50)	(49)
Congestion	5 (10%)	(00)	1 (2%)	()
Edema		1 (2%)	1 (2%)	
Fibrosis	1 (2%)	1 (2%)	1 (2%)	
Hemorrhage	1 (2%)	2 (4%)	2 (4%)	
Infiltration cellular, histiocyte	2 (4%)	3 (6%)	1 (2%)	3 (6%)
Inflammation, chronic	2 (4%)			3 (6%)
Inflammation, chronic active	(05.1)		1 (2%)	
Inflammation, granulomatous	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Alveolar epithelium, hyperplasia	1 (2%)	5 (10%)	2 (4%)	5 (10%)

	Chamber Control	75 ppm	250 ppm	750 ppm
Respiratory System (continued)				
Nose	(50)	(50)	(50)	(49)
Angiectasis			1 (2%)	
Congestion	1 (2%)			
Foreign body	4 (8%)	1 (2%)		1 (2%)
Infiltration cellular, lymphocyte				1 (2%)
Inflammation	10 (20%)	10 (20%)	5 (10%)	1 (2%)
Necrosis			1 (2%)	
Thrombosis	1 (2%)			
Glands, cyst	_ (= + + +)		1 (2%)	
Glands, hyperplasia		1 (2%)	2 (4%)	1 (2%)
Goblet cell, hyperplasia		- (270)	~ (1/0)	1 (2%)
Nasolacrimal duct, inflammation	2 (4%)	1 (2%)		· (270)
Nasolacrimal duct, metaplasia, squamous	1 (2%)	1 (270)		
Respiratory epithelium, hyperplasia	6 (12%)	7 (14%)	5 (10%)	
Respiratory epithelium, metaplasia, squan	0 (1270)	1 (2%)	3 (1076)	
Respiratory epithelium, ulcer	1003	2 (4%)		
Frachea	(50)	(50)	(50)	(49)
			. ,	. ,
Special Senses System				
Eye	(1)		(3)	(1)
Lens, cataract	1 (100%)		2 (67%)	1 (100%)
	1 (100%)			1 (100%)
Retina, degeneration	, ,			(4)
Harderian gland				(1)
				(1) 1 (100%)
Harderian gland Inflammation U rinary System				
Harderian gland Inflammation	(50)	(50)	(50)	
Harderian gland Inflammation U rinary System	(50) 1 (2%)	(50) 1 (2%)		1 (100%)
Harderian gland Inflammation U rinary System Kidney	(50)		(50) 1 (2%)	(49)
Harderian gland Inflammation U rinary System Kidney Cyst	(50) 1 (2%)			(49)
Harderian gland Inflammation U rinary System Kidney Cyst Infarct	(50) 1 (2%) 1 (2%)	1 (2%)	1 (2%)	(49)
Harderian gland Inflammation Urinary System Kidney Cyst Infarct Mineralization Necrosis	(50) 1 (2%) 1 (2%)	1 (2%)	1 (2%) 7 (14%)	(49)
Harderian gland Inflammation Urinary System Kidney Cyst Infarct Mineralization Necrosis Nephropathy	(50) 1 (2%) 1 (2%) 8 (16%)	1 (2%) 11 (22%) 42 (84%)	1 (2%) 7 (14%) 1 (2%) 43 (86%)	(49) 4 (8%)
Harderian gland Inflammation Urinary System Kidney Cyst Infarct Mineralization Necrosis Nephropathy Pigmentation	(50) 1 (2%) 1 (2%) 8 (16%) 38 (76%) 4 (8%)	1 (2%) 11 (22%)	1 (2%) 7 (14%) 1 (2%)	(49) 4 (8%) 46 (94%)
Harderian gland Inflammation Urinary System Kidney Cyst Infarct Mineralization Necrosis Nephropathy Pigmentation Arteriole, inflammation	(50) 1 (2%) 1 (2%) 8 (16%) 38 (76%)	1 (2%) 11 (22%) 42 (84%)	1 (2%) 7 (14%) 1 (2%) 43 (86%) 8 (16%)	(49) 4 (8%) 46 (94%)
Harderian gland Inflammation Urinary System Kidney Cyst Infarct Mineralization Necrosis Nephropathy Pigmentation	(50) 1 (2%) 1 (2%) 8 (16%) 38 (76%) 4 (8%)	1 (2%) 11 (22%) 42 (84%)	1 (2%) 7 (14%) 1 (2%) 43 (86%)	(49) 4 (8%) 46 (94%)

APPENDIX C SUMMARY OF LESIONS IN MALE MICE IN THE 2-YEAR INHALATION STUDY OF ETHYLBENZENE

TABLE C1	Summary of the Incidence of Neoplasms in Male Mice	
	in the 2-Year Inhalation Study of Ethylbenzene	132
TABLE C2	Individual Animal Tumor Pathology of Male Mice	
	in the 2-Year Inhalation Study of Ethylbenzene	136
TABLE C3	Statistical Analysis of Primary Neoplasms in Male Mice	
	in the 2-Year Inhalation Study of Ethylbenzene	158
TABLE C4	Historical Incidence of Alveolar/bronchiolar Neoplasms	
	in Chamber Control Male B6C3F ₁ Mice	161
TABLE C5	Summary of the Incidence of Nonneoplastic Lesions in Male Mice	
	in the 2-Year Inhalation Study of Ethylbenzene	162

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene^a

Disposition Summary Animals initially in study 50 50 50 Early deaths 1 Accidential deaths 1 Accidential deaths 1 1 Moribund 6 2 5 Natural deaths 15 12 13 Died last week of study 1 1 1 Terminal scriftle 28 36 31 Animals examined microscopically 50 50 50 Alimentary System (42) (46) (44) Intestine large, occum (42) (46) (44) Intestine small, iglunum (42) (46) (44) Liver (50) (50) (50) (50) Almentary System 1 (2%) (44) (46) (44) Iter (50) (50) (50) (50) (50) (50) Intestine small, iglunum (42) (46) (44) (46) (44) (46) (44) (46) (46) (41)	750 ppm
Animals initially in study 50 50 50 Early deaths 1 Accidental deaths 1 Moribund 6 2 5 Natural deaths 15 12 13 Survivors 1 1 1 Died last week of study 1 1 1 Terminal sacrifice 28 36 31 Animals examined microscopically 50 50 50 Alimentary System (42) (46) (44) Entestine large, cecum (42) (46) (44) Epithelium, carcinoma 1 (2%) (44) Liver (50) (50) (50) Ing 1 (2%) (44) Cholangiocarcinoma 1 (2%) (44) Liver (50) (50) (50) (50) Ing 1 (2%) (48) (48) Cholangiocarcinoma 1 (2%) (24%) 1 Hemangiosarcoma 1 (2%) 1 (2%) Hepatocellular carcino	
Early deaths 1 Moribund 6 2 5 Natural deaths 1 Terminal sacrifice 28 36 31 Animals examined microscopically 50 50 50 Alimentary System Intestine large, cecum (42) (46) (44) Intestine small, jejunum (44) (46) (44) Epithelium, carcinoma 1 (2%) Alimentary System Intestine small, jejunum (44) (46) (44) Epithelium, carcinoma 1 (2%) Aliveolar/bronchiolar carcinoma, metastatic, lung Cholangiocarcinoma 1 (2%) Hepatocellular carcinoma 1 (2%) 4 (8%) Hepatocellular carcinoma 1 (2%) 4 (8%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) Hepatocholangiocarcinoma 1 (2%) 4 (9%) Hepatocholangiocarcinoma 1 (2%) 4 (9%) Hepatocholangiocarcinoma 1 (2%) 4 (9%) Hepatocholangiocarcinoma 1 (2%) 4 (9%) Hepatocholangiocarcinoma 1 (2%) 4 (9%) Hopatocellular carcinoma 1 (2%) 50 (50) Fibrosarcoma, metastatic, liver 1 (100%) Fibrosarcoma, metastatic, liver 1 (100%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%)	50
Acidental deaths 1 Moribund 6 2 5 Natural deaths 15 12 13 Survivors 1 1 1 Terminal sacrifice 28 36 31 Animals examined microscopically 50 50 50 Alimentary System (42) (46) (44) Intestine large, cecum (42) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) Intestine small, lieum (42) (46) (44) (44) Intestine small, lieum (42) (46) (44) (44) Liver (50) (50) (50) (50) Alue carcinoma, metastatic, somach, glandular 1 (2%) (2%) Hemangiosarcoma 1 (2%) 1 (2%) Hepatocellular carcinoma, multiple 1 (2%) 1 (2%) Hepatocellular carcinoma, metastatic, liver 1 (100%) 1 (2%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) 1 <t< td=""><td>50</td></t<>	50
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	1
Natural deaths 15 12 13 Survivors 1 1 Terminal sacrifice 28 36 31 Animals examined microscopically 50 50 50 Alimentary System (42) (46) (44) Intestine large, cecum (42) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) Liver (50) (50) (50) (50) Alimentary System 1 (2%) (46) (44) Intestine small, ljeum (42) (46) (44) Liver (50) (50) (50) (50) Almentary System 1 (2%) 1 (2%) Hemangiona 1 (2%) 1 (2%) 1 (2%) Hemangiosarcoma 1 (2%) 11 (2%) 11 (2%) 11 (2%) 14 (2%) 14 (3%) 11 (2%) 14 (3%) 12 (2%) 17 (3%) 12 (2%) 17 (3%)	6
Survivors 1 Died last week of study 1 Terminal sacrifice 28 36 31 Animals examined microscopically 50 50 50 Alimentary System 1 (42) (46) (44) Intestine large, cecum (42) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) Liver (50) (50) (50) (50) Alveolar/Noronchiolar carcinoma, metastatic, lung 1 (2%) (46) (44) Cholangiocarcinoma 1 (2%) (46) (44) Hemangioma 1 (2%) (46) (44) Hemangioarcoma 1 (2%) (10) (10) Hepatocellular carcinoma, multiple 1 (2%) 17 (34%) Hepatocellular actinoma, multiple 1 (2%) 17 (34%) Hepatocellular actinoma, metastatic, liver 1 (100%) (10) Hepatocholangiocarcinoma 1 (2%) 1 (2%) (2%) Hepatocholangiocarcinoma, metastati	13
Terminal sacrifice 28 36 31 Animals examined microscopically 50 50 50 Alimentary System Intestine large, cecum (42) (46) (44) Intestine small, jejunum (44) (46) (44) Intestine small, jejunum (42) (46) (44) Liver (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) Cholangiocarcinoma 1 (2%) Hemangtosaccoma 1 (2%) Hemangtosaccoma 1 (2%) Hepatoellular carcinoma, metastatic, stomach, glandular 1 (2%) Hepatoellular carcinoma 17 (34%) 8 Hepatoellular carcinoma, multiple 1 (2%) 1 Hepatoellular carcinoma, multiple 1 (2%) 1 Hepatoellular carcinoma, multiple 1 (2%) 1 Hepatoellular carcinoma, metastatic, liver 1 (100%) 1 Hepatoellular carcinoma, metastatic, liver 1 (100%) 1 Hepatoellular carcinoma, metastatic, liver 1 (2%) 1 Racreas (48) (50) (50) (50) Stomach, forestomach	
Animals examined microscopically 50 50 50 Alimentary System Intestine large, cecum (42) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) Intestine small, jejunum (42) (46) (44) (46) (44) Liver (50) (50) (50) (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, isomach, glandular 1 (2%) (46) (44) Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) Hepatocellular carcinoma, metastatic, stomach, glandular 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	
Alimentary System (42) (46) (44) ntestine small, jejunum (44) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) inestine small, leum (42) (46) (44) intestine small, leum (42) (46) (46) (40) intestine small, leum (12%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1	30
Alimentary System (42) (46) (44) Intestine large, cecum (42) (46) (44) Epithelium, carcinoma 1 (2%) Intestine small, jejunum (42) (46) (44) Epithelium, carcinoma 1 (2%) (46) (44) Liver (50) (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) (2%) Hemangiona 1 (2%) (46) (44) Hemangiona 1 (2%) (2%) (46) (44) Hemangiona 1 (2%) (2%) (46) (44) Hemangiona 1 (2%) (2%) (46) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (49) (48) (49) (48) (49) (48) (49) (48) (49) (48) (49) (48) (49) (48) (49) (48) (49) (48) (49)	50
intestine large, cecum (42) (46) (44) intestine small, jejunum (44) (46) (44) intestine small, ileum (42) (46) (44) intestine small, ileum (42) (46) (44) Liver (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) (46) (41) Hemangiosarcoma 1 (2%) (46) (41) Hemangiosarcoma 1 (2%) (46) (41) Hepatocellular carcinoma, metastatic, stomach, glandular 1 (2%) (48) (46) Hepatocellular carcinoma, multiple 1 (2%) 1 (2%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 1 (2%) 1 (2%) Hepatocellular carcinoma, metastatic, liver 1 (10%) (10) (10) (10) Hepatocellular carcinoma, metastatic, liver 1 (100%) (100%) (2%) (2%) (2%) (2%)	50
ntestine small, jejunum (44) (46) (44) Epithelium, carcinoma 1 (2%) 1 ixter (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) 1 (46) (44) Gholangiocarcinoma 1 (2%) 1 (2%) 1 (2%) 1 Hemangioma 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 1 1 1 1 <t< td=""><td>(10)</td></t<>	(10)
Epithelium, carcinoma 1 (2%) Intestine small, ileum (42) (46) (44) Liver (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) (50) (50) Cholangiocarcinoma 1 (2%) 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Hemangiosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Hepatoblastoma 1 (2%) 2 (4%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 1 (2%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 1 (2%) 1 (2%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) 1 (2%) Pancreas (49) (50) (48) Actinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Stomach, glandular 1 (2%) 1 (2%) <td>(43)</td>	(43)
intestine small, ileum (42) (46) (44) .iver (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Hemangiona 1 (2%) 1 (2%) Hepatocellular carcinoma 1 (2%) 2 (4%) Hepatocellular carcinoma, multiple 1 (2%) 1 (2%) Hepatocellular adenoma 11 (2%) 4 (8%) 1 Hepatocellular carcinoma, metastatic, liver 1 (100%) 1 (2%) 1 (2%) 1 (2%) 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	(43)
Liver (50) (50) (50) Alveolar/bronchiolar carcinoma, metastatic, lung 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Hemangiosarcoma 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular carcinoma 17 (34%) 8 Hepatocellular carcinoma, multiple 1 (2%) 17 Hepatocellular adenoma, multiple 1 (2%) 17 Hepatocellular adenoma, multiple 1 (2%) 17 Hepatocellular adenoma, multiple 1 (2%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 1 (2%) Mesentery (1) (1) (1) (1) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) 1 (2%) Stomach, forestomach (48) (50) (50) (50) (50) Fibrosarcoma 1 (2%) 1 (2%) 1 (2%) Stomach, forestomach (4	(41)
Alveolar/bronchiolar carcinoma, metastatic, lung Cholangiocarcinoma (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) Hepatocellular carcinoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 12 (24%) 17 (34%) Hepatocellular adenoma 11 (2%) 4 (8%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) Hepatocellular carcinoma, metastatic, liver 1 (100%) Hepatocellular carcinoma, metastatic, liver 1 (100%) Hepatocellular carcinoma, metastatic, liver 1 (100%) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (100%) Fibrosarcoma, metastatic, liver 1 (100%) Fibrosarcoma, metastatic, liver 1 (2%) Somach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Fibrosarcoma 1 (2%) Cardiovascular System Slood vessel (48) (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%) Slowach, fibrosarcoma, metastatic, stomach, glandular 1 (2%) Fibrosarcoma 1 (2%) Fibrosarcoma 1 (2%) Cardiovascular System Slood vessel (48) (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	(41)
lung 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Hemangiosarcoma 1 (2%) Hemangiosarcoma 1 (2%) Hepatoblastoma 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular carcinoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 2 (4%) Hepatocellular adenoma 11 (2%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 1 (2%) 1 (2%) Mesentery (1) (1) (1) 1 (2%) Mesentery (1) (1) (1) 1 (2%) Parcreas (49) (50) (48) (50) (50) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Stomach, glandular 1 (2%) 1 (2%) 50) (50) Fibrosarcoma 1 (2%) 1 (2%)	(50)
Cholangiocarcinoma 1 (2%) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Hemangiosarcoma 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular carcinoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular carcinoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular carcinoma, metastatic, liver 1 (100%) 1 (2%) 1 (10%) Pancreas (49) (50) (50) (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 <t< td=""><td>1 (99/)</td></t<>	1 (99/)
Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Hemangtoma 1 (2%) Hemangtosarcoma 1 (2%) Hepatopolastoma 1 (2%) Hepatocellular carcinoma, multiple 1 (2%) Hepatocellular carcinoma, multiple 1 (2%) 17 Hepatocellular adenoma 11 (2%) 2 (4%) Hepatocellular adenoma 11 (2%) 4 (8%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) Mesentery (1) (1) (1) (1) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) (100%) Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma 1 (2%) 50 Stomach, glandular 1 (2%) (1) Odontoma 1 (2%) (1)	1 (2%)
Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) Hepatoblastoma 1 (2%) Hepatoblastoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 2 (4%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) Hepatocholangiocarcinoma, multiple 1 (2%) 4 (8%) Hepatocholangiocarcinoma, multiple 1 (2%) 4 (8%) Mesentery (1) (1) (1) (1) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) (10%) Pancreas (49) (50) (48) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) (2%) Stomach, forestomach (48) (50) (50) (50) Fibrosarcoma 1 (2%) (2%) (2%) Stomach, glandular (48) (50) (50) (50) Fibrosarcoma 1 (2%) (2%) (1) <	
Hemangiosarcoma 1 (2%) Hepatoblastoma 1 (2%) Hepatocellular carcinoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 2 (4%) Hepatocellular adenoma 11 (2%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) 1 (2%) Mesentery (1) (1) (1) 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) 48 48 Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) 50 Stomach, forestomach (48) (50) (50) 50 Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) 50 Stomach, glandular (48) (50) (50) 50 Fibrosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) Stomach, glandular <td></td>	
Hepatoblastoma 1 (2%) Hepatocellular carcinoma, multiple 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 12 (24%) 17 (34%) Hepatocellular adenoma 11 (22%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) 1 (2%) Mesentery (1) (1) (1) (1) 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) 48 Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) Stomach, forestomach (48) (50) (50) (50) Fibrosarcoma Fibrosarcoma 1 (2%) 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma (1) Odontoma 1	
Hepatocellular carcinoma 17 (34%) 8 (16%) 11 (22%) Hepatocellular carcinoma, multiple 1 (2%) 2 (4%) Hepatocellular adenoma 11 (22%) 12 (24%) 17 (34%) Hepatocellular adenoma 11 (22%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) 1 (2%) Mesentery (1) (1) (1) 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) 1 (100%) 1 (100%) Panceas (49) (50) (48) 4 Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) 50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) 500 50) Stomach, glandular (48) (50) (50) 50) 50) Fibrosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) Cardiovascular System 1 (2%) 1 (2%) 48) (49) <td></td>	
Hepatocellular carcinoma, multiple 1 (2%) 2 (4%) Hepatocellular adenoma 11 (22%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Mesentery (1) (1) (1) 1 (2%) Hepatocellular carcinoma, metastatic, liver 1 (100%) 1 (100%) 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) 1 (100%) 1 (2%) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Stomach, glandular 1 (2%) 1 (1) 0 Odontoma 1 (2%) (1) 1 0 Fibrosarcoma 1 (2%) (1) 0 1 0 Odontoma 1 (2%) (48) (48)	10 (20%)
Hepatocellular adenoma 11 (22%) 12 (24%) 17 (34%) Hepatocellular adenoma, multiple 1 (2%) 4 (8%) 1 (2%) Hepatocholangiocarcinoma 1 (2%) 4 (8%) 1 (2%) Mesentery (1) (1) (1) Hepatocellular carcinoma, metastatic, liver 1 (100%) 1 (10%) Panceas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) 3 Stomach, glandular 1 (2%) 1 (2%) 3 3 Stomach, glandular 1 (2%) 1 (2%) 3 3 3 Stomach, glandular 1 (2%) 1 (2%) 3 <td< td=""><td>10 (2070)</td></td<>	10 (2070)
Hepatocellular adenoma, multiple 1 (2%) 4 (8%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) Mesentery (1) (1) (1) Hepatocellular carcinoma, metastatic, liver 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, 1 (2%) Iver 1 (2%) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, 1 (2%) (50) (50) Stomach, forestomach (48) (50) (50) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) (2%) (2%) (50) (17 (34%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%) Mesentery (1) (1) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Stomach, glandular 1 (2%) 1 (2%) (1) Odontoma 1 (2%) (1) (1) Cardiovascular System (1) (1) (1) Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%) (49)	1 (2%)
Mesentery (1) (1) Hepatocellular carcinoma, metastatic, liver 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Squamous cell papilloma 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) Footh (1) Odontoma (48) (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	1 (2%)
Hepatocellular carcinoma, metastatic, liver 1 (100%) Hepatocholangiocarcinoma, metastatic, liver 1 (100%) Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) 1 (2%) 1 (2%) Cooth (1) (1) 0 Odontoma (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%) (49)	1 (170)
Hepatocholangiocarcinoma, metastatic, liver 1 (100%) Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, 1 (2%) 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) 1 (2%) 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) (1) 0 Footh (1) (1) 0 Odontoma (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, 1 (2%) (48) (49)	
Pancreas (49) (50) (48) Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Squamous cell papilloma 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) Footh (1) Odontoma (48) (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	
Acinus, hepatocholangiocarcinoma, metastatic, liver 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) 1 (2%) Squamous cell papilloma 1 (2%) 1 (2%) 1 (2%) Stomach, glandular (48) (50) (50) (50) Fibrosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) Footh 0 (1) 0 0 1 (2%) Cardiovascular System 3 (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%) 1 (2%) 1 (2%)	(48)
liver 1 (2%) Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Squamous cell papilloma 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) Footh (1) Odontoma (48) (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	. /
Stomach, forestomach (48) (50) (50) Fibrosarcoma, metastatic, stomach, glandular 1 (2%) Squamous cell papilloma 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) Footh (1) Odontoma (1) Cardiovascular System Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	
Squamous cell papilloma 1 (2%) Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) (1) Footh (1) (1) Odontoma 0 (1) Cardiovascular System (1) Blood vessel (48) (48) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	(47)
Stomach, glandular (48) (50) (50) Fibrosarcoma 1 (2%) Tooth (1) Odontoma Cardiovascular System Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	
Fibrosarcoma 1 (2%) Tooth (1) Odontoma Cardiovascular System Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	
Tooth (1) Odontoma Cardiovascular System Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	(47)
Odontoma Cardiovascular System Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	
Cardiovascular System Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	(1)
Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	1 (100%)
Blood vessel (48) (48) (49) Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	
Aorta, fibrosarcoma, metastatic, stomach, glandular 1 (2%)	(17)
glandular 1 (2%)	(47)
Aura, nepatuenulai taremonia, metasiane,	
liver 1 (2%)	
Aorta, sarcoma	1 (2%)

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Cardiovascular System (continued) Heart	(50)	(50)	(50)	(50)
Alveolar/bronchiolar carcinoma, metastatic,				1 (90/)
lung Fibrosarcoma, metastatic, stomach, glandula Hepatocholangiocarcinoma, metastatic, liver	ur 1 (2%)		1 (2%)	1 (2%)
Pericardium, hepatocholangiocarcinoma, metastatic, liver	1 (2%)			
Endocrine System	(47)	(47)	(40)	(40)
Adrenal cortex Adenoma	(47) 1 (2%)	(47)	(48) 1 (2%)	(48)
Carcinoma			1 (2%)	
Hepatocellular carcinoma, metastatic, liver Islets, pancreatic	1 (2%) (49)	(50)	(48)	(48)
Adenoma	(43)	(50)	(40)	1 (2%)
Carcinoma	((17)	(1-)	1 (2%)
Pituitary gland Pars distalis, carcinoma	(44)	(45)	(45) 1 (2%)	(47)
Гhyroid gland	(50)	(50)	(50)	(50)
Follicular cell, adenoma Follicular cell, adenoma, multiple	3 (6%)	2 (4%)	1 (2%)	5 (10%) 1 (2%)
General Body System				
Tissue NOS	(2)	(3)	(1)	(2)
Fibrosarcoma	1 (50%)			
Fat, hepatocholangiocarcinoma, metastatic, liver			1 (100%)	
Thoracic, hepatocholangiocarcinoma,				
metastatic, liver Thoracic, sarcoma	1 (50%)			1 (50%)
				1 (50%)
Genital System Epididymis	(49)	(50)	(50)	(50)
Leiomyoma		1 (2%)		
Seminal vesicle Hepatocholangiocarcinoma, metastatic, liver	(49)	(50)	(50) 1 (2%)	(50)
Testes	(49)	(50)	(50)	(50)
Interstitial cell, adenoma	1 (2%)		1 (2%)	1 (2%)
Hematopoietic System		()		
Bone marrow Lymph node	(50) (4)	(50) (7)	(50) (11)	(50) (3)
Fibrosarcoma, metastatic, stomach, glandula		(7)	(11)	(3)
Pancreatic, carcinoma			4 (00)	1 (33%)
Popliteal, hemangioma Renal, cholangiocarcinoma, metastatic, liver		1 (14%)	1 (9%)	
Renal, fibrosarcoma, metastatic, stomach,		1 (14/0)		
glandular	1 (25%)			
Renal, hepatocholangiocarcinoma, metastati liver	С,		1 (9%)	
11701			1 (970)	

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

0	Chamber Control	75 ppm	250 ррт	750 ppm
Hematopoietic System (continued)				
Lymph node, bronchial	(14)	(24)	(27)	(27)
Alveolar/bronchiolar carcinoma, metastatic,				
lung				1 (4%)
Fibrosarcoma, metastatic, stomach, glandular	1 (7%)		1 (10/)	
Hepatocholangiocarcinoma, metastatic, liver Sarcoma			1 (4%)	1 (49/)
Lymph node, mandibular	(43)	(45)	(46)	$ \begin{array}{c} 1 (4\%) \\ (44) \end{array} $
Sarcoma, metastatic, nose	1 (2%)	(43)	(40)	(44)
Lymph node, mesenteric	(45)	(46)	(47)	(48)
Hepatocholangiocarcinoma, metastatic, liver	(10)	(10)	1 (2%)	(10)
Lymph node, mediastinal	(24)	(25)	(27)	(25)
Fibrosarcoma, metastatic, stomach, glandular				
Hepatocholangiocarcinoma, metastatic, liver	1 (4%)			
Sarcoma				1 (4%)
Spleen	(50)	(50)	(49)	(49)
Thymus	(37)	(37)	(39)	(34)
Alveolar/bronchiolar carcinoma, metastatic,				
lung	(00)			1 (3%)
Hepatocholangiocarcinoma, metastatic, liver	1 (3%)			1 (20/)
Sarcoma				1 (3%)
Integumentary System				
Skin	(50)	(50)	(50)	(50)
Fibrosarcoma	1 (2%)			
Hemangioma			1 (2%)	
Musculoskeletal System				
Bone	(50)	(49)	(50)	(50)
Sternum, fibrosarcoma, metastatic, stomach,				
glandular	1 (2%)			
Skeletal muscle	(2)		(2)	
Alveolar/bronchiolar carcinoma, metastatic,			4 (500()	
	1 (500/)		1 (50%)	
Fibrosarcoma, metastatic, stomach, glandular				
Hepatocellular carcinoma, metastatic, liver Hepatocholangiocarcinoma, metastatic, liver	1 (50%)		1 (50%)	
			1 (50%)	
Nervous System				
Brain	(50)	(50)	(50)	(50)

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ррт	750 ppm
Respiratory System				
Larynx	(48)	(49)	(46)	(49)
Lung	(50)	(50)	(50)	(50)
Alveolar/bronchiolar adenoma	5 (10%)	8 (16%)	9 (18%)	15 (30%)
Alveolar/bronchiolar adenoma, multiple		1 (2%)	1 (2%)	1 (2%)
Alveolar/bronchiolar carcinoma	2 (4%)	1 (2%)	5 (10%)	3 (6%)
Cholangiocarcinoma, metastatic, liver		1 (2%)		
Fibrosarcoma, metastatic, stomach, glandula				
Hepatocellular carcinoma, metastatic, liver	5 (10%)	3 (6%)	5 (10%)	3 (6%)
Hepatocholangiocarcinoma, metastatic, liver	1 (2%)		1 (2%)	1 (2%)
Bronchiole, polyp adenomatous		1 (2%)		
Mediastinum, sarcoma	()	()	()	1 (2%)
Nose	(50)	(50)	(50)	(50)
Sarcoma	1 (2%)			(1)
Pleura				(1)
Alveolar/bronchiolar carcinoma, metastatic,				1 (1000/)
lung Trachea	(50)	(50)	(50)	1 (100%) (50)
ו ו מכווכמ	(50)	(30)	(50)	(30)
Special Senses System Harderian gland	(2)	(3)	(9)	
Adenoma	1 (50%)	3 (100%)	(2) 2 (100%)	
Autionia	1 (3076)	3 (10076)	2 (10070)	
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Alveolar/bronchiolar carcinoma, metastatic,	(30)	(30)	(30)	(30)
lung			1 (2%)	1 (2%)
Cholangiocarcinoma, metastatic, liver		1 (2%)	I (4/0)	I (4/0)
Fibrosarcoma, metastatic, stomach, glandula	r 1 (2%)	I (N/0)		
Hepatocellular carcinoma, metastatic, liver	1 (2%)	1 (2%)		
Renal tubule, adenoma	1 (270)	I (w/0)	1 (2%)	
			- (270)	
Systemic Lesions				
Multiple organs ^b	(50)	(50)	(50)	(50)
Leukemia granulocytic		· ·	1 (2%)	1 (2%)
Lymphoma malignant	2 (4%)	2 (4%)	3 (6%)	2 (4%)
Neoplasm Summary				
Total animals with primary neoplasms ^c	35	34	40	41
Total primary neoplasms	50	49	60	68
Total animals with benign neoplasms	20	25	26	30
Total benign neoplasms	24	33	35	43
Fotal animals with malignant neoplasms	21	15	21	16
Total malignant neoplasms	26	16	25	25
Total animals with metastatic neoplasms	9	4	6	5
Total metastatic neoplasms	28	7	17	10

^a Number of animals examined microscopically at the site and the number of animals with neoplasm
 ^b Number of animals with any tissue examined microscopically
 ^c Primary neoplasms: all neoplasms except metastatic neoplasms

Number of Days on Study	0 2 4	0 2 9	2 0 2	2 8 9	4 6 7	5 1 9	5 2 2	5 4 4	5 5 5	5 6 8	5 8 4	5 8 5	5 8 7	6 1 0	6 1 0	6 1 6	6 3 9	6 4 2	6 5 2	6 9 8	7 2 3	7 2 5	7 2 9	7 2 9	2	
Carcass ID Number	0 2 9	4	0 3 1	0 1 8	0 1 2	0 4 7	1	0 4 8	4	0 4 4	3	2	2	1	0 4 1	1		0 3 9	3	0	0 0 5	0 0 8	0 0 3	0 0 6	1	
Alimentary System																										
Esophagus	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Gallbladder	Á		Δ	M	M						+		M	Δ	M	M	+	+	+	+	Å	Δ	+	+	+	
Intestine large, colon					+				+			+		+			+		+	+	+	+	+	+	+	
Intestine large, rectum	A			Ă			+	+	+	+	+	+	+		Ă		+	+	+	+	+	- -	- -	- -	+	
Intestine large, cecum	A				+			+	+	- -	+	+	+	Ă		+	+		Ă			- -	- -	- -	т _	
Intestine small, duodenum	+			+				+	+	+		+	+	+									+	+	- -	
Intestine small, jejunum		, M						+	+	+	+	++					+					A.	+	+	+	
55	A								+	+							+ M		A			+	+	+	+	
Intestine small, ileum	A	. +				A	+	+	+	+	+	+										+	+	+	+	
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, stomach, glandular													Х													
Hemangioma				v		v			v	v			v	v	v	v	v	v		v		v			v	
Hepatocellular carcinoma				Х		Х	37		Х	Х			Х	Х		X	Х	X		Х		Х			Х	
Hepatocellular adenoma							Х								Х						Х		17			
Hepatocellular adenoma, multiple																							Х			
Hepatocholangiocarcinoma					Х																					
Mesentery																		+								
Hepatocellular carcinoma, metastatic, liver																		Х								
Pancreas	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	+	+	A	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, stomach, glandular													Х													
Stomach, glandular	+	+	А	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma													Х													
Cardiovascular System																										
Blood vessel		M	[+	-	-	-	_	-	-	-	-	-	-	-	-	-	+	М	-	-	-	-	-	-	-	
Aorta, fibrosarcoma, metastatic,	-	10.	. –	T	т	т	т	т	т	т	т	Ŧ	т	т	т	т	-	111	т	т	т	т	т	т	т	
stomach, glandular													Х													
Aorta, hepatocellular carcinoma,													Λ													
metastatic, liver				Х																						
Heart				+																						
	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma, metastatic, stomach, glandular													Λ													
Pericardium, hepatocholangiocarcinoma,					v																					
metastatic, liver					Х																					
Endocrine System																										
Adrenal cortex	+	+	+	+	+	Μ	Μ	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																										
Hepatocellular carcinoma, metastatic, liver																		Х								
Adrenal medulla	+	+	+	+	+	М	М	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Islets, pancreatic	+	+	+	+	+	A	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Parathyroid gland	+	Ň	· [+	+	+				M			+	+	+			M				M	M	+	+	M	
Pituitary gland		+		+	+	+	M				M			+	+	+	+	+	+	+	+	+	+	+	+	
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Follicular cell, adenoma	т	r	1.			'			'	'			'	'			'			'	'				'	
i omeunai cen, auchoma																										

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: Chamber Control

+: Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	
	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	0	0	0	0	0	0	0	0	0	0	
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Total
Carcass ID Number	1	1	1	2	2	2	2	2	3	3	3	3	4	4	5	0	0	0	0	1	2	2	3	3	4	Tissues/
	3	6	7	1	2	3	6	7	4	5	7	8	0	5	0	1	4	7	9	9	0	5	2	3	2	Tumors
Alimentary System																										
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	М	+	+	+	+	+	+	+	+	+	47
Gallbladder	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	33
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	46
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	42
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	42
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibrosarcoma, metastatic, stomach, glandular																										1
Hemangioma																	Х									1
Hepatocellular carcinoma				Х	Х	Х													Х							17
Hepatocellular adenoma		Х		Х			Х		Х	Х	Х			Х				Х								11
Hepatocellular adenoma, multiple																										1
Hepatocholangiocarcinoma																										1
Mesentery																										1
Hepatocellular carcinoma, metastatic, liver																										1
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Fibrosarcoma, metastatic, stomach, glandular																										1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Fibrosarcoma																										1
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Aorta, fibrosarcoma, metastatic,	-1	т	Τ'	т	г	г	ſ	1-	F	Г	Г	Г	Г	r	17	1	1.	1.	1.	ſ	г	г	Г	г	г	UF.
stomach, glandular																										1
Aorta, hepatocellular carcinoma,																										1
metastatic, liver																										1
Heart																										50
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1
Fibrosarcoma, metastatic, stomach, glandular																										1
Pericardium, hepatocholangiocarcinoma,																										1
metastatic, liver																										1
Endocrine System																										
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Adenoma										Х																1
Hepatocellular carcinoma, metastatic, liver																										1
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Parathyroid gland	Μ	[+	+	Μ	Μ	+	М	М	М	Μ	Μ	+	+	М	+	М	М	М	М	М	Μ	Μ	Μ	+	+	22
Pituitary gland	+	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma								Х	Х												Х					3

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene	: Chamber Control
(continued)	

(continued)																										
Number of Days on Study	0 2 4	0 2 9	2 0 2	2 8 9	4 6 7	5 1 9	5 2 2	5 4 4	5 5 5	5 6 8	5 8 4	5 8 5	5 8 7	6 1 0	1	6 1 6	6 3 9	6 4 2	6 5 2	6 9 8	7 2 3	7 2 5	7 2 9	7 2 9	2	
Carcass ID Number	0 2 9	0 4 9	0 3 1	0 1 8	1	4	1	4	4	4	3	2	0 2 8		4	1	4	0 3 9	3	0 0 2	0 0 5	0 0 8	0 0 3	0 0 6	1	
General Body System Tissue NOS Fibrosarcoma Thoracic, hepatocholangiocarcinoma, metastatic, liver					+ X								+ X													
Genital System		М		+																						
Epididymis Penis	+	IVI	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Preputial gland	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	А	+	+	+	+	+	+	
Prostate	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	Μ	+	+	+	+	+	+	+	
Seminal vesicle	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Testes	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Interstitial cell, adenoma																			Х							
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
_ymph node			+				+					+	+													
Fibrosarcoma, metastatic, stomach, glandular													Х													
Renal, fibrosarcoma, metastatic,																										
stomach, glandular		_											Х													
Lymph node, bronchial	Μ	+	+	Μ	Μ	+	+	Μ	Μ	Μ	Μ	Μ	+	Μ	Μ	Μ	+	Μ	Μ	Μ	+	+	Μ	+	М	
Fibrosarcoma, metastatic, stomach, glandular											M		Х		N			M		NЛ						
Lymph node, mandibular Sarcoma, metastatic, nose	+	+	+	+	+	+	+	+ X	+	+	IVI	+	+	+	IVI	+	+	IVI	+	IVI	+	+	+	+	+	
Lymph node, mesenteric	+	+	+	+	+	м	+		+	+	+	+	+	+	+	+	+	+	+	м	+	+	+	м	+	
Lymph node, mediastinal	+	+											+													
Fibrosarcoma, metastatic, stomach, glandular													X													
Hepatocholangiocarcinoma, metastatic, liver					Х																					
Spleen	+	+	+	+									+									+	+	+	+	
Thymus	+	+	+	+		Μ	М	+	+	Μ	+	+	М	+	М	Μ	+	Μ	+	Μ	Μ	Μ	+	+	+	
Hepatocholangiocarcinoma, metastatic, liver					Х																					
Integumentary System																										
Mammary gland	Μ	M	Μ	Μ	М	+	М	М	М	Μ	М	М	М	М	М	М	Μ	М	М	М	М	М	М	М	М	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibrosarcoma																										
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Sternum, fibrosarcoma, metastatic,												•														
stomach, glandular													Х													
Skeletal muscle													+					+								
Fibrosarcoma, metastatic, stomach, glandular													Х													
Hepatocellular carcinoma, metastatic, liver																		Х								

(continueu)																									
Number of Days on Study	7 2	7 2	7 2	7 2	7 2	7 2	2	2	2	2	77 22	2 2	2	7 2	7 3										
	9	9	9	9	9	9	9	9	9	9	9 9	9	9	9	0	0	0	0	0	0	0	0	0	0	
	0	0	0	0	0	0	0	0	0	0	0 0) ()	0	0	0	0	0	0	0	0	0	0	0	0	Total
Carcass ID Number	1	1	1	2	2	2					3 3			5	0	0	0	0	1	2	2	3	3	4	Tissues/
	3	6		1							78								9	0	5	2	3		Tumors
General Body System																									
Tissue NOS																									2
Fibrosarcoma																									ĩ
Thoracic, hepatocholangiocarcinoma,																									
metastatic, liver																									1
Genital System																						_			
Epididymis	+	+	+	+	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	49
Penis					+					•			'												10
Preputial gland	+	+	+	+	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	48
Prostate	+	+	+	+	+	+	+	+	+	+	+ +	⊢ +	- +	+	+	+	+	+	M	+	+	+	+	+	46
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	49
Testes	+	+	+	+	+	+	+	+	+	+	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	49
Interstitial cell, adenoma																									1
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Lymph node					•																				4
Fibrosarcoma, metastatic, stomach, glandular																									1
Renal, fibrosarcoma, metastatic,																									
stomach, glandular																									1
Lymph node, bronchial	+	+	Μ	Μ	М	+	М	М	Μ	Μ	MN	ΛN	ΙM	M	М	М	М	М	+	М	+	М	М	М	14
Fibrosarcoma, metastatic, stomach, glandular																									1
Lymph node, mandibular	Μ	[+	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	М	+	+	М	+	+	+	+	43
Sarcoma, metastatic, nose																									1
Lymph node, mesenteric					+				+				- M					+			+	+	+	+	45
Lymph node, mediastinal	Μ	M	+	Μ	+	М	М	+	М	+	+ 1	√1 +	• +	Μ	+	Μ	Μ	+	Μ	+	Μ	+	+	+	24
Fibrosarcoma, metastatic, stomach, glandular																									1
Hepatocholangiocarcinoma, metastatic, liver																									1
Spleen	+	+	+	+	+	+	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	50
Thymus Hepatocholangiocarcinoma, metastatic, liver	+	+	+	+	+	М	+	+	+	+	+ -	+ +	- M	[+	+	+	+	Μ	+	+	+	+	+	+	37 1
																						—	—		
Integumentary System	1.4	[\ .4	• • •	١ſ	М	М	м	м	м	м		ر آ ر	л.	۱ <i>۸</i>	M	м	м	М	ŊЛ	м	М	M	M	M	0
Mammary gland Skin	1VI										+ 1												M +		3 50
Fibrosarcoma	+	+	+	+ X	+	+	+	+	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	50 1
Museulesheletel Sustan																									
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	50
Sternum, fibrosarcoma, metastatic,						•	·	•	•	•												ŕ	·	•	50
stomach, glandular																									1
Skeletal muscle																									2
Fibrosarcoma, metastatic, stomach, glandular																									1
Hepatocellular carcinoma, metastatic, liver																									1

(continueu)																										
Number of Days on Study	0 2 4	0 2 9	2 0 2	2 8 9	4 6 7	5 1 9	5 2 2	5 4 4	5 5 5	5 6 8	5 8 4	5 8 5	5 8 7	6 1 0	6 1 0	6 1 6	6 3 9	6 4 2	6 5 2	6 9 8	7 2 3	7 2 5	7 2 9	7 2 9	7 2 9	
Carcass ID Number	0 2 9	0 4 9	0 3 1	0 1 8	0 1 2	0 4 7	0 1 1	0 4 8	0 4 6	0 4 4	0 3 0	0 2 4	0 2 8	0 1 4	0 4 1	0 1 5	0 4 3	0 3 9	0 3 6	0 0 2	0 0 5	0 0 8	0 0 3	0	0 1 0	
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Fibrosarcoma, metastatic, stomach, glandular Hepatocellular carcinoma, metastatic, liver Hepatocholangiocarcinoma, metastatic, liver Nose Sarcoma Trachea				+ + X +	X +	+	+	Х				+ + + +	+ + + X +	+ + X +	++++++	+ + X + +	+ + X + +	x	+ + + +	+ + + X +	+ + + +	+ + + +	+ + + +	+ + + +	++++++	
Special Senses System Harderian gland Adenoma																										
Urinary System Kidney Fibrosarcoma, metastatic, stomach, glandular Hepatocellular carcinoma, metastatic, liver Urinary bladder	+	+ M	+	+	++	+ A	+	+	+	+	+	+	+ X +	+	+	+ X +	+	+	+	+	+++	+++	+	+	+	
Systemic Lesions Multiple organs Lymphoma malignant	+	+	+	+	+	+	+ X	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	

Number of Days on Study	7 2 9	7 3 0																								
Carcass ID Number	0 1 3	0 1 6	0 1 7	0 2 1	0 2 2	0 2 3	0 2 6	0 2 7	0 3 4	0 3 5	0 3 7	0 3 8	0 4 0	0 4 5	0 5 0	0 0 1	0 0 4	0 0 7	0 0 9	0 1 9	0 2 0	0 2 5	0 3 2	0 3 3	0 4 2	Total Tissues/ Tumors
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Fibrosarcoma, metastatic, stomach, glandular Hepatocellular carcinoma, metastatic, liver	+ +	++	++	++	+ + X	+ +	+ +	+ +	+ +	+ + X	+ + X	+ +	+ +	M +	++	++	+++	++	+ +	++	+++	++	++	++	++	48 50 5 2 1 5
Hepatocholangiocarcinoma, metastatic, liver Nose Sarcoma Trachea	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+ +	1 50 1 50
Special Senses System Harderian gland Adenoma	+ X																+									2 1
Urinary System Kidney Fibrosarcoma, metastatic, stomach, glandular Hepatocellular carcinoma, metastatic, liver Urinary bladder	+	+	+	++++++	+	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	++++	++	+++	+	50 1 1 48
Systemic Lesions Multiple organs Lymphoma malignant	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	50 2

Individual Animal Tumor Patholog	ogy of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm	
	3 3 4 5 5 5 5 5 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7	
Number of Days on Study	6 8 8 1 3 3 7 8 9 4 4 7 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
	0 0 5 4 1 6 8 0 4 0 1 7 9 5 9 9 9 9 9 9 9 9 9 9 9 9 9	
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Carcass ID Number	1 3 2 1 0 2 4 3 1 1 3 0 2 1 0 0 0 0 0 1 2 2 2 2	
	3 0 9 2 9 0 8 4 9 0 6 1 4 1 2 3 4 6 7 8 5 1 5 7 8	
Alimentary System		
Esophagus	+ + + + + + + + + + + + + + + + + + +	
Gallbladder	M + + M + + A M M + A A + + M + + + + +	
Intestine large, colon	+ + + + + + M + + + + A + + + + + + + + +	
Intestine large, rectum	+ + + A + + + + + + + + + + + + + + + +	
Intestine large, cecum	+ + + + A + A + + A A + + + + + + + + +	
Intestine small, duodenum	+ + + + + + M + + + + A + + + + + + + + +	
Intestine small, jejunum	+ + + A A + A + + + A + + + + + + + + +	
Epithelium, carcinoma	Х	
Intestine small, ileum	A + + + A + A + + + A + + + + + + + + +	
Liver	+ + + + + + + + + + + + + + + + + + +	
Cholangiocarcinoma	Х	
Hemangiosarcoma		
Hepatoblastoma		
Hepatocellular carcinoma	X X X X	
Hepatocellular carcinoma, multiple		
Hepatocellular adenoma	X X X X XX XX X	
Hepatocellular adenoma, multiple	X X	
Pancreas	+ + + + + + + + + + + + + + + + + + + +	
Salivary glands	+ + + + + + + + + + + + + + + + + + + +	
Stomach, forestomach	+ + + + + + + + + + + + + + + + + + + +	
Squamous cell papilloma	Х	
Stomach, glandular	+ + + + + + + + + + + + + + + + + + + +	
Cardiovascular System		
Blood vessel	M + + + + + + + + + + + + + + + + + + +	
Heart	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Endocrine System		
Adrenal cortex	+ + + M M M + + + + + + + + + + + + + +	
Adrenal medulla	+ + + M M M + + + + + M + + + + + + + +	
Islets, pancreatic	+ + + + + + + + + + + + + + + + + + + +	
Parathyroid gland	+ + M + + + + M M M + + M + + + M M + M + + + + +	
Pituitary gland	+ M + + + + M + M + + M + + + + + + + +	
Thyroid gland	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$ $+$	
Follicular cell, adenoma	Х	
General Body System Tissue NOS		
Genital System		
Epididymis	+ + + + + + + + + + + + + + + + + + + +	
Leiomyoma	· · · · · · · · · · · · · · · · · · ·	
Penis	+	
Preputial gland	+ + + + + + + + + + + + + + + + + M + + + + +	
Prostate	+ + + + + + + + + + + + + + + + + M +	
Prostate		
Seminal vesicle	+ + + + + + + + + + + + + + + + + + + +	

 TABLE C2

 Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 75 ppm

Individual Animal Tumor Patholog	y or wra	le	TAT	ice					cai			uau	101	1.51	uuu	y .			.				•••	× 1	· P ·		Jitiliueu)
		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study		2	2	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
		9	9	9	9	9	9	9	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number		3	3	3	3	4	4	4	4	0	1	1	1	1	2	2	2	3	3	3	4	4	4	4	4	5	Tissues/
		2	7	8	9	3	4	6	9	5	4	6	7	8				1	3			1	2	5	7	0	Tumors
Alimentary System			_	_																							
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder		+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	М	М	+	+	+	+	+	+	+	+	39
Intestine large, colon		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, rectum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
ntestine large, cecum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
ntestine small, duodenum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
ntestine small, jejunum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Epithelium, carcinoma																											1
Intestine small, ileum		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Liver		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cholangiocarcinoma																											1
Hemangiosarcoma		Х																									1
Hepatoblastoma		·																			Х						1
Hepatocellular carcinoma						Х							Х								-	Х			Х		8
Hepatocellular carcinoma, multiple						-							-			Х						-			-		1
Hepatocellular adenoma								Х						Х		-			Х		Х						12
Hepatocellular adenoma, multiple								-		Х				-					-		-					Х	4
Pancreas		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Squamous cell papilloma																											1
Stomach, glandular		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cardiovascular System																											
Blood vessel		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	48
Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
E ndocrine System Adrenal cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Adrenal medulla		т +		-r -L	т 	- - -	- - -	-r -	-r -	 	-r -	 	 	 	-r +	-r +		-r -	-r -	 	 	 	- -	-T -L	-T -L	+	47
slets, pancreatic		т +		+	т 	- - -	- - -	-r -	+	+	-r -	+	+	+	+	+	+	+	+	 	 	 	- -	-T -L	-T -L	+	40 50
Parathyroid gland		т +		+ M	M		+	+	+		+ M		+	Ť		+ M			+	+	 	 	- -	-T -L	-T -L	+ M	30 34
Pituitary gland		т +		1V1	1VI	- - -	- - -	-r -	-r -	1V1 		 	+	+	+	+	+	+ M	+	+	 	 	- -	++	+	+	34 45
Thyroid gland		т -	- -	++	++	+	++	++	++	++	++	++	++	++	++	++	++	+	++	++	++	+	+	++	++	++	43 50
Follicular cell, adenoma		г	т.	Ť	Ŧ	T	Ŧ	T	-	Ē	-	T	-r	-	77	Ŧ		-r	-	T	-	T	т	Ŧ	т	X	2
General Body System			_		_																						
Tissue NOS			+				+																			+	3
Genital System																											
Epididymis		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Leiomyoma		•		Ť									, i								•						1
Penis																				+							2
Preputial gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Prostate										'																	
Prostate Seminal vesicle		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50

	3	3	4	5	5	5	5	5	5	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	6 0	8 0				3 6	7 8	8 0	9 4	4 0	4 1	7 7	0 9	2 5	2 9										
	-	-	-	_	1			-		-								-	1	-	-	-		1	
Carcass ID Number	1					2	4							1		0	0	0	0	0	1	2	2	2	2
	3	0	9	2	9	0	8	4						1	2	3	4	6	7	8	5	1	5	7	8
Hematopoietic System																									
Bone marrow	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node					+		+					+		+		+					+				+
Renal, cholangiocarcinoma, metastatic, liver												х													
Lymph node, bronchial	Ν	1 +	- +	+	- +	+	+	+	+	М	М		+	+	М	м	м	М	+	+	М	+	+	М	М
Lymph node, mandibular	+	+	- +	- +	- +	+	M																+	+	+
Lymph node, mesenteric	+	+	+ +	- +	- M	+	А	+	+	+	М	+	М	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node, mediastinal	Ν	1 +	- +				М						+	+		+	+	+	М	М	+	М	М	+	+
Spleen	+	- + 1	- +		- + // M				+ M						+	+	+ M	+	+ +	+	+	+	+	+	+
Thymus	IV	1 +	- +	- 1	/1 IV	IVI	IVI	+	11/1	+	IVI	11/1	11/1	+	+	+	11/1	+	+	+	+	+	+	+	Ŧ
Integumentary System	-			-											۰.		۰	۰.							
Mammary gland	N				/I +																				
Skin	+	- +	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Musculoskeletal System																									
Bone	+	- +	- +	• +	- +	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+
Nervous System																									
Brain	+	+	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System																									
Larynx	+	N	Λ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lung	+	+	+ +	- +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma					Х							Х	Х							• •		Х			
Alveolar/bronchiolar adenoma, multiple															х					Х					
Alveolar/bronchiolar carcinoma Cholangiocarcinoma, metastatic, liver												х			л										
Hepatocellular carcinoma, metastatic, liver								Х			х														
Bronchiole, polyp adenomatous																									Х
Nose	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Trachea	+	+	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Special Senses System		_	_	_		_		_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	
Harderian gland													+												
Adenoma													Х												
Urinary System																									
Kidney	+	+	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cholangiocarcinoma, metastatic, liver												Х													
Hepatocellular carcinoma, metastatic, liver Urinary bladder							,				X									,	,				
	+	- +	- +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Systemic Lesions																									
Multiple organs	+	+	- +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	X^+	+	+	+	+
Lymphoma malignant				X																	v				

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	3 0	3 0	3 0	3 0	3 0	3 0												
_	1	1			1	1	1	1	1	1	1	1							1	1	1	1	1	1		Total
Carcass ID Number	3 2	3 7	3 8		4 3	4 4	4 6	4 9								2 6	3 1	3 3	3 5	4 0	4 1	4 2		4 7		Tissues/ Tumors
Hematopoietic System																										
Bone marrow Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 7
Renal, cholangiocarcinoma,																										
metastatic, liver Lymph node, bronchial	Ν	1 N	1+	Μ	I M	М	+	+	М	М	М	+	М	М	+	+	М	М	+	М	М	М	[+	+	+	1 24
Lymph node, mandibular	+	+	+	+									+								+	+			+	45
Lymph node, mesenteric Lymph node, mediastinal	+	+	+	+									+ M													46 25
Spleen	+	+	+	+	+	+	+	+	+						+								+	+	+	20 50
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	Μ	Μ	+	+	+	+	+	+	37
Integumentary System																									.,	
Mammary gland Skin					1 M +																					2 50
Musculoskeletal System ³ one	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										
Larynx	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Lung Alveolar/bronchiolar adenoma	+	+	+	+	+ X	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+ X	50 8
Alveolar/bronchiolar adenoma, multiple																										1
Alveolar/bronchiolar carcinoma																										1
Cholangiocarcinoma, metastatic, liver Hepatocellular carcinoma, metastatic, liver					х																					3
Bronchiole, polyp adenomatous																										1
Nose Frachea	+ +	+	+	++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	50 50
Special Senses System																										
Harderian gland			+					+																		3
Adenoma			Х					Х																		3
J rinary System Kidney																										50
Cholangiocarcinoma, metastatic, liver	+	+	+	+	+	+	+	Ŧ	Ŧ	т	т	т	Ŧ	т	т	Ŧ	т	+	+	+	+	+	+	+	Ŧ	50
Hepatocellular carcinoma, metastatic, liver																										1
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Systemic Lesions Multiple organs	.1	J		-	-	- L	-	+	+	+	+	+	+	+	+	+	+	+	+	<u>ــ</u>	ـ ـ	-	-	<i>т</i>	+	50
Lymphoma malignant	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 2

| | | | | | | |
 | |

 | |
 |
 | 5
 | | | 0
 | | | |
 | | — | |
|--------|---|--|--|--|---|---
--
--|---
--
--|---
--
--
--

--
---|---|---|---|--
---|---|---|---|---|---|
| 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5
 | 6 | 6

 | 6 | 6
 | 6
 | 66
 | 37 | 7 | 7
 | 7 | 7 | 7 | 7
 | 7 | 7 | 7 |
| 8 | 2 | 6 | 7 | 7 | | |
 | |

 | |
 |
 |
 | | |
 | 2 | 2 | 2 | 2
 | 2 | 2 | 2 |
| 0 | 4 | 3 | 0 | 4 | 9 | 9 | 8
 | 2 | 2

 | 0 | 3
 | 8
 | 1 6
 | 3 5 | 5 2 | 4
 | 9 | 9 | 9 | 9
 | 9 | 9 | 9 |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2
 | 2 | 2

 | 2 | 2
 | 2
 | 2 2
 | 2 2 | 2 2 | 2
 | 2 | 2 | 2 | 2
 | 2 | 2 | 2 |
| 2 | 3 | 4 | 2 | 3 | 0 | 4 | 2
 | 1 | 1

 | 2 | 2
 | 1
 | 1 (
 |) 1 | 0 | 0
 | 0 | 0 | 0 | 1
 | 1 | 1 | 2 |
| 2 | 0 | 5 | 4 | 5 | 3 | 1 | 5
 | 4 | 8

 | 8 | 1
 | 5
 | 9 1
 | 1 (|) 5 | 9
 | 2 | 4 | 7 | 1
 | 2 | 6 | 0 |
| | | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | +
 | + | + | + | +
 | + | + | + |
| Α | А | Μ | + | А | А | М | М
 | + | А

 | А | +
 | Μ
 | + 1
 | M - | ⊦ + | +
 | Μ | + | + | +
 | + | + | Μ |
| + | + | + | + | + | + | + | А
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | +
 | + | + | + | +
 | + | + | + |
| + | + | + | + | + | Α | + | А
 | + | А

 | + | +
 | +
 | + -
 | + - | + + | • +
 | + | + | + | +
 | + | + | + |
| + | + | + | + | + | А | + | А
 | + | +

 | А | А
 | +
 | + -
 | + - | + + | A
 | + | + | + | +
 | + | + | + |
| + | А | + | + | + | А | + | А
 | + | А

 | А | А
 | +
 | + -
 | + - | + + | A
 | + | + | + | +
 | + | + | + |
| + | А | | | | | |
 | |

 | |
 |
 |
 | | |
 | | + | + | +
 | + | + | + |
| + | + | + | | | | |
 | |

 | |
 |
 |
 | | |
 | | | + | +
 | + | + | + |
| + | + | + | | | | |
 | |

 | |
 |
 |
 | | |
 | | | | +
 | + | + | + |
| x | | x | | | | • | •
 | • |

 | |
 |
 | •
 | | | '
 | | | |
 | | | |
| Λ | | ~ | ~ | 1 | 2 1 | | x
 | |

 | 2 h | <i>2</i> 1
 | 11
 |
 | 1 | • | |
 | | | |
 | | | |
| | | | | | | | ~ 1
 | |

 | |
 |
 | x
 | x | v | <u>r</u>
 | v | x | | | | | |
 | | x | |
| | | | | | | ~ |
 | |

 | |
 |
 | 2 x 2
 | | Λ | •
 | л | л | | | | | |
 | | Λ | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | ۸ | |
 | | ١л

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | + | + | А | + | +
 | + | IVI

 | + | +
 | +
 | + -
 | + - | - + | - +
 | + | + | + | +
 | + | + | + |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | • +
 | + | + | + | +
 | + | + | + |
| + | + | + | + | + | + | + | +
 | + | +

 | • |
 |
 |
 | | |
 | + | + | + | +
 | + | + | + |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | +
 | + | + | + | +
 | + | + | + |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | + | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | +
 | + | + | + | +
 | + | + | + |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | +
 | + | + | + | +
 | + | + | + |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | _ | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | м | + | + | + | +
 | + | +

 | + | +
 | М
 | + -
 | + - | + + | . +
 | + | + | + | +
 | + | + | + |
| | | 1 | 141 | ' | | • | •
 | • | ·

 | 1 | •
 | .,,
 |
 | | | | | | | |
 | 1. | ' | · · |
 | | | |
| | | | | | | |
 | |

 | |
 |
 | 1
 | x | | |
 | | | |
 | | | |
| + | + | + | м | + | + | + | +
 | + | +

 | + | +
 | М
 |
 | | L .L |
 | + | + | + | +
 | + | + | + |
| т
1 | т
- | т
- | | | | |
 | |

 | |
 |
 |
 | | |
 | | т
- | т
- | -
 | г
- | г
- | + |
| +
M | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | +
\/ | - - | т
- |
| | | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | IVI | + | + | IVI | + | IVI | +
 | |

 | + | +
 | +
 | + -
 | + - | - + | • +
 | + | + | + | +
 | + | + | + |
| | | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | • +
 | + | + | + | +
 | + | + | + |
| | _ | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | _ | _ | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | | | | | |
 | | | |
 | | | |
| | | | | | | |
 | |

 | |
 |
 |
 | | | |
 | | | |
 | | | |
| + | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | | . +
 | + | + | + | +
 | + | + | + |
| M | т
- | т
- | - | м | + | + | +
 | + | +

 | + | +
 | +
 | -
-
 |
+ | . T | т

 | т
- | т
- | т
- | -
 | г
- | г
- | + |
| IVI | + | + | + | 1VI | +
+ | +
+ | +
+
 | +
+ | +
+

 | +
+ | +
+
 | +
+
 |
 | +
⊨ | - +
 | · +
 | + | + | + | +
 | + | + | - - |
| | | | T | т. | - T | - T | -17
 | 77 | -r

 | -r | -1-
 | -r
 | τ -
 | с Т | · + | +
 | + | + | Ŧ | Ŧ
 | т | Ŧ | T |
| + | + | | Ĵ | _ | - | - | -
 | - | _

 | - | -
 | -
 | -
 | L. | L 1 |
 | | | | -1
 | | | - |
| +
+ | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | + + | +
 | + | + | + | +
 | + | + | + |
| ++ | + | + | + | + | + | + | +
 | + | +

 | + | +
 | +
 | + -
 | + - | ⊦ +
 | • +
 | + | + | + | +
 | + | + | + |
| | 4 8 0
2 2 2 2
+ A + + + + + + + + + + + + + + + + + + | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 4 5 5 5 5 8 2 6 7 7 0 4 3 0 4 2 2 2 2 2 2 2 3 4 2 3 2 0 5 4 5 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + | 4 5 5 5 5 5 8 2 6 7 7 7 0 4 3 0 4 9 2 2 2 2 2 2 2 2 3 4 2 3 0 2 2 3 4 2 3 0 2 2 0 5 4 5 3 + + + + + + + + + + + + + + + + + + + + A + + + + + + A + + + + + + A + + + + + + A + + + + + + A + + + + + + + X | 4 5 5 5 5 5 5 8 2 6 7 7 7 7 0 4 3 0 4 9 9 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 9 9 2 3 1 <t< td=""><td>4 5 5 5 5 5 5 5 8 2 6 7 7 7 7 8 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 2 2 2 0 5 4 5 3 1 5 + + + + + + + + + A M + A M M M M M +</td><td>4 5 5 5 5 5 5 5 6 8 2 6 7 7 7 7 8 0 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 2 1 2 0 5 4 5 3 1 5 4 + + + + + + + + + + + + + + + + + + + + + + + + + + + + X X X X X X X X + + + + + + + + + X X X X X X<!--</td--><td>4 5 5 5 5 5 5 5 6 6 8 2 6 7 7 7 7 8 0 4 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 2 1 1 2 0 5 4 5 3 1 5 4 8 + + + + + + + + + + A M + A A M + A + + + A M + A A H +</td><td>4 5 5 5 5 5 5 6 6 6 8 2 6 7 7 7 7 8 0 4 8 0 4 3 0 4 9 9 8 2 2 0 2 3 3 3<!--</td--><td>4 5 5 5 5 5 5 5 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 0 4 3 0 4 9 9 8 2 2 0 3 2<!--</td--><td>4 5 5 5 5 5 5 6 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 8 0 4 3 0 4 9 9 8 2 2 0 3 8 2 1 1 2 2 1 1 2 2 1 1 5 3 1 5 4 8 8 1 5<!--</td--><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6
 6 6</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 6 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 3 8 1 6 5 2</td><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 4 3 0 4 9 9 8 2 2 0 3 8 1 6 5 2 4 2<!--</td--><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 6 6 6 6 6 7</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td></td></td></td></td></td></t<> | 4 5 5 5 5 5 5 5 8 2 6 7 7 7 7 8 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 2 2 2 0 5 4 5 3 1 5 + + + + + + + + + A M + A M M M M M + | 4 5 5 5 5 5 5 5 6 8 2 6 7 7 7 7 8 0 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 2 1 2 0 5 4 5 3 1 5 4 + + + + + + + + + + + + + + + + + + + + + + + + + + + + X X X X X X X X + + + + + + + + + X X X X X X </td <td>4 5 5 5 5 5 5 5 6 6 8 2 6 7 7 7 7 8 0 4 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 4 2 3
 0 4 2 1 1 2 0 5 4 5 3 1 5 4 8 + + + + + + + + + + A M + A A M + A + + + A M + A A H +</td> <td>4 5 5 5 5 5 5 6 6 6 8 2 6 7 7 7 7 8 0 4 8 0 4 3 0 4 9 9 8 2 2 0 2 3 3 3<!--</td--><td>4 5 5 5 5 5 5 5 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 0 4 3 0 4 9 9 8 2 2 0 3 2<!--</td--><td>4 5 5 5 5 5 5 6 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 8 0 4 3 0 4 9 9 8 2 2 0 3 8 2 1 1 2 2 1 1 2 2 1 1 5 3 1 5 4 8 8 1 5<!--</td--><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 6 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 3 8 1 6 5 2</td><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 4 3 0 4 9 9 8 2 2 0 3 8 1 6 5 2 4 2<!--</td--><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 6 6 6 6 6 7
7</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td></td></td></td></td> | 4 5 5 5 5 5 5 5 6 6 8 2 6 7 7 7 7 8 0 4 0 4 3 0 4 9 9 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 4 2 3 0 4 2 1 1 2 0 5 4 5 3 1 5 4 8 + + + + + + + + + + A M + A A M + A + + + A M + A A H + | 4 5 5 5 5 5 5 6 6 6 8 2 6 7 7 7 7 8 0 4 8 0 4 3 0 4 9 9 8 2 2 0 2 3 3 3 </td <td>4 5 5 5 5 5 5 5 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 0 4 3 0 4 9 9 8 2 2 0 3 2<!--</td--><td>4 5 5 5 5 5 5 6 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 8 0 4 3 0 4 9 9 8 2 2 0 3 8 2 1 1 2 2 1 1 2 2 1 1 5 3 1 5 4 8 8 1 5<!--</td--><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 6 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 3 8 1 6 5 2</td><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 4 3 0 4 9 9 8 2 2 0 3 8 1 6 5 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
2 2<!--</td--><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 6 6 6 6 6 7</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td></td></td></td> | 4 5 5 5 5 5 5 5 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 0 4 3 0 4 9 9 8 2 2 0 3 2 </td <td>4 5 5 5 5 5 5 6 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 8 0 4 3 0 4 9 9 8 2 2 0 3 8 2 1 1 2 2 1 1 2 2 1 1 5 3 1 5 4 8 8 1 5<!--</td--><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6</td><td>4 5 5 5 5 5 5 6 6 6
 6 6 6 6 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 3 8 1 6 5 2</td><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 4 3 0 4 9 9 8 2 2 0 3 8 1 6 5 2 4 2<!--</td--><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 6 6 6 6 6 7</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td></td></td> | 4 5 5 5 5 5 5 6 6 6 6 6 8 2 6 7 7 7 7 8 0 4 8 8 8 0 4 3 0 4 9 9 8 2 2 0 3 8 2 1 1 2 2 1 1 2 2 1 1 5 3 1 5 4 8 8 1 5 </td <td>4 5 5 5 5 5 5 6</td> <td>4 5 5 5 5 5 5 6
 6 6</td> <td>4 5 5 5 5 5 5 6 6 6 6 6 6 6 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 3 8 1 6 5 2</td> <td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 4 3 0 4 9 9 8 2 2 0 3 8 1 6 5 2 4 2<!--</td--><td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2</td><td>4 5 5 5 5 5 6 6 6 6 6 7</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td><td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td></td> | 4 5 5 5 5 5 5 6 | 4 5 5 5 5 5 5 6 | 4 5 5 5 5 5 5 6 6 6 6 6 6 6
 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 3 8 1 6 5 2 | 4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 2 0 4 3 0 4 9 9 8 2 2 0 3 8 1 6 5 2 4 2 </td <td>4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2</td> <td>4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2</td> <td>4 5 5 5 5 5 6 6 6 6 6 7</td> <td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td> <td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td> <td>8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2</td> | 4 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 8 0 4 8 8 9 9 0 2 | 4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 8 2 6 7 7 7 7 8 0 4 8 8 9 9 0 2 | 4 5 5 5 5 5 6 6 6 6 6 7
 7 7 | 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 | 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 | 8 2 6 7 7 7 8 0 4 8 8 8 9 9 0 2 |

11	ntinued)
7 7 7 3 3 3 0 0 0	
4 4 5 Tis	Total 'issues/ Fumors
- + + +	50
- + + +	37
- + + +	48
- + + +	45
- + + +	44
- + + +	43
- + + +	44
- + + +	44
- + + +	50
K	11
	2
Х	17
	1
	1
	1
	48
	10
	1
	50
- + + +	
- + + +	50
- + + +	50 1
- + + + - + + +	49 50 1
	48
	10
	1
	48
	40 48
- + + + - M + M	48 28
$-1 v_1 + 1 v_1$ - + + +	20 45
- + + +	45 1
	50
- + + +	1
	1
	1
	1
- + + +	50
- + + +	48
	40 50
	50 50
т т т	1
	50
+	50 1
	- + + - + + - + + - + +

	4	5	5	5	5	5	5	5	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	8 0	2 4	6 3	7 0	7 4	7 9					8 0	8	8		9	0	2	2	2	2	2 9	2 9	2 9	2 9	2
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Carcass ID Number	2 2	3	4	2 4									1 5										1 2		
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node		+		+					+		+	+		+		+	+								
Popliteal, hemangioma														Х											
Renal, hepatocholangiocarcinoma,																									
metastatic, liver																									
Lymph node, bronchial	М	Μ	+	Μ	+	+	М	М	М	Μ	Μ	+	+	+	+	+	М	+	М	+	+	М	Μ	Μ	+
Hepatocholangiocarcinoma, metastatic, liver																									
Lymph node, mandibular	+	+	+	+									+										Μ		
Lymph node, mesenteric	+	+	+	+	+	Μ	+	+	+	Μ	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+
Hepatocholangiocarcinoma, metastatic, liver								• •	• •		• •														
Lymph node, mediastinal	M												+									+		+	
Spleen	+												+												
Гhymus	+	IVI	+	IVI	+	IVI	+	IVI	+	IVI	IVI	+	+	IVI	+	+	+	+	+	+	+	+	+	+	+
Integumentary System																									
Mammary gland													М												
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+
Hemangioma																		Х							
Musculoskeletal System																									
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Skeletal muscle								+																	
Alveolar/bronchiolar carcinoma,																									
metastatic, lung								Х																	
Hepatocholangiocarcinoma, metastatic, liver																									
Nervous System																									
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System																									
Larynx	+	+	+	+	+	+	+	М	+	+	+	М	+	+	М	+	+	+	+	+	+	+	+	+	+
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma														Х			Х								
Alveolar/bronchiolar adenoma, multiple									Х																
Alveolar/bronchiolar carcinoma								Х		Х					Х					Х					
Hepatocellular carcinoma, metastatic, liver					Х			Х			Х		Х												
Hepatocholangiocarcinoma, metastatic, liver																									
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Special Senses System																									
Harderian gland																									
Adenoma																									
Urinary System																									
Kidney	г	<u>т</u>	<u> </u>	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+
Alveolar/bronchiolar carcinoma,	Ŧ	т	Ŧ	-	T		Τ.	Τ'	7			-1-	77	Τ.	Τ'	т	т	т	г	Τ'	-1-		-	-	1
metastatic, lung								х																	
Renal tubule, adenoma								••																	
Ureter																+		+							
Urinary bladder																		A							

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued) 7 Number of Days on Study 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 9 9 9 99 9 99 9 9 9 9 9 9 0 0 0 0 0 0 0 0 0 0 0 2 Total **Carcass ID Number** 2 2 2 2 3 3 3 3 3 3 3 3 4 4 0 0 1 1 4 4 4 4 4 4 5 Tissues/ 3 6 7 9 1 2 3 6 7 8 9 3 7 6 8 3 7 0 2 6 8 9 0 Tumors 4 4 **Hematopoietic System** Bone marrow 50 Lymph node 11 Popliteal, hemangioma 1 Renal, hepatocholangiocarcinoma, metastatic, liver 1 Lymph node, bronchial 27 M M M M +Μ M M + MM + + + Μ Hepatocholangiocarcinoma, metastatic, liver Х 1 Lymph node, mandibular + 46 + + Lymph node, mesenteric + + + + 47 + Hepatocholangiocarcinoma, metastatic, liver Х 1 Lymph node, mediastinal + M + M + M ++ ΜМ + + Μ + M M M M M ++ M + 27 + Spleen + + + + 49 + Thymus + + ++ + + M + + + M + + + ++ + M M 39 + + ++++**Integumentary System** Mammary gland 3 Skin + + + + + + + + 50 + + + + + + + + Hemangioma 1 **Musculoskeletal System** 50 Bone + Skeletal muscle 2 Alveolar/bronchiolar carcinoma, metastatic, lung 1 Hepatocholangiocarcinoma, metastatic, liver Х 1 **Nervous System** 50 Brain + + + + ++ ++ + + + + + **Respiratory System** Larynx 46 + 50 Lung + + X Alveolar/bronchiolar adenoma ХХ Х х х 9 Alveolar/bronchiolar adenoma, multiple 1 Alveolar/bronchiolar carcinoma Х 5 Hepatocellular carcinoma, metastatic, liver Х 5 Hepatocholangiocarcinoma, metastatic, liver Х 1 50 Nose + + + Trachea + 50 + + + + + + + + + ++ + ++ + ++ + + $^{+}$ + + ++ **Special Senses System** Harderian gland 2 + Adenoma Х Х 2 **Urinary System** 50 Kidney + Alveolar/bronchiolar carcinoma, metastatic, lung 1 Renal tubule, adenoma Х 1 Ureter 2 Urinary bladder 49 + + + + ++ + + +++ +

TABLE C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

Number of Days on Study	4 5 5 5 5 5 5 6 6 6 6 7
Carcass ID Number	2 2
Systemic Lesions Multiple organs Leukemia granulocytic Lymphoma malignant	+ + + + + + + + + + + + + + + + + + +

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued)

Number of Days on Study	•	2	•	7 2 9	•	2	•	•	2	2	2	2	2	2	•	3	3	3	3	•	3	•	•	7 3 0		
Carcass ID Number	2	~	~		3	3	3	3	3	3	3	3	4	4	~	0	1	1	4	4	2 4 4	2 4 6	2 4 8	2 4 9	~	Total Tissues/ Tumors
Systemic Lesions Multiple organs Leukemia granulocytic Lymphoma malignant	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	50 1 3

Number of Days on Study	1 7	2 5	4 1	4 3	4 8	5 2				6 1		6 4							7 0	7 2	7 2	7 2	7 2	7 2	7 2	
	9		8	0															8	5	9	9	9	9	9	
Carcass ID Number	3 2		3 3	3 2	3 3										3 3						3 0	3 0	3 1	3 1		
	6	5	8	4	9	0	6	7	4	5	8	6	1	7	7	4	9	3	0	9	2	4	2	3	6	
Alimentary System												м														
Esophagus Gallbladder	+	A A	+ A	+ A					+			A		++					+ +	++	++	++	+	++	+	
Intestine large, colon	+	+	+				+					A							M	+	+	+	+	+	+	
Intestine large, rectum	+	A	+	+								+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	A	Μ	А	А	А	+	Α	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	А	А	+	А	+	+	+	Α	А	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	+	+	М	А	А	А	+	А	+	A	+	+	+	+	+	+	+	A	+	+	+	+	+	+	+	
Intestine small, ileum	+	A	Μ	А	А	А	+	A	+	A	+	А	+	+	+	+	+	Μ	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar carcinoma,																										
metastatic, lung				1 7	X 7	37			17				v	17			v		X	1 7				1 7		
Hepatocellular carcinoma				Х	Х	Х			Х	v			Х	Х			X		Х	Х				Х	v	
Hepatocellular adenoma										Х							Х								Х	
Hepatocellular adenoma, multiple			v																							
Hepatocholangiocarcinoma Pancreas		+	X +	+		М	+	۸		+	+	+									,					
Salivary glands	+	+	+	+	+						++	++	++	++	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	т +	- -	+	+ +	Δ			Ă			+	+	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	
Stomach, glandular	+	· +	+	+		A		A						+	+	+	+	+	+	+	+	+	+	+	+	
Tongue				·	••	••		••	·			·	·					·		·		Ċ	Ċ			
Tooth											+															
Odontoma											Х															
Cardiovascular System																										
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	
Aorta, sarcoma			Х																							
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Alveolar/bronchiolar carcinoma,																										
metastatic, lung																			Х							
Endocrine System																										
Adrenal cortex	Ν	1 +	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adrenal medulla	Ν	1 +	+	+	+	+		A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Islets, pancreatic	+	+	+	+	+	М	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma																• •										
Carcinoma																X					۰.	۰.	۰.			
Parathyroid gland	Ν	1+		+ M																		M	M	M	+	
Pituitary gland	+	+	+	M	+	M			+										+	+	+	+	+	+	+	
Thyroid gland Follicular coll_adonoma	+	+	+	+	+	+	+	+	+	+		+ X		+ X	+	+	+	+	+	+	+	+	+	+	+ X	
Follicular cell, adenoma Follicular cell, adenoma, multiple												л		л											л	
General Body System																										
Fissue NOS			,									J														
Thoracic, sarcoma			+ X									+														
·			Л																							—
Genital System																							,	,		
Epididymis Proputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Preputial gland Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Seminal vesicle	+	+	+	+	⊤ +	+ +	+ +	τ +	+ +	τ +	+ +	+ +	+ +	+ +	-π +	τ +	-π +	τ +	+ +	+ +	+ +	+	+	+	+	
Testes	т +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
	'				•		•					•	•	•		•	•			•						

152

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	2				2 9	2 9	2 9	3 0	3	3 0	3 0	3	3 0													
		0	0	0	0	0	0	0	0	0											0	0	0			m . 1
Carcass ID Number	3	3 2			3 3	3 4	3 4	3 0	3 0	3 0	3 1	3 1	3 2	3 2	3 2	3 3	3 3	3 3	3 4		3 4	3 4	3	3 4	3 5	Total /Tissues
Carcass ID Number	8					4 2	4 8	3	8	9	1		2 1	2 3		3 0	3 1	5 6		4 1		4 4	4 5		0	Tumors
Alimentary System																										
Esophagus	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Gallbladder	+	- +	· N	1 +	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	38
Intestine large, colon	+	- +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Intestine large, rectum	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, cecum	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Intestine small, duodenum	+	- +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Intestine small, jejunum	+	- +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Intestine small, ileum	+	- +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	41 50
Liver Alveolar/bronchiolar carcinoma,	+	- +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
metastatic, lung																										1
Hepatocellular carcinoma																										10
Hepatocellular adenoma		х	· x	хх		x	х	x	x			x	х						x	x	Х			x	Х	10
Hepatocellular adenoma, multiple		7			X	Λ	Λ	Λ	Λ			Λ	Λ						Λ	л	л			л	Λ	1
Hepatocholangiocarcinoma					21																					1
Pancreas	+	- +	. +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Salivary glands		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	- +	• +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Stomach, glandular	+	- +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Tongue											+															1
Tooth																										1
Odontoma																										1
Cardiovascular System																										
Blood vessel															М								+		М	47
Aorta, sarcoma	+	- +	- +	- +	+	+	+	÷	+	+	+	+	+	+	IVI	+	+	+	+	+	+	+	+	+	IVI	47
Heart	L			- +	-	-	-	+	+	-	+	+	+	+	+	+	+	+	+	+	+	-	+	-	+	50
Alveolar/bronchiolar carcinoma,	Т				т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	50
metastatic, lung																										1
Endocrine System																										
Adrenal cortex	+	- +	+	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Adrenal medulla	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Islets, pancreatic	+	- +			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Adenoma			Х	Č.																						1
Carcinoma																										1
Parathyroid gland	Ν	1 N	1 +	- N	1 M	Μ	+	Μ	+	Μ	+	Μ	Μ	Μ	+	+	+	Μ	+	+	Μ	Μ	+	Μ	+	25
Pituitary gland	+	- +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Thyroid gland	+	- +	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma						Х							Х													5
Follicular cell, adenoma, multiple				Х																						1
General Body System																										
Fissue NOS																										2
Thoracic, sarcoma																										1 1
Genital System																										
Epididymis	4	- +	. +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	+	· +	· +	· +	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	49
Prostate	+	· +	· +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Seminal vesicle	+	- +	• +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Testes	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Interstitial cell, adenoma																										

	1	2	4	4	4	5	5	5	6	6	6	6	6	6	6	6	6	6	7	7	7	7	7	7	7	
Number of Days on Study	7		1	3						1	3	4	5			6	7	7	0	2	2	2	2	2	2	
trainiber of Duys on Study	9		8					2			2		9				9	9	8	5	9	9	9	9		
	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
Carcass ID Number	2	1	3	2	3	2	0	0	3	0	2	4	0	4	3	1	1	3	1	2	0	0	1	1	1	
	6	5	8	4	9	0	6	7	4	5	8	6	1	7	7	4	9	3	0	9	2	4	2	3	6	
Hematopoietic System																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Lymph node							+			+						+										
Pancreatic, carcinoma																Х										
Lymph node, bronchial	Μ	М	+	М	М	М	М	+	М	М	+	М	+	М	М	М	+	М	+	М	Μ	+	Μ	Μ	Μ	
Alveolar/bronchiolar carcinoma,																										
metastatic, lung																			Х							
Sarcoma			Х																							
Lymph node, mandibular	Μ			+	+	М	+	Μ	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	
Lymph node, mesenteric						А																				
Lymph node, mediastinal						М																				
Sarcoma			Х																							
Spleen	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Thymus	+	А	+	+	М	М	М	М	М	+	М	М	М	+	М	+	+	+	+	+	+	+	+	+	М	
Alveolar/bronchiolar carcinoma,																										
metastatic, lung																			Х							
Sarcoma			Х																							
Integumentary System																										
Mammary gland	т.	м	м	м	м	+	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	
Skin						+																				
Skii	т	т	т	т	т	Ŧ	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	-	Ŧ	т	
Musculoskeletal System																										
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System	۸4										,									,	,					
Larynx		+															+	+	+	+	+	+	+	+	+	
Lung	+	+				+	+	+	+	+	+	+	+	+	+	+	+		+	+	X^+		+			
Alveolar/bronchiolar adenoma			Х		Х													Х			л		л	Х		
Alveolar/bronchiolar adenoma, multiple																			37			17				
Alveolar/bronchiolar carcinoma					v												v		Х			Х		v		
Hepatocellular carcinoma, metastatic, liver			v		Х												Х							Х		
Hepatocholangiocarcinoma, metastatic, liver			X																							
Mediastinum, sarcoma			Х																							
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pleura																			+							
Alveolar/bronchiolar carcinoma,																			17							
metastatic, lung																			Х							
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued)

													-	-												
Number of Days on Study	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	2	7 3 0																		
Carcass ID Number	3 1 8	3 2 2	3 2 7	3	3	3 4 2	4	0		0	1		2		2	3 3 0	3	3 3 6		4	3 4 3	4	3 4 5	3 4 9	5	Total Tissues/ Tumors
Hematopoietic System																										50
Bone marrow Lymph node Pancreatic, carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 3 1
Lymph node, bronchial Alveolar/bronchiolar carcinoma, metastatic, lung Sarcoma	+	+	+	+	М	+	Μ	+	+	+	М	+	+	+	+	+	+	+	+	+	+	М	Μ	+	+	27 1 1
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	44
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Lymph node, mediastinal Sarcoma	Μ	Μ	Μ	+	М	+	+	+	+	+	+	+	М	М	+	+	+	М	М	+	М	М	+	+	+	25 1
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Thymus Alveolar/bronchiolar carcinoma, metastatic, lung Sarcoma	+	+	+	+	+	М	Μ	М	+	+	М	+	+	+	+	+	+	М	+	+	+	+	+	+	+	34 1 1
Integumentary System																										
Mammary gland Skin	M +	M +				M +			M +		M +	M +					M +					M +			M +	3 50
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										10
Larynx Lung	+	+	++	+	+	+	+	++	+	++	+ +	++	++	++	++	+ +	+	++	++	++	++	+	++	++	+ +	49 50
Alveolar/bronchiolar adenoma	+	+ X	+	+ X	+ X	+	+		+ X	+	+	+	+ X	+	+	+	+ X	+	+ X	+	+ X	+ X	+	+	+	50 15
Alveolar/bronchiolar adenoma, multiple																									Х	1
Alveolar/bronchiolar carcinoma																Х										3
Hepatocellular carcinoma, metastatic, liver																										3
Hepatocholangiocarcinoma, metastatic, liver Mediastinum, sarcoma																										1
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pleura																										1
Alveolar/bronchiolar carcinoma, metastatic, lung																										1
Trachea	+	+	+	+	+	+	+	+	+	+		+					+		+	+	+	+	+	+	-	50

TABLE C2

Individual Animal Tumor Patholog	ogy of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued)
	1 2 4 4 4 5 5 5 6 6 6 6 6 6 6 6 6 6 6 7 7 7 7 7 7
Number of Days on Study	$7 \ 5 \ 1 \ 3 \ 8 \ 2 \ 6 \ 8 \ 0 \ 1 \ 3 \ 4 \ 5 \ 5 \ 6 \ 6 \ 7 \ 7 \ 0 \ 2 \ 2 \ 2 \ 2 \ 2 \ 2$
5 5	9 9 8 0 0 0 5 2 7 8 2 7 9 9 0 9 9 8 5 9 9 9 9 9
	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Carcass ID Number	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
	$6 \ 5 \ 8 \ 4 \ 9 \ 0 \ 6 \ 7 \ 4 \ 5 \ 8 \ 6 \ 1 \ 7 \ 7 \ 4 \ 9 \ 3 \ 0 \ 9 \ 2 \ 4 \ 2 \ 3 \ 6$
Urinary System	
Kidney	+ + + + + + + + + + + + + + + + + + + +
Alveolar/bronchiolar carcinoma,	
metastatic, lung	Х
Ureter	+
Urinary bladder	+ + + + + A + + + + + + + + + + + + + +
Systemic Lesions	
Multiple organs	+ + + + + + + + + + + + + + + + + + + +
Leukemia granulocytic	Х
Lymphoma malignant	Х

Individual Animal Tumor Pathology of Male Mice in the 2-Year Inhalation Study of Ethylbenzene: 750 ppm (continued)

Number of Days on Study	7 2 9	7 3 0																								
Carcass ID Number	3 1 8	2	3 2 7	3 3 2	3 3 5	3 4 2	3 4 8	3 0 3	3 0 8	3 0 9	3 1 1	3 1 7	3 2 1	3 2 3	3 2 5	3 3 0	3 3 1	3 3 6	3 4 0	3 4 1	3 4 3	3 4 4	3 4 5	3 4 9	3 5 0	Total Tissues/ Tumors
Urinary System Kidney Alveolar/bronchiolar carcinoma,	+	+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
metastatic, lung Ureter Urinary bladder	+	-+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 1 49
Systemic Lesions Multiple organs Leukemia granulocytic	+	-+	 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
Lymphoma malignant															Х											2

TABLE C3 Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ppm	750 ppm
Harderian Gland: Adenoma				
Overall rate ^a	1/50 (2%)	3/50 (6%)	2/50 (4%)	0/50 (0%)
Adjusted rate ^b	3.6%	8.0%	6.3%	0.0%
Terminal rate ^c	1/28 (4%)	2/36 (6%)	2/32 (6%)	0/30 (0%)
First incidence (days)	729 (T)	709	729 (T)	e
Life table test ^d	P = 0.192N	P = 0.398	P = 0.547	P = 0.486N
Logistic regression test	P = 0.182N	P = 0.375	P = 0.547	P = 0.486 N
Cochran-Armitage test ^d	P = 0.183N			
Fisher exact test ^d		P=0.309	P=0.500	P=0.500N
Liver: Hepatocellular Adenoma				
Overall rate	12/50 (24%)	16/50 (32%)	17/50 (34%)	18/50 (36%)
Adjusted rate	37.6%	39.1%	46.7%	55.8%
Terminal rate	9/28 (32%)	12/36 (33%)	13/32 (41%)	16/30 (53%)
First incidence (days)	522	360	579	618
Life table test	P = 0.142	P = 0.503	P = 0.324	P=0.186
Logistic regression test	P = 0.182	P = 0.322	P = 0.329	P=0.189
Cochran-Armitage test	P = 0.178			
Fisher exact test		P=0.252	P=0.189	P=0.138
Liver: Hepatocellular Carcinoma				
Overall rate	17/50 (34%)	9/50 (18%)	13/50 (26%)	10/50 (20%)
Adjusted rate	41.1%	21.5%	28.5%	23.8%
Terminal rate	5/28 (18%)	5/36 (14%)	3/32 (9%)	1/30 (3%)
First incidence (days)	289	514	480	430
Life table test	P = 0.228N	P = 0.032N	P=0.170N	P = 0.083N
Logistic regression test	P = 0.196N	P = 0.064N	P = 0.321N	P = 0.091 N
Cochran-Armitage test	P = 0.200N			
Fisher exact test		P = 0.055N	P=0.257N	P = 0.088N
Liver: Hepatocellular Adenoma or Carcinoma				
Overall rate	27/50 (54%)	24/50 (48%)	30/50 (60%)	27/50 (54%)
Adjusted rate	63.7%	54.9%	64.6%	66.7%
Terminal rate	13/28 (46%)	17/36 (47%)	16/32 (50%)	17/30 (57%)
First incidence (days)	289	360	480	430
Life table test	P = 0.413	P = 0.127N	P = 0.505N	P = 0.433N
Logistic regression test	P = 0.465	P = 0.321N	P = 0.389	P = 0.521N
Cochran-Armitage test	P = 0.447			
Fisher exact test		P = 0.345N	P = 0.343	P= 0.579N
Liver: Hepatocellular Carcinoma or Hepatoblast				
Overall rate	17/50 (34%)	10/50 (20%)	13/50 (26%)	10/50 (20%)
Adjusted rate	41.1%	24.1%	28.5%	23.8%
Terminal rate	5/28 (18%)	6/36 (17%)	3/32 (9%)	1/30 (3%)
First incidence (days)	289 D. 0.000N	514	480	430
Life table test	P = 0.202N	P = 0.049N	P = 0.170N	P = 0.083N
Logistic regression test	P = 0.167N	P = 0.101N	P = 0.321N	P = 0.091 N
Cochran-Armitage test	P = 0.173N	D 0.000M	D 0.077N	D 0.000NI
Fisher exact test		P = 0.088N	P = 0.257N	P = 0.088N

TABLE	C3
-------	----

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Liver: Hepatocellular Adenoma, Hepatoco	llular Carcinoma, or Henatohl	astoma		
Overall rate	27/50 (54%)	24/50 (48%)	30/50 (60%)	27/50 (54%)
Adjusted rate	63.7%	54.9%	64.6%	66.7%
Terminal rate	13/28 (46%)	17/36 (47%)	16/32 (50%)	17/30 (57%)
First incidence (days)	289	360	480	430
Life table test	P = 0.413	P = 0.127N	P = 0.505N	P = 0.433N
Logistic regression test	P = 0.465	P = 0.321N	P = 0.389	P = 0.521N
Cochran-Armitage test	P = 0.447	1 010#111	1 01000	1 0102111
Fisher exact test	1 0111	P = 0.345N	P=0.343	P=0.579N
Lung: Alveolar/bronchiolar Adenoma				
Overall rate	5/50 (10%)	9/50 (18%)	10/50 (20%)	16/50 (32%)
Adjusted rate	15.1%	22.7%	27.4%	47.3%
Ferminal rate	2/28 (7%)	6/36 (17%)	6/32 (19%)	13/30 (43%)
First incidence (days)	616	531	602	418
Life table test	P = 0.005	P = 0.341	P = 0.218	P = 0.014
Logistic regression test	P = 0.006	P = 0.234	P = 0.193	P = 0.009
Cochran-Armitage test	P = 0.006			
Fisher exact test		P=0.194	P=0.131	P=0.006
Lung: Alveolar/bronchiolar Carcinoma				
Overall rate	2/50 (4%)	1/50 (2%)	5/50 (10%)	3/50 (6%)
Adjusted rate	6.2%	2.8%	13.1%	9.6%
Ferminal rate	1/28 (4%)	1/36 (3%)	2/32 (6%)	2/30 (7%)
First incidence (days)	610	729 (T)	588	708
Life table test	P = 0.341	P=0.430N	P = 0.285	P = 0.534
Logistic regression test	P = 0.351	P = 0.474N	P = 0.227	P = 0.529
Cochran-Armitage test	P = 0.348			
isher exact test		P = 0.500N	P=0.218	P = 0.500
Lung: Alveolar/bronchiolar Adenoma or	Carcinoma			
Overall rate	7/50 (14%)	10/50 (20%)	15/50 (30%)	19/50 (38%)
Adjusted rate	20.6%	25.2%	37.9%	55.0%
Ferminal rate	3/28 (11%)	7/36 (19%)	8/32 (25%)	15/30 (50%)
First incidence (days)	610	531	588	418
Life table test	P = 0.004	P = 0.482	P = 0.114	P = 0.014
ogistic regression test	P = 0.004	P = 0.355	P = 0.064	P = 0.008
Cochran-Armitage test	P = 0.004			
Fisher exact test		P=0.298	P=0.045	P=0.006
Fhyroid Gland (Follicular Cell): Adenoma				
Overall rate	3/50 (6%)	2/50 (4%)	1/50 (2%)	6/50 (12%)
Adjusted rate	10.7%	5.1%	3.1%	17.8%
Ferminal rate	3/28 (11%)	1/36 (3%)	1/32 (3%)	4/30 (13%)
First incidence (days)	729 (T)	640	729 (T)	647
Life table test	P = 0.069	P = 0.390N	P = 0.257N	P = 0.294
Logistic regression test	P = 0.072	P = 0.437N	P = 0.257N	P = 0.278
Cochran-Armitage test	P = 0.073			
Fisher exact test		P = 0.500N	P = 0.309N	P = 0.243

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
All Organs: Malignant Lymphoma				
Overall rate	2/50 (4%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
Adjusted rate	4.8%	4.8%	8.4%	6.5%
Terminal rate	0/28 (0%)	1/36 (3%)	1/32 (3%)	1/30 (3%)
First incidence (days)	522	514	680	725
Life table test	P = 0.608	P = 0.655N	P = 0.564	P = 0.673N
Logistic regression test	P = 0.609N	P = 0.629	P = 0.474	P = 0.691
Cochran-Armitage test	P = 0.606N			
Fisher exact test		P=0.691N	P = 0.500	P=0.691N
All Organs: Benign Neoplasms				
Overall rate	20/50 (40%)	25/50 (50%)	26/50 (52%)	30/50 (60%)
Adjusted rate	56.4%	56.4%	68.1%	78.3%
Terminal rate	13/28 (46%)	17/36 (47%)	20/32 (63%)	22/30 (73%)
First incidence (days)	522	360	579	418
Life table test	P = 0.045	P = 0.564	P = 0.364	P = 0.100
Logistic regression test	P = 0.046	P = 0.304	P = 0.341	P = 0.053
Cochran-Armitage test	P = 0.046			
Fisher exact test		P=0.211	P=0.158	P=0.036
All Organs: Malignant Neoplasms				
Overall rate	21/50 (42%)	15/50 (30%)	21/50 (42%)	16/50 (32%)
Adjusted rate	46.4%	35.2%	44.5%	36.4%
Terminal rate	5/28 (18%)	9/36 (25%)	7/32 (22%)	4/30 (13%)
First incidence (days)	289	514	480	259
Life table test	P = 0.349N	P = 0.082N	P = 0.381N	P = 0.184N
Logistic regression test	P = 0.287N	P = 0.179N	P = 0.448	P = 0.212N
Cochran-Armitage test	P = 0.309N			
Fisher exact test		P = 0.149N	P=0.580N	P = 0.204N
All Organs: Benign or Malignant Neoplasms				
Overall rate	35/50 (70%)	34/50 (68%)	40/50 (80%)	41/50 (82%)
Adjusted rate	76.0%	70.8%	80.0%	89.0%
Terminal rate	17/28 (61%)	22/36 (61%)	22/32 (69%)	25/30 (83%)
First incidence (days)	289	360	480	259
Life table test	P = 0.131	P = 0.159N	P = 0.549N	P = 0.379
Logistic regression test	P = 0.069	P = 0.423N	P = 0.248	P = 0.162
Cochran-Armitage test	P = 0.063			D
Fisher exact test		P = 0.500N	P = 0.178	P = 0.121

(T)Terminal sacrifice

^a Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for liver, lung, and thyroid gland; for other tissues, denominator is number of animals necropsied.

^b Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

^e Not applicable; no neoplasms in animal group

TABLE C4 Historical Incidence of Alveolar/bronchiolar Neoplasms in Chamber Control Male B6C3F1 Micea

		Incidence in Controls		
Study	Adenoma	Carcinoma	Adenoma or Carcinoma	
Historical Incidence at IIT Research	Institute			
Isobutyl Nitrite	7/50	1/50	8/50	
Overall Historical Incidence				
Total Standard deviation Range	141/947 (14.9%) 7.0% 6%-36%	75/947 (7.9%) 5.7% 0%-16%	205/947 (21.7%) 8.0% 10%-42%	

^a Data as of 12 May 1995

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Ethylbenzene^a

	Chambe	r Control	75	ó ppm	250) ppm	750) ppm
Dimovition Commons								
Disposition Summary Animals initially in study	5	0		50		50		50
Early deaths				00		50		50
Accidental deaths		1						1
Moribund		6		2		5		6
Natural deaths	1	5		12		13		13
Survivors								
Died last week of study						1		
Terminal sacrifice	2	8		36		31		30
Animals examined microscopically	5	0		50		50		50
Alimentowy System								
Alimentary System Gallbladder	(33)		(39)		(37)		(38)	
Epithelium, hyperplasia	(55)		(33)			(3%)	(00)	
Intestine small, duodenum	(45)		(48)		(43)	(370)	(45)	
Parasite metazoan	(10)		(15)			(2%)	(-3)	
Epithelium, hyperplasia						(2%)	1	(2%)
ntestine small, jejunum	(44)		(46)		(44)	-	(43)	
Cyst				(2%)				
Epithelium, dysplasia								
Peyer's patch, hyperplasia		(2%)		(2%)	<i></i>			
ntestine small, ileum	(42)	(00)	(46)		(44)		(41)	
Peyer's patch, hyperplasia		(2%)	(50)		(50)		(50)	
liver	(50)		(50)		(50)		(50)	(2%)
Angiectasis Basophilic focus	3	(6%)	2	(6%)	5	(10%)		(2%)
Clear cell focus		(10%)		(8%)		(10%)		(6%)
Cyst		(2%)		(2%)		(11/0)	0	(070)
Eosinophilic focus		(12%)		(16%)	8	(16%)	12	(24%)
Eosinophilic focus, multiple		(2%)						· /
Fibrosis			1	(2%)			1	(2%)
Hemorrhage							2	(4%)
Hepatodiaphragmatic nodule					1	(2%)		
Inflammation, chronic			2	(4%)				
Mineralization	2	(00/)	^	(40/)	1	(2%)		(00/)
Mixed cell focus		(6%)		(4%)	10	(900/)		(2%)
Necrosis Thrombosis	1	(14%)	8	(16%)	10	(20%)		(20%) (2%)
Hepatocyte, hyperplasia								(2%)
Hepatocyte, hypertrophy	1	(2%)						(34%)
Hepatocyte, necrosis		(2%)	1	(2%)	3	(6%)		(20%)
Hepatocyte, syncytial alteration	-			(10%)		(16%)		(46%)
Hepatocyte, vacuolization cytoplasmic	4	(8%)		(4%)		(8%)		(6%)
Vein, thrombosis		(2%)				(4%)		
ancreas	(49)		(50)		(48)		(48)	
Inflammation	1	(2%)						
Acinus, hyperplasia		(22.1)		(22.1)			1	(2%)
Duct, cyst	1	(2%)	1	(2%)				(00/)
Duct, degeneration	4	(90/)					1	(2%)
Duct, fibrosis		(2%)	(50)		(50)		(50)	
Salivary glands Infiltration cellular	(50)	(42%)	(50)	(52%)	(50)	(34%)	(50)	(40%)

^a Number of animals examined microscopically at the site and the number of animals with lesion

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

Alimentary System (continued) (48) (50) (50) (50) (47) Storach, forestomach (48) (50) (50) (47) (2%) Explicition, hyperplaxia 1 (2%) 1 (2%) 1 (2%) Stroach, findmatafor (48) (50) (50) (50) (47) Inflamation 1 (2%) 1 (2%) 1 (2%) Inflamation 1 (2%) 1 (2%) 1 (2%) Inflamation, granulomatous 1 (2%) 1 (10) (1) (1) Developmental maformation 2 (4%) 36 (72%) 29 (5%) (50) (50) Cardiovascular System 1 (2%) 2 (3%) 1 (2%) Inflamation 1 (2%) 2 (3%) 1 (2%) Inflamation 1 (2%) 2 (3%) 1 (2%) Metalization 1		Chamber Control	75 ppm	250 ppm	750 ppm
$\begin{array}{ccccc} \mbox{cyst} & (48) & (50) & (50) & (77) & (126) & 1 & (276) & 1 & (1000\%) & 2 & (37\%) & 2 & (38\%) & 36 & (72\%) & 2 & (38\%) & 36 & (72\%) & 2 & (38\%) & (38) $	Alimontory System (continued)				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Stomach, forestomach	(48)	(50)	(50)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Ulcer Epithelium, hyperplasia	1 (2%)			1 (2%)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Stomach, glandular		(50)	(50)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Inflammation			1 (2%)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Mineralization	1 (270)		2 (4%)	(1)
Cardiovascular System (50) (50) (50) (50) (50) Cardionyopathy 18 (8%) 36 (72%) 29 (58%) 25 (50%) Inflammation 2 (4%) 36 (72%) 29 (58%) 25 (50%) Pericardium, niprezplasia 1 (2%) Pericardium, hyperplasia 1 (2%) Pericardium, denal cortical nodule 1 (2%) 2 (4%) 1 (2%) Degeneration 1 (2%) 2 (4%) 1 (2%) 1 (2%) Hemorrhage 1 (2%) 8 (17%) 9 (19%) 4 (8%) Vaculzation cytoplasmic 1 (2%) 20 (42%) 17 (35%) Vaculzation cytoplasmic 1 (2%) 2 (4%) (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 </td <td>Inflammation, granulomatous Cooth</td> <td></td> <td></td> <td></td> <td>1 (100%)</td>	Inflammation, granulomatous Cooth				1 (100%)
fear (50) (50) (50) (50) (50) (50) (50) Cardiomyopathy 18 (36%) 36 (72%) 29 (58%) 25 (50%) Myocardium, mineralization 1 (2%) 29 (58%) 25 (50%) Pericardium, hyperplasia 1 (2%) 29 (48) (48) Adrenal cortex (47) (47) (48) (48) (48) Degeneration 1 (2%) 2 (4%) 1 (2%) Hemorrhage 1 (2%) 2 (4%) 1 (2%) Vacuolization cytoplasmic 1 (2%) 20 (42%) 17 (35%) Adrenal medulla (47) (46) (48) (48) (48) (48) (48) (48) (48) (48) (2%) 1 (2%) 2 (4%) (4%) (4%) (4%) (4%) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) (48) <	Developmental malformation			1 (100%)	
$\begin{array}{ccc} Cardiomyopathy & 18 (36\%) & 36 (72\%) & 29 (58\%) & 25 (50\%) \\ 1nflammation & 2 (4\%) \\ Myocardium, mineralization & 1 (2\%) \\ Pericardium, hyperplasia & 1 (2\%) \\ \hline \\ $					
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			36 (72%)	29 (58%)	25 (50%)
Pericardium, hyperplasia 1 (2%) Endocrine System (47) (47) (48) (48) Accessory adrenal cortical nodule 1 (2%) 2 (4%) 1 (2%) 1 (2%) Degeneration 1 (2%) 2 (4%) 1 (2%) 1 (2%) Hemorrhage 1 (2%) 2 (4%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) 20 (42%) 17 (35%) Capsule, hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) Orgeneration 1 (2%) 2 (4%) 17 (35%) 30 (48) (48) Degeneration 1 (2%) 20 (42%) 17 (35%) 30 (48) 48) 30 (2%) 31 (2%) 30 (2%) 31 (2%) 32 (64%)					
Endocrine System drend cortical nodule (47) (47) (48) (48) Idrenal cortex (47) (47) (48) (48) Accessory adrenal cortical nodule 1 (2%) 2 (4%) 1 (2%) 1 (2%) Degeneration 1 (2%) 2 (4%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) 17 (35%) Vacuolization cytoplasmic 19 (40%) 22 (47%) 20 (42%) 17 (35%) 17 (35%) Orgeneration 1 (2%) 2 (4%) 1 (2%) 17 (35%) 16 (2%) Hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) 17 (35%) Obegeneration 1 (2%) 2 (4%) 1 (2%) 17 (35%) 17 (35%) Hyperplasia 19 (40%) 50 (10%) 8 (17%) 1 (2%) 1 (2%) Begeneration 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Adrenal cortex (47) (47) (48) (48) Accessory adrenal cortical nodule 1 (2%) 1 (2%) 1 (2%) Degeneration 1 (2%) 2 (4%) 1 (2%) 1 (2%) Hemorrhage 1 (2%) 2 (4%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) 7 (35%) 20 (42%) 17 (35%) Adrenal medulla (47) (46) (48) (48) 48 48 Degeneration 1 (2%) 1 (2%) 17 (35%) Mineralization 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1<	rencurulum, hyperplasia	1 (270)			
Accessory adrenal cortical nodule 1 (2%) 1 (2%) Degeneration 1 (2%) 1 (2%) Hemorrhage 1 (2%) 1 (2%) Hyperplasia 13 (28%) 8 (17%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) 20 (42%) 17 (35%) Adrenal medulla (47) (46) (48) (48) 48 Degeneration 1 (2%) 1 (2%) 17 (35%) Adrenal medulla (47) (46) (48) (48) 48 49 45 45 47 49 445 45 47 49 445 45 47 49 445 445 445 445					
Degeneration 1 (2%) 2 (4%) 1 (2%) Hemorrhage 1 (2%) 1 (2%) Hyperplasia 13 (28%) 8 (17%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) T 23%) 4 (8%) Capsule, hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 17 (35%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 17 (35%) Vacuolization cytoplasmic 1 (2%) 1 (2%) 1 (2%) Degeneration 1 (2%) 1 (2%) 1 (2%) Hyperplasia (47) (46) (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Hyperplasia 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) 1 (2%) Thyroid gland (50) (50)			(47)	(48)	(48)
Hemorrhage 1 (2%) 1 (2%) 1 (2%) Hyperplasia 13 (28%) 8 (17%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) 20 (42%) 17 (35%) Capsule, hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) Adrenal medulla (47) (46) (48) (48) Degeneration 1 (2%) 1 (2%) 1 1 Hyperplasia 5 (10%) 50 (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Hyperplasia 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) 50 60 Follicle, cyst Follicle, cyst 1 (2%) 2 (64%) 2 (64%) 50					
Hyperplasia 13 (28%) 8 (17%) 9 (19%) 4 (8%) Vacuolization cytoplasmic 1 (2%) (40%) 22 (47%) 20 (42%) 17 (35%) Capsule, hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) Adrenal medulla (47) (46) (48) (48) Degeneration 1 (2%) 2 (4%) 1 Hyperplasia 2 (4%) 1 (2%) 3 Degeneration 1 (2%) 2 (4%) 48) Degeneration 1 (2%) 2 (4%) 48) Degeneration 1 (2%) 1 (2%) 3 48) Degeneration 1 (2%) 48) (48) 48) Degeneration 1 (2%) 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) 50) 60) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) 64%) 1 (33%) 1 (33%)			2 (4%)	1 (2%)	
Vacualization cytoplasmic 1 (2%) Capsule, hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) Adrenal medulla (47) (46) (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) Mineralization 2 (4%) 1 (2%) 20 (42%) 1 (35%) Mineralization 1 (2%) 2 (4%) 1 (2%) 1 (2%) Sets, pancreatic (49) (50) (48) (48) (48) Degeneration 1 (2%) 1 (2			a (1 a)()	0 (100())	
Capsule, hyperplasia 19 (40%) 22 (47%) 20 (42%) 17 (35%) ddrenal medulla (47) (46) (48) (48) Degeneration 1 (2%) 2 (4%) 17 (35%) Hyperplasia 2 (4%) 1 (2%) 1 Mineralization 1 (2%) 2 (4%) (48) Degeneration 1 (2%) (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) 1 (2%) Follicle, cyst 1 (2%) 21 (42%) 29 (58%) 32 (64%) Seneeral Body System 1 (33%) 1 (33%) 1 (2%) 1 (2%)			8 (17%)	9 (19%)	4 (8%)
Adrenal medulla (47) (46) (48) (48) Degeneration 1 (2%) (46) (48) Hyperplasia 2 (4%) 1 (2%) Mineralization 1 (2%) (48) (48) Degeneration 1 (2%) (48) (48) Degeneration 1 (2%) (48) (48) Degeneration 1 (2%) (47) (46) (48) Degeneration 1 (2%) (47) (2%) (47) Pars distalis, cyst 1 (2%) (47) (2%) (47) Pars distalis, hyperplasia 1 (2%) 1 (2%) (2%) (50) (50) (50) (50) (50) (50) (50) (50) (50) (50) (2%) (2%) (42%) 29 (58%) 32 (64%) Pars distalis, hyperplasia 21 (42%) 29 (58%) 32 (64%) (2%) (2%) (2)	Vacuolization cytoplasmic		00 (1701)	00 (1001)	4.9 (0.50.)
Degeneration 1 (2%) Hyperplasia 2 (4%) Mineralization 1 (2%) Sets, pancreatic (49) (50) (48) (48) Degeneration 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pituitary gland (44) (45) (45) (47) 1 (2%) 1 (2) 1 (2) 1 (2) 1 (2) 1 (2) 1 (2) 1 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Hyperplasia 2 (4%) Mineralization 1 (2%) slets, pancreatic (49) (50) (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pars distalis, cyst 1 (2%) (44) (45) (45) (47) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) 1 (2%) Follicle, cyst 1 (2%) 1 (2%) 50) (50) (50) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) Ceneral Body System Cissue NOS (2) (3) (1) (2) Cyst 1 (33%) 1 (33%) 1 (2)		(47)	(46)		(48)
Mineralization 1 (2%) slets, pancreatic (49) (50) (48) (48) Degeneration 1 (2%) 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pituitary gland (44) (45) (45) (47) Pars distalis, cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 50) Follicle, cyst 1 (2%) 1 (2%) 50) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) General Body System Fissue NOS (2) (3) (1) (2) Cyst 1 (33%) 1 (33%) 1 1					
slets, pancreatic (49) (50) (48) (48) Degeneration 1 (2%) 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) Pars distalis, cyst 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Follicle, cyst 1 (2%) 1 (2%) 32 (64%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 32 (64%) Ceneral Body System Cissue NOS (2) (3) (1) (2) Cyst 1 (33%)					
Degeneration 1 (2%) Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pituitary gland (44) (45) (45) (47) Pars distalis, cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Follicle, cyst 1 (2%) 1 (2%) 50) (50) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) General Body System Fissue NOS (2) (3) (1) (2) Cyst 1 (33%) 1 (33%) 1 (33%) 1 (3%) 1 (3%)		(40)	(50)		(48)
Hyperplasia 5 (10%) 5 (10%) 8 (17%) 1 (2%) Pars distalis, cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 50) (50) Follicle, cyst 1 (2%) 1 (2%) 32 (64%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%)		(49)	(30)		(40)
Pituitary gland (44) (45) (45) (47) Pars distalis, cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Thyroid gland (50) (50) (50) (50) Follicle, cyst 1 (2%) 1 (2%) 29 (58%) 32 (64%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) Ceneral Body System Tissue NOS (2) (3) (1) (2) Cyst 1 (33%) 1 (33%) 1 (35%) 1 (35%)		5 (10%)	5 (10%)		1 (9%)
Pars distalis, cyst 1 (2%) 2 (4%) 1 (2%) Pars distalis, hyperplasia 1 (2%) 1 (2%) 1 (2%) Phyroid gland (50) (50) (50) (50) Follicle, cyst 1 (2%) 1 (2%) 1 (2%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) Ceneral Body System Cissue NOS (2) (3) (1) (2) Cyst 1 (33%) 1 (33%) 1 (2)					
Pars distalis, hyperplasia 1 (2%) 1 (2%) Chyroid gland (50) (50) (50) Follicle, cyst 1 (2%) 1 (2%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) Ceneral Body System Cissue NOS (2) (3) (1) (2) Cyst 1 (33%) (1) (2) (2)		(דד)			
Chyroid gland (50) (50) (50) (50) Follicle, cyst 1 (2%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%)		1 (2%)			· (~/0)
Follicle, cyst 1 (2%) Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) General Body System Image: Constraint of the system Image: Constraint of the system Image: Constraint of the system Cissue NOS (2) (3) (1) (2) Cyst 1 (33%) 1 (3)					(50)
Follicular cell, hyperplasia 21 (42%) 21 (42%) 29 (58%) 32 (64%) General Body System Image: Constraint of the system Image: Constrainto of the system Image: Constraint of the system <td></td> <td>()</td> <td>(/</td> <td></td> <td>(/</td>		()	(/		(/
Cissue NOS (2) (3) (1) (2) Cyst 1 (33%)		21 (42%)	21 (42%)		32 (64%)
Cissue NOS (2) (3) (1) (2) Cyst 1 (33%)	General Body System				
Cyst 1 (33%)		(2)	(3)	(1)	(2)
		(~)	1 (33%)	(1)	(~)
Fat, necrosis 2 (67%) 1 (50%)			2 (67%)		1 (50%)

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber	Control	7:	5 ppm	250	ppm	75) ppm
Genital System								
Epididymis	(49)		(50)		(50)		(50)	
Atypia cellular		(2%)		(2%)	. ,			
Cyst	1	(2%)						
Degeneration							2	(4%)
Fibrosis				(2%)				
Granuloma sperm	2	(4%)		(2%)	1	(2%)		
Infiltration cellular			1	(2%)				
Inflammation	1	(2%)						
Mineralization	1	(2%)						
Bilateral, fibrosis					1	(2%)		
Penis	(1)		(2)					
Concretion				(50%)				
Inflammation		(100%)		(50%)				
Preputial gland	(48)		(49)		(48)	(22.1)	(49)	
Cyst		(00)		(00)		(2%)		(1.2.2.1)
Degeneration	3	(6%)		(6%)	9	(19%)	6	(12%)
Degeneration, cystic			1	(2%)		(22.1)		
Fibrosis		(22.1)				(2%)		
Hyperplasia		(2%)	-	(100/)		(2%)		(00/)
Infiltration cellular		(2%)		(10%)		(13%)	4	(8%)
Inflammation	6	(13%)		(22%)	11	(23%)	13	(27%)
Mineralization			1	(2%)		(00)		
Necrosis	(10)		(10)			(2%)	(50)	
Prostate	(46)	(00)	(49)		(50)		(50)	
Atrophy		(2%)	0	(40/)		(00/)	0	(10/)
Infiltration cellular		(2%)		(4%)		(2%)		(4%)
Inflammation		(13%)		(10%)		(10%)		(12%)
Seminal vesicle	(49)	(40/)	(50)	(00/)	(50)	(00/)	(50)	(00/)
Atrophy		(4%)		(2%)		(6%)		(2%)
Degeneration		(39%)		(52%)		(32%)	22	(44%)
Inflammation		(2%)		(2%)		(4%)	(50)	
Testes	(49)		(50)	(00/)	(50)		(50)	(0 0/)
Atrophy			1	(2%)				(2%)
Mineralization			1	(90/)			1	(2%)
Germinal epithelium, atrophy			1	(2%)			1	(90/)
Germinal epithelium, degeneration			1	(90/)			1	(2%)
Interstitial cell, hyperplasia			1	(2%)	1	(90/)		
Tunic, fibrosis					1	(2%)		
Hematopoietic System								
Bone marrow	(50)		(50)		(50)		(50)	
Hematopoietic cell proliferation			1	(2%)				
Hyperplasia		(2%)		(()
Pigmentation, hemosiderin		(4%)		(4%)		(100)		(2%)
Myeloid cell, hyperplasia		(4%)		(8%)		(18%)		(8%)
_ymph node	(4)	(050())	(7)	(1.10)	(11)		(3)	
Inguinal, hyperplasia	1	(25%)		(14%)				
Inguinal, pigmentation			1	(14%)		(00)		
Lumbar, congestion		(2 = 2 ()		(200)		(9%)		(0.70.()
Lumbar, hyperplasia	1	(25%)	4	(57%)		(36%)	2	(67%)
Lumbar, inflammation				(1.10.1)	2	(18%)		(0.0.0.1)
Lumbar, pigmentation			1	(14%)		(100)	1	(33%)
Renal, congestion			-	(100)		(18%)		
Renal, hyperplasia			3	(43%)	3	(27%)		

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Hematopoietic System (continued)				
Lymph node, mandibular	(43)	(45)	(46)	(44)
Pigmentation, hemosiderin		1 (2%)		1 (2%)
Lymph node, mesenteric	(45)	(46)	(47)	(48)
Atrophy				1 (2%)
Congestion	1 (2%)	3 (7%)	1 (2%)	2 (4%)
Hematopoietic cell proliferation Hyperplasia	1 (90/)	3 (7%) 2 (4%)	3 (6%)	
Inflammation	1 (2%)	2 (4%)	3 (070)	1 (2%)
Lymph node, mediastinal	(24)	(25)	(27)	(25)
Hyperplasia	1 (4%)	(20)		(20)
Spleen	(50)	(50)	(49)	(49)
Atrophy	1 (2%)			
Hematopoietic cell proliferation	3 (6%)	4 (8%)	2 (4%)	
Lymphoid follicle, atrophy	2 (4%)		1 (2%)	1 (2%)
Lymphoid follicle, hyperplasia	(0.7)	(0.7)	2 (4%)	
Thymus	(37)	(37)	(39)	(34)
Atrophy	18 (49%) 1 (2%)	11 (30%)	20 (51%)	11 (32%)
Cyst	1 (3%)			
Integumentary System				
Mammary gland	(3)	(2)	(3)	(3)
Atrophy	1 (33%)	1 (50%)	2 (67%)	1 (33%)
Skin	(50)	(50) 1 (2%)	(50)	(50)
Cyst Infiltration cellular, melanocyte		1 (2%)		
Inflammation	3 (6%)	6 (12%)	4 (8%)	3 (6%)
Necrosis	1 (2%)	0 (1270)	4 (870)	3 (070)
Ulcer	1 (2%)	5 (10%)	2 (4%)	3 (6%)
Hair follicle, atrophy		1 (2%)	2 (170)	0 (070)
Prepuce, degeneration			1 (2%)	
Prepuce, hyperplasia, lymphoid			1 (2%)	
Prepuce, inflammation			2 (4%)	
Prepuce, ulcer			2 (4%)	
Sebaceous gland, cyst		1 (2%)		
Musculoskeletal System				
Bone	(50)	(49)	(50)	(50)
Vertebra, degeneration	1 (2%)			1 (2%)
Vervous System				
Brain	(50)	(50)	(50)	(50)
Mineralization	21 (42%)	18 (36%)	19 (38%)	19 (38%)
Respiratory System				
Larynx	(48)	(49)	(46)	(49)
Foreign body	(10)	()	1 (2%)	()
Hemorrhage			()	1 (2%)
Infiltration, cellular	1 (2%)	4 (8%)	4 (9%)	· · /
Glands, degeneration		1 (2%)	3 (7%)	2 (4%)
Glands, inflammation		1 (2%)	2 (4%)	

TABLE C5 Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Respiratory System (continued)				
Lung	(50)	(50)	(50)	(50)
Congestion			1 (2%)	
Hemorrhage				1 (2%)
Infiltration cellular, histiocyte	2 (4%)		1 (2%)	2 (4%)
Inflammation	1 (2%)			
Pigmentation, hemosiderin			1 (2%)	
Thrombosis			1 (2%)	
Alveolar epithelium, hyperplasia	1 (2%)	5 (10%)	2 (4%)	4 (8%)
Alveolar epithelium, metaplasia		1 (2%)	2 (4%)	6 (12%)
Nose	(50)	(50)	(50)	(50)
Edema				1 (2%)
Hemorrhage	1 (2%)			1 (2%)
Inflammation	7 (14%)	3 (6%)	4 (8%)	1 (2%)
Polyp, inflammatory	2 (4%)	1 (2%)	2 (4%)	
Nasolacrimal duct, inflammation	3 (6%)	· · /	1 (2%)	1 (2%)
Respiratory epithelium, inflammation	- ()		()	1 (2%)
Respiratory epithelium, metaplasia, squar	mous	1 (2%)		()
Pleura		- ((1)
Frachea	(50)	(50)	(50)	(50)
Glands, cyst	(00)	(00)		1 (2%)
Glands, hemorrhage				1 (2%)
Special Senses System None				
None				
None Urinary System	(50)	(50)	(50)	(50)
None U rinary System Kidney	(50) 1 (2%)	(50)	(50)	(50)
None U rinary System Kidney Degeneration	1 (2%)	(50)	(50)	(50)
None Urinary System Kidney Degeneration Infarct	1 (2%) 1 (2%)			
None Urinary System Kidney Degeneration Infarct Inflammation	1 (2%)	5 (10%)	(50) 5 (10%)	(50) 3 (6%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous	1 (2%) 1 (2%)	5 (10%) 1 (2%)		
None U rinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization	1 (2%) 1 (2%) 3 (6%)	5 (10%) 1 (2%) 1 (2%)	5 (10%)	3 (6%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy	1 (2%) 1 (2%) 3 (6%) 34 (68%)	5 (10%) 1 (2%)		
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%)	5 (10%) 40 (80%)	3 (6%) 36 (72%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%)	5 (10%) 40 (80%) 5 (10%)	3 (6%) 36 (72%) 4 (8%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%)	5 (10%) 40 (80%) 5 (10%) 3 (6%)	3 (6%) 36 (72%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%)	5 (10%) 40 (80%) 5 (10%) 3 (6%) 1 (2%)	3 (6%) 36 (72%) 4 (8%) 2 (4%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$	3 (6%) 36 (72%) 4 (8%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%)
None Urinary System Gidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Jreter	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $2 (2%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1)
None Urinary System Gidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Jreter Degeneration	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (50%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%)
None Urinary System Gidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Jreter Degeneration Inflammation	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%) 2 (4%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (50%)$ $1 (50%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1) 1 (100%)
Vone Urinary System Gidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Jreter Degeneration Inflammation Jrinary bladder	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%) (48)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%) 2 (4%) (50)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ (2) $1 (50%)$ $1 (50%)$ (49)	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1) 1 (100%) (49)
None Virinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Ureter Degeneration Inflammation Urinary bladder Calculus, microscopic observation only	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%) 2 (4%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (50%)$ $1 (50%)$ (49) $2 (4%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1) 1 (100%) (49) 2 (4%)
Vone Virinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Jreter Degeneration Inflammation Jrinary bladder Calculus, microscopic observation only Infiltration cellular	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%) (48) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%) 2 (4%) (50) 1 (2%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $(2%)$ $1 (50%)$ $1 (50%)$ (49) $2 (4%)$ $1 (2%)$	$\begin{array}{c} 3 & (6\%) \\ 36 & (72\%) \\ 4 & (8\%) \\ 2 & (4\%) \\ 3 & (6\%) \\ (1) \\ 1 & (100\%) \\ (49) \\ 2 & (4\%) \\ 1 & (2\%) \end{array}$
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Ureter Degeneration Inflammation Urinary bladder Calculus, microscopic observation only Infiltration cellular Inflammation	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%) (48)	$\begin{array}{c} 5 & (10\%) \\ 1 & (2\%) \\ 1 & (2\%) \\ 38 & (76\%) \\ 8 & (16\%) \\ 4 & (8\%) \\ 2 & (4\%) \\ \end{array}$ $(50) \\ 1 & (2\%) \\ 12 & (24\%) \end{array}$	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (50%)$ $1 (50%)$ (49) $2 (4%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1) 1 (100%) (49) 2 (4%)
None Virinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Ureter Degeneration Inflammation Urinary bladder Calculus, microscopic observation only Infiltration cellular Inflammation Ulcer	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%) (48) 1 (2%)	5 (10%) 1 (2%) 1 (2%) 38 (76%) 8 (16%) 4 (8%) 2 (4%) (50) 1 (2%)	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ (2) $1 (50%)$ (2) $1 (50%)$ (49) $2 (4%)$ $1 (2%)$ $6 (12%)$	$\begin{array}{c} 3 & (6\%) \\ 36 & (72\%) \\ 4 & (8\%) \\ 2 & (4\%) \\ 3 & (6\%) \\ (1) \\ 1 & (100\%) \\ (49) \\ 2 & (4\%) \\ 1 & (2\%) \end{array}$
None Virinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Ureter Degeneration Inflammation Urinary bladder Calculus, microscopic observation only Infiltration cellular Inflammation Ulcer Muscularis, inflammation	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%) (48) 1 (2%)	$\begin{array}{c} 5 & (10\%) \\ 1 & (2\%) \\ 1 & (2\%) \\ 38 & (76\%) \\ 8 & (16\%) \\ 4 & (8\%) \\ 2 & (4\%) \\ \end{array}$ $(50) \\ 1 & (2\%) \\ 12 & (24\%) \end{array}$	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ (2) $1 (50%)$ (2) $1 (50%)$ (49) $2 (4%)$ $1 (2%)$ $6 (12%)$ $1 (2%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1) 1 (100%) (49) 2 (4%) 1 (2%)
None Urinary System Kidney Degeneration Infarct Inflammation Metaplasia, osseous Mineralization Nephropathy Pigmentation, bile Cortex, cyst Papilla, inflammation Papilla, necrosis Pelvis, dilatation Renal tubule, vacuolization cytoplasmic Ureter Degeneration Inflammation Urinary bladder Calculus, microscopic observation only Infiltration cellular Inflammation Ulcer	1 (2%) 1 (2%) 3 (6%) 34 (68%) 1 (2%) 1 (2%) 3 (6%) 1 (2%) (48) 1 (2%)	$\begin{array}{c} 5 & (10\%) \\ 1 & (2\%) \\ 1 & (2\%) \\ 38 & (76\%) \\ 8 & (16\%) \\ 4 & (8\%) \\ 2 & (4\%) \\ \end{array}$ $(50) \\ 1 & (2\%) \\ 12 & (24\%) \end{array}$	5 (10%) $40 (80%)$ $5 (10%)$ $3 (6%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ $1 (2%)$ (2) $1 (50%)$ (2) $1 (50%)$ (49) $2 (4%)$ $1 (2%)$ $6 (12%)$	3 (6%) 36 (72%) 4 (8%) 2 (4%) 3 (6%) (1) 1 (100%) (49) 2 (4%) 1 (2%)

APPENDIX D SUMMARY OF LESIONS IN FEMALE MICE IN THE 2-YEAR INHALATION STUDY OF ETHYLBENZENE

Summary of the Incidence of Neoplasms in Female Mice	
in the 2-Year Inhalation Study of Ethylbenzene	168
Individual Animal Tumor Pathology of Female Mice	
in the 2-Year Inhalation Study of Ethylbenzene	172
Statistical Analysis of Primary Neoplasms in Female Mice	
in the 2-Year Inhalation Study of Ethylbenzene	190
Historical Incidence of Alveolar/bronchiolar Neoplasms	
in Chamber Control Female B6C3F ₁ Mice	194
Historical Incidence of Hepatocellular Neoplasms	
in Chamber Control Female B6C3F ₁ Mice	194
Summary of the Incidence of Nonneoplastic Lesions in Female Mice	
in the 2-Year Inhalation Study of Ethylbenzene	195
	in the 2-Year Inhalation Study of Ethylbenzene

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene^a

	Chamber Control	75 ppm	250 ppm	750 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Accidental deaths	1		1	
Moribund	5	6	1	4
Natural deaths	9	6	8	9
Survivors				
Died last week of study	1		10	
Terminal sacrifice	34	38	40	37
Animals examined microscopically	50	50	50	50
Alimentary System				
Esophagus	(48)	(48)	(50)	(50)
Gallbladder	(43)	(40)	(44)	(46)
Intestine large, rectum	(49)	(48)	(49)	(47)
Intestine large, cecum	(49)	(47)	(48)	(44)
Intestine small, duodenum	(45)	(48)	(47)	(46)
Polyp adenomatous			1 (2%)	
Intestine small, jejunum	(46)	(46)	(46)	(45)
Intestine small, ileum	(47)	(47)	(47)	(46)
Liver	(50)	(50)	(50)	(50)
Cholangiocarcinoma		1 (2%)		
Fibrosarcoma, metastatic, pancreas	1 (2%)			
Hemangioma	- (1 (2%)	- /	
Hepatocellular carcinoma	7 (14%)	4 (8%)	3 (6%)	10 (20%)
Hepatocellular carcinoma, multiple	0 (100())	0 (100()	0 (100()	2 (4%)
Hepatocellular adenoma	6 (12%)	8 (16%)	9 (18%)	12 (24%)
Hepatocellular adenoma, multiple	(50)	1 (2%)	3 (6%)	4 (8%)
Pancreas Fibrosarcoma	(50) 1 (2%)	(50)	(50)	(49)
Salivary glands	(50)	(50)	(50)	(50)
Stomach, forestomach	(50)	(49)	(48)	(50)
Squamous cell papilloma	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Stomach, glandular	(50)	(49)	(48)	(50)
Serosa, sarcoma, metastatic, uterus	(00)	1 (2%)	(10)	(00)
Cardiovascular System				
Blood vessel	(46)	(48)	(48)	(50)
Adventitia, hepatocellular carcinoma,	(10)	(10)	(10)	(00)
metastatic, liver	1 (2%)			
Heart	(50)	(49)	(50)	(50)
Fibrosarcoma, metastatic, pancreas	1 (2%)	× /		· ·
Endocrine System				
Adrenal cortex	(47)	(50)	(50)	(49)
Adenoma		(50)	1 (2%)	(10)
Adrenal medulla	(47)	(50)	(50)	(49)
Pheochromocytoma malignant		1 (00/)	1 (2%)	
Pheochromocytoma benign	(50)	1 (2%)	1 (2%)	(40)
Islets, pancreatic Adenoma	(50)	(50)	(50) 1 (2%)	(49)
Auciolia			1 (2%)	

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Endocrine System (continued)				
Pituitary gland	(48)	(49)	(47)	(49)
Pars distalis, adenoma	4 (8%)	8 (16%)	7 (15%)	5 (10%)
Pars intermedia, adenoma Thyroid gland	(50)	(50)	1 (2%) (50)	(50)
Follicular cell, adenoma	5 (10%)	4 (8%)	3 (6%)	4 (8%)
Follicular cell, adenoma, multiple		2 (4%)		- ()
General Body System				
Tissue NOS	(1)	(6)	(4)	(1)
Hemangiosarcoma	((000))	1 (17%)		
Leiomyosarcoma Abdominal, osteosarcoma	1 (100%)	1 (17%)		
Pelvic, sarcoma		1 (17%)	1 (25%)	
Genital System				
Clitoral gland	(41)	(47)	(48)	(48)
Fibrosarcoma				1 (2%)
Ovary	(49)	(50)	(49)	(49)
Cystadenoma	2 (4%)			2 (4%)
Fibrosarcoma, metastatic, pancreas Granulosa cell tumor benign	1 (2%) 1 (2%)			
Uterus	(50)	(50)	(50)	(50)
Leiomyosarcoma	1 (2%)	(00)	(50)	(00)
Polyp stromal	2 (4%)	1 (2%)	1 (2%)	
Sarcoma		1 (2%)		
Endometrium, adenoma	1 (2%)		. (
Myometrium, hemangioma	(1)		1 (2%)	
Vagina Leiomyosarcoma	(1) 1 (100%)			
	1 (10070)			
Hematopoietic System	(49)	(50)	(50)	(50)
Bone marrow Lymph node	(48) (3)	(50) (7)	(50) (2)	(50) (5)
Iliac, hemangioma	(0)	1 (14%)	(~)	(0)
Lumbar, osteosarcoma, metastatic, tissue N	OS	1 (14%)		
Renal, hemangiosarcoma		1 (14%)		
Lymph node, bronchial	(32)	(40)	(29)	(38)
Fibrosarcoma, metastatic, pancreas	1 (3%)			
Hepatocellular carcinoma, metastatic, liver	1 (3%)	(49)	(17)	(AA)
Lymph node, mandibular Lymph node, mesenteric	(47) (48)	(48) (48)	(47) (46)	(44) (44)
Fibrosarcoma, metastatic, pancreas	(48)	(40)	(40)	(44)
Lymph node, mediastinal	(34)	(42)	(41)	(31)
Fibrosarcoma, metastatic, pancreas	1 (3%)	(<i>)</i>	(/	(/
Hepatocellular carcinoma, metastatic, liver	1 (3%)			
Spleen	(50)	(50)	(50)	(49)
Capsule, fibrosarcoma, metastatic, pancreas			(17)	(10)
Thymus	(42)	(44)	(45)	(46)
Hepatocellular carcinoma, metastatic, liver	1 (2%)			

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Integumentary System				
Mammary gland	(49)	(50)	(48)	(49)
Carcinoma	1 (2%)	3 (6%)		
Skin	(50)	(50)	(49)	(50)
Fibroma		0 (10)		1 (2%)
Fibrosarcoma		2 (4%)		1 (90/)
Fibrous histiocytoma Hemangioma		1 (2%)	2 (4%)	1 (2%)
Squamous cell carcinoma		1 (2%)	2 (470)	
Sebaceous gland, adenoma			1 (2%)	
Musculoskeletal System				
Bone	(49)	(50)	(50)	(50)
Rib, sarcoma, metastatic, tissue NOS			1 (2%)	
Vertebra, osteosarcoma		(0)	1 (2%)	
Skeletal muscle		(2) (500%)		
Carcinoma, metastatic, mammary gland Rhabdomyosarcoma		1 (50%) 1 (50%)		
Kilabuoliiyosarconia		1 (50%)		
Nervous System				
Brain Combany align has discuss hout as	(50)	(50)	(50)	(50)
Cerebrum, oligodendroglioma benign	1 (2%)			
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Carcinoma, metastatic, harderian gland Carcinoma, metastatic, mammary gland Hepatocellular carcinoma, metastatic, liver Osteosarcoma, metastatic, tissue NOS Sarcoma, metastatic, tissue NOS Sarcoma, metastatic, uterus	(49) (50) 3 (6%) 1 (2%) 1 (2%) 3 (6%)	(49) (50) 4 (8%) 2 (4%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	(47) (49) 4 (8%) 1 (2%) 2 (4%) 1 (2%)	(48) (50) 8 (16%) 1 (2%)
Squamous cell carcinoma, metastatic, lacrimal gland		2 (270)		1 (2%)
Nose	(49)	(50)	(50)	(50)
Carcinoma, metastatic, harderian gland	1 (2%)			
Pleura	(1)			
Hepatocellular carcinoma, metastatic, liver		(50)	(50)	(50)
Frachea	(50)	(50)	(50)	(50)
Special Senses System	(1)		(1)	(3)
	(1)		(1) 1 (100%)	(3) 3 (100%)
Special Senses System Harderian gland	(1) 1 (100%)			3 (100%)
Special Senses System Harderian gland Adenoma				

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ppm	750 ppm
Urinary System				
Kidney	(50)	(50)	(50)	(50)
Cholangiocarcinoma, metastatic, liver		1 (2%)		
Cortex, fibrosarcoma, metastatic, pancreas	1 (2%)			
Ureter		(1)		(1)
Urinary bladder	(47)	(48)	(47)	(49)
Serosa, sarcoma, metastatic, uterus		1 (2%)		
Systemic Lesions Multiple organs ^b Leukemia granulocytic Lymphoma malignant	(50) 1 (2%) 3 (6%)	(50) 6 (12%)	(50) 5 (10%)	(50) 5 (10%)
Neoplasm Summary				
Total animals with primary neoplasms ^c	29	38	31	38
Total primary neoplasms	44	58	50	60
Total animals with benign neoplasms	20	26	27	28
Total benign neoplasms	27	34	39	40
Total animals with malignant neoplasms	13	20	9	18
Total malignant neoplasms	17	24	11	20
Total animals with metastatic neoplasms	5	5	3	2
Total metastatic neoplasms	18	9	4	2

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms а b

с

2 4 5 5 5 5 6 6 6 7 7 7 1 2 0 6 7 9 9 1 2 3 8 9 1 1 2 3 5 3 1 5 8 2 7 8 9 9 8 4 5 8 5 0	
0 0	5 7 7 7 9 5 5 5 5 6
M + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + +
A + + + + A + + + M A + + + + + + + + +	+ + + + + M + + + +
+ + + + + + + + + M + + A + + + + + + +	+ + + + + + + + + + +
A + + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + +
A + + + + + + + + + + + + + + + + + + +	+ $+$ $+$ $+$ $+$ $+$ $+$ $+$
M + + + + + + + + A + A + A + + + + + +	+ + + + + + M + + +
A + + + + + + + + A + A + A + + + + + +	+ + + + + + + + + + +
A + + + + + + + + A A + + + + + + + + +	+ + + + + + + + + +
+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + +
Х	
X X X X	X X
	XX
	+
+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + +
+ + + + + + + + + + + + + + + + + + +	
	+ + + + + + + + + +
Х	
+ + + + + + + + + + + + + + + + + + + +	+ + + + + + + + +
+ + + + + M + + M + + + + + + +	+ + + + + M + + + M
Х	
	+ + + + + + + + + +
X	
W W W	
	$\begin{array}{ccccc} + & + & + & + & + & + & + & + & + & + $
λ .	X X
+	
Х	
	M
+ + + + + + + + + + + + + + + + + + + +	$+$ + + + + + + + + + + \mathbf{v} \mathbf{v} \mathbf{v}
	X X
Х	
	1 2 0 6 7 9 9 1 2 3 8 9 1 1 2 3 5 3 1 5 8 2 7 8 9 9 8 4 5 8 5 6 0

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Ethylbenzene: Chamber Control

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

(continueu)																								
	7	' 7	7	7	7	7	7	7	77	7	7	7	7	7	7 3	77	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3 3	3	3	3	3	3	3 3	3 3	3	3	3	3	3	3	3	
	1		1	1	1	1			1 1		2	2	2			2 2		2	2	2	2	2		
	0) ()	0	0	0	0	0	0 0	0 (0	0	0	0	0	0 () (0	0	0	0	0	0	1	Total
Carcass ID Number	6		6	7	7				88		5	5	5			78		8	8	9	9	9		Tissues/
	2				8				69			4				4 1			8	1		8		Tumors
	~	0	5	~	0	2	т	5	0 0	5	9	т	'	5	0 -	T 1	9	'	0	1	0	0	0	1 unior 3
Alimentary System																								
Esophagus	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ 1	M -	- +	+	+	+	+	+	+	48
Gallbladder	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ 1	Λ+	+	+	+	+	+	+	44
Intestine large, colon	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	48
Intestine large, rectum	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	49
Intestine large, cecum	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	+ +	+	+	+	+	+	+	49
Intestine small, duodenum	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	45
Intestine small, jejunum	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	46
Intestine small, ileum	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	47
Liver	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ •	+ -	- +	+	+	+	+	+	+	50
Fibrosarcoma, metastatic, pancreas																								1
Hepatocellular carcinoma				Х																				7
Hepatocellular adenoma									2	ζ				Х	Х						Х			6
Mesentery														+										2
Pancreas	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	50
Fibrosarcoma																								1
Salivary glands	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ •	+ -	- +	+	+	+	+	+	+	50
Stomach, forestomach	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ •	+ -	- +	+	+	+	+	+	+	50
Squamous cell papilloma																								1
Stomach, glandular	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ •	+ -	- +	+	+	+	+	+	+	50
CIt																								
Cardiovascular System																								10
Blood vessel	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	46
Adventitia, hepatocellular carcinoma,																								
metastatic, liver																								1
Heart	+	- +	+	+	+	+	+	+ ·	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	50
Fibrosarcoma, metastatic, pancreas																								1
Endocrine System																								
Adrenal cortex	+	- +	+	+	+	+	+	+ •	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	47
Adrenal medulla	+	- +	+	+	+	+	+	+ •	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	47
Islets, pancreatic	+	- +	+	+	+	+	+	+ •	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	50
Parathyroid gland	N	νí +	+	Μ	M	+	М	M	M	ЛŇ	1 M	+	+	M	MI	MN	л́+	+	+	M	[+	+	+	26
Pituitary gland	+	- +	+	+	+	+	+		+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	48
Pars distalis, adenoma										Ċ											X		X	4
Thyroid gland	+	- +	+	+	+	+	+	+ •	+ -	- +	+	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	50
Follicular cell, adenoma								x												X		·		5
General Body System																								
Tissue NOS																								1
Leiomyosarcoma																								1
Genital System																								
		N	۲.		м					,		+	NЛ	+									,	A 1
Clitoral gland	+	⊦ N	1 + ,		11/1					- +						+ -	- +	+	+	+	+	+	+	41
Ovary	+	- +	+	+	+	+	+	+ ·	+ -	- +	IVI	+	+	+	+ -	+ -	- +	+	+	+	+	+	+	49
Cystadenoma																								2
Fibrosarcoma, metastatic, pancreas																								1
Granulosa cell tumor benign														Х										1

(continueu)																										
Number of Days on Study	2 1 5	4 2 3	5 0 1	5 6 5	5 7 8	5 9 2		1 :		3	8	9	1	7 1 8	7 2 5	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	
Carcass ID Number	0 8 0	9	0 9 0	0 6 4	6	9	0 (7 9 5 4	9		6		9	6		5	5		7	7	0 9 5	0 5 1	0 5 2	0 5 5	0 5 9	6	
Genital System (continued) Uterus Leiomyosarcoma Polyp stromal Endometrium, adenoma Vagina Leiomyosarcoma	+	+	+	+ X X	+ + X	+	+ -	+ -	+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	
Hematopoietic System Bone marrow Lymph node Lymph node, bronchial	+ M	+ + +	+ M	+	+ + M	+	+ - + + -		+ - M -				+								+	++	++	++	+ M	
Fibrosarcoma, metastatic, pancreas Hepatocellular carcinoma, metastatic, liver Lymph node, mandibular Lymph node, mesenteric Fibrosarcoma, metastatic, pancreas	+ M	+ [+	+ +	+ +	+ +	M +		+ -	+ - + -			+	+		+ +			+ +								
Lymph node, mediastinal Fibrosarcoma, metastatic, pancreas Hepatocellular carcinoma, metastatic, liver Spleen Capsule, fibrosarcoma, metastatic, pancreas	M +	+	++	М +	++	М +	M -	+]	M] + ·	М +			Х	Х	+		+	+	++	М +	++	++	++	М +	+	
Thymus Hepatocellular carcinoma, metastatic, liver	М	[+	+	+	М	+	MI	M	M ·	+	M	+	М	+ X	+	+	+	+	+	+	+	+	М	+	+	
Integumentary System Mammary gland Carcinoma Skin	+	+	+	+	+	+	+ -	+ ·	+ -	+	+	+	+	+	+	+	M +	+	+	+	+	++	++	+	+ +	
Musculoskeletal System Bone	+	+	+	+	+	+	+ -	+ ·	+ -	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	
Nervous System Brain Cerebrum, oligodendroglioma benign Spinal cord	+	+	+	+	+ X	+	+ -	+ ·	+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple	+ +	+ +	+ +	+ +	+ +	+ +	+ -	+ •	+ 1 + -	M +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	
Carcinoma, metastatic, harderian, gland Hepatocellular carcinoma, metastatic, liver Nose Carcinoma, metastatic, harderian gland Pleura	М	[+	+	+	+	+	+ -	+ -	+ -		X +	+		X + +	+	+	+	+	+	+	+	+	X +	+	+	
Hepatocellular carcinoma, metastatic, liver Trachea	+	+	+	+	+	+	+ -	+ ·	+ -	+	+	+		X +	+	+	+	+	+	+	+	+	+	+	+	

(continued)																										
Number of Days on Study	7 3 1	7 3 2																								
Carcass ID Number	0 6 2	0 6 8	0 6 9	0 7 2	0 7 8			0 8 5	8	0 8 9	0 9 3	5	0 5 4	5	0 6 3	0 7 0	0 7 4	0 8 1	0 8 3	0 8 7	0 8 8	0 9 1	0 9 6	0 9 8	0	Total Tissues/ Tumors
Genital System (continued) Uterus Leiomyosarcoma Polyp stromal Endometrium, adenoma Vagina Leiomyosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	50 1 2 1 1 1
Hematopoietic System Bone marrow Lymph node Lymph node, bronchial	+	+ M	+	+ M	+	+ M	+	+	+	+	+ M	+	+	+ M	+	+ M	+	+ M	+	+	+	+	+	+ M	+ M	48 3 32
Fibrosarcoma, metastatic, pancreas Hepatocellular carcinoma, metastatic, liver Lymph node, mandibular Lymph node, mesenteric	+ +	+ +	+ +	+++	+++	+ +	+ +	+++	+++	++	+++		+++			+++	+ +	++	+ +	+ +	+++	+++	+++	+ +	++++	1 1 47 48
Fibrosarcoma, metastatic, pancreas Lymph node, mediastinal Fibrosarcoma, metastatic, pancreas Hepatocellular carcinoma, metastatic, liver	М	[+	М	í M	+	+	+	+	М	М	М	+	+	М	+	+	+	+	+	+	+	М	+	+	+	1 34 1 1
Spleen Capsule, fibrosarcoma, metastatic, pancreas Thymus Hepatocellular carcinoma, metastatic, liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 42 1
Integumentary System Mammary gland Carcinoma Skin	+	+	+	+	+	+	+	+ X +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49 1 50
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Nervous System Brain Cerebrum, oligodendroglioma benign Spinal cord	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 1
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple Carcinoma, metastatic, harderian gland	+ +	+ +	++	+++	++	+ +	+ +	++	+ +	++	++	+ + X	+ +	+ +	+ +	+ + X	++	++	+ +	++	+ +	++	++	+ + X	+ +	49 50 3 1 1
Hepatocellular carcinoma, metastatic, liver Nose Carcinoma, metastatic, harderian gland Pleura	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	3 49 1 1
Hepatocellular carcinoma, metastatic, liver Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 50

Number of Days on Study	2 4 1 2 5 3	5 0 1	5 6 5	5 7 8	5 5 9 9 2 7	56 91 78	6 2 9	6 3 9	6 8 8	6 9 4	7 7 1 1 5 8	7 2 5	7 3 0	7 3 0	7 3 0	7 3 0	7 3 0	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	
Carcass ID Number	0 0 8 9 0 7	0 9 0	0 6 4	0 6 7	0 (9 7 2 5	0 79 54	0 7 3	0 6 5	0 6 0	0 9 9	0 () 6 7 6 7	0 5 8	0 5 6	0 7 1	0 7 6	0 7 9	0 9 5	0 5 1	0 5 2	0 5 5	0 5 9	0 6 1	
Special Senses System Harderian gland Carcinoma								+ X															
Urinary System Kidney Cortex, fibrosarcoma, metastatic, pancreas Urinary bladder	+ + + +	- +	+	+	+ -	+ + + +	+ M	+	+		+ - X + -	- +	++	+	+	+	+	++	+	+		++	
Systemic Lesions Multiple organs Leukemia granulocytic Lymphoma malignant	+ + >	- + K	+	+	+ - X	+ +	+ X	+	+	+	+ -	- +	+	+	+	+ X	+	+	+	+	+	+	

Number of Days on Study	7 3 1	7 3 2																								
Carcass ID Number	0 6 2	0 6 8	0 6 9	0 7 2	0 7 8	0 8 2	0 8 4	0 8 5	0 8 6	0 8 9	0 9 3	0 5 3	0 5 4	0 5 7	0 6 3	0 7 0	0 7 4	0 8 1	0 8 3	0 8 7	0 8 8	0 9 1	0 9 6	0 9 8	1 0 0	Total Tissues/ Tumors
Special Senses System Harderian gland Carcinoma																										1 1
Urinary System Kidney Cortex, fibrosarcoma, metastatic, pancreas Urinary bladder	+	+	+	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ M		50 1 47
Systemic Lesions Multiple organs Leukemia granulocytic Lymphoma malignant	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 3

Individual Animal Tumor Pathology	y of Fem	ale		ice	m	the	e z-	Ye	ar	In	ha	lati	on	St	udy	y Oi	fE	th	ylb	en	zei	ie:	-7:	<u> </u>	pm
	3	4	5	5	5	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	0 0			8 4	9 0	0 2	3 9	4 2	9 7	9 7	0 3	2 3	3 0	3 0	3 0	3 1	3 1	3 1							
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Carcass ID Number	5 2	5 3	8 7	8	5 5	6	9 4	9	7	8 3	6	8 4	6	7	7 7	5	5	5 7	6 6	6 9	7 0	7 2	7 4	7 6	
Alimentary System	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	0	'	0	0	1	-	0	0	0	'	-	0		,	1	1	,	U	0	0	~	-	0	0
Esophagus	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder	A	· +	+	+	À	+	+		+	+	+	M	+	+	+	M	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	A	. +	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	А	. +	+	+	А	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	А	. +	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	+	+	Μ	+			А		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, ileum	А	· +	+	+	А	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cholangiocarcinoma					Х																				
Hemangioma						v						v			Х										
Hepatocellular carcinoma			v			Х					v	Х						v					v		
Hepatocellular adenoma			Х								Х							Х					Х		
Hepatocellular adenoma, multiple Pancreas							,			,	,	,	,												
Fancreas Salivary glands	+	. +	+	+	+	+	+	+	+	+	++	++	++	+	+	+	+	+	+	+	+	+	+	+	- -
Stomach, forestomach	+	· +	+	++	+ A	+	++	+ +	++	++				++	+ +	++	++	++	+	+	+	+	+	+	
Squamous cell papilloma	т	-1	X		Л	т	Г	ſ	r	ſ	r	r	X	1-	1.	1.	1-	г	г	т	т	т	т	т	
Stomach, glandular	+	. +			А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Serosa, sarcoma, metastatic, uterus		X						-																	
Cardiovascular System																									
Blood vessel	А	. +	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+
Heart	+	• +	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+
Endocrine System																									
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma benign							,																		
Islets, pancreatic Parathyroid gland	+	• +	+	+ \/	+	+	+ +		+ M				+ M						+		+	+ M	+ N/	+ M	+
Paratnyrold gland Pituitary gland	+	• +	+	M		+ M	++																- MI +		
Pars distalis, adenoma	+	+	+	+	+	IVI	+	Ŧ	+ X	Ŧ	+ X	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	+	+	+		+ X	+	-T"
Thyroid gland	1		+	+	+	+	+	+		+		+	+	+	+	+	+	+	+	+	+		л +	+	+
Follicular cell, adenoma	т	-1	Τ'	т	т	т	r	r.	E.	ſ	r	r	ſ		1.	1.	1.	Г	F	X	т	т	т	т	
Follicular cell, adenoma, multiple									Х							Х				~1					
General Body System																									
Tissue NOS			+		+											+									
Hemangiosarcoma																									
Abdominal, osteosarcoma			Х																						
Genital System																									
Clitoral gland	+	N	1 +	+	M	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Ovary	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Uterus Bolun stromol	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Polyp stromal																									

Individual Animal Tumor Pathology	of rem	uit										ILLE			<u></u>	, •			<i>,</i>					- I	P ^m	(continued
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
· ·	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number	8	8	9	9	9	9	0	5	5	5	6	6	6	6	6	7	7	7	8	8	8	9	9	9	9	Tissues/
	6	9				9	0	6	8		2		4			3		9			2			2		Tumors
Alimentary System																										
Esophagus	+	+	• +	· +	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	48
Gallbladder	+	+	• +	M	1 +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
Intestine large, colon	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Intestine large, rectum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, cecum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine small, duodenum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
Intestine small, ileum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Liver	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Cholangiocarcinoma																										1
Hemangioma																										1
Hepatocellular carcinoma																	Х					Х				4
Hepatocellular adenoma				X								Х					Х									8
Hepatocellular adenoma, multiple		Х	2																							1
Pancreas	+	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Salivary glands	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Squamous cell papilloma																										2
Stomach, glandular	+	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Serosa, sarcoma, metastatic, uterus																							_			1
Cardiovascular System																										
Blood vessel	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Heart	+	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Endocrine System																										
Adrenal cortex	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Adrenal medulla	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pheochromocytoma benign																									Х	1
Islets, pancreatic	+	+	• +	+	+	+	+	+	+	+	+	+	+	+		+			+				+	+		50
Parathyroid gland	Ν	1 +	• +	+	Μ	Μ	Μ		+		+				М											24
Pituitary gland	+	+	• +	+	+	+	+	+		+		+	+	+	+		+	+	+		+	+	+	+	+	49
Pars distalis, adenoma									Х		Х					Х				Х						8
Thyroid gland	+	+	• +	+		+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma					Х									Х	Х											4
Follicular cell, adenoma, multiple																							_			2
General Body System																										
Fissue NOS			+								+						+									6
Hemangiosarcoma																	Х									1
Abdominal, osteosarcoma																										1
Genital System																										
Clitoral gland	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Ovary	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Uterus	+	+	• +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Polyp stromal							X																			1
Sarcoma																										-

180

TABLE D2

Individual Animal Tumor Pathology of	гсш																							-	
	3	4	5	5	5	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	0	9			9	0	3	4	9	9	0	2	3	3	3	3	3	3	3	3	3	3	3	3	3
	0	5	2	4	0	2	9	2	7	7	3	3	0	0	0	1	1	1	1	1	1	1	1	1	1
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Carcass ID Number	5	5	-			6	9	9	7	8	6	8	6			5	5	5	6		7	7	7	7	8
	2	3	7	8	5	1	4	6	8	3	7	4	0	1	7	1	4	7	6	9	0	2	4	6	5
Hematopoietic System																									
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node			+	+			+				+			+		+									
Iliac, hemangioma																									
Lumbar, osteosarcoma, metastatic,																									
tissue NOS			Х	[
Renal, hemangiosarcoma																									
_ymph node, bronchial	+	+	+		+															+		+	+	+	+
_ymph node, mandibular	+	+	+						Μ					+			+	+	+	+	+	+	+	+	+
Lymph node, mesenteric	N		+ /		+ M				+		+				+	+	+	+	+	+	+	+	+	+	+ M
Lymph node, mediastinal	+	N			• M								M	+	+	+ +	+	+	+	+	+	+	+	+	M
Spleen Fhymus	+ N	+ [+			· +							++	++	++	++	++	++	++	++	++	++	++	++	++	+
•	18	- r	14	- r	1.	. • 1		.,1	'				•		•	•					•	•		•	
Integumentary System																									
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Carcinoma								Х				Х		Х											
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Fibrosarcoma															Х						τ,				
Hemangioma Squamous cell carcinoma																					Х				
Squanous con curentonia																									
Musculoskeletal System																									
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Skeletal muscle										+		+													
Carcinoma, metastatic, mammary gland										37		Х													
Rhabdomyosarcoma										Х															
Nervous System																									
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System																									
Larynx	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lung	+	+	. +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma	Т	ſ	ſ	ſ												'					X		X		
Alveolar/bronchiolar carcinoma					Х																-		-		
Carcinoma, metastatic, mammary gland								Х																	
Hepatocellular carcinoma, metastatic, liver												Х													
Osteosarcoma, metastatic, tissue NOS			Х																						
Sarcoma, metastatic, uterus		Х																							
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Frachea	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Special Senses System None																									
Urinary System								-							-							-			
Kidney	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cholangiocarcinoma, metastatic, liver					X		·		•																
Ureter							+																		
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	М	+	+
Serosa, sarcoma, metastatic, uterus		Х																							
vetomic Losions																									
Systemic Lesions Aultiple organs	-	L	ــ .		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

TABLE D2 Individual Anii

Individual Animal Tumor Pathology of	rema	ue	IVI	uce	e m	un	e Z-	• 1 6	ar	ın	na	ati	ION	30	uđ	y 0	ſĔ	un'	y ID	en	zei	1e:	73	• p]	րա	(continued)
Number of Days on Study	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 1	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	7 3 2	
Carcass ID Number	1 8 6	1 8 9	1 9 3	9	1 9 8	1 9 9	2 0 0	1 5 6	1 5 8	1 5 9	1 6 2	1 6 3	6	1 6 5	1 6 8	1 7 3	1 7 5	1 7 9	1 8 0	1 8 1	1 8 2	1 9 0	1 9 1	1 9 2	9	Total Tissues/ Tumors
Hematopoietic System Bone marrow Lymph node Iliac, hemangioma Lumbar, osteosarcoma, metastatic,	+	+	+	+ +	+	+	+	+	+	+	+ + X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 7 1
tissue NOS Renal, hemangiosarcoma .ymph node, bronchial .ymph node, mandibular .ymph node, mesenteric .ymph node, mediastinal ipleen Thymus	M + + + +	+ + + + +	+ + + + N	· + · + · + · + · +	+ + + + +	+ + + + +	+ + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	X + + + + + + +	+++++++++++++++++++++++++++++++++++++++	M + + + + +	+ + + + + +	+ + + + + + +	+ + + + + +	M + + + +	+ + + + + + +	+ + + M + +	M + + + +	+ + + + + +	+ + + + + +	+ + + + + +		+ + M +	1 1 40 48 48 42 50 44
ntegumentary System Aammary gland Carcinoma Skin Fibrosarcoma Hemangioma Squamous cell carcinoma	+ +	+	+ + X		+ +	+ +	+ + X	+ +	+	+ +	+ +	+	+ +	+	+ +	+ +	+ +	+ +	+ +	+	+	+ +	+	+ +	+ +	50 3 50 2 1 1
Musculoskeletal System Bone Skeletal muscle Carcinoma, metastatic, mammary gland Rhabdomyosarcoma	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 2 1 1
Vervous System Brain	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Carcinoma, metastatic, mammary gland Hepatocellular carcinoma, metastatic, liver Osteosarcoma, metastatic, tissue NOS Sarcoma, metastatic, uterus Nose Frachea	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++++++++++++++++++++++++++++++++++	· + · +	+++++++	+++++	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + X + +	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	M + X + +	+ + + + +	+ + + + +	+++++++++++++++++++++++++++++++++++++++	++++++	+ + + X + +	+++++++++++++++++++++++++++++++++++++++	++++++	49 50 4 2 1 1 1 1 50 50
Special Senses System None																										
U rinary System Kidney Cholangiocarcinoma, metastatic, liver Jreter Jrinary bladder Serosa, sarcoma, metastatic, uterus	+ +	+	+	· +	+	+	+	+	+	+ +	+	+ +	+	+	+	+ +	+ +	+	+	+ +	+	+	+	+ +	+	50 1 1 48 1
Systemic Lesions Multiple organs Lymphoma malignant	+	+ X	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 6

Individual Animal Tumor Patholog	gy of Female Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm	
	0 4 4 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
Number of Days on Study	8 3 4 5 8 9 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
tumber of Days on Study	6 7 6 9 2 4 1 5 7 8 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1	
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
Carcass ID Number	6 7 6 9 7 9 8 8 8 7 7 7 8 9 5 5 5 5 5 5 6 6 6 7 7	
Carcass ID Number	8 9 0 4 4 3 5 6 0 6 2 3 4 9 1 2 5 6 8 9 5 7 9 1 7	
A line and arrest Crustom		
Alimentary System Esophagus	+ + + + + + + + + + + + + + + + + + + +	
Gallbladder	A A + + M A A + + + M + + + + + + + + +	
Intestine large, colon	A + + + + + + + A + + + + + + + + + + +	
Intestine large, rectum	M + + + + + + + + + + + + + + + + + + +	
Intestine large, cecum	A + + + + A + + + + + + + + + + + + + +	
Intestine small, duodenum	A + + + A + A + + + + + + + + + + + + +	
Polyp adenomatous	X	
Intestine small, jejunum	A + + + + + M A A + + + + + + + + + + +	
Intestine small, ileum	A + + + + A A + + + + + + + + + + + + +	
Liver	+ + + + + + + + + + + + + + + + + + +	
Hepatocellular carcinoma	Х	
Hepatocellular adenoma	X X X X X	
Hepatocellular adenoma, multiple	X X	
Pancreas	+ + + + + + + + + + + + + + + + + + +	
Salivary glands	+ + + + + + + + + + + + + + + + + + +	
Stomach, forestomach	+ + + + + + A + A + + + + + + + + + + +	
Squamous cell papilloma		
Stomach, glandular	+ + + + + + A + A + + + + + + + + + + +	
-		
Cardiovascular System		
Blood vessel	M + + + M + + + + + + + + + + + + + + +	
Heart	+ + + + + + + + + + + + + + + + + + + +	
Endocrine System		
Adrenal cortex	+ + + + + + + + + + + + + + + + + + + +	
Adenoma	X	
Adrenal medulla		
Pheochromocytoma malignant	X	
Pheochromocytoma benign	Х	
slets, pancreatic		
Adenoma	+ + + + + + + + + + + + + + + + + + + +	
	· M · · · M · · · · · · · · · · · · · ·	
Parathyroid gland	+ M + + M + + + + M M + + + + M M + M +	
Pituitary gland	+ + + + + + M + + + + + + + + + + + + +	
Pars distalis, adenoma	X X X X X	
Pars intermedia, adenoma	Х	
Гhyroid gland	+ + + + + + + + + + + + + + + + + + +	
Follicular cell, adenoma	Х	
General Body System		
Fissue NOS		
	+ + + + X	
Pelvic, sarcoma	Λ	
Genital System		
Clitoral gland	+ + + + + + + + + M + + + + + + + + + +	
Dvary	+ + + + + M + + + + + + + + + + + + + +	
Uterus	+ + + + + + + + + + + + + + + + + + + +	
Polyp stromal		
Myometrium, hemangioma	Х	

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued) 7 Number of Days on Study 3 1 1 1 1 1 1 1 1 1 1 2 Total **Carcass ID Number** 8 8 8 8 9 9 9 9 0 5 5 5 6 6 6 6 6 7 7 7 8 8 99 9 Tissues/ 8 1 3 8 9 0 1 2 7 0 3 4 7 1 2 3 4 6 0 5 2 7 5 6 8 Tumors **Alimentary System** Esophagus 50 Gallbladder 44 Intestine large, colon 48 + + + + + + + + + + + Intestine large, rectum 49 + Intestine large, cecum 48 + 4 + + + + Intestine small, duodenum 47 Polyp adenomatous 1 Intestine small, jejunum 46 Intestine small, ileum + + 47 + + Liver 50 + + + + + + + Hepatocellular carcinoma Х X 3 Hepatocellular adenoma ХХ Х ХХ 9 Hepatocellular adenoma, multiple Х 3 50 Pancreas + + + + + + ++ + Salivary glands 50 Stomach, forestomach 48 + Squamous cell papilloma Х 1 Stomach, glandular 48 + + + + + + + + ++ ++ +**Cardiovascular System** 48 Blood vessel + + + + + + + + + + ++ + ++ + + + + ++ + Heart 50 + + + + + + + + + + **Endocrine System** 50 Adrenal cortex Adenoma 1 Adrenal medulla 50 Pheochromocytoma malignant 1 Pheochromocytoma benign 1 Islets, pancreatic 50 Adenoma Х 1 Parathyroid gland 34 M Μ Μ М + + +Pituitary gland 47 Pars distalis, adenoma 7 X Pars intermedia, adenoma 1 Thyroid gland 50 + + + + + + Follicular cell, adenoma ХХ 3 **General Body System** Tissue NOS + 4 Pelvic, sarcoma 1 **Genital System** Clitoral gland 48 Μ +Ovary 49 + + + + + + + + + + + + ++ + Uterus + 50 + + ++ + + + + + + + Х Polyp stromal 1 Myometrium, hemangioma 1

Individual Animal Tumor Pathology of	Fem				e m	th	e z	- Y (ear	In	ha	au	lon	St	ud	y o		th	yid	en	zei	ie:	2:	00	ppm (continued
	0	4	4	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7
Number of Days on Study	8	3	4	5	8	9	0	0	0	0	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	6	7	6	9	2	4	1	5	7	8	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Carcass ID Number	6						8	8	8	7	7	7	8	9	5	5	5	5	5	5	6	6	6	7	7
	8	9	0	4	4	3	5	6	0	6	2	3	4	9	1	2	5	6	8	9	5	7	9	1	7
Hematopoietic System																									
Bone marrow	+	+	+	• -+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node									+																
Lymph node, bronchial	+	N	1 +		- +	N	[+	+	+	+	+	Μ	+	+	+	М	М	М	М	Μ	+	Μ	Μ	+	+
Lymph node, mandibular	+	+	• +	• +	- +	+		+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+
Lymph node, mesenteric		1 +		• - +	- +	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node, mediastinal	Ν	1 +	• +	• -+	- +		[+			+	+	+	+	+	+	Μ	+	+	Μ	+	Μ	+	+	+	М
Spleen	+	+	• +	• +	- +	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Thymus	+	+	·A	1	- +	N	ΙM	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Integumentary System																									
Mammary gland	Ν	1 +	• +	· N	A +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Skin	Ν	1 +	• +	• -+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Hemangioma																									
Sebaceous gland, adenoma																									
Musculoskeletal System																									
Bone	+	-+	· +	• -+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Rib, sarcoma, metastatic, tissue NOS			X																					-	
Vertebra, osteosarcoma																									
Nervous System																									
Brain	+	+	• +	• -+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System																									
Larynx	+	N	ſΑ		- +	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lung					- +									+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar adenoma		• •			X		Ċ	Ċ			X			·		·	·	·		·	Ċ	Ċ	·	·	
Alveolar/bronchiolar adenoma, multiple							Х																		
Hepatocellular carcinoma, metastatic, liver															Х										
Sarcoma, metastatic, tissue NOS			Х	C											-										
Nose	+	+	• +		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Trachea	+	+	• +	• -+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Special Senses System Harderian gland Adenoma																									
Urinary System																									
Kidney	+	-	+		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Urinary bladder	+	+	• +	• -+	- +	+	M	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+
Systemic Lesions																									
Multiple organs	+	+	. +	• -+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymphoma malignant		Σ	,		Χ				X																

Individual Animal Tumor Pathology of Female Mice in the 2-Year Inhalation Study of Ethylbenzene: 250 ppm (continued) 7 Number of Days on Study 3 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 Total **Carcass ID Number** 8 8 8 8 9 9 9 9 0 5 5 5 6 6 6 6 6 7 7 8 7 8 99 9 Tissues/ 8 3 8 9 0 1 2 7 0 3 4 7 $1 \ 2 \ 3 \ 4$ 6 0 5 2 7 5 6 8 Tumors 1 **Hematopoietic System** Bone marrow 50 2 Lymph node Lymph node, bronchial 29 ΜМ МММ Μ Μ M M + Μ + ++++ Μ +++ ++ + Lymph node, mandibular 47 М Μ + + + + + + + + Lymph node, mesenteric 46 Μ Μ + + + + + + + + + + Lymph node, mediastinal Μ Μ М 41 + + + + + + + + + + + + 50 Spleen + + + +++ + ++ + + + + + + ++ + ++ + Thymus 45 Μ Μ + **Integumentary System** 48 Mammary gland Skin 49 + + + + + + + + + Х Х Hemangioma 2 Sebaceous gland, adenoma Х 1 **Musculoskeletal System** Bone 50 Rib, sarcoma, metastatic, tissue NOS 1 Vertebra, osteosarcoma Х 1 **Nervous System** Brain 50 + + + + + + + + + + + + + + + + + **Respiratory System** 47 Larynx Lung 49 + $^+$ + + + Alveolar/bronchiolar adenoma Х 4 Alveolar/bronchiolar adenoma, multiple 1 Hepatocellular carcinoma, metastatic, liver Х 2 Sarcoma, metastatic, tissue NOS 1 Nose 50 $^+$ + + + + ++ ++ + + +++++ $^{+}$ ++++++Trachea 50 ++ +++ +++ $^{+}$ +++ + +++ ++ + ++ $^{+}$ +**Special Senses System** Harderian gland 1 + Х Adenoma 1 **Urinary System** 50 Kidney + Urinary bladder 47 ++ Systemic Lesions 50 Multiple organs + Lymphoma malignant Х 5

186

	0	1	5	P	c	e	6	7	7 ~	, ~	7	~	7	7	7	7	7	7	7	7	7	7	7	7
Normhan of Doug on Study					6	6					1	7								7	7			
Number of Days on Study	0 7	6 9			1 4	6 6			1 1 2 2		8	2 3	3 0	3 0	3 0	3 1	3 1	3 1	3 1	3 1	3 1	3 1	3 1	3 1
	3	3	3	3	3	4	3	3	3 3	33	3	3	3	3	3	3	3	3	3	3	3	3	3	3
Carcass ID Number	7 2	8 0			6 3	0 0		6 1	56 89				5 1	9 3	9 5	5 4	5 5	6 2	7 5	7 7	7 8	7 9	8 2	8 3
Alimentary System																								
Esophagus	+	. +	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Gallbladder	+	A	۰ +	+	+	А	М	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, colon	+	+	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, rectum	+	A	۰ +	A	+	+	А	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine large, cecum	Ν	1 A	A N	1 A	+	А	А	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, duodenum	+	A	۰ +	A	+	А	М	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, jejunum	A	N	Λ +	A	+	А	+	+	+ -	+ +	+	A	+	+	+	+	+	+	+	+	+	+	+	+
Intestine small, ileum	+	- A	4 +	A	+	+	А	+	+ -	+ +	A	. +	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	• +	- +	+	+	+	+	+	+ -				+	+	+	+	+	+	+	+	+	+	+	+
Hepatocellular carcinoma											X	X					Х	Х						Х
Hepatocellular carcinoma, multiple				Х					2	K														
Hepatocellular adenoma Hepatocellular adenoma, multiple					Х									Х	х		Х			Х				
Pancreas	+	• +	- +	+	+	+	А	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Salivary glands	+	• +	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach, forestomach	+	• +	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Squamous cell papilloma																								
Stomach, glandular	+	· +	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cardiovascular System																								
Blood vessel	+		+		+	+	+	+	÷ -	∟ →	. +	+	+	+	+	+	+	+	+	+	+	+	+	+
Heart	+				+	+	+	+	+ -	 	. +	+	+	+	+	+	+	+	+	+	+	+	+	+
Endocrine System																								
Adrenal cortex	+	+	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adrenal medulla	+	• +	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Islets, pancreatic	+	+	- +	+	+	+			+ -	+ +			+		+	+	+	+	+	+	+	+	+	+
Parathyroid gland	+	• +	- +	+	Μ	+	+	M	+ -	+ +	M	1 M	+	Μ		+	+		Μ	Μ	+	+	+	+
Pituitary gland	+	• +	- +	N	[+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pars distalis, adenoma																			Х			Х		
Thyroid gland	+	• +	- +	+	+	+	+	+	+ -	+ +	• +	+				+	+	+	+	+	+	+	+	+
Follicular cell, adenoma													Х		Х									
General Body System Tissue NOS																								
Genital System																								
Clitoral gland	+	. +	- +	+	+	+	+	Μ	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Fibrosarcoma	1	'	x	. '			•				'				•	'								
Ovary	+	· +	- +	+	+	+	+	+	+ -	+ +	. +	М	+	+	+	+	+	+	+	+	+	+	+	+
Cystadenoma									x															
Uterus	+	+	- +	+	+	+	+	+		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Homotopoistic System																								
Hematopoietic System																								
Bone marrow	+	• +	- +	+	+	+	+	+	+ -	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node	x	+ יוז	- /	N	г л <i>г</i>	+	+					f 1.4				,		+ \\			٨.			
Lymph node, bronchial		-	-		[M				+ -	-	-	1 M	. +	+	+	+	+	1 VI	+	+	M	+	+	+
Lymph node, mandibular Lymph node, mesenteric	+ N					+	+ M		+ -	+ N		+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph node, mesenteric Lymph node, mediastinal	_			-	+ M		M	+ M 1	י + או M				+ M	+	+	+	+	+	+	+	+	+	+	т
Spleen	IV.	1 IN	/I IV	1 +	IVI	+				vı + + +		1 +	+	+	+	+	+	+	+	+	+	+	+	т _
Thymus	+	+	+	+	+	т	-Τ			+ + VI +				т	τ	т	т	т	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	т

			~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	~	
	7	7		7	7	7		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	•	
Number of Days on Study	3	3	3	3	3 1	3 1	3 1	3 2																		
	-	-	-	-	-	-	-			_						-				-						
	3			3	3	3				3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		Total
Carcass ID Number	8			8	9	9				5	6	6	6	6 7	6	7	7	7	7	8	8	9	9	9 7	9	Tissues/
	5	6	7	8	1	4	9	2	3	7	4	5	6	7	8	1	3	4	6	1	9	0	2	7	8	Tumors
Alimentary System																										
Esophagus	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	46
ntestine large, colon	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
ntestine large, rectum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
ntestine large, cecum	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
ntestine small, duodenum	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
ntestine small, jejunum	+	· +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
ntestine small, ileum	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46
liver	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular carcinoma			Х								Х						Х							Х		10
Hepatocellular carcinoma, multiple		,		v	v								17				v				17	17		v		2
Hepatocellular adenoma	Х			Х	Х					v			Х			17	Х				Х	Х	v	Х		12
Hepatocellular adenoma, multiple										X	,					X	,	,					X			4
ancreas	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
alivary glands tomach, forestomach	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 50
Squamous cell papilloma	+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	^+_X	+	+	+	+	+	+	50 1
Stomach, glandular	+					+					+		+	+	+	+	+				+			+		50
	Т	- 1	- т	т	т	Ŧ	т	Т	т	т	Т	т	т	т	т	T	т	Т	т	т	т	Т	т	Т	т	50
Cardiovascular System																										
Blood vessel	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Ieart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Endocrine System																										
Adrenal cortex	L			-	-	-	-	-	-	-	-	_	-	-	-	-	-	-	-	_	-	-	-	_	М	49
Adrenal medulla	T L			т 	+ +	- -	т _	т _	+ +	+ +	т _	+ +	+ +	+	+ +	+ +	т _	- -	т 	+ +	- -	- -	+ +	+	M	49
slets, pancreatic	т +		. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	49
Parathyroid gland	+	. N	4 M	ÍM	M	+	M			+	+		M		+	+	+	+		M	M				M	27
Pituitary gland	+	. +	. +	+	+	+				+	+	+	+			+	+	+	+	+	+	+	+	+	+	49
Pars distalis, adenoma	'				'	'				x													'	'	x	5
Thyroid gland	+	• +	• +	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma						-				-	X					X	-			-			-	-		4
General Body System Fissue NOS				+																						1
issue NOS				+																						1
Genital System																										
Clitoral gland	+	· +	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Fibrosarcoma																										1
Dvary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Cystadenoma														Х												2
Jterus	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
lematopoietic System																										
one marrow	+	ı	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
ymph node	+		-1-	Τ'	Г	r	1.	1.	1.	17	r	Г	г	г	Г	Г	r	r	Г	Г	г	г	т	т	1.	5
ymph node, bronchial	+		· +	+	+	+	+	+	+	+	м	м	М	+	+	+	+	М	+	+	+	+	+	+	+	38
ymph node, mandibular	т 1	۳ بد .	- M		+	+	м	+		+	+	+	+	+	+	+	+ +	M	+	+	+	+	+	+	+	44
ymph node, mesenteric	т 4	т 	. +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	M		+	+	+	+	+	+	44
Jymph node, mediastinal	+	. N	4 M	[+]	+	+	+	Ň		+	+				M		M		M	+	M	+	+	+	+	31
Spleen	+	. 4	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Thymus						'	•		·	•	1	1													•	46

TABLE D2 Individual Anim

TABLE D2 Individual Animal Tumor Pathology of	f Fem a	ale	M	ice	in	the	e 2 -	Ye	ar	In	ha	lati	ion	St	udy	y o	f E	th	ylb	en	zei	ne:	7	50	ppm (continued
Number of Days on Study	0 0 7	1 6 9	5 6 8	6 1 2	6 1 4	6 6 6	-	7 1 1	7 1 2		7 1 3	7 1 8	7 2 3	7 3 0	7 3 0	7 3 0	7 3 1								
Carcass ID Number	3 7 2	3 8 0	3 8 4	3 5 9	3 6 3	4 0 0	5	3 6 1	5	6	3 7 0	6	9	3 5 1	3 9 3	9	3 5 4	3 5 5	3 6 2	7	3 7 7	3 7 8	3 7 9	3 8 2	3 8 3
Integumentary System Mammary gland Skin Fibroma Fibrous histiocytoma	+ +	A +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Respiratory System Larynx Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver Squamous cell carcinoma, metastatic, lacrimal gland	+ +	M +	[+ +	+++	+ +	+ +	+++	+ +	+++	+ +	+++	+ + X	+ + X	+ + X	+ +	+ +	M +	+++	+ + X	+ +	+ +	+ +	+ +	+ + X	+ +
Nose Trachea	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +
Special Senses System Harderian gland Adenoma Lacrimal gland Squamous cell carcinoma												+ X											+ X		
Urinary System Kidney Ureter Urinary bladder	+ +	+ A	++	++	+	++++++	++	+	++	++	+	+	++	++	+ +	+	++	++	+	++	++	++	+	++	+ +
Systemic Lesions Multiple organs Lymphoma malignant	+	+	+	+	+		+ X	+	+	+	+	+	+	+	+	+	+	+		+ X	+	+	+	+	+

	7				7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		
Number of Days on Study	3 1	3 1	3 1		3 1	3 1	3 1	3 2																		
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	T.4.1
Carcass ID Number	3 8	3 8	3 8		3 9	3 9	3 9	3 5	3 5	3 5	3 6	3 6	3 6	3 6		3 7	3 7	3 7	3 7	3 8	3 8	3 9	3 9	3 9	3 9	Total Tissues/
	5	6				9 4	9 9	2	3	3 7	4						3	4		o 1	9		3 2	9 7		Tumors
Integumentary System																										
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Fibroma Fibrous histiocytoma																										1
, ,																										1
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Nervous System																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Respiratory System																										
Larynx	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Lung	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver				Х							Х						Х				Х		Х			8 1
Squamous cell carcinoma, metastatic,																										1
lacrimal gland																										1
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Special Senses System																										
Harderian gland																	+			+						3
Adenoma																	Х			Х						3
Lacrimal gland Squamous cell carcinoma																										1
-																										-
Urinary System Kidney	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Ureter	Т	T	т	F	ſ	1.			'	'		'	'			'				'			'		'	1
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Systemic Lesions																										
Multiple organs	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymphoma malignant	Х																									5

189

TABLE D3 Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene

	Chamber Control	75 ppm	250 ppm	750 ppm
Harderian Gland: Adenoma				
Overall rate ^a	0/50 (0%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Adjusted rate ^b	0.0%	0.0%	2.5%	8.1%
Ferminal rate ^C	0/35 (0%)	0/38 (0%)	1/40 (3%)	3/37 (8%)
First incidence (days)	e		730 (T)	730 (T)
Life table test ^d	P = 0.021	f	P = 0.527	P = 0.131
ogistic regression test	P = 0.021	_	P = 0.527	P=0.131
Cochran-Armitage test ^d	P = 0.021			
Fisher exact test ⁸		—	P = 0.500	P=0.121
Harderian Gland: Adenoma or Carcinoma				
Overall rate	1/50 (2%)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Adjusted rate	2.4%	0.0%	2.5%	8.1%
Ferminal rate	0/35 (0%)	0/38 (0%)	1/40 (3%)	3/37 (8%)
First incidence (days)	639	_ ` `	730 (T)	730 (T)
Life table test	P=0.083	P=0.486N	P = 0.730N	P=0.330
Logistic regression test	P = 0.081	P = 0.516N	P = 0.761	P = 0.310
Cochran-Armitage test	P = 0.080			
Fisher exact test		P=0.500N	P=0.753N	P=0.309
Liver: Hepatocellular Adenoma				
Overall rate	6/50 (12%)	9/50 (18%)	12/50 (24%)	16/50 (32%)
Adjusted rate	17.1%	22.1%	27.5%	41.8%
Terminal rate	6/35 (17%)	7/38 (18%)	9/40 (23%)	15/37 (41%)
First incidence (days)	730 (T)	562	659	614
Life table test	P = 0.013	P = 0.345	P = 0.165	P=0.018
Logistic regression test	P = 0.014	P=0.311	P = 0.128	P = 0.022
Cochran-Armitage test	P = 0.011			
Fisher exact test		P=0.288	P=0.096	P=0.014
Liver: Hepatocellular Carcinoma				
Overall rate	7/50 (14%)	4/50 (8%)	3/50 (6%)	12/50 (24%)
Adjusted rate	17.3%	9.7%	7.5%	28.3%
Terminal rate	3/35 (9%)	2/38 (5%)	3/40 (8%)	7/37 (19%)
First incidence (days)	565	602	730 (T)	612
Life table test	P = 0.029	P = 0.238N	P = 0.127N	P = 0.205
Logistic regression test	P = 0.022	P = 0.259N	P = 0.150N	P = 0.162
Cochran-Armitage test	P = 0.022			
Fisher exact test		P = 0.262N	P=0.159N	P=0.154
Liver: Hepatocellular Adenoma or Carcinoma				
Overall rate	13/50 (26%)	12/50 (24%)	15/50 (30%)	25/50 (50%)
Adjusted rate	32.8%	28.2%	34.5%	57.9%
Ferminal rate	9/35 (26%)	8/38 (21%)	12/40 (30%)	19/37 (51%)
First incidence (days)	565	562	659	612
Life table test	P = 0.004	P = 0.426N	P = 0.562	P=0.029
Logistic regression test	P = 0.002	P=0.478N	P = 0.471	P = 0.015
Cochran-Armitage test	P=0.002			
Fisher exact test		P = 0.500N	P = 0.412	P = 0.011

TABLE D3 Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ррт	750 ррт
Lung: Alveolar/bronchiolar Adenoma				
Overall rate	4/50 (8%)	4/50 (8%)	5/49 (10%)	8/50 (16%)
Adjusted rate	10.9%	10.5%	11.4%	21.6%
Terminal rate	3/35 (9%)	4/38 (11%)	2/40 (5%)	8/37 (22%)
First incidence (days)	694	730 (T)	682	730 (T)
Life table test	P = 0.106	P = 0.598N	P = 0.579	P = 0.206
Logistic regression test	P = 0.111	P = 0.618N	P = 0.525	P=0.218
Cochran-Armitage test	P = 0.096			
Fisher exact test		P=0.643N	P=0.487	P=0.178
Lung: Alveolar/bronchiolar Adenoma or Carci	noma			
Overall rate	4/50 (8%)	6/50 (12%)	5/49 (10%)	8/50 (16%)
Adjusted rate	10.9%	15.0%	11.4%	21.6%
Terminal rate	3/35 (9%)	5/38 (13%)	2/40 (5%)	8/37 (22%)
First incidence (days)	694	590	682	730 (T)
Life table test	P = 0.184	P = 0.419	P = 0.579	P = 0.206
Logistic regression test	P = 0.181	P = 0.386	P = 0.525	P = 0.218
Cochran-Armitage test	P = 0.169	D	D 0 10#	D 0 4 P 0
Fisher exact test		P = 0.370	P=0.487	P=0.178
Mammary Gland: Carcinoma				
Overall rate	1/50 (2%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
Adjusted rate	2.9%	7.3%	0.0%	0.0%
Ferminal rate	1/35 (3%)	1/38 (3%)	0/40 (0%)	0/37 (0%)
First incidence (days)	730 (T)	642	— D 0 (70)	— D. 0.40001
Life table test	P = 0.144N	P = 0.336	P = 0.473N	P = 0.489N
Logistic regression test	P = 0.149N	P = 0.311	P = 0.473N	P = 0.489N
Cochran-Armitage test Fisher exact test	P = 0.150N	P=0.309	P=0.500N	P=0.500N
Tislier exact test		r=0.309	P = 0.300 N	r = 0.3000
Pituitary Gland (Pars Distalis): Adenoma	1/10 (00/)	0/40 (400/)	A (4 F (4 F (4))	5 (10 (100))
Overall rate	4/48 (8%)	8/49 (16%)	7/47 (15%)	5/49 (10%)
Adjusted rate	11.1%	19.8%	17.0%	13.5%
Ferminal rate	3/35 (9%)	6/38 (16%)	5/38 (13%)	5/37 (14%) 720 (T)
First incidence (days)	725 D. 0.445N	697 P= 0.223	659 P = 0.322	730 (T)
Life table test Logistic regression test	P = 0.445N P = 0.425N	P = 0.223 P = 0.203	P = 0.322 P = 0.276	P = 0.533 P = 0.542
Cochran-Armitage test	P = 0.4251N P = 0.459N	r = 0.203	r = 0.270	f = 0.342
Fisher exact test	1 - 0.4551	P=0.188	P=0.249	P=0.513
Chymrid Cland (Fallicular Call), Adapama				
Fhyroid Gland (Follicular Cell): Adenoma Overall rate	5/50 (10%)	6/50 (12%)	3/50 (6%)	4/50 (8%)
Adjusted rate	13.7%	15.2%	7.1%	10.8%
Ferminal rate	4/35 (11%)	5/38 (13%)	2/40 (5%)	4/37 (11%)
First incidence (days)	694	697	682	730 (T)
Life table test	P = 0.355N	P = 0.557	P = 0.288N	P = 0.462N
Logistic regression test	P = 0.339N	P = 0.532	P = 0.320N	P = 0.449N
Cochran-Armitage test	P = 0.372N			
Fisher exact test		P = 0.500	P=0.357N	P=0.500N

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Inhalation Study of Ethylbenzene (continued)

	Chamber Control	75 ppm	250 ррт	750 ppm
All Organs: Hemangioma				
Overall rate	0/50 (0%)	3/50 (6%)	3/50 (6%)	0/50 (0%)
Adjusted rate	0.0%	7.9%	7.0%	0.0%
Terminal rate	0/35 (0%)	3/38 (8%)	2/40 (5%)	0/37 (0%)
First incidence (days)	_ ```	730 (T)	659	_ ``
Life table test	P = 0.280N	P = 0.136	P = 0.149	_
ogistic regression test	P = 0.281N	P = 0.136	P = 0.123	_
Cochran-Armitage test	P = 0.291N			
Fisher exact test		P=0.121	P=0.121	—
All Organs: Hemangioma or Hemangiosarcoma				
Overall rate	0/50 (0%)	4/50 (8%)	3/50 (6%)	0/50 (0%)
Adjusted rate	0.0%	10.5%	7.0%	0.0%
Ferminal rate	0/35 (0%)	4/38 (11%)	2/40 (5%)	0/37 (0%)
First incidence (days)	—	730 (T)	659	—
Life table test	P = 0.212N	P = 0.074	P = 0.149	—
Logistic regression test	P = 0.211N	P = 0.074	P = 0.123	—
Cochran-Armitage test	P = 0.222N			
Fisher exact test		P=0.059	P = 0.121	_
All Organs: Malignant Lymphoma				
Overall rate	3/50 (6%)	6/50 (12%)	5/50 (10%)	5/50 (10%)
Adjusted rate	7.1%	13.4%	10.7%	12.2
Ferminal rate	1/35 (3%)	2/38 (5%)	1/40 (3%)	3/37 (8%
First incidence (days)	423	300	437	666
Life table test	P = 0.496	P = 0.278	P = 0.416	P = 0.393
Logistic regression test	P = 0.237	P = 0.175	P = 0.340	P = 0.358
Cochran-Armitage test	P = 0.469			
Fisher exact test		P = 0.243	P = 0.357	P=0.357
All Organs: Benign Neoplasms				
Overall rate	20/50 (40%)	26/50 (52%)	27/50 (54%)	28/50 (56%)
Adjusted rate	50.8%	63.2%	59.9%	71.6%
Cerminal rate	16/35 (46%)	23/38 (61%)	22/40 (55%)	26/37 (70%)
First incidence (days)	565	562	659	614
ife table test	P = 0.163	P = 0.260	P = 0.284	P = 0.122
Logistic regression test	P = 0.176	P = 0.190	P = 0.163	P = 0.116
Cochran-Armitage test	P = 0.132	D 0 150	D 0 115	D 0.000
'isher exact test		P = 0.158	P=0.115	P = 0.080
All Organs: Malignant Neoplasms	19/50 (000/)	20/50 (400/)	0/50 (190/)	10/50 (000/)
Overall rate	13/50 (26%)	20/50 (40%)	9/50 (18%)	18/50 (36%)
Adjusted rate	28.5%	40.5%	19.3%	39.7%
Ferminal rate	4/35 (11%)	9/38 (24%)	4/40 (10%)	10/37 (27%)
First incidence (days) Life table test	423 P- 0 380	300 P- 0 181	437 P-0 101N	568 P- 0.270
	P = 0.380 P = 0.075	P = 0.181 P = 0.045	P = 0.191N P = 0.265N	P = 0.279 P = 0.192
Logistic regression test		r = 0.043	P = 0.265N	r = 0.132
Cochran-Armitage test Fisher exact test	P = 0.322	P=0.101	P=0.235N	P = 0.194
יואוטר טאמטר ובאר		1 - 0.101	1 - 0.2001	1 - 0.134

Statistical Analysis of Primary	V Neoplasms in 1	Female Mice in the 2-Year	r Inhalation Study of Ethylbenzene (conti	inued)
J J J	1		J J X	

	Chamber Control	75 ppm	250 ppm	750 ppm
All Organs: Benign or Malignant Neoplasms				
Overall rate	29/50 (58%)	38/50 (76%)	31/50 (62%)	38/50 (76%)
Adjusted rate	62.9%	76.0%	64.5%	80.8%
Terminal rate	18/35 (51%)	26/38 (68%)	23/40 (58%)	28/37 (76%)
First incidence (days)	423	300	437	568
Life table test	P = 0.229	P = 0.187	P = 0.466N	P = 0.161
Logistic regression test	P = 0.042	P = 0.041	P = 0.431	P = 0.045
Cochran-Armitage test	P = 0.116			
Fisher exact test		P = 0.044	P = 0.419	P = 0.044

(T)Terminal sacrifice

¹ Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for liver, lung, pituitary gland, and thyroid gland; for other tissues, denominator is number of animals necropsied.

^b Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

^c Observed incidence at terminal kill

^d Beneath the chamber control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the chamber controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

^e Not applicable; no neoplasms in animal group

f Value of statistic cannot be computed.

TABLE D4a

Historical Incidence of Alveolar/bronchiolar Neoplasms in Chamber Control Female B6C3F1 Micea

		Incidence in Controls					
Study	Adenoma	Carcinoma	Adenoma or Carcinoma				
Historical Incidence at IIT Researc	ch Institute						
Isobutyl Nitrite	4/51	2/51	6/51				
Overall Historical Incidence							
Total Standard deviation Range	61/939 (6.5%) 3.2% 0%-14%	38/939 (4.1%) 3.2% 0%-12%	97/939 (10.3%) 3.7% 0%-16%				

^a Data as of 12 May 1995

TABLE D4b Historical Incidence of Hepatocellular Neoplasms in Chamber Control Female B6C3F1 Micea

		Incidence in Controls						
Study	Adenoma	Carcinoma	Adenoma or Carcinoma					
Historical Incidence at IIT Research	h Institute							
Isobutyl Nitrite	6/51	4/51	10/51					
Overall Historical Incidence								
Total Standard deviation Range	114/937 (12.2%) 9.7% 0%-40%	103/937 (11.0%) 6.7% 0%-30%	200/937 (21.3%) 11.9% 3%-54%					

^a Data as of 12 May 1995

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Inhalation Study of Ethylbenzene^a

	Chamber Control	75 ppm	250 ppm	750 ppm
Disposition Summary				
Animals initially in study	50	50	50	50
Early deaths				
Accidental deaths	1		1	
Moribund	5	6	1	4
Natural deaths	9	6	8	9
Survivors				
Died last week of study	1	20	10	07
Terminal sacrifice	34	38	40	37
Animals examined microscopically	50	50	50	50
Alimentary System				
Gallbladder	(44)	(44)	(44)	(46)
Infiltration cellular	1 (2%)	· ·	· /	. ,
ntestine small, duodenum	(45)	(48)	(47)	(46)
Ulcer				1 (2%)
ntestine small, jejunum	(46)	(46)	(46)	(45)
Peyer's patch, hyperplasia				1 (2%)
ntestine small, ileum	(47)	(47)	(47)	(46)
Peyer's patch, hyperplasia	(50)	1 (2%)	(50)	(50)
iver	(50)	(50)	(50)	(50)
Angiectasis	0 (00()	1 (2%)	4 (00()	0 (00/)
Basophilic focus	3 (6%)		4 (8%)	3 (6%)
Clear cell focus	1 (2%)	7 (14%)	1 (2%) 6 (12%)	99 (440/)
Eosinophilic focus Hemorrhage	5 (10%)	7 (1470)	1 (2%)	22 (44%) 1 (2%)
Hepatodiaphragmatic nodule			2 (4%)	1 (2/0)
Infiltration cellular	3 (6%)		2 (170)	
Inflammation	1 (2%)	3 (6%)	1 (2%)	1 (2%)
Mineralization	- (w/0)	0 (070)	- (₩/0)	1 (2%)
Mixed cell focus			1 (2%)	1 (2%)
Necrosis	1 (2%)	4 (8%)	3 (6%)	4 (8%)
Pigmentation, hemosiderin	1 (2%)	1 (2%)		
Bile duct, cyst	. ,	. /		1 (2%)
Hepatocyte, hypertrophy				1 (2%)
Hepatocyte, necrosis		1 (2%)		
Hepatocyte, syncytial alteration			1 (2%)	
Hepatocyte, vacuolization cytoplasmic	2 (4%)		2 (4%)	1 (2%)
Serosa, inflammation				1 (2%)
Aesentery	(2)			
Fat, necrosis	2 (100%)	(50)	(50)	(10)
ancreas	(50)	(50)	(50)	(49)
Angiectasis		1 (2%)		
Atrophy		2 (4%)		
Cyst		1 (2%) 1 (2%)		
Degeneration Fibrosis		1 (2%) 1 (2%)		
Infiltration cellular	7 (14%)	1 (2%) 12 (24%)	12 (24%)	10 (20%)
Necrosis	/ (14/0)	12 (24%) 1 (2%)	12 (24/0)	10 (2070)
Acinus, hyperplasia	1 (2%)	I (~/0)		
Duct, cyst	1 (2/0)			1 (2%)

^a Number of animals examined microscopically at the site and the number of animals with lesion

				5 ppm) ppm) ppm
Alimentary System (continued)								
Salivary glands	(50)		(50)		(50)		(50)	
Atrophy			1	(2%)				
Infiltration cellular	30	(60%)	32	(64%)	33	(66%)		(60%)
Stomach, forestomach	(50)		(49)		(48)		(50)	
Hyperplasia							2	(4%)
Ulcer					1	(2%)		
Epithelium, cyst								(4%)
Epithelium, hyperplasia				(4%)				(2%)
Stomach, glandular	(50)	()	(49)		(48)		(50)	
Infiltration cellular		(2%)						
Glands, cyst	1	(2%)						(00)
Glands, hyperplasia								(2%)
Serosa, infiltration cellular							1	(2%)
Cardiovascular System								
Heart	(50)		(49)		(50)		(50)	
Cardiomyopathy		(20%)		(47%)		(46%)		(30%)
J I I J	-				-		-	
Endocrine System								
Adrenal cortex	(47)		(50)		(50)		(49)	
Accessory adrenal cortical nodule		(4%)		(2%)				
Degeneration		(26%)		(8%)		(8%)		(10%)
Hemorrhage		(4%)		(2%)		(4%)		(6%)
Hyperplasia	3	(6%)		(10%)	3	(6%)	3	(6%)
Infiltration cellular				(4%)				
Inflammation			3	(6%)				
Necrosis		(2%)						
Vacuolization cytoplasmic		(2%)						
Capsule, hyperplasia		(98%)		(98%)		(96%)		(94%)
Adrenal medulla	(47)	(22.1)	(50)		(50)		(49)	
Hemorrhage		(2%)		(00)				(00)
Hyperplasia		(4%)		(6%)	/ -			(2%)
slets, pancreatic	(50)		(50)	(10)	(50)	(10)	(49)	
Hyperplasia		(00)	2	(4%)		(4%)		
Infiltration cellular		(2%)	(0.4)			(4%)	(07)	
Parathyroid gland	(26)		(24)	(40/)	(34)		(27)	
Infiltration cellular	(10)			(4%)	(47)			
Pituitary gland	(48)		(49)		(47)	(0 0/)	(49)	(40/)
Pars distalis, angiectasis			1	(90/)	4	(9%)	2	(4%)
Pars distalis, cyst	n	(60/)	1	(2%)	1	(9%)	1	(90/)
Pars distalis, hemorrhage Pars distalis, hyperplasia		(6%) (21%)	10	(940/)		(2%)		(2%) (45%)
	10	(21%)	12	(24%)	23	(49%)		(45%)
Pars distalis, necrosis Pars intermedia, hyperplasia	0	(1%)	1	(9%)				
Pars intermedia, hyperplasia Thyroid gland	(50)	(4%)	(50)	(2%)	(50)		(50)	(2%)
Infiltration cellular	(50)		(50)			(2%)	(50)	
Follicle, degeneration	1	(2%)			1	(~ /0)		
Follicular cell, hyperplasia		(278)	92	(46%)	95	(50%)	25	(70%)

	Chambe	r Control	75	ó ppm	250	ppm	75) ppm
General Body System								
Tissue NOS	(1)		(6)		(4)		(1)	
Fat, necrosis			4	(67%)	3	(75%)	1	(100%)
Genital System								
Clitoral gland	(41)		(47)		(48)		(48)	
Atrophy					1	(2%)		/··
Degeneration	(10)		(7.0)		(10)			(2%)
Ovary	(49)	(10)	(50)	(00)	(49)		(49)	
Angiectasis	2	(4%)		(2%)		(00/)		
Atrophy	0	(100/)		(2%)		(2%)	10	(000/)
Cyst		(16%)	8	(16%)		(20%)	10	(20%)
Hemorrhage Infiltration cellular	1	(2%)				(2%) (4%)		
Mineralization					2	(4/0)	1	(2%)
Uterus	(50)		(50)		(50)		(50)	(~ /0)
Angiectasis	(30)		(00)			(2%)	(30)	
Degeneration	2	(4%)	1	(2%)	1	(270)	1	(2%)
Hemorrhage	2	(-/0)	-	(1	(2%)		(2%)
Infiltration cellular					1	· · · · ·		(2%)
Inflammation	3	(6%)						(2%)
Thrombosis	-	. ,			1	(2%)	-	. ,
Endometrium, hyperplasia	44	(88%)	46	(92%)		(94%)	46	(92%)
H ematopoietic System Bone marrow Hematopoietic cell proliferation	(48)		(50) 1	(2%)	(50)		(50)	
Infiltration cellular, histiocyte				(1	(2%)
Inflammation	1	(2%)						
Myelofibrosis							2	(4%)
Pigmentation, hemosiderin		(6%)	1	(2%)	1	(2%)		(2%)
Myeloid cell, hyperplasia		(2%)						(2%)
Lymph node	(3)		(7)	<i></i>	(2)		(5)	
Iliac, hyperplasia			1	(14%)				(000)
Inguinal, hyperplasia		(00)					1	(20%)
Inguinal, pigmentation, hemosiderin		(33%)	•	(900/)				
Lumbar, hyperplasia	1	(33%)	2	(29%)			1	(200%)
Pancreatic, hyperplasia Banal, hyperplasia	1	(33%)					1	(20%)
Renal, hyperplasia Renal, necrosis	1	(33%)	1	(14%)				
Renal, necrosis Lymph node, bronchial	(32)		(40)	(14/0)	(29)		(38)	
Hyperplasia	(32)			(5%)		(3%)		(5%)
Lymph node, mandibular	(47)		(48)	(070)	(47)	(0,0)	(44)	(370)
Hyperplasia		(2%)		(4%)	()			(5%)
Lymph node, mesenteric	(48)		(48)		(46)		(44)	
Hematopoietic cell proliferation		(2%)			()		、 - <i>/</i>	
Hyperplasia		(8%)	3	(6%)	3	(7%)	2	(5%)
Inflammation			2	(4%)				
	1	(2%)	1	(2%)				
Inflammation, granulomatous Necrosis	1	(2 /0)		(2%)				

	Chamber Control	75 ppm	250 ppm	750 ppm
Hematopoietic System (continued)				
Lymph node, mediastinal	(34)	(42)	(41)	(31)
Hyperplasia	3 (9%)	4 (10%)		2 (6%)
Hyperplasia, histiocytic	1 (3%)			
Spleen	(50)	(50)	(50)	(49)
Hematopoietic cell proliferation	4 (8%)	7 (14%)	2 (4%)	1 (2%)
Hyperplasia	1 (2%)			
Necrosis		1 (2%)		
Pigmentation, hemosiderin	4 (8%)	1 (2%)	1 (2%)	4 (8%)
Lymphoid follicle, hyperplasia	9 (18%)	5 (10%)	1 (2%)	3 (6%)
Thymus	(42)	(44)	(45)	(46)
Atrophy	5 (12%)	5 (11%)	5 (11%)	6 (13%)
Thymocyte, hyperplasia	1 (2%)	2 (5%)		
Integumentary System				
Mammary gland	(49)	(50)	(48)	(49)
Galactocele		1 (2%)	1 (2%)	
Hyperplasia		1 (2%)		
Skin	(50)	(50)	(49)	(50)
Fibrosis			1 (2%)	
Inflammation	1 (2%)		2 (4%)	
Necrosis	1 (2%)			
Ulcer	1 (2%)		2 (4%)	
Musculoskeletal System				
Bone	(49)	(50)	(50)	(50)
Arthrosis			1 (2%)	
Fracture		2 (4%)		
Periosteum, femur, inflammation	1 (2%)			
Nervous System				
Brain	(50)	(50)	(50)	(50)
Hemorrhage	2 (4%)			
Mineralization	19 (38%)	17 (34%)	26 (52%)	25 (50%)
Cerebellum, atrophy	1 (2%)		. ,	
Cerebrum, atrophy	2 (4%)	1 (2%)	2 (4%)	
Cerebrum, gliosis				1 (2%)
Cerebrum, hemorrhage				1 (2%)
Medulla, atrophy	1 (2%)			
Medulla, hemorrhage	1 (2%)			
Meninges, infiltration cellular		2 (4%)	1 (2%)	
Spinal cord	(1)			
Hemorrhage	1 (100%)			
Myelin, degeneration	1 (100%)			

	Chamber Control	75 ppm	250 ppm	750 ppm
Respiratory System				
Larynx	(49)	(49)	(47)	(48)
Degeneration			1 (2%)	
Infiltration cellular	1 (2%)		1 (2%)	1 (2%)
Glands, degeneration		2 (4%)	2 (4%)	2 (4%)
Glands, inflammation			1 (2%)	
Lung	(50)	(50)	(49)	(50)
Hemorrhage	1 (2%)		1 (2%)	
Hyperplasia, lymphoid		1 (2%)		
Infiltration cellular, histiocyte	1 (2%)			
Alveolar epithelium, hyperplasia		1 (2%)	3 (6%)	1 (2%)
Alveolar epithelium, metaplasia				1 (2%)
Vein, thrombosis	1 (2%)			
Nose	(49)	(50)	(50)	(50)
Hemorrhage	1 (2%)			
Inflammation	3 (6%)	2 (4%)	3 (6%)	
Nasolacrimal duct, inflammation	1 (2%)			
Respiratory epithelium, metaplasia, squam			1 (2%)	
Pleura	(1)	(()	(
Trachea	(50)	(50)	(50)	(50)
Smootal Samaa Sustam				
Special Senses System None Urinary System Kidney Casts protein Urfilter selleler	(50) 1 (2%)	(50)	(50)	(50) 1 (2%)
None Urinary System Kidney Casts protein Infiltration cellular		(50) 1 (2%)	(50)	1 (2%)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization	1 (2%)	1 (2%)		1 (2%) 1 (2%)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization Nephropathy			9 (18%)	1 (2%) 1 (2%) 21 (42%)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization Nephropathy Cortex, cyst	1 (2%)	1 (2%) 7 (14%)		1 (2%) 1 (2%)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization Nephropathy Cortex, cyst Cortex, metaplasia, osseous	1 (2%) 13 (26%)	1 (2%) 7 (14%) 1 (2%)	9 (18%) 1 (2%)	1 (2%) 1 (2%) 21 (42%) 1 (2%)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization Nephropathy Cortex, cyst Cortex, metaplasia, osseous Urinary bladder	1 (2%) 13 (26%) (47)	1 (2%) 7 (14%)	9 (18%)	1 (2%) 1 (2%) 21 (42%)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization Nephropathy Cortex, cyst Cortex, metaplasia, osseous Urinary bladder Hemorrhage	1 (2%) 13 (26%) (47) 1 (2%)	1 (2%) 7 (14%) 1 (2%) (48)	9 (18%) 1 (2%) (47)	1 (2%) 1 (2%) 21 (42%) 1 (2%) (49)
None Urinary System Kidney Casts protein Infiltration cellular Mineralization Nephropathy Cortex, cyst Cortex, metaplasia, osseous Urinary bladder	1 (2%) 13 (26%) (47)	1 (2%) 7 (14%) 1 (2%)	9 (18%) 1 (2%)	1 (2%) 1 (2%) 21 (42%) 1 (2%)

APPENDIX E GENETIC TOXICOLOGY

SALMONELLA	MUTAGENICITY TEST PROTOCOL	202
MOUSE LYM	PHOMA MUTAGENICITY TEST PROTOCOL	202
CHINESE HAD	MSTER OVARY CELL CYTOGENETICS PROTOCOLS	203
MOUSE PERI	PHERAL BLOOD MICRONUCLEUS TEST PROTOCOL	204
RESULTS		204
TABLE E1	Mutagenicity of Ethylbenzene in Salmonella typhimurium	205
TABLE E2	Induction of Trifluorothymidine Resistance in L5178Y Mouse Lymphoma Cells	
	by Ethylbenzene	206
TABLE E3	Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells	
	by Ethylbenzene	207
TABLE E4	Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells	
	by Ethylbenzene	208
TABLE E5	Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice	
	Following Treatment with Ethylbenzene by Inhalation for 13 Weeks	209

GENETIC TOXICOLOGY

SALMONELLA MUTAGENICITY TEST PROTOCOL

Testing was performed as reported by Zeiger *et al.* (1988). Ethylbenzene was sent to the laboratory as a coded aliquot from Radian Corporation (Austin, TX). It was incubated with the *Salmonella typhimurium* tester strains (TA97, TA98, TA100, and TA1535) either in buffer or S9 mix (metabolic activation enzymes and cofactors from Aroclor 1254-induced male Sprague-Dawley rat or Syrian hamster liver) for 20 minutes at 37° C. Top agar supplemented with L-histidine and d-biotin was added, and the contents of the tubes were mixed and poured onto the surfaces of minimal glucose agar plates. Histidine-independent mutant colonies arising on these plates were counted following incubation for 2 days at 37° C.

Each trial consisted of triplicate plates of concurrent positive and negative controls and five doses of ethylbenzene. The high dose was limited by toxicity. Trials performed in the absence of S9 were repeated. Trials initially performed with 10% S9 were repeated with 30% S9.

In this assay, a positive response is defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal response is defined as an increase in revertants that is not dose related, not reproducible, or is of insufficient magnitude to support a determination of mutagenicity. A negative response is obtained when no increase in revertant colonies is observed following chemical treatment. There was no minimum percentage or fold increase required for a chemical to be judged positive or weakly positive.

MOUSE LYMPHOMA MUTAGENICITY TEST PROTOCOL

The experimental protocol is presented in detail by McGregor *et al.* (1988). Ethylbenzene was supplied as a coded aliquot by Radian Corporation. The high dose of 160 μ g/mL was determined by toxicity. L5178Y mouse lymphoma cells were maintained at 37° C as suspension cultures in supplemented Fischer's medium; normal cycling time was approximately 10 hours. To reduce the number of spontaneously occurring trifluorothymidine-resistant cells, subcultures were exposed to medium containing THMG (thymidine, hypoxanthine, methotrexate, and glycine) for 1 day, to medium containing THG (thymidine, hypoxanthine, and glycine) for 1 day, and to normal medium for 3 to 5 days. For cloning, the horse serum content was increased and Noble agar was added.

All treatment levels within an experiment, including concurrent positive and solvent controls, were replicated. Treated cultures contained 6×10^6 cells in 10 mL medium. This volume included the S9 fraction in those experiments performed with metabolic activation. Incubation with ethylbenzene continued for 4 hours, at which time the medium plus ethylbenzene was removed and the cells were resuspended in fresh medium and incubated for an additional 2 days to express the mutant phenotype. Cell density was monitored so that log phase growth was maintained. After the 48-hour expression period, cells were plated in medium and soft agar supplemented with trifluorothymidine (TFT) for selection of TFT-resistant (TK^{-/-}) cells, and cells were plated in nonselective medium and soft agar to determine cloning efficiency. Plates were incubated at 37° C in 5% CO₂ for 10 to 12 days. The test was initially performed without S9. Because a clearly positive response was obtained, the test was not performed with S9.

Minimum criteria for accepting an experiment as valid and a detailed description of the statistical analysis and data evaluation are presented in Caspary *et al.* (1988). All data were evaluated statistically for trend and peak responses. Both responses had to be significant ($P \le 0.05$) for ethylbenzene to be considered

Ethylbenzene, NTP TR 466

positive, i.e., capable of inducing TFT resistance. A single significant response led to a "questionable" conclusion, and the absence of both a trend and peak response resulted in a "negative" call.

CHINESE HAMSTER OVARY CELL CYTOGENETICS PROTOCOLS

Testing was performed as reported by Galloway *et al.* (1987). Ethylbenzene was sent to the laboratory as a coded aliquot by Radian Corporation. It was tested in cultured Chinese hamster ovary (CHO) cells for induction of sister chromatid exchanges (SCEs) and chromosomal aberrations (Abs), both in the presence and absence of Aroclor 1254-induced male Sprague-Dawley rat liver S9 and cofactor mix. Cultures were handled under gold lights to prevent photolysis of bromodeoxyuridine-substituted DNA. Each test consisted of concurrent solvent and positive controls and of four doses of ethylbenzene; the high dose was limited by toxicity. A single flask per dose was used.

Sister Chromatid Exchange Test: In the SCE test without S9, CHO cells were incubated for 26 hours with ethylbenzene in supplemented McCoy's 5A medium. Bromodeoxyuridine (BrdU) was added 2 hours after culture initiation. After 26 hours, the medium containing ethylbenzene was removed and replaced with fresh medium plus BrdU and Colcemid, and incubation was continued for 1.5 hours. Cells were then harvested by mitotic shake-off, fixed, and stained with Hoechst 33258 and Giemsa. In the SCE test with S9, cells were incubated with ethylbenzene, serum-free medium, and S9 for 2 hours. The medium was then removed and replaced with medium containing serum and BrdU and no ethylbenzene, and incubation proceeded for an additional 25.8 hours, with Colcemid present for the final 2 hours. Harvesting and staining were the same as for cells treated without S9. All slides were scored blind and those from a single test were read by the same person. Fifty second-division metaphase cells were scored for frequency of SCEs/cell from each dose level.

Statistical analyses were conducted on the slopes of the dose-response curves and the individual dose points (Galloway *et al.*, 1987). An SCE frequency 20% above the concurrent solvent control value was chosen as a statistically conservative positive response. The probability of this level of difference occurring by chance at one dose point is less than 0.01; the probability for such a chance occurrence at two dose points is less than 0.001. An increase of 20% or greater at any single dose was considered weak evidence of activity; increases at two or more doses resulted in a determination that the trial was positive. A statistically significant trend (P < 0.005) in the absence of any responses reaching 20% above background led to a call of "equivocal."

Chromosomal Aberrations Test: In the Abs test without S9, cells were incubated in McCoy's 5A medium with ethylbenzene for 8.5 hours; Colcemid was added and incubation continued for 2 hours. The cells were then harvested by mitotic shake-off, fixed, and stained with Giemsa. For the Abs test with S9, cells were treated with ethylbenzene and S9 for 2 hours, after which the treatment medium was removed and the cells were incubated for 8.5 hours in fresh medium, with Colcemid present for the final 2 hours. Cells were harvested in the same manner as for the treatment without S9.

Cells were selected for scoring on the basis of good morphology and completeness of karyotype $(21 \pm 2 \text{ chromosomes})$. All slides were scored blind and those from a single test were read by the same person. One hundred first-division metaphase cells were scored at each dose level. Classes of aberrations included simple (breaks and terminal deletions), complex (rearrangements and translocations), and other (pulverized cells, despiralized chromosomes, and cells containing 10 or more aberrations).

Chromosomal aberration data are presented as percentage of cells with aberrations. To arrive at a statistical call for a trial, analyses were conducted on both the dose response curve and individual dose points. For a

single trial, a statistically significant ($P \le 0.05$) difference for one dose point and a significant trend ($P \le 0.015$) were considered weak evidence for a positive response; significant differences for two or more doses indicated the trial was positive. A positive trend test in the absence of a statistically significant increase at any one dose resulted in an equivocal call (Galloway *et al.*, 1987). Ultimately, the trial calls were based on a consideration of the statistical analyses as well as the biological information available to the reviewers.

MOUSE PERIPHERAL BLOOD MICRONUCLEUS TEST PROTOCOL

A detailed discussion of this assay can be found in MacGregor *et al.* (1990). Peripheral blood samples were obtained from male and female B6C3F₁ mice at the end of a 13-week toxicity study (NTP, 1992). Smears were immediately prepared and fixed in absolute methanol, stained with a chromatin-specific fluorescent dye mixture of Hoechst 33258/pyronin Y (MacGregor *et al.*, 1983), and coded. Slides were scanned at $630 \times$ or $1,000 \times$ to determine the frequency of micronuclei in 2,000 polychromatic erythrocytes (PCEs) and 10,000 normochromatic erythrocytes (NCEs) in each animal of each dose group. The criteria of Schmid (1976) were used to define micronuclei, with the additional requirement that the micronuclei exhibit the characteristic fluorescent emissions of DNA (blue with 360 nm and orange with 510 nm ultraviolet illumination); the minimum size limit was approximately one-twentieth the diameter of the NCE cell. In addition, the percentage of PCEs among the total erythrocyte population was determined.

Log transformation of the NCE data, testing for normality by the Shapiro-Wilk test, and testing for heterogeneity of variance by Cochran's test were performed before statistical analyses. The frequency of micronucleated cells among NCEs was analyzed by analysis of variance using the SAS GLM procedure. The NCE data for each dose group were compared with the concurrent solvent control using Student's *t*-test. The frequency of micronucleated cells among PCEs was analyzed by the Cochran-Armitage trend test, and individual dose groups were compared to the concurrent solvent control by Kastenbaum-Bowman's binomial test. The percentage of PCEs among total erythrocytes was analyzed by an analysis of variance on ranks (classed by sex), and individual dose groups were compared with the concurrent solvent control using a *t*-test on ranks.

RESULTS

Ethylbenzene was not mutagenic in *S. typhimurium* strain TA97, TA98, TA100, or TA1535 with or without Aroclor-induced rat or hamster liver S9 (Table E1; Zeiger *et al.*, 1988). A positive response was observed with ethylbenzene in the L5178Y mouse lymphoma cell assay in the absence of S9 at the highest nonlethal dose tested ($80 \mu g/mL$); the assay was not performed with S9 (Table E2; McGregor *et al.*, 1988). A significant amount of cytotoxicity was noted at this dose level (relative total growth was reduced to 34% and 13% of the control level in each of two trials). No increases in SCEs (Table E3) or Abs (Table E4) were induced by ethylbenzene in cultured CHO cells, with or without S9. *In vivo*, no increases in frequencies of micronucleated erythrocytes were observed in peripheral blood samples from male and female mice treated for 13 weeks with ethylbenzene (Table E5).

	Revertants/plate ^b								
Strain Dose	-59)	+ hams	ster S9	+ rat S 9				
(µg/plate)	Trial 1	Trial 2	10%	30%	10%	30 %			
ГА100									
0	112 ± 9.3	147 ± 4.0	114 ± 8.2	136 ± 3.3	111 ± 2.1	154 ± 7.8			
10	104 ± 0.9	161 ± 5.8	120 ± 11.5	138 ± 9.5	$100~\pm~5.0$	155 ± 9.0			
33	100 ± 4.4	147 ± 4.1	137 ± 22.7	140 ± 138	110 ± 8.1	155 ± 9.3			
100	97 ± 4.8	157 ± 3.2	109 ± 7.1	138 ± 12.2	$105~\pm~2.3$	161 ± 14.5			
333	97 ± 6.9	118 ± 11.5	97 ± 7.1	137 ± 1.2	111 ± 4.7	127 ± 13.2			
666	76 ± 6.2	$74 \pm 4.0^{\circ}$							
1,000			$98~\pm~1.7$	$112\pm~6.1$	77 ± 8.2	$109~\pm~8.8$			
Trial summary	Negative	Negative	Negative	Negative	Negative	Negative			
Positive control ^d	375 ± 12.3	394 ± 32.5	873 ± 46.0	740 ± 18.0	$1,304 \pm 306.0$	352 ± 19.8			
FA1535									
0	14 ± 3.7	$29~\pm~3.8$	7 ± 1.5	11 ± 2.3	9 ± 2.0	12 ± 1.2			
10	19 ± 1.3	$26~\pm~3.2$	9 ± 1.3	14 ± 1.5	8 ± 0.7	13 ± 2.5			
33	$21~\pm~4.6$	19 ± 2.5	6 ± 0.7	11 ± 1.5	9 ± 3.0	$8~\pm~0.6$			
100	16 ± 1.5	25 ± 2.5	8 ± 1.5	10 ± 2.4	5 ± 0.6	10 ± 1.5			
333	16 ± 2.1	$14~\pm~0.3$	9 ± 1.2	9 ± 2.7	8 ± 2.4	6 ± 0.9			
666	0 ± 0.0^{e}	0 ± 0.0							
1,000			5 ± 1.8	11 ± 1.9	5 ± 1.5	9 ± 1.5			
rial summary	Negative	Negative	Negative	Negative	Negative	Negative			
ositive control	$418~\pm~23.1$	$520~\pm~20.0$	703 ± 16.5	$431~\pm~36.9$	$393~\pm~72.0$	101 ± 11.4			
FA97									
0	182 ± 1.5	111 ± 9.5	$195~\pm~12.3$	$184~\pm~18.2$	$200~\pm~10.0$	$218~\pm~6.5$			
10	$203~\pm~1.8$	$120~\pm~16.3$	$194~\pm~10.3$	$210~\pm~22.5$	$190~\pm~15.1$	$249~\pm~20.2$			
33	$198~\pm~6.9$	$144~\pm~2.4$	$195~\pm~3.5$	$186~\pm~22.4$	$193~\pm~5.3$	$227~\pm~16.5$			
100	$195~\pm~9.9$	$124~\pm~5.2$	$191~\pm~7.1$	$227~\pm~1.8$	$179~\pm~7.8$	12 ± 13.0			
333	$188~\pm~5.7$	108 ± 9.1	173 ± 3.5	$202~\pm~8.3$	$211~\pm~3.3$	$211~\pm~6.4$			
666	$103~\pm~1.5$	$6 \pm 5.7^{\circ}$							
1,000			$124~\pm~9.6$	$180~\pm~15.9$	$189~\pm~23.4$	195 ± 15.3			
rial summary	Negative	Negative	Negative	Negative	Negative	Negative			
Positive control	$856~\pm~20.8$	$954~\pm~47.1$	$1,587 \pm 146.1$	$1,123 \pm 30.4$	$647~\pm~154.3$	540 ± 12.7			
ГА98									
0	$26~\pm~1.8$	$29~\pm~5.5$	$24~\pm~3.2$	35 ± 3.8	$34~\pm~3.3$	34 ± 7.2			
10	16 ± 2.3	$27~\pm~4.4$	$29~\pm~1.8$	34 ± 4.7	$26~\pm~1.8$	$32~\pm~4.1$			
33	$22~\pm~4.8$	$35~\pm~7.8$	$26~\pm~0.6$	$34~\pm~4.5$	$34~\pm~3.5$	$32~\pm~2.3$			
100	$21~\pm~2.4$	16 ± 2.1	$28~\pm~4.7$	26 ± 1.2	32 ± 2.3	$30~\pm~4.2$			
333	18 ± 1.5	20 ± 8.4	$23~\pm~3.0$	30 ± 0.7	30 ± 2.3	$28~\pm~5.6$			
666	13 ± 1.2	$27 \pm 14.5^{\circ}$							
1,000			21 ± 2.3	30 ± 0.9	26 ± 1.5	30 ± 3.5			
rial summary	Negative	Negative	Negative	Negative	Negative	Negative			
Positive control	$845~\pm~69.2$	566 ± 45.0	$1,082 \pm 174.8$	285 ± 32.9	784 ± 214.8	149 ± 10.7			

TABLE E1 Mutagenicity of Ethylbenzene in Salmonella typhimurium^a

а Study was performed at SRI International. The detailed protocol and these data are presented in Zeiger et al. (1988). 0 µg/plate was the solvent control. Revertants are presented as mean \pm standard error from three plates. b

с Slight toxicity

d The positive controls in the absence of metabolic activation were sodium azide (TA100 and TA1535), 9-aminoacridine (TA97), and 4-nitro-o-phenylenediamine (TA98). The positive control for metabolic activation with all strains was 2-aminoanthracene.

e Precipitate on plate, toxic

Induction of Trifluorothymidine Resistance in L5178Y Mouse Lymphoma Cells by Ethylbenzene^a

compound Concentration (μg/mL)		Cloning Efficiency (%)	Relative Total Growth (%)	Mutant Count	Mutant Fraction ^b	Average Mutant Fraction
-S9						
Trial 1						
Dimethylsulfoxide ^c		84	94	159	63	
DimeniyiSunoxide		89	106	150	56	
		78	108	155	66	
		87	92	138	53	60
	d					
Ethylmethane sulfon	ate ^d 250	81	85	357	147	1.10+
		83	95	374	150	149*
Methylmethane sulfo	onate ^d 15	61	40	251	138	
steary meetiane suite		52	39	238	152	145*
				200	108	
Ethylbenzene	10	81	103	123	51	
-		86	106	157	61	56
	20	81	90	130	54	
		81	93	127	52	53
	40	87	82	175	67	
		73	72	144	66	67
	80	74	36	1,235	559	
		71	32	1,335	619	589*
	160	Lethal				
Trial 2						
Dimethylsulfoxide		85	106	87	34	
EmicinyiSunoxide		69	95	63	34	
		82	98	75	30	
		100	101	91	30	31
Ethylmethane sulfon	ate 250	50	67	302	201	
		51	67	381	250	225*
Mathulmathana and	anata 15	10	34	199	94	
Methylmethane sulfo	onate 15	43 42	34 32	122 152	94 120	107*
		42	32	132	120	107
Ethylbenzene	20	83	83	109	44	
<i>j</i>	~~	82	83	102	41	42
	40	78	61	75	32	
	-	73	54	58	27	29
	60	64	37	91	48	
		68	60	79	39	43
	80	48	10	228	159	
		55	15	233	142	150*
	100	Lethal				

*

Significant positive response (P \leq 0.05) versus the solvent control Study was performed at Inveresk Research International. The detailed protocol and these data are presented in McGregor *et al.* (1988). Mutant fraction (MF) (frequency) is a ratio of the mutant count to the cloning efficiency, divided by 3 [to arrive at MF/10⁶ cells а

b

treated]). Solvent control Positive control с

d

TABLE	E3
-------	----

Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by Ethylbenzene^a

Compound	Dose (µg/mL)	Total Cells Scored	No. of Chromo- somes	No. of SCEs	SCEs/ Chromo- some	SCEs/ Cell	Hrs in BrdU	Relative Change of SCEs/ Chromosome ^b (%)
- S9 Summary: Negative								
Dimethylsulfoxide ^c		50	1,045	555	0.53	11.1	25.5	
Mitomycin-C ^d	0.001 0.010	50 5	1,041 103	773 220	0.74 2.13	15.5 44.0	25.5 25.5	39.81 302.17
Ethylbenzene	75.5 99.5 125 ^e 151 ^e	50 50 50 0	1,046 1,049 1,033	551 522 590	0.52 0.49 0.57 P= 0.207^{f}	11.0 10.4 11.8	25.5 25.5 25.5 25.5	-0.82 -6.31 7.54
+ S9 Summary: Negative								
Dimethylsulfoxide		50	1,047	531	0.50	10.6	25.8	
Cyclophosphamide ^d	0.35 2	50 5	1,048 108	723 159	0.68 1.47	14.5 31.8	25.8 25.8	36.03 190.29
Ethylbenzene	125 137.5 150 ^e 175 ^e	50 50 50 0	1,044 1,041 1,037	561 531 516	0.53 0.51 0.49	11.2 10.6 10.3	25.8 25.8 25.8	5.95 0.58 -1.89
					P=0.713			

а Study was performed at Litton Bionetics, Inc. A detailed description of the protocol is presented in Galloway et al. (1987). SCE= sister chromatid exchange; BrdU= bromodeoxyuridine SCEs/chromosome in treated cells versus SCEs/chromosome in solvent control cells b

с Solvent control

d Positive control

e

Precipitate on plate Significance of SCEs/chromosome tested by the linear regression trend test versus log of the dose \mathbf{f}

TABLE E4

Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells by Ethylbenzene^a

	-S9						+ S9				
	Dose	Total Cells	No. of	Abs/	Cells with	1	Dose [Fotal Cell	s No. of	Abs/	Cells with
(µg/mL)	Scored	Abs	Cell	Abs (%)	(µį	g/mL)	Scored	Abs	Cell	Abs (%)
Harvest tin Summary:						Harvest time Summary: N					
Dimethylsu	ılfoxide ^b	100	3	0.03	3	Dimethylsulf	òxide	100	3	0.03	3
Mitomycin	-C ^c					Cyclophosph	amide ^c				
5	1	50	16	0.32	22	5 1 1	50	50	23	0.46	36
Ethylbenze	ene					Ethylbenzen	e				
5	75	100	1	0.01	1	5	75	100	4	0.04	4
	100	100	3	0.03	3		100	100	1	0.01	1
	125	100	5	0.05	5		125	100	1	0.01	1
	150	0					150	0			
					$P = 0.150^{d}$						P=0.917

а Study was performed at Litton Bionetics, Inc. The detailed protocol is presented in Galloway et al. (1987). Abs= aberrations

b

Solvent control Positive control с

d Significance of percent cells with aberrations tested by the linear regression trend test versus log of the dose

TABLE E5 Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice Following Treatment with Ethylbenzene by Inhalation for 13 Weeks^a

Compound	Dose	Number of Mice with Erythrocytes	Micronucleated	PCEs ^b	
	(ppm)	Scored	PCEs	NCEs	(%)
Male					
	0	8	$2.18~\pm~0.56$	$1.54~\pm~0.16$	$2.22~\pm~0.10$
	500	10	$2.04~\pm~0.31$	$1.68~\pm~0.13$	$3.13~\pm~0.94$
	750	9	$1.90~\pm~0.53$	$1.90~\pm~0.13$	$1.97~\pm~0.09$
	1,000	10	$1.21~\pm~0.20$	$1.59~\pm~0.16$	$2.02~\pm~0.14$
Trend test ^c			P=0.928	P=0.816	
ANOVA ^d					P=0.278
Female					
	0	10	$1.54~\pm~0.56$	0.92 ± 0.11	1.74 ± 0.14
	500	10	2.64 ± 0.53	1.01 ± 0.12	$1.83~\pm~0.18$
	750	10	$1.87~\pm~0.38$	1.32 ± 0.22	$1.85~\pm~0.15$
	1,000	10	1.01 ± 0.26	$1.12~\pm~0.12$	$1.80~\pm~0.15$
Trend test			P=0.817	P=0.077	
ANOVA					P=0.886
Overall trend			P=0.951	P = 0.149	
Overall ANOVA					P = 0.684

Study was performed at the USDA Western Regional Center. The protocol is presented in MacGregor *et al.* (1990). PCE= polychromatic erythrocyte; NCE= normochromatic erythrocyte. At least 2,000 PCEs and 10,000 NCEs were scored from each animal. Mean ± standard error Cochran-Armitage linear regression of proportions for PCEs or linear contrasts from analysis of variance for NCEs Analysis of variance on ranks а

b

с

d

APPENDIX F CHEMICAL CHARACTERIZATION AND GENERATION OF CHAMBER CONCENTRATIONS

PROCUREME	NT AND CHARACTERIZATION OF ETHYLBENZENE	212
VAPOR GENE	RATION AND EXPOSURE SYSTEM	213
VAPOR CONC	CENTRATION MONITORING	214
CHAMBER AT	Imosphere Characterization	214
FIGURE F1	Infrared Absorption Spectrum of Ethylbenzene	216
FIGURE F2	Nuclear Magnetic Resonance Spectrum of Ethylbenzene	217
FIGURE F3	Schematic of Generation and Delivery System	218
FIGURE F4	Inhalation Suite	219
TABLE F1	Summary of Chamber Concentrations in the 2-Year Inhalation Studies	
	of Ethylbenzene	220

CHEMICAL CHARACTERIZATION AND GENERATION OF CHAMBER CONCENTRATIONS

PROCUREMENT AND CHARACTERIZATION OF ETHYLBENZENE

Ethylbenzene was obtained from ARCO Chemical Company (Newtown Square, PA) in two lots (A060989 and A051890) that were used during the 2-year studies. Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO). Reports on analyses performed in support of the ethylbenzene studies are on file at the National Institute of Environmental Health Sciences.

The chemical, a clear, colorless, pungent smelling, volatile liquid, was identified as ethylbenzene by infrared, ultraviolet/visible (lot A060989 only), and nuclear magnetic resonance spectroscopy. All spectra were consistent with the literature spectra (*Sadtler Standard Spectra*) of ethylbenzene. The infrared and nuclear magnetic resonance spectra are presented in Figures F1 and F2. The boiling point and density of the chemical were also consistent with literature references (*Merck Index*, 1983).

The purity of lot A060989 was determined by elemental analyses, Karl Fischer water analysis, peroxide determination, and gas chromatography. To determine peroxide concentrations, a sample of ethylbenzene was refluxed with isopropyl alcohol, glacial acetic acid, and sodium iodide; liberated iodine was titrated with 0.1 N sodium thiosulfate to the starch endpoint. Gas chromatography was performed using a flame ionization detector. Two systems were used:

- A) 1% SP-1000 on 80/100 Supelcoport glass column, with a nitrogen carrier gas at a flow rate of 70 mL/minute, and an oven temperature program of 50° C for 5 minutes, then 50° to 250° C at 10° C per minute.
- B) DB-5 Megabore capillary fused-silica column with a helium carrier gas at a flow rate of 10 mL/minute, a makeup gas of nitrogen at a flow rate of 20 mL/minute, and an oven temperature program of 50° C for 5 minutes, then 50° to 250° C at 10° C per minute.

Elemental analyses for carbon and hydrogen were in agreement with the theoretical values for ethylbenzene. Karl Fischer water analysis indicated less than 0.05% water. Iodometric titration revealed no peroxide. Gas chromatography by each system revealed a major peak and no impurities with areas greater than 0.1% relative to the major peak. Major peak comparisons of lot A060989 with a previously analyzed lot of ethylbenzene (lot K061786) not used in the current studies indicated a purity of $101.0\% \pm 0.5\%$ for lot A060989 relative to lot K061786. The overall purity of lot A060989 was determined to be greater than 99%.

Additional analyses of lot A060989 were performed with gas chromatography/mass spectrometry to identify and quantify cumene in the bulk ethylbenzene. The gas chromatograph system included a DB-5 fused-silica capillary column with a helium carrier gas at a linear flow rate of 30 cm³/second and an oven temperature program of 60° C for 5 minutes, then 60° to 200° C at 10° C per minute; injection was performed with a 30-second splitless delay. Tridecane was added as an internal standard to the cumene standard solution. Cumene was identified by comparison of retention times and specific ion ratios to the cumene standard. Cumene in lot A060989 had a retention time of 5.8 minutes and a specific ion ratio of 19:100:23, compared to a retention time of 5.6 minutes and an ion ratio of 20:100:24 for the standard. System B described for purity analyses, with cumene added as a standard, was used to quantify cumene; 62 ± 3.1 ppm was detected. The purity of lot A051890 was determined by iodometric titration for peroxide and by gas chromatography with system A, but with a 10% SP-1000 on 80/100 Supelcoport glass column. Less than 2 ppm peroxide was detected. Gas chromatography indicated one impurity with an area of 0.1% relative to the major peak. The overall purity of lot A051890 was determined to be greater than 99%.

Accelerated stability studies of lot K061786 were performed by the analytical chemistry laboratory. Gas chromatography was performed with system A but with a 10% SP-1000 column and 87° C isothermal temperature. These studies indicated that ethylbenzene is stable as a bulk chemical for at least 2 weeks when stored protected from light at temperatures up to 60° C. To ensure stability, the bulk chemical was stored at room temperature in the original steel containers until just prior to use, when it was transferred to amber glass bottles with Teflon[®]-lined caps and a nitrogen headspace. The rapid use and small shipment sizes of ethylbenzene made stability monitoring unnecessary during the studies; however, the peroxide content of the bulk chemical was tested monthly with iodometric titration. The concentration of peroxide ranged from 1.12 to 10.7 ppm.

VAPOR GENERATION AND EXPOSURE SYSTEM

A diagram of the ethylbenzene generation and delivery system is shown in Figure F3. Ethylbenzene vapor was produced by flash evaporator units. Liquid ethylbenzene was pumped by fine metering pumps from a reservoir into the top of a 30-cm-long, 20-mm internal diameter, Hempel distillation column packed with 3-mm diameter glass beads. At its lower end, the column was fitted into a two-armed 500-mL glass flask. One arm of the flask allowed access by a thermocouple that, in conjunction with a thermostated heating tape, maintained the column temperature at $150^{\circ} \pm 15^{\circ}$ C. Nitrogen carrier gas at 95 psi was bled from a high-pressure liquid nitrogen tank monitored by a weight scale, was passed through a manifold, and entered the flask through the second arm; it was heated to $200^{\circ} \pm 50^{\circ}$ C by a mantle surrounding the flask. The nitrogen gas carried ethylbenzene vapor into stainless steel transfer lines heated to 75° C by a heating tape. Magnehelic gauges were installed in the carrier gas lines immediately before the flash evaporators to monitor for blockages; pressure alarms ensured that the nitrogen gas pressure remained within the appropriate range. Transfer lines led to exposure chambers. Each exposure chamber was supplied by a separate flash evaporator unit.

Exposure concentrations for individual exposure chambers were created by varying the ethylbenzene flow rate to the individual flash evaporation units. Ethylbenzene vapor concentrations of 75, 250, and 750 ppm were created by ethylbenzene flow rates of 0.19, 0.63, and 1.9 mL/minute. To prevent saturation of the vapor streams, nitrogen flow rates were maintained at 5 L/minute for 75 and 250 ppm chambers and 10 L/minute for 750 ppm chambers. Each carrier gas line was fitted with a pressure release valve to shield the glass flash evaporator from pressure buildup due to blockage. At the chamber inlets, the ethylbenzene vapor passed through venturi-type plenums to enhance complete mixing with HEPA- and charcoal-filtered air.

Stainless-steel chambers (Hazleton H-2000[®]) manufactured by Lab Products, Inc. (Maywood, NJ) were used throughout the studies. A diagram of the inhalation suite is shown in Figure F4. The total volume of each chamber was 2.3 m³; the active mixing volume of each chamber was 1.7 m³. The chamber was designed so that uniform vapor concentrations could be maintained throughout the chamber when catch pans were in place.

The 750 ppm chambers were sampled once during the first full week of exposure for the presence of aerosol by a Quartz Crystal Microbalance Cascade Impactor (California Measurements, Sierra Madre, CA). Aerosol concentrations prior to and during exposure were $0.1492 \pm 0.0121 \text{ mg/m}^3$ and $0.0904 \pm 0.0270 \text{ mg/m}^3$, respectively, for rats and $0.1772 \pm 0.0633 \text{ mg/m}^3$ and $0.2522 \pm 0.0605 \text{ mg/m}^3$,

respectively, for mice. These results indicate that aerosol formation due to test atmosphere generation was not significant.

VAPOR CONCENTRATION MONITORING

The chamber concentrations of ethylbenzene were monitored automatically by an on-line gas chromatograph (Hewlett Packard Model 5880A; Hewlett Packard, Palo Alto, CA) with a flame ionization detector and a 10% SP-1000 on 80/100 Supelcoport glass column. Samples were drawn from supply lines leading to exposure chambers and the control chamber at least once every hour by a six-port gas sample valve in conjunction with a 10-port stream selector valve. A similarly equipped gas chromatograph was used as a backup and for the analysis of grab samples.

The on-line monitoring system was calibrated using certified gas standards prepared by Scott Specialty Gases (Troy, MI) and Air Products Specialty Gases (Chicago, IL). Calibration was then verified by analyzing liquid standards prepared gravimetrically with bulk ethylbenzene. Calibrations were performed prior to the beginning of the studies, weekly for the first 2 weeks of the studies, and monthly thereafter using the certified gas standards. Daily calibration checks were performed by analyzing a randomly selected standard gas sample; if the concentration deviated by more than 10% from the current calibration curve, a full-range recalibration was performed at the earliest convenient time.

Monthly calibrations of the backup gas chromatograph used in these studies were performed by collecting samples of the gas standards in gas-tight syringes and injecting them into the gas chromatograph. Daily calibration checks were performed by analyzing randomly selected standard gas samples; if the concentration deviated by more than 10% from the current calibration curve, a full range recalibration was performed. Summaries of the chamber concentrations are presented in Table F1.

CHAMBER ATMOSPHERE CHARACTERIZATION

The times for the exposure concentration to build up to 90% of the final exposure concentration (T_{90}) and to decay to 10% of the exposure concentration (T_{10}) were measured in the 750 ppm exposure chambers with animals present during the first 2 weeks of the studies. At a chamber airflow rate of 15 air changes per hour, the theoretical value for both T_{90} and T_{10} is 10 minutes. Plots of time-concentration histories during the first 2 weeks of the studies indicated T_{90} and T_{10} values of 15 minutes; therefore, 15 minutes was used for the T_{90} value throughout the studies. Actual T_{90} values ranged from 11.4 to 15 minutes for rats and from 8.9 to 12.3 minutes for mice. Actual T_{10} values ranged from 10.5 to 11.7 minutes for rats and from 9.9 to 10.7 minutes for mice.

Inhalation chambers were sampled to determine the uniformity of ethylbenzene concentrations; grab samples from 12 shelf positions within the exposure chamber were analyzed by an off-line gas chromatograph. Grab samples were collected in gas-tight syringes from sampling ports in the exposure chambers without animals present before exposures began and with animals present approximately every 90 days during the studies. Chamber concentration uniformity was maintained throughout the studies.

The persistence of ethylbenzene following exposure was monitored by gas chromatography in the 750 ppm chambers without animals present, at 4-minute intervals for at least 2 hours, and with animals present once per hour for at least 2 hours during the first week of the studies and at 90-day intervals afterward. No ethylbenzene was detectable after 2 hours (detection limit 0.44 ppm).

The stability of ethylbenzene was monitored in the generator reservoirs of the 75 and 750 ppm chambers. Samples were collected without animals in the chambers, before the studies began, over a 3-day simulated

exposure period; samples were collected at the beginning of the first day and after 6 hours of ethylbenzene generation on the third day. Samples were also collected on day 1 of the studies, during the first hour of exposure, and on day 5, during the sixth hour of exposure. Grab samples (1 mL) were diluted to 100 mL with methylene chloride and analyzed by gas chromatography. No contaminants or degradation products with peak areas of 0.1% or greater relative to the major peak were found in any of the generator reservoir samples.

Grab samples from occupied and unoccupied 75 and 750 ppm chambers were analyzed for degradation products. Grab samples (10 mL) of chamber atmospheres were collected in gas-tight syringes and analyzed by gas chromatography. Samples were collected without animals in the chambers, before the studies began, over a 3-day simulated exposure period; samples were collected at the beginning of the first day and after 6 hours of ethylbenzene generation on the third day. Sampling was also performed every 90 days throughout the study; samples were collected during the first hour of the first day of the exposure week and during the sixth hour of day 5 of the exposure week. One small impurity with an area less than 0.04% of the ethylbenzene peak area was detected in samples taken from the 750 ppm chambers.




FIGURE F1 Infrared Absorption Spectrum of Ethylbenzene




FIGURE F2 Nuclear Magnetic Resonance Spectrum of Ethylbenzene




FIGURE F3 Schematic of Generation and Delivery System




FIGURE F4 Inhalation Suite

Total Number of Readings ^a	Average Concentration ^b (ppm)
104	74.8 ± 1.7
104	250 ± 4
104	749 ± 7
103	75.2 ± 1.5
103	248 ± 5
103	748 ± 9
	104 104 104 104 103 103

TABLE F1

Summary of Chamber Concentrations in the 2-Year Inhalation Studies of Ethylbenzene

APPENDIX G INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NIH-07 RAT AND MOUSE RATION

TABLE G1	Ingredients of NIH-07 Rat and Mouse Ration	222
TABLE G2	Vitamins and Minerals in NIH-07 Rat and Mouse Ration	222
TABLE G3	Nutrient Composition of NIH-07 Rat and Mouse Ration	223
TABLE G4	Contaminant Levels in NIH-07 Rat and Mouse Ration	224

Ingredients ^b	Percent by Weight	
Ground #2 yellow shelled corn	24.50	
Ground hard winter wheat	23.00	
Soybean meal (49% protein)	12.00	
Fish meal (60% protein)	10.00	
Wheat middlings	10.00	
Dried skim milk	5.00	
Alfalfa meal (dehydrated, 17% protein)	4.00	
Corn gluten meal (60% protein)	3.00	
Soy oil	2.50	
Dried brewer's yeast	2.00	
Dry molasses	1.50	
Dicalcium phosphate	1.25	
Ground limestone	0.50	
Salt	0.50	
Premixes (vitamin and mineral)	0.25	

TABLE G1 Ingredients of NIH-07 Rat and Mouse Ration^a

^a NCI, 1976; NIH, 1978
 ^b Ingredients were ground to pass through a U.S. Standard Screen No. 16 before being mixed.

TABLE G2 Vitamins and Minerals in NIH-07 Rat and Mouse Ration^a

	Amount	Source	
Vitamins			
А	5,500,000 IU	Stabilized vitamin A palmitate or acetate	
D_{2}	4,600,000 IU	D-activated animal sterol	
D ₃ K ₃	2.8 g	Menadione	
$d - \alpha$ -Tocopheryl acetate	20,000 IŬ		
Choline	560.0 g	Choline chloride	
Folic acid	2.2 g		
Niacin	30.0 g		
d-Pantothenic acid	18.0 g	d-Calcium pantothenate	
Riboflavin	3.4 g		
Thiamine	10.0 g	Thiamine mononitrate	
B ₁₂	4,000 µg		
Pyridoxine	1.7 g	Pyridoxine hydrochloride	
Biotin	140.0 mg	<i>d</i> -Biotin	
Minerals			
Iron	120.0 g	Iron sulfate	
Manganese	60.0 g	Manganous oxide	
Zinc	16.0 g	Zinc oxide	
Copper	4.0 g	Copper sulfate	
Iodine	1.4 g	Calcium iodate	
Cobalt	0.4 g	Cobalt carbonate	

^a Per ton (2,000 lb) of finished product

TABLE G3 Nutrient Composition of NIH-07 Rat and Mouse Ration

Nutrient	Mean ± Standard Deviation	Range	Number of Samples
Protein (% by weight)	23.42 ± 0.56	22.2 - 24.3	25
Crude fat (% by weight)	5.30 ± 0.16	5.00 - 5.60	25
Crude fiber (% by weight)	3.49 ± 0.41	2.60 - 4.30	25
Ash (% by weight)	$6.37~\pm~0.18$	6.11 - 6.81	25
Amino Acids (% total diet)			
Arginine	1.280 ± 0.083	1.110 - 1.390	11
Cystine	0.308 ± 0.071	0.181 - 0.400	11
Glycine	1.158 ± 0.048	1.060 - 1.220	11
Histidine	0.584 ± 0.027	0.531 - 0.630	11
Isoleucine	0.917 ± 0.033	0.867 - 0.965	11
Leucine	1.975 ± 0.051	1.850 - 2.040	11
Lysine	1.274 ± 0.049	1.200 - 1.370	11
Methionine	0.437 ± 0.109	0.306 - 0.699	11
Phenylalanine	0.999 ± 0.120	0.665 - 1.110	11
Threonine	0.904 ± 0.058	0.824 - 0.985	11
Tryptophan	0.218 ± 0.153	0.107 - 0.671	11
Tyrosine	0.685 ± 0.094	0.564 - 0.794	11
Valine	1.086 ± 0.055	0.962 - 1.170	11
Essential Fatty Acids			
Linoleic	2.407 ± 0.227	1.830 - 2.570	10
Linolenic	0.259 ± 0.065	0.100 - 0.320	10
Vitamins			
Vitamin A (IU/kg)	$6,595 \pm 1,548$	4,180 - 11,450	25
Vitamin D (IU/kg)	$4,450 \pm 1,382$	3,000 - 6,300	4
α-Tocopherol (ppm)	35.43 ± 8.98	22.5 - 48.9	11
Thiamine (ppm)	18.16 ± 1.54	15.0 - 21.0	25
Riboflavin (ppm)	7.83 ± 0.923	6.10 - 9.00	11
Niacin (ppm)	99.22 ± 24.27	65.0 - 150.0	11
Pantothenic acid (ppm)	30.55 ± 3.52	23.0 - 34.6	11
Pyridoxine (ppm)	9.11 ± 2.53	5.60 - 14.0	11
Folic acid (ppm)	2.46 ± 0.63	1.80 - 3.70	11
Biotin (ppm)	0.268 ± 0.047	0.190 - 0.354	11
Vitamin B ₁₂ (ppb)	40.5 ± 19.1	10.6 - 65.0	11
Choline (ppm)	$2,991~\pm~382$	2,300 - 3,430	10
Minerals			
Calcium (%)	1.17 ± 0.10	1.00 - 1.49	25
Phosphorus (%)	$0.93~\pm~0.03$	0.850 - 1.00	25
Potassium (%)	0.886 ± 0.063	0.772 - 0.971	9
Chloride(%)	0.529 ± 0.087	0.380 - 0.635	9
Sodium (%)	0.316 ± 0.033	0.258 - 0.371	11
Magnesium (%)	0.166 ± 0.010	0.148 - 0.181	11
Sulfur (%)	0.272 ± 0.059	0.208 - 0.420	10
Iron (ppm)	350.5 ± 87.3	255.0 - 523.0	11
Manganese (ppm)	$92.48~\pm~5.14$	81.7 - 99.4	11
Zinc (ppm)	59.33 ± 10.2	46.1 - 81.6	11
Copper (ppm)	11.81 ± 2.50	8.09 - 15.4	11
Iodine (ppm)	3.54 ± 1.19	1.52 - 5.83	10
Chromium (ppm)	1.66 ± 0.46	0.85 - 2.09	11
Cobalt (ppm)	0.76 ± 0.23	0.49 - 1.15	7

	$\begin{array}{rl} \textbf{Mean \pm Standard} \\ \textbf{Deviation}^{b} \end{array}$	Range	Number of Samples
ontaminants			
Arsenic (ppm)	0.37 ± 0.18	0.10 - 0.70	25
Cadmium (ppm)	0.10 ± 0.07	0.05 - 0.20	25
Lead (ppm)	0.30 ± 0.23	0.10 - 1.00	25
Mercury (ppm) ^c	0.02	0.02 - 0.03	25
Selenium (ppm)	0.33 ± 0.12	0.05 - 0.60	25
Aflatoxins (ppm)	< 5.0	0.00 0.00	25
Nitrate nitrogen (ppm) ^d	11.72 ± 5.20	2.90 - 21.0	25
Nitrite nitrogen (ppm) ^d	0.23 ± 0.18	0.10 - 0.70	25
BHA (ppm) ^e	1.88 ± 1.94	1.00 - 10.0	25
BHT (ppm) ^e	1.56 ± 1.54 1.56 ± 1.58	1.0 - 8.00	25
			25
Aerobic plate count (CFU/g)	$78,748 \pm 143,028$	4,100 - 710,000	25 25
Coliform (MPN/g)	3 ± 0.2	3 - 4	
Escherichia coli (MPN/g)	< 3		25
Salmonella (MPN/g)	Negative	4.00 11.40	25
Total nitrosoamines (ppb) ^f	7.25 ± 1.71	4.80 - 11.40	25
<i>N</i> -Nitrosodimethylamine (ppb) ^t	5.50 ± 1.30	3.80 - 9.10	25
<i>N</i> -Nitrosopyrrolidine (ppb) ^f	1.75 ± 1.00	1.00 - 4.30	25
esticides (ppm)			
α-BHC	< 0.01		25
β-ВНС	< 0.02		25
ү-ВНС	< 0.01		25
δ-BHC	< 0.01		25
Heptachlor	< 0.01		25
Aldrin	< 0.01		25
Heptachlor epoxide	< 0.01		25
DDE	< 0.01		25
DDD	< 0.01		25
DDT	< 0.01		25
HCB	< 0.01		25
Mirex	< 0.01		25
Methoxychlor	< 0.05		25
Dieldrin	< 0.01		25
Endrin	< 0.01		25
Telodrin	< 0.01		25
Chlordane	< 0.05		25
Toxaphene	< 0.10		25
Estimated PCBs	< 0.20		25
Ronnel	< 0.01		25
Ethion	< 0.02		25
Trithion	< 0.02		25
Diazinon	< 0.10		25
Methyl parathion	< 0.02		25
Ethyl parathion	< 0.02		25
Malathion	< 0.02 0.24 ± 0.21	0.05 - 0.97	25
Endosulfan I	< 0.01	0.03 - 0.37	25
Endosulfan II	< 0.01		25
Endosulfan sulfate	< 0.01		25 25
Linuosunali sunate	< 0.03		20

TABLE G4 **Contaminant Levels in NIH-07 Rat and Mouse Ration**^a

CFU= colony-forming units; MPN= most probable number; BHC= hexachlorocyclohexane or benzene hexachloride For values less than the limit of detection, the detection limit is given as the mean. All but three values were less than the detection limit; the detection limit was used for the low end of the range. Sources of contamination: alfalfa, grains, and fish meal Sources of contamination: soy oil and fish meal All values were corrected for percent recovery. а b

С

d

e

 \mathbf{f}

APPENDIX H SENTINEL ANIMAL PROGRAM

METHODS		226
TABLE H1	Murine Virus Antibody Determinations for Rats and Mice	
	in the 2-Year Inhalation Studies of Ethylbenzene	227

SENTINEL ANIMAL PROGRAM

METHODS

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals and the study animals are all subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Serum samples were collected from randomly selected rats and mice during the 2-year studies. Blood from each animal was collected and allowed to clot, and the serum was separated. The samples were processed appropriately and sent to Microbiological Associates, Inc. (Bethesda, MD), for determination of antibody titers. The laboratory serology methods and viral agents for which testing was performed are tabulated below; the times at which the blood was collected during the studies are also listed.

Method and Test

RATS

ELISA Mycoplasma arthritidis Mycoplasma pulmonis PVM (pneumonia virus of mice) RCV/SDA (rat coronavirus/sialodacryoadenitis virus) Sendai

Hemagglutination Inhibition H-1 (Toolan's H-1 virus) KRV (Kilham rat virus)

MICE

ELISA Ectromelia virus EDIM (epizootic diarrhea of infant mice) GDVII (mouse encephalomyelitis virus) LCM (lymphocytic choriomeningitis virus) Mouse adenoma virus-FL MHV (mouse hepatitis virus) *M. arthritidis M. pulmonis* PVM Reovirus 3 Sendai

Time of Analysis

Study terminationStudy termination6, 12, and 18 months, study termination

6, 12, and 18 months, study termination

6, 12, and 18 months, study termination

6, 12, and 18 months, study termination 6, 12, and 18 months, study termination

6, 12, and 18 months, study termination
6 and 18 months, study termination
6, 12, and 18 months, study termination
7, 2, and 18 months, study termination
8, 12, and 18 months, study termination
9, 12, and 18 months, study termination
12, and 18 months, study termination
12, and 18 months, study termination
6, 12, and 18 months, study termination
6, 12, and 18 months, study termination
6, 12, and 18 months, study termination

Method and Test

MICE (continued) Immunofluorescence Assay EDIM 6 and 12 months, study termination **GDVII** 12 months MHV 6 and 12 months Mouse adenoma virus-FL Study termination **Reovirus 3** 6 and 12 months Sendai 6 months Hemagglutination Inhibition K (papovavirus) 6, 12, and 18 months, study termination MVM (minute virus of mice) 6, 12, and 18 months, study termination Polyoma virus 6, 12, and 18 months, study termination

Results of serology tests are presented in Table H1.

TABLE H1 Murine Virus Antibody Determinations for Rats and Mice in the 2-Year Inhalation Studies of Ethylbenzene

Interval	Incidence of Antibody in Sentinel Animals	Positive Serologic Reaction for
Rats		
6 Months	0/24	None positive
12 Months	0/24	None positive
18 Months	0/22	None positive
Study termination	1/10	Mycoplasma arthritidis ^a
Mice		
6 Months	0/10	None positive
12 Months	1/9	Reovirus 3
18 Months	0/8	None positive
Study termination	0/10	None positive

а Further evaluation of the sample positive for M. arthritidis by immunoblot and Western blot procedures indicated that the positive titer may have been due to cross reaction with antibodies of nonpathogenic Mycoplasma or other agents. Only one sample was positive, and there were no clinical findings or histopathologic changes of M. athritidis infection in the rat with the positive titer. Accordingly, the M. arthritidispositive titer was considered to be a false positive.

Time of Analysis